rearrangement	amino_acid	frame_type	rearrangement_type	templates	reads	frequency	productive_frequency	cdr3_length	v_family	v_gene	v_allele	d_family	d_gene	d_allele	j_family	j_gene	j_allele	v_deletions	d5_deletions	d3_deletions	j_deletions	n2_insertions	n1_insertions	v_index	n1_index	n2_index	d_index	j_index	v_family_ties	v_gene_ties	v_allele_ties	d_family_ties	d_gene_ties	d_allele_ties	j_family_ties	j_gene_ties	j_allele_ties	sequence_tags	v_shm_count	v_shm_indexes	antibody	bio_identity	v_resolved	d_resolved	j_resolved	sample_name	species	locus	product_subtype	kit_pool	sku	test_name	sample_catalog_tags	sample_rich_tags	sample_rich_tags_json	kit_control	total_templates	productive_templates	outofframe_templates	stop_templates	dj_templates	total_rearrangements	productive_rearrangements	outofframe_rearrangements	stop_rearrangements	dj_rearrangements	total_reads	total_productive_reads	total_outofframe_reads	total_stop_reads	total_dj_reads	productive_clonality	productive_entropy	sample_clonality	sample_entropy	sample_amount_ng	sample_cells_mass_estimate	fraction_productive_of_cells_mass_estimate	sample_cells	fraction_productive_of_cells	max_productive_frequency	max_frequency	counting_method	primer_set	sequence_result_status	release_date	upload_date	sample_tags	fraction_productive	order_name	kit_id	total_t_cells	total_templates_agg
GACTCGGCCATGTATCGCTGTGCCAGCAGCCCCCCAGGGGGAGCGGACGAGCAGTACTTCGGGCCG	CASSPPGGADEQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	42	TCRBV07	TCRBV07-06	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	1	5	4	5	18	30	41	34	46														CASSPPGGADEQYF+TCRBV07-06+TCRBJ02-07	TCRBV07-06*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCATGTATCGCTGTGCCAGCGAAGTGGGGGGCCGGGCTGGGGAAGCTTTCTTTGGACAA	CASEVGGRAGEAFF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	42	TCRBV07	TCRBV07-06	01				TCRBJ01	TCRBJ01-01	01	8	6	0	8	6	9	18	27	39	33	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASEVGGRAGEAFF+TCRBV07-06+TCRBJ01-01	TCRBV07-06*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTAGTTCGGCTATGGCAGGGTGACCCCTACGAGCAGTACTTCGGGCCG	CASSLVRLWQGDPYEQYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	54	TCRBV07	TCRBV07-06	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	4	3	2	11	5	18	34	50	45	55														CASSLVRLWQGDPYEQYF+TCRBV07-06+TCRBJ02-07	TCRBV07-06*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTGCCGCCGGGAATAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	23	7.568204328354771E-5		47	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	3	8	3	0	5	1	18	32	42	37	43														X+TCRBV07-06+TCRBJ01-05	TCRBV07-06*01	TCRBD02-01*02	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTTGGGGGAATTGGTACTGAAGCTTTCTTTGGACAA	CASSFGGIGTEAFF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV07	TCRBV07-06	01				TCRBJ01	TCRBJ01-01	01	3	6	1	5	1	7	18	32	38	33	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFGGIGTEAFF+TCRBV07-06+TCRBJ01-01	TCRBV07-06*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCCCCGGCTCAGGGGTTAACTCTGGAAACACCATATATTTTGGAGAG	CASSPGSGVNSGNTIYF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	51	TCRBV07	TCRBV07-06	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	4	2	0	7	4	18	30	43	37	47														CASSPGSGVNSGNTIYF+TCRBV07-06+TCRBJ01-03	TCRBV07-06*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTATTATCGGGGGGGCGGGATACGCAGTATTTTGGCCCA	CASSLLSGGRDTQYF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	45	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	2	8	0	6	4	3	18	33	45	37	48														CASSLLSGGRDTQYF+TCRBV07-06+TCRBJ02-03	TCRBV07-06*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTGTCCCCTTAGCTAGCGGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	30	9.87157086307144E-5		52	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	3	4	6	1	10	0	18	32	-1	42	48						01,02								X+TCRBV07-06+TCRBJ02-02	TCRBV07-06*01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCGTGGACAGTTTCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSVDSFSGANVLTF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	48	TCRBV07	TCRBV07-06	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	1	5	0	2	3	18	30	38	32	41														CASSVDSFSGANVLTF+TCRBV07-06+TCRBJ02-06	TCRBV07-06*01	TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTGAGGACAGGGCCATTGTACCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	32	1.0529675587276204E-4		50	TCRBV07	TCRBV07-06	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	1	3	0	2	7	18	31	41	33	48														X+TCRBV07-06+TCRBJ02-05	TCRBV07-06*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTAGTTGGCGGGGTTGCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	36	1.1845885035685729E-4		43	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	1	7	3	7	3	3	18	34	43	37	46														X+TCRBV07-06+TCRBJ01-05	TCRBV07-06*01	TCRBD02-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTCCGGGCGCGGGAGCCAAGAGACCCAGTACTTCGGGCCA	CASSSGRGSQETQYF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	45	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	4	7	2	1	6	0	18	31	-1	37	44														CASSSGRGSQETQYF+TCRBV07-06+TCRBJ02-05	TCRBV07-06*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTCCGAGGGGGCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSSEGAGANVLTF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	45	TCRBV07	TCRBV07-06	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	4	5	1	2	3	0	18	31	-1	34	40														CASSSEGAGANVLTF+TCRBV07-06+TCRBJ02-06	TCRBV07-06*01	TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTCGACTAGTGGGGGGACAGATACGCAGTATTTTGGCCCA	CASSSTSGGTDTQYF	In	VDJ	1	73	2.402082243347384E-4	3.015133491937616E-4	45	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	4	2	8	3	1	7	18	31	38	32	45						01,02								CASSSTSGGTDTQYF+TCRBV07-06+TCRBJ02-03	TCRBV07-06*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTAGAGGCTAGCGGTGAATACGAGCAGTACTTCGGGCCG	CASSLEASGEYEQYF	In	VDJ	2	129	4.2447754711207194E-4	5.328112609040444E-4	45	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	4	5	4	3	4	18	34	44	37	48						01,02								CASSLEASGEYEQYF+TCRBV07-06+TCRBJ02-07	TCRBV07-06*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCTGTGTATCTCTGTGCCAGCAGTCATTCTCAGGAGTTCAGGTGGGACTCCTACGAGCAGTACTTCGGGCCG	CASSHSQEFRWDSYEQYF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	54	TCRBV07	TCRBV07-05	01				TCRBJ02	TCRBJ02-07	01	8	0	8	0	23	0	19	27	-1	50	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSHSQEFRWDSYEQYF+TCRBV07-05+TCRBJ02-07	TCRBV07-05*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCYGTGTATSTCTGTGTCAGAAGCTTTCGGGTCGGTTGTGGCTGTGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	50	1.6452618105119069E-4		52	TCRBV07	TCRBV07-05	02	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	3	8	4	0	1	13	18	32	37	33	50						01,02								X+TCRBV07-05+TCRBJ01-01	TCRBV07-05*02	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGCCACAGATACGCAGTATTTTGGCCCA	CASSVATDTQYF	In	VJ	1	20	6.581047242047627E-5	8.260639703938673E-5	36	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-03	01	0	0	0	2	0	1	23	-1	39	-1	40			01,02										Vb 1	CASSVATDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTGGGGACAGGGATGGTCAATGAGCAGTTCTTCGGGCCA	CASSVGTGMVNEQFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	0	3	6	1	5	23	37	47	38	52			01,02										Vb 1	CASSVGTGMVNEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCTTTACTAGCGGGGGCTTAAGAGACCCAGTACTTCGGGCCA	CASSALLAGA*ETQYF	Stop	VDJ	1	21	6.910099604150008E-5		48	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	3	3	2	3	4	3	23	36	51	40	54			01,02										Vb 1	CASSALLAGA*ETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGAAGCGGGGGCAAGCTCCTACGAGCAGTACTTCGGGCCG	CASSVEAGASSYEQYF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	48	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	6	2	0	1	4	23	39	48	40	52			01,02										Vb 1	CASSVEAGASSYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAACCCCCGAGTGTTCGAAAAACTGTTTTTTGGCAGT	CANPRVFEKLFF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	36	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	9	11	2	8	6	5	23	30	39	36	44			01,02										Vb 1	CANPRVFEKLFF+TCRBV09-01+TCRBJ01-04	TCRBV09-01	TCRBD02-01*02	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGAGGGCGGGGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSVEGGANTGELFF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	48	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	0	7	3	0	3	0	23	39	-1	42	48			01,02										Vb 1	CASSVEGGANTGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD02-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGTCTCTACGGGGCCCAAGAGACCCAGTACTTCGGGCCA	CASSLYGAQETQYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	42	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-05	01	5	7	0	1	7	0	23	34	-1	41	46			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSLYGAQETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGAGGGGGTGGACGGGACCGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	24	7.897256690457152E-5		49	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	5	1	1	0	11	23	-1	42	36	53			01,02										Vb 1	X+TCRBV09-01+TCRBJ01-01	TCRBV09-01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGGGGCTAGCACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	24	7.897256690457152E-5		43	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-07	01	0	7	0	2	0	5	23	-1	44	39	49			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	X+TCRBV09-01+TCRBJ02-07	TCRBV09-01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGTCCGGTAGGAAGAGATACGCAGTATTTTGGCCCA	CASSVGPVGRDTQYF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	45	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-03	01	0	1	8	5	8	2	23	39	50	47	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVGPVGRDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGTACCTAGCGGGGGGTACAATGAGCAGTTCTTCGGGCCA	CASSVVPSGGYNEQFF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	48	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	4	1	4	3	0	23	39	-1	42	53			01,02										Vb 1	CASSVVPSGGYNEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTTGGGACAGGGCGCTTCACAGATACGCAGTATTTTGGCCCA	CASSVGTGRFTDTQYF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	48	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	0	3	2	1	5	23	37	47	38	52			01,02										Vb 1	CASSVGTGRFTDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCCGCGCCCAGGCGGGGAGCTGTTTTTTGGAGAA	CASSPRPGGELFF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	39	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	4	4	7	7	0	23	35	-1	42	46			01,02										Vb 1	CASSPRPGGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCAGGGACAGTGTCCAATTCACCCCTCCACTTTGGGAAC	CASSAGTVSNSPLHF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	3	0	5	7	2	5	23	36	45	38	50			01,02										Vb 1	CASSAGTVSNSPLHF+TCRBV09-01+TCRBJ01-06	TCRBV09-01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGGACTAGTTGGCGGGGAGCTGTTTTTTGGAGAA	CASSGLVGGELFF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	39	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	3	2	8	7	0	4	23	-1	42	36	46			01,02			01,02							Vb 1	CASSGLVGGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTCGGGACAGTGAGCACCGGGGAGCTGTTTTTTGGAGAA	CASSVGTVSTGELFF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	2	0	5	4	1	4	23	37	45	38	49			01,02										Vb 1	CASSVGTVSTGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCATGGGAGGGCTACAAGAGACCCAGTACTTCGGGCCA	CASMGGLQETQYF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	39	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	6	9	0	2	1	3	23	33	41	34	44			01,02										Vb 1	CASMGGLQETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCCTGAGGCAGGGGGCGGCTATGGCTACACCTTCGGTTCG	CASSPEAGGGYGYTF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	4	0	4	7	2	23	35	50	42	52			01,02										Vb 1	CASSPEAGGGYGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCGTAACAGGGGGGGCATCAGCCCCAGCATTTTGGTGAT	CASSA*QGGHQPQHF	Stop	VDJ	1	30	9.87157086307144E-5		45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	3	1	5	4	3	23	36	48	40	51			01,02										Vb 1	CASSA*QGGHQPQHF+TCRBV09-01+TCRBJ01-05	TCRBV09-01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCTCGCACCGGGGAGCTGTTTTTTGGAGAA	CASSARTGELFF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	36	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	3	4	10	4	0	2	23	-1	38	36	40			01,02			01,02							Vb 1	CASSARTGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTCGGGACTACCCAAGAGACCCAGTACTTCGGGCCA	CASSVGTTQETQYF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	42	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	2	0	9	1	1	1	23	37	45	38	46			01,02			01,02							Vb 1	CASSVGTTQETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTGGGGGACACCTACCAAGAGACCCAGTACTTCGGGCCA	CASSVGDTYQETQYF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	0	6	0	2	3	23	37	45	39	48			01,02										Vb 1	CASSVGDTYQETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGGGTTCAAAATGAAAAACTGTTTTTTGGCAGT	CASSVGVQNEKLFF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	42	TCRBV09	TCRBV09-01					TCRBJ01	TCRBJ01-04	01	0	0	9	5	0	5	23	-1	42	39	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVGVQNEKLFF+TCRBV09-01+TCRBJ01-04	TCRBV09-01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGTTCGGGGTTGTCAGGTGGCTACGAGCAGTACTTCGGGCCG	CASSVGSGLSGGYEQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	51	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	8	3	3	3	11	23	39	47	42	58			01,02										Vb 1	CASSVGSGLSGGYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCACCAAAGGACTAGCCGTTACCACAGATACGCAGTATTTTGGCCCA	CASTKGLAVTTDTQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	48	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	1	7	2	5	6	23	33	46	38	52			01,02			01,02							Vb 1	CASTKGLAVTTDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGAAGTTTGAACACTGAAGCTTTCTTTGGACAA	CASSVGSLNTEAFF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	42	TCRBV09	TCRBV09-01					TCRBJ01	TCRBJ01-01	01	0	2	8	0	0	4	23	-1	41	39	45			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVGSLNTEAFF+TCRBV09-01+TCRBJ01-01	TCRBV09-01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCAGGGGACTATCCCCCATAATGAGCAGTTCTTCGGGCCA	CASSQGTIPHNEQFF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	45	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	0	9	7	3	8	23	35	45	38	53			01,02			01,02							Vb 1	CASSQGTIPHNEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTCCAAGGTGGGGCTTATGGCTACACCTTCGGTTCG	CASSVQGGAYGYTF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	7	0	5	7	1	23	37	49	44	50			01,02										Vb 1	CASSVQGGAYGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGTCCTAATTGGGGAATGGAGACCCAGTACTTCGGGCCA	CASSPNWGMETQYF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	42	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-05	01	5	0	8	5	9	3	23	34	47	43	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSPNWGMETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTCAGCGGGCCAAACTACAATGAGCAGTTCTTCGGGCCA	CASSVSGPNYNEQFF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	45	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	6	4	3	1	5	23	37	44	38	49			01,02			01,02							Vb 1	CASSVSGPNYNEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGCGGCCGGGGTACCAGATACGCAGTATTTTGGCCCA	CASSVAAGVPDTQYF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	45	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	8	3	4	4	3	23	39	48	43	51			01,02										Vb 1	CASSVAAGVPDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTCGGACAGAGCTCCTATAATTCACCCCTCCACTTTGGGAAC	CASSVGQSSYNSPLHF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	48	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	2	1	5	0	1	2	23	37	44	38	46			01,02										Vb 1	CASSVGQSSYNSPLHF+TCRBV09-01+TCRBJ01-06	TCRBV09-01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTCGGGACGCTAGGCGGAGAGACCCAGTACTTCGGGCCA	CASSVGTLGGETQYF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	45	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-05	01	2	0	7	4	1	9	23	37	43	38	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVGTLGGETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGAGGGGCCCGGGGACCTTTATGGCTACACCTTCGGTTCG	CASSEGPGDLYGYTF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	45	TCRBV09	TCRBV09-01					TCRBJ01	TCRBJ01-02	01	3	0	7	5	9	3	23	36	50	45	53			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSEGPGDLYGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGGACAGGCGACCTCCCCTACGAGCAGTACTTCGGGCCG	CASSVGTGDLPYEQYF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	48	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	1	4	2	0	8	23	-1	46	39	54			01,02										Vb 1	CASSVGTGDLPYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGGCCCCACCGATGACAGGGGGATCTATGGCTACACCTTCGGTTCG	CASSGPTDDRGIYGYTF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	51	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	2	1	4	11	2	23	36	56	47	58			01,02										Vb 1	CASSGPTDDRGIYGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCAAAAGACTAGCGGGGGCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	46	1.5136408656709542E-4		47	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	3	2	2	2	5	0	23	36	-1	41	53			01,02										Vb 1	X+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCACCGGACAGGGCTCTGGAAACACCATATATTTTGGAGAG	CASTGQGSGNTIYF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	6	1	3	0	2	0	23	33	-1	35	43			01,02										Vb 1	CASTGQGSGNTIYF+TCRBV09-01+TCRBJ01-03	TCRBV09-01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGGGGGCACTCGACTAACACCGGGGAGCTGTTTTTTGGAGAA	CASSVGGHSTNTGELFF	In	VDJ	1	49	1.6123565743016686E-4	2.023856727464975E-4	51	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	0	6	0	2	0	8	23	-1	45	39	53			01,02										Vb 1	CASSVGGHSTNTGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGAGCGGGAGGGCCCCGCTGGAAACACCATATATTTTGGAGAG	CASSEREGPAGNTIYF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	48	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	3	6	0	2	0	5	23	-1	46	36	51			01,02										Vb 1	CASSEREGPAGNTIYF+TCRBV09-01+TCRBJ01-03	TCRBV09-01	TCRBD02-01*02	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCAGAGGACAACAGGGGAGTCAATGAGCAGTTCTTCGGGCCA	CASSAEDNRGVNEQFF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	48	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	3	2	6	9	3	23	36	52	45	55			01,02										Vb 1	CASSAEDNRGVNEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTTTCCGGGACCTCTAACTATGGCTACACCTTCGGTTCG	CASSVSGTSNYGYTF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	45	TCRBV09	TCRBV09-01					TCRBJ01	TCRBJ01-02	01	2	0	7	0	4	2	23	37	46	41	48			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVSGTSNYGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGGCGGGGTTTCCTACGAGCAGTACTTCGGGCCG	CASSGGVSYEQYF	In	VDJ	1	58	1.908503700193812E-4	2.395585514142215E-4	39	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	3	7	3	1	0	2	23	-1	42	36	44			01,02										Vb 1	CASSGGVSYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGAGGGACAGGCCCTTGAAGCTTTCTTTGGACAA	CASSVEGQALEAFF	In	VDJ	1	61	2.0072194088245263E-4	2.5194951097012955E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	0	4	7	1	4	23	39	48	40	52			01,02										Vb 1	CASSVEGQALEAFF+TCRBV09-01+TCRBJ01-01	TCRBV09-01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTCGGGACCTTAAGCTCCTACGAGCAGTACTTCGGGCCG	CASSVGTLSSYEQYF	In	VDJ	1	67	2.204650826085955E-4	2.7673143008194554E-4	45	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-07	01	2	0	7	0	1	6	23	37	43	38	49			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVGTLSSYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCTCTCCCAAGCTACAGGGTTACGCCGGGGAGCTGTTTTTTGGAGAA	CASSPKLQGYAGELFF	In	VDJ	1	74	2.434987479557622E-4	3.056436690457309E-4	48	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	7	3	3	6	11	5	23	32	49	43	54			01,02										Vb 1	CASSPKLQGYAGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCCCGGCCAATGGACTAGCGGGGGGACAATGAGCAGTTCTTCGGGCCA	CASSARPMD*RGDNEQFF	Stop	VDJ	1	75	2.46789271576786E-4		54	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	1	1	5	10	0	23	36	-1	46	60			01,02										Vb 1	CASSARPMD*RGDNEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCAAACCTCGGACAACGCACCTACACCTTCGGTTCG	CASSANLGQRTYTF	In	VDJ	1	80	2.632418896819051E-4	3.3042558815754694E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	1	6	10	8	6	23	36	49	44	55			01,02										Vb 1	CASSANLGQRTYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGSACGGTTAATGAAAAACTGTTTTTTGGCAGT	CASSVGTVNEKLFF	In	VDJ	1	80	2.632418896819051E-4	3.3042558815754694E-4	42	TCRBV09	TCRBV09-01		unresolved			TCRBJ01	TCRBJ01-04	01	0	1	7	4	0	3	23	-1	43	39	46			01,02	TCRBD01,TCRBD02									Vb 1	CASSVGTVNEKLFF+TCRBV09-01+TCRBJ01-04	TCRBV09-01	unresolved	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCCACAGACGGCAGATACGCAGTATTTTGGCCCA	CASSPQTADTQYF	In	VDJ	1	85	2.7969450778702416E-4	3.510771874173936E-4	39	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	3	5	4	2	4	23	35	41	37	45			01,02										Vb 1	CASSPQTADTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCAAAAACCGGGGAGCTGTTTTTTGGAGAA	CASSAKTGELFF	In	VDJ	1	87	2.8627555502907175E-4	3.593378271213323E-4	36	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	4	6	5	0	3	23	-1	38	36	41			01,02										Vb 1	CASSAKTGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTATTCCCCGCTGGAAACACCATATATTTTGGAGAG	CASSVFPAGNTIYF	In	VDJ	1	87	2.8627555502907175E-4	3.593378271213323E-4	42	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	1	8	6	2	5	0	23	38	-1	43	45			01,02			01,02							Vb 1	CASSVFPAGNTIYF+TCRBV09-01+TCRBJ01-03	TCRBV09-01	TCRBD02-01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGCACTTCCCGGGATGGATGGCTACACCTTCGGTTCG	CASSVALPGMDGYTF	In	VDJ	1	88	2.895660786500956E-4	3.634681469733016E-4	45	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	0	8	3	6	7	3	23	39	51	46	54			01,02										Vb 1	CASSVALPGMDGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTTTGGGTTTAGGAGACCCAGTACTTCGGGCCA	CASSVWV*ETQYF	Stop	VDJ	1	94	3.093092203762385E-4		39	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-05	01	2	0	9	5	2	5	23	37	42	39	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVWV*ETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTGGGGACGGGACAATCTGAGACCCAGTACTTCGGGCCA	CASSVGTGQSETQYF	In	VDJ	1	96	3.158902676182861E-4	3.965107057890563E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	0	6	5	6	4	23	37	49	43	53			01,02										Vb 1	CASSVGTGQSETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCCCGGACAGGGGGCAGCTGAAGCTTTCTTTGGACAA	CASSPGQGAAEAFF	In	VDJ	1	98	3.224713148603337E-4	4.04771345492995E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	1	0	6	3	2	23	35	49	38	51			01,02										Vb 1	CASSPGQGAAEAFF+TCRBV09-01+TCRBJ01-01	TCRBV09-01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCCCCACGCGAGCTCCTATAATTCACCCCTCCACTTTGGGAAC	CASSPHASSYNSPLHF	In	VDJ	1	102	3.3563340934442896E-4	4.2129262490087234E-4	48	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	4	7	6	0	6	2	23	35	44	41	46			01,02			01,02							Vb 1	CASSPHASSYNSPLHF+TCRBV09-01+TCRBJ01-06	TCRBV09-01	TCRBD02-01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCCCGGAGGGAACACTGAAGCTTTCTTTGGACAA	CASSPGGNTEAFF	In	VDJ	2	112	3.6853864555466714E-4	4.6259582342056567E-4	39	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	4	10	1	1	3	0	23	35	-1	38	43			01,02										Vb 1	CASSPGGNTEAFF+TCRBV09-01+TCRBJ01-01	TCRBV09-01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCACCGGGACAGGGGCTAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	114	3.7511969279671473E-4		50	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	0	2	2	4	2	23	36	50	40	52			01,02										Vb 1	X+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGGGGGGCTGGCAATCAGCCCCAGCATTTTGGTGAT	CASSVGGAGNQPQHF	In	VDJ	2	114	3.7511969279671473E-4	4.7085646312450437E-4	45	TCRBV09	TCRBV09-01					TCRBJ01	TCRBJ01-05	01	0	6	0	2	1	2	23	39	46	40	48			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVGGAGNQPQHF+TCRBV09-01+TCRBJ01-05	TCRBV09-01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCTGGGGGACAGATAATTCACCCCTCCACTTTGGGAAC	CASSWGTDNSPLHF	In	VDJ	2	117	3.8499126365978617E-4	4.832474226804124E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	0	5	5	3	0	23	35	-1	38	45			01,02										Vb 1	CASSWGTDNSPLHF+TCRBV09-01+TCRBJ01-06	TCRBV09-01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCATCACGAACAGAGCCTACGAGCAGTACTTCGGGCCG	CASSITNRAYEQYF	In	VDJ	2	121	3.9815335814388146E-4	4.997687020882897E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	3	5	2	7	2	23	35	46	42	48			01,02										Vb 1	CASSITNRAYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGCCAGCGACAGTGCCTACGAGCAGTACTTCGGGCCG	CASSVASDSAYEQYF	In	VDJ	2	124	4.0802492900695285E-4	5.121596616441978E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	2	5	2	5	2	23	39	49	44	51			01,02										Vb 1	CASSVASDSAYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCATTGGGACAGTTCATCAGCCCCAGCATTTTGGTGAT	CASSIGTVHQPQHF	In	VDJ	2	130	4.2776807073309573E-4	5.369415807560138E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	0	5	5	3	3	23	35	45	38	48			01,02										Vb 1	CASSIGTVHQPQHF+TCRBV09-01+TCRBJ01-05	TCRBV09-01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGAGGCGGGGACGGTTCTGGGCTACACCTTCGGTTCG	CASSVEAGTVLGYTF	In	VDJ	2	137	4.5080173608026247E-4	5.658538197197992E-4	45	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	0	7	3	8	2	9	23	39	47	41	56			01,02										Vb 1	CASSVEAGTVLGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCTCCGACAGGGACCAATGAAAAACTGTTTTTTGGCAGT	CASSAPTGTNEKLFF	In	VDJ	3	194	6.383615824786199E-4	8.012820512820513E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	2	3	5	4	3	23	36	47	40	50			01,02										Vb 1	CASSAPTGTNEKLFF+TCRBV09-01+TCRBJ01-04	TCRBV09-01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTTGGGACGACAACCTACAATGAGCAGTTCTTCGGGCCA	CASSVGTTTYNEQFF	In	VDJ	3	194	6.383615824786199E-4	8.012820512820513E-4	45	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-01	01	2	0	7	2	1	5	23	37	43	38	48			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVGTTTYNEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCTCGGGACAGTCTTGGGGGAGCAGTACTTCGGGCCG	CASSLGTVLGEQYF	In	VDJ	3	201	6.613952478257865E-4	8.301942902458366E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	5	7	3	8	23	35	45	38	53			01,02										Vb 1	CASSLGTVLGEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGATGGCACAGATACGCAGTATTTTGGCCCA	CASSVDGTDTQYF	In	VJ	3	204	6.712668186888579E-4	8.425852498017447E-4	39	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-03	01	0	0	0	1	0	3	23	-1	39	-1	42			01,02										Vb 1	CASSVDGTDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCAGGGACAGTCCAAGAGACCCAGTACTTCGGGCCA	CASSAGTVQETQYF	In	VDJ	3	206	6.778478659309056E-4	8.508458895056833E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	0	5	1	2	1	23	36	45	38	46			01,02										Vb 1	CASSAGTVQETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGATCCCTGGCGTACAATGAGCAGTTCTTCGGGCCA	CASSVGSLAYNEQFF	In	VDJ	3	221	7.272057202462628E-4	9.128006872852234E-4	45	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-01	01	0	9	0	4	7	1	23	39	49	46	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVGSLAYNEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCCGGGGACGGTTTTTCAAGAGACCCAGTACTTCGGGCCA	CASSPGTVFQETQYF	In	VDJ	3	230	7.568204328354772E-4	9.499735659529474E-4	45	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-05	01	4	0	7	2	3	7	23	35	43	38	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSPGTVFQETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGCACTAACCACAGATACGCAGTATTTTGGCCCA	CASSVALTTDTQYF	In	VDJ	3	233	7.666920036985485E-4	9.623645255088555E-4	42	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	3	9	2	1	2	23	39	44	40	46			01,02			01,02							Vb 1	CASSVALTTDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCGGACAGGGCTTGGACTGAAGCTTTCTTTGGACAA	CASSADRAWTEAFF	In	VDJ	4	280	9.213466138866678E-4	0.0011564895585514142	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	1	3	5	1	5	23	36	45	37	50			01,02										Vb 1	CASSADRAWTEAFF+TCRBV09-01+TCRBJ01-01	TCRBV09-01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGCAGAGGGATCACGCAGTATTTTGGCCCA		Out	VDJ	5	351	0.0011549737909793585		38	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	0	11	0	9	2	3	23	39	46	41	49			01,02										Vb 1	X+TCRBV09-01+TCRBJ02-03	TCRBV09-01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCTCTCGGGACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	6	401	0.0013194999720305492		38	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	8	4	5	4	0	23	36	-1	40	44			01,02			01,02							Vb 1	X+TCRBV09-01+TCRBJ02-01	TCRBV09-01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTATTTAGGGGGGATGAGCAGTTCTTCGGGCCA	CASSVFRGDEQFF	In	VDJ	8	574	0.001888760558467669	0.002370803595030399	39	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-01	01	1	5	1	8	3	1	23	38	47	41	48			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVFRGDEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGGACCCTCCAACAAGAGACCCAGTACTTCGGGCCA	CASSVGTLQQETQYF	In	VDJ	10	731	0.002405372766968408	0.003019263811789585	45	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-05	01	0	1	7	2	0	7	23	-1	43	39	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVGTLQQETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGGACAGTCGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSVGTVGTGELFF	In	VDJ	11	759	0.0024975074283570746	0.0031349127676447265	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	0	1	5	4	0	4	23	-1	45	39	49			01,02										Vb 1	CASSVGTVGTGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCATGTATCTCTGTGCCAGCAGCTTAGGGGCGGGCGGGCAGCCCCAGCATTTTGGTGAT	CASSLGAGGQPQHF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	42	TCRBV11	TCRBV11-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	1	7	4	7	2	4	19	35	42	37	46						01,02								CASSLGAGGQPQHF+TCRBV11-01+TCRBJ01-05	TCRBV11-01*01	TCRBD02-01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCATGTATCTCTGTGCCAGCAGCTGGGAGCGGGCAGGGGGGTTCACTGAAGCTTTCTTTGGACAA	CASSWERAGGFTEAFF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	48	TCRBV11	TCRBV11-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	4	1	4	9	3	19	32	48	41	51														CASSWERAGGFTEAFF+TCRBV11-01+TCRBJ01-01	TCRBV11-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCATGTATCTCTGTGCCAGCAGTTCAGGGTTGGTCGGCACTGAAACTTTCTTTGGACAA	CASSSGLVGTETFF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	42	TCRBV11	TCRBV11-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	4	3	12	2	16	19	30	37	32	53														CASSSGLVGTETFF+TCRBV11-01+TCRBJ01-01	TCRBV11-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGATCCAGGGGGCACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	20	6.581047242047627E-5		44	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	0	3	2	0	29	46	-1	48	56													Vb 16	X+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCCACGTTTGGTGGCAGAACTGGAGGATTCTGGAGTTATTTCTGTGCCAGCAGCCTCCAGGGGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	20	6.581047242047627E-5		38	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	23	4	3	1	20	0	43	37	-1	57	62													Vb 16	X+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGTAACCAAATCCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	24	7.897256690457152E-5		37	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-02	01	6	3	7	6	2	5	29	40	44	42	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	X+TCRBV14-01+TCRBJ02-02	TCRBV14-01*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGCGTTAAGTTGGGAGGGCCACACTGAAGCTTTCTTTGGACAA	CASSQALSWEGHTEAFF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	51	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	1	9	0	3	9	2	29	45	61	54	63													Vb 16	CASSQALSWEGHTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ACGTTTGGTGGCAGAACTGGAGGATTCGGAGTTTATTTCTGTGCCAGCAGCCGGTACTCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSRYSTNEKLFF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	42	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	4	3	10	0	3	0	39	52	-1	55	58						01,02							Vb 16	CASSRYSTNEKLFF+TCRBV14-01+TCRBJ01-04	TCRBV14-01*01	TCRBD02-01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGCCCCGCCCAGGACGGGGGATACGCAGTATTTTGGCCCA	CASSQAPPRTGDTQYF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	48	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	8	3	6	12	0	29	45	-1	57	62													Vb 16	CASSQAPPRTGDTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCGGCTGGACAGGTGGAGGGGAGTACGAGCAGTACTTCGGGCCG	CASSGWTGGGEYEQYF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	48	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	4	4	4	10	29	41	52	45	62													Vb 16	CASSGWTGGGEYEQYF+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ACGTTTGGTGGCAGAACTGGAGGATCTGGAGTTTATTTCTGTGCCAGCAGCCGGTACTCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSRYSTNEKLFF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	42	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	4	3	10	0	3	0	39	52	-1	55	58						01,02							Vb 16	CASSRYSTNEKLFF+TCRBV14-01+TCRBJ01-04	TCRBV14-01*01	TCRBD02-01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ACGTTTGGTGGCAGAACTGGAGGATTCTGAGTTTATTTCTGTGCCAGCAGCCGGTACTCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSRYSTNEKLFF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	42	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	4	3	10	0	3	0	39	52	-1	55	58						01,02							Vb 16	CASSRYSTNEKLFF+TCRBV14-01+TCRBJ01-04	TCRBV14-01*01	TCRBD02-01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ACGTTTGGTGGCAGAACGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGGTACTCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSRYSTNEKLFF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	42	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	4	3	10	0	3	0	39	52	-1	55	58						01,02							Vb 16	CASSRYSTNEKLFF+TCRBV14-01+TCRBJ01-04	TCRBV14-01*01	TCRBD02-01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCTCACTCGGGGGGGGACCTATGGCTACACCTTCGGTTCG	CASSLTRGGTYGYTF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	45	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	4	8	0	4	5	3	29	42	55	47	58													Vb 16	CASSLTRGGTYGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAGGTCGGGGGTCCAGATACGCAGTATTTTGGCCCA	CASSQVGGPDTQYF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	42	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	3	8	2	4	3	2	29	43	52	46	54													Vb 16	CASSQVGGPDTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCAGGGAGCTTGGGCTACACCTTCGGTTCG	CASSPGSLGYTF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	36	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-02	01	4	4	3	8	0	6	29	-1	47	42	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSPGSLGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCTCGTAGACAGGATTGAAGCTTTCTTTGGACAA	CASSLVDRIEAFF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	39	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	2	4	7	5	2	29	42	53	47	55													Vb 16	CASSLVDRIEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCGATCCTACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	41	1.3491146846197636E-4		37	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-02	01	4	2	8	3	1	4	29	42	45	43	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	X+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGGTACTCAACTAATGAAAAACTGTTTTTGGCAGT		Out	VDJ	1	41	1.3491146846197636E-4		41	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	4	3	9	18	8	11	29	42	54	50	65						01,02							Vb 16	X+TCRBV14-01+TCRBJ01-04	TCRBV14-01*01	TCRBD02-01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGTGGGGGCCGCAGATACGCAGTATTTTGGCCCA	CASSQVGAADTQYF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	42	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	1	6	0	4	1	2	29	45	52	46	54													Vb 16	CASSQVGAADTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCTTTCAGGGGAGGGGGCACTGAAGCTTTCTTTGGACAA	CASSPFRGGGTEAFF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	45	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	4	9	0	4	7	2	29	42	56	49	58													Vb 16	CASSPFRGGGTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCGGGGAGTATTGGCTACACCTTCGGTTCG	CASSPGSIGYTF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	36	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	4	8	3	7	0	5	29	-1	47	42	52						01,02							Vb 16	CASSPGSIGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGGGCGGGCCCCATCGGATACGCAGTATTTTGGCCCA	CASSQGRAPSDTQYF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	45	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	7	4	6	1	8	29	45	51	46	59						01,02							Vb 16	CASSQGRAPSDTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCTCGGTGGACAGGGAGTCAACTATGGCTACACCTTCGGTTCG	CASSLGGQGVNYGYTF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	48	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	1	3	2	5	4	29	42	55	47	59													Vb 16	CASSLGGQGVNYGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGCCGGGATAGATACGCAGTATTTTGGCCCA	CASSQAGIDTQYF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	39	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	1	8	3	5	1	1	29	45	51	46	52													Vb 16	CASSQAGIDTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ACGTTTGGTGGCAGAACTGRRGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGGTACTCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSRYSTNEKLFF	In	VDJ	1	52	1.711072282932383E-4	2.147766323024055E-4	42	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	4	3	10	0	3	0	39	52	-1	55	58						01,02							Vb 16	CASSRYSTNEKLFF+TCRBV14-01+TCRBJ01-04	TCRBV14-01*01	TCRBD02-01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCCGGCCAGGGGGAATTTGGGGCTACACCTTCGGTTCG	CASRPGGIWGYTF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	39	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	8	4	1	8	4	7	29	38	49	42	56													Vb 16	CASRPGGIWGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGGCCGACAGGGAAGGACGAGCAGTACTTCGGGCCG	CASRPTGKDEQYF	In	VDJ	1	59	1.94140893640405E-4	2.4368887126619086E-4	39	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	3	5	3	4	29	40	50	43	54													Vb 16	CASRPTGKDEQYF+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCATGATCCAGGGCGCACCGAGCAGTACTTCGGGCCG	CASSHDPGRTEQYF	In	VDJ	1	60	1.974314172614288E-4	2.478191911181602E-4	42	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	4	3	6	5	5	29	43	53	48	58													Vb 16	CASSHDPGRTEQYF+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGTCGGAGGGGGTGAAGCTTTCTTTGGACAA	CASSQVGGGEAFF	In	VDJ	1	62	2.0401246450347642E-4	2.560798308220989E-4	39	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-01	01	1	5	1	7	4	0	29	45	-1	49	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSQVGGGEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAAGATCAGGGAACACTGAAGCTTTCTTTGGACAA	CASSQRSGNTEAFF	In	VDJ	1	63	2.0730298812450025E-4	2.602101506740682E-4	42	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	4	4	1	4	0	29	44	-1	48	52													Vb 16	CASSQRSGNTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGATGCGAGACTAGCGTACTCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	64	2.1059351174552407E-4		50	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	2	6	3	5	4	29	46	59	51	63						01,02							Vb 16	X+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCATCTCAAGGCCGGGACTAGCGGGGGAGAGACCCAGTACTTCGGGCCA	CASSHLKAGTSGGETQYF	In	VDJ	1	64	2.1059351174552407E-4	2.643404705260375E-4	54	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	3	0	2	4	10	0	27	41	-1	51	65													Vb 16	CASSHLKAGTSGGETQYF+TCRBV14-01+TCRBJ02-05	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCACCCGGGAGAGTTTATTGGGGAGAAATGAGCAGTTCTTCGGGCCA	CASTRESLLGRNEQFF	In	VDJ	1	65	2.1388403536654787E-4	2.684707903780069E-4	48	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	8	2	7	2	15	29	39	47	41	62													Vb 16	CASTRESLLGRNEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCATCGATACTCGGGACAGGGGGCGAGCAGGGGCTACACCTTCGGTTCG	CASSHRYSGQGASRGYTF	In	VDJ	1	66	2.171745589875717E-4	2.726011102299762E-4	54	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	0	0	8	9	7	27	41	62	50	69													Vb 16	CASSHRYSGQGASRGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAGTTTACAGGGTTCAACTATGGCTACACCTTCGGTTCG	CASSQFTGFNYGYTF	In	VDJ	1	76	2.5007979519780984E-4	3.139043087496696E-4	45	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	3	3	2	4	3	29	43	53	47	56													Vb 16	CASSQFTGFNYGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCTACCGGGACTAGCGGCCTGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	88	2.895660786500956E-4		50	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	0	5	1	4	3	29	41	56	45	59						01,02							Vb 16	X+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGGCCCCAGGGGTGGCTACACCTTCGGTTCG	CASSQGPRGGYTF	In	VDJ	1	89	2.928566022711194E-4	3.6759846682527094E-4	39	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	4	2	7	4	0	29	45	-1	49	55													Vb 16	CASSQGPRGGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGGAAGGAATTCACCCCTCCACTTTGGGAAC	CASSQGRNSPLHF	In	VDJ	1	90	2.961471258921432E-4	3.7172878667724027E-4	39	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-06	01	1	5	4	7	2	0	29	45	-1	47	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSQGRNSPLHF+TCRBV14-01+TCRBJ01-06	TCRBV14-01*01		TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAAGTCTCAGGCAGAGGTTAGTAACACCATATATTTTGGAGAG		Out	VDJ	1	97	3.1918079123930993E-4		50	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-03	01	2	4	4	7	5	11	29	44	53	49	64				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	X+TCRBV14-01+TCRBJ01-03	TCRBV14-01*01		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCTGTCAGGGCCAGAGGGTAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	100	3.2905236210238137E-4		49	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-06	01	4	4	3	6	4	8	29	42	51	46	59				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	X+TCRBV14-01+TCRBJ01-06	TCRBV14-01*01		TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGGCTAGCGGGGGCTCTGGGGATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	103	3.389239329654528E-4		47	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	4	2	8	2	8	29	42	54	44	62													Vb 16	X+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAGAGGGCCTCCTACGAGCAGTACTTCGGGCCG	CASSQRASYEQYF	In	VDJ	1	104	3.422144565864766E-4	4.29553264604811E-4	39	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	11	0	0	0	1	29	-1	48	43	49													Vb 16	CASSQRASYEQYF+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGATGCCAGGGGGCTAGGAGACCCAGTACTTCGGGCCA		Out	VDJ	2	108	3.5537655107057185E-4		46	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	4	0	5	3	3	29	46	57	49	60													Vb 16	X+TCRBV14-01+TCRBJ02-05	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAACCGCAAAAATAAGGGGCACTGAAGCTTTCTTTGGACAA	CASSQTAKIRGTEAFF	In	VDJ	2	114	3.7511969279671473E-4	4.7085646312450437E-4	48	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	5	2	4	12	0	29	44	-1	56	61													Vb 16	CASSQTAKIRGTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCTTTGGTGGGGGGGGCTTTCTTTGGACAA	CASSPLVGGAFF	In	VDJ	2	125	4.113154526279767E-4	5.162899814961671E-4	36	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	4	9	0	11	7	0	29	42	-1	49	56													Vb 16	CASSPLVGGAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGAAGGGACCTACCGCAATGAGCAGTTCTTCGGGCCA	CASSQEGTYRNEQFF	In	VDJ	2	134	4.40930165217191E-4	5.534628601638911E-4	45	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-01	01	0	0	7	6	1	6	29	46	52	47	58				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSQEGTYRNEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGTATACAATGAGCAGTTCTTCGGGCCA	CASSQVYNEQFF	In	VDJ	2	155	5.100311612586911E-4	6.401995770552472E-4	36	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	5	9	4	0	0	29	-1	-1	45	47						01,02							Vb 16	CASSQVYNEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCTTCGAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	2	175	5.758416336791674E-4		38	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	4	8	6	0	2	0	29	42	-1	44	46						01,02							Vb 16	X+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGTTTCCGGTGACAGGCTATTTAGGACACTGAAGCTTTCTTTGGACAA		Out	VDJ	3	195	6.416521060996437E-4		56	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	2	4	3	8	9	25	41	55	49	64													Vb 16	X+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGAAAGACAGGGTGGTTGAAAAACTGTTTTTTGGCAGT		Out	VDJ	3	195	6.416521060996437E-4		46	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	2	3	7	2	4	29	46	55	48	59													Vb 16	X+TCRBV14-01+TCRBJ01-04	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGCGGCGGCCTACGAGCAGTACTTCGGGCCG	CASSQAAAYEQYF	In	VDJ	3	202	6.646857714468103E-4	8.343246100978059E-4	39	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	7	5	2	2	0	29	45	-1	47	51						01,02							Vb 16	CASSQAAAYEQYF+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCACCTACGACTAGCGGCCCTTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	3	205	6.745573423098817E-4		50	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	3	2	5	1	5	4	29	43	57	48	61						01,02							Vb 16	X+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGAACCTGGGAAAGCTTTCTTTGGACAA	CASSQEPGKAFF	In	VDJ	3	218	7.173341493831914E-4	9.004097277293154E-4	36	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-01	01	0	0	8	9	4	0	29	46	-1	50	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSQEPGKAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGAGAGGACTAGCGGGGTTTACAATGAGCAGTTCTTCGGGCCA	CASSQERTSGVYNEQFF	In	VDJ	3	218	7.173341493831914E-4	9.004097277293154E-4	51	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	1	3	4	2	2	29	46	60	48	62													Vb 16	CASSQERTSGVYNEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGATTGGTCGAGCAGTACTTCGGGCCG		Out	VDJ	3	224	7.370772911093343E-4		35	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-07	01	0	0	10	6	2	1	29	46	50	48	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	X+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGTAACCGGACTAGCGGGAGACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	3	225	7.403678147303581E-4		49	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	1	2	5	6	0	29	42	-1	48	61													Vb 16	X+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCTGATGGGCTTGGGGGTCGAAGCTTTCTTTGGACAA	CASSLMGLGVEAFF	In	VDJ	3	236	7.7656357456162E-4	9.747554850647634E-4	42	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-01	01	4	6	1	8	10	2	29	42	57	52	59				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSLMGLGVEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ACGTTTGGTGGCAGAACTGGAGGATTCTGGAGTTWWTTCTGTGCCAGCAGCCGGTACTCAACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	4	263	8.65407712329263E-4		41	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-04	01	23	4	5	0	10	11	40	34	47	44	58				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	X+TCRBV14-01+TCRBJ01-04	TCRBV14-01*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAGGAAACTAGTGTTCCCACAGATACGCAGTATTTTGGCCCA	CASSQETSVPTDTQYF	In	VDJ	4	265	8.719887595713106E-4	0.0010945347607718742	48	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	3	8	2	4	6	29	43	52	47	58						01,02							Vb 16	CASSQETSVPTDTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCGTTCCGGGAGCAAATGAGCAGTTCTTCGGGCCA	CASSVPGANEQFF	In	VDJ	4	292	9.608328973389536E-4	0.0012060533967750463	39	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	8	2	7	4	2	29	41	51	45	53													Vb 16	CASSVPGANEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGTGGGACGGAATGAGCAGTTCTTCGGGCCA	CASSQVGRNEQFF	In	VDJ	5	332	0.001092453842179906	0.0013712661908538196	39	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-01	01	1	0	7	7	1	2	29	45	51	46	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSQVGRNEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAACAGGGGGCTGGCGGGGAGCTGTTTTTTGGAGAA	CASSQQGAGGELFF	In	VDJ	5	336	0.0011056159366640012	0.0013877874702616971	42	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	2	4	0	7	0	3	29	-1	52	44	55													Vb 16	CASSQQGAGGELFF+TCRBV14-01+TCRBJ02-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGATAAGTGGGACTAGCGGGAGTGAGCAGTTCTTCGGGCCA		Out	VDJ	5	394	0.0012964663066833825		49	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	0	2	9	5	0	29	46	-1	51	65													Vb 16	X+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAGGCTCATCGGGCCGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	6	399	0.0013129189247885016		46	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-01	01	3	8	0	1	8	1	29	43	55	51	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	X+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGGGACCCGAACACTGAAGCTTTCTTTGGACAA	CASSRDPNTEAFF	In	VDJ	8	567	0.0018657268931205023	0.0023418913560666137	39	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-01	01	4	0	7	1	0	2	29	-1	47	42	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSRDPNTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCCGCGAGGGACCCAGTACTTCGGGCCA		Out	VDJ	9	670	0.002204650826085955		34	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	4	11	1	7	4	0	29	42	-1	46	50													Vb 16	X+TCRBV14-01+TCRBJ02-05	TCRBV14-01*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCTCCAGGGGAACACTGAAGCTTTCTTTGGACAA	CASSLQGNTEAFF	In	VDJ	30	2185	0.007189794111937033	0.009024748876553	39	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	4	3	1	2	0	29	42	-1	44	49													Vb 16	CASSLQGNTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGGTACTCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSRYSTNEKLFF	In	VDJ	255	18365	0.060430466300102334	0.07585332408141686	42	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	4	3	10	0	3	0	29	42	-1	45	48						01,02							Vb 16	CASSRYSTNEKLFF+TCRBV14-01+TCRBJ01-04	TCRBV14-01*01	TCRBD02-01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGTAGACGGCAGCAATCAGCCCCAGCATTTTGGTGAT	CASSVDGSNQPQHF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	42	TCRBV21	TCRBV21-or09_02	01				TCRBJ01	TCRBJ01-05	01	5	2	7	1	3	3	24	36	42	39	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSVDGSNQPQHF+TCRBV21-or09_02+TCRBJ01-05	TCRBV21-or09_02*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCAAAGAGGGGGCGGTCTCTCCTTGCTACGAGCAGTACTTCGGGCCG	CASSKEGAVSPCYEQYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	51	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	5	0	3	0	12	24	-1	47	40	59														CASSKEGAVSPCYEQYF+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGTGGGGGACAGGGGAACCGGGGAGCTGTTTTTTGGAGAA	CASSVGDRGTGELFF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	45	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	0	2	5	4	1	24	36	50	40	51														CASSVGDRGTGELFF+TCRBV21-or09_02+TCRBJ02-02	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGTAGATGGTCTAGACGAGCAGTACTTCGGGCCG	CASSVDGLDEQYF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	39	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	4	8	5	9	0	24	36	-1	45	49						01,02								CASSVDGLDEQYF+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTTGGGCTTCAGTTTACAATGAGCAGTTCTTCGGGCCA	CASSWASVYNEQFF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	42	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	8	0	4	2	7	24	35	41	37	48														CASSWASVYNEQFF+TCRBV21-or09_02+TCRBJ02-01	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCTTTGCGCGGTCTAGCGAGTTCTTCGGGCCA	CASSFARSSEFF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	36	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	4	6	14	10	0	24	36	-1	46	52						01,02								CASSFARSSEFF+TCRBV21-or09_02+TCRBJ02-01	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCTTGCGGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSLRSSYNEQFF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	42	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	7	5	0	2	2	24	36	42	38	44						01,02								CASSLRSSYNEQFF+TCRBV21-or09_02+TCRBJ02-01	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCCCCAGGACATTTCCTAACTATGGCTACACCTTCGGTTCG	CASSPRTFPNYGYTF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	45	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	1	6	0	4	4	24	36	45	40	49														CASSPRTFPNYGYTF+TCRBV21-or09_02+TCRBJ01-02	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCTTACGGTCGTCCTACAATGAGCAGTTCTTCGGGCCA	CASSLRSSYNEQFF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	42	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	8	5	1	3	3	24	36	42	39	45						01,02								CASSLRSSYNEQFF+TCRBV21-or09_02+TCRBJ02-01	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGTAAATAGCTACACCGGGGAGCTGTTTTTTGGAGAA	CASSVNSYTGELFF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	42	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	5	5	7	3	5	1	24	36	45	41	46						01,02								CASSVNSYTGELFF+TCRBV21-or09_02+TCRBJ02-02	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCTTAGGCCTCGGGGCGTCGGGCACTGAAGCTTTCTTTGGACAA	CASSLGLGASGTEAFF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	48	TCRBV21	TCRBV21-or09_02	01				TCRBJ01	TCRBJ01-01	01	5	7	0	4	9	6	24	36	50	45	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGLGASGTEAFF+TCRBV21-or09_02+TCRBJ01-01	TCRBV21-or09_02*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGAGGGGGGGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	2	154	5.067406376376673E-4		35	TCRBV21	TCRBV21-or09_02	01				TCRBJ01	TCRBJ01-05	01	10	5	1	2	1	1	24	31	38	32	39				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV21-or09_02+TCRBJ01-05	TCRBV21-or09_02*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCGACGATCGGAGAGGTGGGGCCAACGTCCTGACTTTCGGGGCC	CASDDRRGGANVLTF	In	VDJ	3	182	5.988752990263341E-4	7.517182130584193E-4	45	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	10	10	2	3	9	3	24	31	44	40	47														CASDDRRGGANVLTF+TCRBV21-or09_02+TCRBJ02-06	TCRBV21-or09_02*01	TCRBD02-01*02	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCCCTAGGACGGATCTACCGTACCAAGAGACCCAGTACTTCGGGCCA	CASSPRTDLPYQETQYF	In	VDJ	4	254	8.357929997400486E-4	0.0010491012424002114	51	TCRBV21	TCRBV21-or09_02	01				TCRBJ02	TCRBJ02-05	01	5	1	7	0	4	11	24	36	44	40	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPRTDLPYQETQYF+TCRBV21-or09_02+TCRBJ02-05	TCRBV21-or09_02*01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCGCGCCAATGACAGTTAAAGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	9	678	0.0022309750150541455		43	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	11	2	5	1	8	5	24	30	43	38	48														X+TCRBV21-or09_02+TCRBJ01-01	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTGAAGACGTCCGCTCCTACGAGCAGTACTTCGGGCCG	CASSEDVRSYEQYF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	42	TCRBV06	TCRBV06-01	01				TCRBJ02	TCRBJ02-07	01	1	3	7	0	0	5	23	-1	41	39	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEDVRSYEQYF+TCRBV06-01+TCRBJ02-07	TCRBV06-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTGAAGGAGCGGCAACCTACTATGGCTACACCTTCGGTTCG	CASSEGAATYYGYTF	In	VDJ	1	56	1.8426932277733357E-4	2.3129791171028284E-4	45	TCRBV06	TCRBV06-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	1	6	5	3	1	6	23	39	45	40	51						01,02								CASSEGAATYYGYTF+TCRBV06-01+TCRBJ01-02	TCRBV06-01*01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAGCTACCCCGCCGCTATCCTACGAGCAGTACTTCGGGCCG	CASSEATPPLSYEQYF	In	VDJ	1	81	2.6653241330292887E-4	3.3455590800951626E-4	48	TCRBV06	TCRBV06-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	4	9	1	10	0	23	40	-1	50	53						01,02								CASSEATPPLSYEQYF+TCRBV06-01+TCRBJ02-07	TCRBV06-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAATGAAGCCTAGCGATRAGACCCAGTACTTCGGGCCA		Out	VDJ	2	144	4.7383540142742915E-4		40	TCRBV06	TCRBV06-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	0	4	6	6	0	3	23	-1	46	40	49						01,02								X+TCRBV06-01+TCRBJ02-05	TCRBV06-01*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAGCCCGGGACAGTTACTACGAGCAGTACTTCGGGCCG	CASSEARDSYYEQYF	In	VDJ	2	161	5.297743029848339E-4	6.649814961670632E-4	45	TCRBV06	TCRBV06-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	0	5	3	2	3	23	40	49	42	52														CASSEARDSYYEQYF+TCRBV06-01+TCRBJ02-07	TCRBV06-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTCAGCTGTGTATCTCTGTGCCAGCAGCTTGAAAGGGGGCTTGAATGAGCAGTTCTTCGGGCCA	CASSLKGGLNEQFF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	42	TCRBV07	TCRBV07-04	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	5	0	7	3	3	22	36	46	39	49														CASSLKGGLNEQFF+TCRBV07-04+TCRBJ02-01	TCRBV07-04*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTCAGCTGTGTATCTCTGTGCCAGCAGCCTCAGTGGGCAGGGAGATACGCAGTATTTTGGCCCA	CASSLSGQGDTQYF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV07	TCRBV07-04	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	4	3	5	9	0	22	34	-1	43	48														CASSLSGQGDTQYF+TCRBV07-04+TCRBJ02-03	TCRBV07-04*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTCAGCTGTGTATCTCTGTGCCAGCAGCTTAGATCGCGGCGGTGAAGCTTTCTTTGGACAA	CASSLDRGGEAFF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	39	TCRBV07	TCRBV07-04	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	1	7	5	7	3	3	22	38	45	41	48						01,02								CASSLDRGGEAFF+TCRBV07-04+TCRBJ01-01	TCRBV07-04*01	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTCAGCTGTGTATCTCTGTGCCAGCAGCTCGGACTAGCGGGGCCTCTACGAGCAGTACTTCGGGCCG	CASSSD*RGLYEQYF	Stop	VDJ	1	58	1.908503700193812E-4		45	TCRBV07	TCRBV07-04	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	4	1	3	3	1	3	22	35	48	36	51														CASSSD*RGLYEQYF+TCRBV07-04+TCRBJ02-07	TCRBV07-04*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTCAGCTGTGTATCTCTGTGCCAGCAGCTTAGATCCTGCGGAGATACGAGCAGTACTTCGGGCCG		Out	VDJ	1	88	2.895660786500956E-4		43	TCRBV07	TCRBV07-04	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	7	5	4	5	3	22	38	47	43	50						01,02								X+TCRBV07-04+TCRBJ02-07	TCRBV07-04*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTAAGGTCGCGGGGAAGCAGTTCTTCGGGCCA	CAWSKVAGKQFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	36	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	7	3	11	6	1	26	38	50	44	51													Vb 20	CAWSKVAGKQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGCCGGGGGGGGCTAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	20	6.581047242047627E-5		41	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-04	01	1	8	0	6	1	3	26	39	48	40	51													Vb 20	X+TCRBV30-01+TCRBJ02-04	TCRBV30-01*01	TCRBD02-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTAGGTCTAGGGGCAGTCGTGCCCAAGGCGGGCTACACCTTCGGTTCG	CAWSVGLGAVVPKAGYTF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	54	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	5	2	8	6	17	26	40	51	46	68			unresolved										Vb 20	CAWSVGLGAVVPKAGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGTCGTACTATAATTCACCCCTCCACTTTGGGAAC	CAWSYYNSPLHF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	36	TCRBV30	TCRBV30-01	02	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	5	5	9	3	3	0	26	35	-1	38	40						01,02							Vb 20	CAWSYYNSPLHF+TCRBV30-01+TCRBJ01-06	TCRBV30-01*02	TCRBD02-01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTAGTAGGAACTGGCTACACCTTCGGTTCG	CAWSVVGTGYTF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	36	TCRBV30	TCRBV30-01	02				TCRBJ01	TCRBJ01-02	01	0	1	8	7	4	2	26	40	47	44	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSVVGTGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*02		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGTTGGGACAGGGCGTCTATGGCTACACCTTCGGTTCG	CAWLGQGVYGYTF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	39	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	3	4	2	3	26	35	46	37	49													Vb 20	CAWLGQGVYGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTACAGGGGGGGAACACTGAAGCTTTCTTTGGACAA	CAWSVQGGNTEAFF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	42	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	3	1	1	0	1	26	-1	48	40	49													Vb 20	CAWSVQGGNTEAFF+TCRBV30-01+TCRBJ01-01	TCRBV30-01*02	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTGGGCGGAAACGAGCAGTACTTCGGGCCG	CAWSVGGNEQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	36	TCRBV30	TCRBV30-01	01				TCRBJ02	TCRBJ02-07	01	0	8	0	5	0	4	26	-1	44	40	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSVGGNEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTGGGCGGGAAGGTATACGAGCAGTACTTCGGGCCG	CAWSVGGKVYEQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	42	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	7	3	4	2	5	26	40	48	42	53			unresolved										Vb 20	CAWSVGGKVYEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGACTCGGACAGGGGGCCGAAGGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	35	1.1516832673583348E-4		49	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	1	0	1	3	5	26	36	50	39	55													Vb 20	X+TCRBV30-01+TCRBJ02-03	TCRBV30-01*02	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTCGGACAGGGAAGGGAGACGAGCAGTACTTCGGGCCG	CAWSRTGKGDEQYF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	42	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	1	3	5	1	7	26	38	47	39	54			unresolved										Vb 20	CAWSRTGKGDEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTTTCCCTGGGGGACTGGCGGAACTATGGCTACACCTTCGGTTCG	CAWSVSLGDWRNYGYTF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	51	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	0	0	10	2	8	5	26	40	54	48	59			unresolved			01,02							Vb 20	CAWSVSLGDWRNYGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGATATCTCGCCGACTAGCGGGAGAAAATGAGCAGTTCTTCGGGCCA	CAWISRRLAGENEQFF	In	VDJ	1	49	1.6123565743016686E-4	2.023856727464975E-4	48	TCRBV30	TCRBV30-01	02	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	2	2	7	9	2	26	36	57	45	59													Vb 20	CAWISRRLAGENEQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*02	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTCCGAATATCTTGGTGCAGGGTGAAGCTTTCTTTGGACAA	CAWSPNILVQGEAFF	In	VDJ	1	54	1.7768827553528592E-4	2.2303727200634416E-4	45	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	4	3	7	15	0	26	38	-1	53	58													Vb 20	CAWSPNILVQGEAFF+TCRBV30-01+TCRBJ01-01	TCRBV30-01*02	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGGACACGGTGGGACCATATATTTTGGAGAG	CAWGHGGTIYF	In	VDJ	1	60	1.974314172614288E-4	2.478191911181602E-4	33	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	1	6	10	0	7	26	-1	40	35	47													Vb 20	CAWGHGGTIYF+TCRBV30-01+TCRBJ01-03	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTCGCCCCACCTAGCGGGAGATTACGGAATGAACAGTTCTTCGGGCCA	CAWSVAPPSGRLRNEQFF	In	VDJ	1	64	2.1059351174552407E-4	2.643404705260375E-4	54	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	4	2	13	8	13	26	40	58	48	71			unresolved										Vb 20	CAWSVAPPSGRLRNEQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGACGGTCGGGGCTGGGAACACTGAAGCTTTCTTTGGACAA	CAWTVGAGNTEAFF	In	VDJ	1	67	2.204650826085955E-4	2.7673143008194554E-4	42	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-01	01	4	7	0	1	5	3	26	36	46	41	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWTVGAGNTEAFF+TCRBV30-01+TCRBJ01-01	TCRBV30-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTCGACCGGGACAGGATCTCCTAGGGAGCAGTACTTCGGGCCG	CASTGTGSPREQYF	In	VDJ	1	68	2.237556062296193E-4	2.8086174993391486E-4	42	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	0	4	7	5	10	26	33	46	38	56			unresolved										Vb 20	CASTGTGSPREQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGTTCGGGACAGGGGGATCTGGCTACACCTTCGGTTCG	CAWFGTGGSGYTF	In	VDJ	1	72	2.3691770071371457E-4	2.973830293417922E-4	39	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	1	7	3	3	26	35	49	38	52													Vb 20	CAWFGTGGSGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTACTGGACAGTTCACCCCTCCACTTTGGGAAC	CAWSVLDSSPLHF	In	VDJ	1	76	2.5007979519780984E-4	3.139043087496696E-4	39	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	0	1	5	9	3	0	26	40	-1	43	49			unresolved										Vb 20	CAWSVLDSSPLHF+TCRBV30-01+TCRBJ01-06	TCRBV30-01*02	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTACTCGGAGGGGAAGGTGTCCGGGGCCAACGTCCTGACTTTCGGGGCC	CAYSEGKVSGANVLTF	In	VDJ	1	79	2.599513660608813E-4	3.2629526830557756E-4	48	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	7	10	0	4	4	10	26	33	43	37	53			unresolved										Vb 20	CAYSEGKVSGANVLTF+TCRBV30-01+TCRBJ02-06	TCRBV30-01*01	TCRBD02-01*02	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAAAGGGGGCTAATGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	82	2.698229369239527E-4		41	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	5	0	0	1	3	26	36	44	37	47			unresolved										Vb 20	X+TCRBV30-01+TCRBJ01-01	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTACACCCCAGACAGGGGGCGCGTGGCTACACCTTCGGTTCG	CAWSVHPRQGARGYTF	In	VDJ	1	93	3.0601869675521464E-4	3.841197462331483E-4	48	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	2	0	7	8	3	26	40	58	48	61													Vb 20	CAWSVHPRQGARGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGCGGGACCGACTTGGCCCCAGCATTTTGGTGAT	CAWSAGPTWPQHF	In	VDJ	1	98	3.224713148603337E-4	4.04771345492995E-4	39	TCRBV30	TCRBV30-01	02				TCRBJ01	TCRBJ01-05	01	1	0	7	9	1	7	26	39	45	40	52			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSAGPTWPQHF+TCRBV30-01+TCRBJ01-05	TCRBV30-01*02		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGATAGGGTCAGGGGACCCGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	99	3.257618384813575E-4		44	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	4	4	2	4	6	4	26	36	48	42	52													Vb 20	X+TCRBV30-01+TCRBJ01-03	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTATCGGGGGGCGCGACTATGGCTACACCTTCGGTTCG	CAWSIGGRDYGYTF	In	VDJ	1	101	3.3234288572340517E-4	4.1716230504890297E-4	42	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	2	8	1	3	2	4	26	38	47	40	51													Vb 20	CAWSIGGRDYGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTACTATCAGGAGACTATGGCTACACCTTCGGTTCG	CAWSVLSGDYGYTF	In	VDJ	2	110	3.619575983126195E-4	4.5433518371662703E-4	42	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-02	01	0	4	4	3	5	2	26	40	49	45	51			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSVLSGDYGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGACCCAGACAGGGGTTCTAGGGCAGCCCCAGCATTTTGGTGAT	CAWTQTGVLGQPQHF	In	VDJ	2	115	3.784102164177386E-4	4.749867829764737E-4	45	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	2	2	7	4	8	26	36	48	40	56			unresolved										Vb 20	CAWTQTGVLGQPQHF+TCRBV30-01+TCRBJ01-05	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTACTGGGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CAWSVLGSGANVLTF	In	VDJ	2	115	3.784102164177386E-4	4.749867829764737E-4	45	TCRBV30	TCRBV30-01	01				TCRBJ02	TCRBJ02-06	01	0	0	9	0	3	0	26	40	-1	43	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSVLGSGANVLTF+TCRBV30-01+TCRBJ02-06	TCRBV30-01*01		TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGCTGATGGACCGAATGAAAAACTGTTTTTTGGCAGT	CAWADGPNEKLFF	In	VDJ	2	115	3.784102164177386E-4	4.749867829764737E-4	39	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-04	01	5	1	7	5	6	2	26	35	45	41	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWADGPNEKLFF+TCRBV30-01+TCRBJ01-04	TCRBV30-01*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTACAGGGGGACTCCCCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	133	4.376396415961672E-4		50	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	3	1	0	0	6	26	-1	48	40	54			unresolved										Vb 20	X+TCRBV30-01+TCRBJ02-01	TCRBV30-01*02	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGAGGGGGACAAAACTACGAGCAGTACTTCGGGCCG	CAWRGGQNYEQYF	In	VDJ	2	142	4.672543541853815E-4	5.865054189796458E-4	39	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	6	3	3	3	26	37	46	40	49			unresolved										Vb 20	CAWRGGQNYEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAATGTGGCTGCGGATACGCAGTATTTTGGCCCA	CAWNVAADTQYF	In	VDJ	2	147	4.837069722905006E-4	6.071570182394925E-4	36	TCRBV30	TCRBV30-01	02				TCRBJ02	TCRBJ02-03	01	0	9	0	6	0	4	26	-1	43	40	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWNVAADTQYF+TCRBV30-01+TCRBJ02-03	TCRBV30-01*02		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTACGAGGGGGGATGATGGGCTGAAGCTTTCTTTGGACAA		Out	VDJ	2	147	4.837069722905006E-4		46	TCRBV30	TCRBV30-01	02				TCRBJ01	TCRBJ01-01	01	0	5	1	6	3	9	26	40	49	43	58			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	X+TCRBV30-01+TCRBJ01-01	TCRBV30-01*02		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTTTCTCGGGCAGATATGGCTACACCTTCGGTTCG	CAWSFSGRYGYTF	In	VDJ	2	156	5.133216848797149E-4	6.443298969072165E-4	39	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-02	01	2	8	0	5	5	3	26	38	47	43	50			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSFSGRYGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGATTTAAGGGGAGGACAGGGCCTCCTCTGGAAACACCATATATTTTGGAGAG	CAWI*GEDRASSGNTIYF	Stop	VDJ	2	161	5.297743029848339E-4		54	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	4	1	3	0	10	4	26	36	54	46	58			unresolved										Vb 20	CAWI*GEDRASSGNTIYF+TCRBV30-01+TCRBJ01-03	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGACCCTACCGGGTAAGCCCCAGCATTTTGGTGAT	CAWTLPGKPQHF	In	VDJ	2	172	5.659700628160959E-4	7.104150145387258E-4	36	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	4	8	4	8	6	2	26	36	46	42	48						01,02							Vb 20	CAWTLPGKPQHF+TCRBV30-01+TCRBJ01-05	TCRBV30-01*01	TCRBD02-01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGCGCGGGGACTGTTAAGACCCAGTACTTCGGGCCA	CAWSAGTVKTQYF	In	VDJ	3	182	5.988752990263341E-4	7.517182130584193E-4	39	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	3	0	10	6	4	4	26	37	47	41	51			unresolved			01,02							Vb 20	CAWSAGTVKTQYF+TCRBV30-01+TCRBJ02-05	TCRBV30-01*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTGAGTCTTGGAACGCTACGAGCAGTACTTCGGGCCG		Out	VDJ	3	188	6.18618440752477E-4		43	TCRBV30	TCRBV30-01	01				TCRBJ02	TCRBJ02-07	01	0	1	8	3	7	3	26	40	50	47	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	X+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTCTTGGCAGGGGTAATGGCTACACCTTCGGTTCG	CAWSLGRGNGYTF	In	VDJ	3	209	6.87719436793977E-4	8.632368490615913E-4	39	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	4	2	6	5	2	26	38	49	43	51													Vb 20	CAWSLGRGNGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGAGGGCCTTTGGGACTAGCGGGGGGGTAATGAGCAGTTCTTCGGGCCA	CAWSEGLWD*RGGNEQFF	Stop	VDJ	3	229	7.535299092144533E-4		54	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	1	0	0	7	9	1	26	39	64	48	65													Vb 20	CAWSEGLWD*RGGNEQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGGATGAAAACAGCGCTCACTGAAGCTTTCTTTGGACAA	CAWRMKTALTEAFF	In	VDJ	4	269	8.851508540554058E-4	0.0011110560401797515	42	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-01	01	3	3	5	4	7	4	26	37	48	44	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWRMKTALTEAFF+TCRBV30-01+TCRBJ01-01	TCRBV30-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTAAGGGGACTAGCCAACAATGAGCAGTTCTTCGGGCCA	CAWSVRGLANNEQFF	In	VDJ	4	270	8.884413776764296E-4	0.0011151863600317208	45	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	0	7	5	3	2	26	40	52	43	54			unresolved			01,02							Vb 20	CAWSVRGLANNEQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTCCACTCGACAGGCGATGGCTACACCTTCGGTTCG	CAWSVHSTGDGYTF	In	VDJ	4	275	9.048939957815487E-4	0.0011358379592915676	42	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	2	4	6	6	2	26	40	52	46	54													Vb 20	CAWSVHSTGDGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGGGCCGGGGCGGAGATCAATGAGCAGTTCTTCGGGCCA	CAWRAGAEINEQFF	In	VDJ	4	295	9.70704468202025E-4	0.0012184443563309543	42	TCRBV30	TCRBV30-01	01				TCRBJ02	TCRBJ02-01	01	3	7	0	6	4	6	26	37	46	41	52			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWRAGAEINEQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGCTGACAAGGGCGGCAATCAGCCCCAGCATTTTGGTGAT	CAWADKGGNQPQHF	In	VDJ	4	298	9.805760390650964E-4	0.0012308353158868622	42	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-05	01	5	2	6	2	3	6	26	35	42	38	48			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWADKGGNQPQHF+TCRBV30-01+TCRBJ01-05	TCRBV30-01*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGCATCGTTTCCCCCTGACGAGCAGTACTTCGGGCCG	CAWSASFPPDEQYF	In	VDJ	5	386	0.0012701421177151921	0.0015943034628601639	42	TCRBV30	TCRBV30-01	01				TCRBJ02	TCRBJ02-07	01	1	4	6	5	0	13	26	-1	41	39	54			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSASFPPDEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAACAGTCCAAATGAAAAACTGTTTTTTGGCAGT	CAWNSPNEKLFF	In	VDJ	5	392	0.001289885259441335	0.00161908538197198	36	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	3	5	5	0	4	26	-1	40	36	44													Vb 20	CAWNSPNEKLFF+TCRBV30-01+TCRBJ01-04	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTATACGACACTGAAGCTTTCTTTGGACAA	CAWSVYDTEAFF	In	VDJ	6	446	0.0014675735349766207	0.001842122653978324	36	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-01	01	0	3	7	3	2	1	26	40	44	42	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSVYDTEAFF+TCRBV30-01+TCRBJ01-01	TCRBV30-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGCCAAGGGGAGCCAGCCCCAGCATTTTGGTGAT	CAWSAKGSQPQHF	In	VDJ	9	677	0.002227684491433122	0.002796226539783241	39	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-05	01	1	5	2	7	3	3	26	39	47	42	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSAKGSQPQHF+TCRBV30-01+TCRBJ01-05	TCRBV30-01*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCGGCGAGCGGGACGTCAATGGGGGCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	15	1079	0.003550474987084695		47	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	8	6	3	2	4	12	26	32	43	36	55			unresolved										Vb 20	X+TCRBV30-01+TCRBJ02-05	TCRBV30-01*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGCTCGGGACAGGGGACTATGGCTACACCTTCGGTTCG		Out	VDJ	22	1584	0.00521218941570172		43	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	0	2	3	3	0	26	39	-1	42	52			unresolved										Vb 20	X+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGAGATGAGGGGGAACACTGAAGCTTTCTTTGGACAA	CASSQEMRGNTEAFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	45	TCRBV01	TCRBV01-01	01				TCRBJ01	TCRBJ01-01	01	0	5	2	1	4	0	23	40	-1	44	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQEMRGNTEAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAATCAGCGCAGGGGGGAACTCACCCCTCCACTTTGGGAAC	CASSQISAGGNSPLHF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	48	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	2	4	1	10	7	4	23	38	52	45	56														CASSQISAGGNSPLHF+TCRBV01-01+TCRBJ01-06	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGATCTAGCGGGGGGAACCAAAAACATTCAGTACTTCGGCGCC	CASSQDLAGGTKNIQYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	51	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-04	01	0	4	1	2	1	2	23	40	52	41	54														CASSQDLAGGTKNIQYF+TCRBV01-01+TCRBJ02-04	TCRBV01-01*01	TCRBD02-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGATGTAGGGGGTCAGCCCCAGCATTTTGGTGAT	CASSQDVGGQPQHF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	5	1	6	3	0	23	40	-1	43	49														CASSQDVGGQPQHF+TCRBV01-01+TCRBJ01-05	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGAGTATACGGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSQEYTGTGELFF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	45	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	0	8	4	4	5	0	23	40	-1	45	49						01,02								CASSQEYTGTGELFF+TCRBV01-01+TCRBJ02-02	TCRBV01-01*01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGATGGCGGGGCTTCTTTATCCTACAATGAGCAGTTCTTCGGGCCA	CASSQDGGASLSYNEQFF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	54	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	7	3	1	2	8	23	40	48	42	56														CASSQDGGASLSYNEQFF+TCRBV01-01+TCRBJ02-01	TCRBV01-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCACCAGCAGCCAAGACCCGTGACAGGGGGGGATAGGAAGCTTTCTTTGGACAA		Out	VDJ	1	34	1.1187780311480965E-4		49	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	2	1	8	5	6	23	40	54	45	60														X+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGCGAGACCGGGACAGAACTACGAGCAGTACTTCGGGCCG	CASSQARPGQNYEQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	48	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	0	5	3	7	2	23	39	53	46	55														CASSQARPGQNYEQYF+TCRBV01-01+TCRBJ02-07	TCRBV01-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGGGGTGGGGGATCAGCCCCAGCATTTTGGTGAT	CASSQGVGDQPQHF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	42	TCRBV01	TCRBV01-01	01				TCRBJ01	TCRBJ01-05	01	1	6	1	5	4	0	23	39	-1	43	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQGVGDQPQHF+TCRBV01-01+TCRBJ01-05	TCRBV01-01*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAGGATATATCGGCCGCCCCCGATACGCAGTATTTTGGCCCA	CASSQDISAAPDTQYF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	48	TCRBV01	TCRBV01-01	01				TCRBJ02	TCRBJ02-03	01	3	1	8	6	0	16	23	-1	40	37	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDISAAPDTQYF+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCACGGACACCTTCGGGAGGCTTTCTTTGGACAA	CASSHGHLREAFF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	39	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	3	8	2	11	10	0	23	37	-1	47	53														CASSHGHLREAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCACGACACAAGGGGGCGCGGTAATGGCTACACCTTCGGTTCG	CASSHDTRGRGNGYTF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	48	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	5	0	6	7	6	23	37	51	44	57														CASSHDTRGRGNGYTF+TCRBV01-01+TCRBJ01-02	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCACTACGGACAGGGAGGGAGAGATACGCAGTATTTTGGCCCA	CASSHYGQGGRDTQYF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	48	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	1	3	5	4	6	23	37	49	41	55														CASSHYGQGGRDTQYF+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGTAAGCGGGATGGGGACAGATACGCAGTATTTTGGCCCA	CASSQVSGMGTDTQYF	In	VDJ	1	54	1.7768827553528592E-4	2.2303727200634416E-4	48	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	1	6	3	3	2	5	23	39	48	41	53														CASSQVSGMGTDTQYF+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGGGGTGAGCAGCCATTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSQGVSSHSGANVLTF	In	VDJ	1	63	2.0730298812450025E-4	2.602101506740682E-4	54	TCRBV01	TCRBV01-01	01				TCRBJ02	TCRBJ02-06	01	1	0	9	1	0	11	23	-1	42	39	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQGVSSHSGANVLTF+TCRBV01-01+TCRBJ02-06	TCRBV01-01*01		TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCTCCTCCTCAAGAGGGCAGGGGACGAAGGCTACACCTTCGGTTCG		Out	VDJ	1	68	2.237556062296193E-4		44	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	14	4	2	8	18	5	23	26	50	44	55														X+TCRBV01-01+TCRBJ01-02	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCACCTGTCTAGCGGGATCAACTTCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	74	2.434987479557622E-4		47	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	10	4	3	3	5	7	23	30	44	35	51														X+TCRBV01-01+TCRBJ02-01	TCRBV01-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGAGGGAGAGGGAGAGACCCAGTACTTCGGGCCA	CASSQEGEGETQYF	In	VDJ	1	75	2.46789271576786E-4	3.097739888977002E-4	42	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	0	9	2	4	0	4	23	-1	45	40	49														CASSQEGEGETQYF+TCRBV01-01+TCRBJ02-05	TCRBV01-01*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGATTGGGTTAGGGGGACTTCATACACTGAAGCTTTCTTTGGACAA	CASSQDWVRGTSYTEAFF	In	VDJ	1	85	2.7969450778702416E-4	3.510771874173936E-4	54	TCRBV01	TCRBV01-01	01				TCRBJ01	TCRBJ01-01	01	0	5	1	3	7	7	23	40	53	47	60				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDWVRGTSYTEAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCCCGAGGGCGGGGGGGCCCATGAGCAGTTCTTCGGGCCA	CASSPEGGGAHEQFF	In	VDJ	1	97	3.1918079123930993E-4	4.0064102564102563E-4	45	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	7	0	8	6	3	23	36	51	42	54														CASSPEGGGAHEQFF+TCRBV01-01+TCRBJ02-01	TCRBV01-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCACCAGCAGCGGGATTAGCGGGTACCCTAACACCGGGGAGCTGTTTTTTGGAGAA	CTSSGISGYPNTGELFF	In	VDJ	1	98	3.224713148603337E-4	4.04771345492995E-4	51	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	5	5	4	2	5	6	23	35	47	40	53						01,02								CTSSGISGYPNTGELFF+TCRBV01-01+TCRBJ02-02	TCRBV01-01*01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGGGATGGACACTGAAGCTTTCTTTGGACAA	CASSQGMDTEAFF	In	VDJ	1	98	3.224713148603337E-4	4.04771345492995E-4	39	TCRBV01	TCRBV01-01	01				TCRBJ01	TCRBJ01-01	01	1	1	8	3	0	3	23	-1	42	39	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQGMDTEAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCACCAGCAGCCAAGACATACTAGCGGGGGGGCCGGACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	105	3.455049802075004E-4		55	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	3	0	3	3	4	23	40	56	43	60														X+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGATCGAGAGGGATTAGATACGCAGTATTTTGGCCCA	CASSQDREGLDTQYF	In	VDJ	2	116	3.817007400387624E-4	4.79117102828443E-4	45	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	0	11	0	5	4	3	23	40	49	44	52														CASSQDREGLDTQYF+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCCCGGGACAGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSPGTANTGELFF	In	VDJ	2	124	4.0802492900695285E-4	5.121596616441978E-4	45	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	0	5	0	2	0	23	36	-1	38	45														CASSPGTANTGELFF+TCRBV01-01+TCRBJ02-02	TCRBV01-01*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGCCCCTGACACGAACACTGAAGCTTTCTTTGGACAA	CASSQAPDTNTEAFF	In	VDJ	2	143	4.7054487780640535E-4	5.906357388316151E-4	45	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	2	6	1	5	1	23	39	48	44	49														CASSQAPDTNTEAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGCAGAGACTGAGGGCACCACTGAAGCTTTCTTTGGACAA	CASSQAETEGTTEAFF	In	VDJ	2	148	4.869974959115244E-4	6.112873380914618E-4	48	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	1	11	0	4	8	3	23	39	52	47	55														CASSQAETEGTTEAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGATCGCCTAAGGTCCGGGGCGGGCGGGGAGCTGTTTTTTGGAGAA	CASSQDRLRSGAGGELFF	In	VDJ	2	160	5.264837793638101E-4	6.608511763150939E-4	54	TCRBV01	TCRBV01-01	01				TCRBJ02	TCRBJ02-02	01	0	7	0	7	13	3	23	40	58	53	61				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDRLRSGAGGELFF+TCRBV01-01+TCRBJ02-02	TCRBV01-01*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGATTGAACCCGATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	165	5.429363974689292E-4		40	TCRBV01	TCRBV01-01	01				TCRBJ02	TCRBJ02-01	01	0	2	8	8	2	5	23	40	44	42	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV01-01+TCRBJ02-01	TCRBV01-01*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGATCTTAGAGGAGGGAATGAAAAACTGTTTTTTGGCAGT	CASSQDLRGGNEKLFF	In	VDJ	2	168	5.528079683320006E-4	6.938937351308486E-4	48	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	0	10	0	5	7	0	23	40	-1	47	53														CASSQDLRGGNEKLFF+TCRBV01-01+TCRBJ01-04	TCRBV01-01*01	TCRBD02-01*02	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGAACAGGGCGACAATGAGCAGTTCTTCGGGCCA	CASSQEQGDNEQFF	In	VDJ	2	169	5.560984919530245E-4	6.980240549828179E-4	42	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	3	3	5	0	2	23	-1	46	40	48														CASSQEQGDNEQFF+TCRBV01-01+TCRBJ02-01	TCRBV01-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGATTCGACCGTGGCCTATGGCTACACCTTCGGTTCG	CASSQDSTVAYGYTF	In	VDJ	2	175	5.758416336791674E-4	7.228059740946339E-4	45	TCRBV01	TCRBV01-01	01				TCRBJ01	TCRBJ01-02	01	0	2	7	4	3	6	23	40	46	43	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDSTVAYGYTF+TCRBV01-01+TCRBJ01-02	TCRBV01-01*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCACCAGCAGCCCTCCTAGCGGGGGGGCAGATACGCAGTATTTTGGCCCA	CTSSPPSGGADTQYF	In	VDJ	3	206	6.778478659309056E-4	8.508458895056833E-4	45	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	4	0	4	3	0	23	36	-1	39	51														CTSSPPSGGADTQYF+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAGTCGACAGGGTCAAATGAAAAACTGTTTTTTGGCAGT	CASSQSTGSNEKLFF	In	VDJ	3	211	6.943004840360246E-4	8.7149748876553E-4	45	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	2	3	5	3	3	23	37	47	40	50														CASSQSTGSNEKLFF+TCRBV01-01+TCRBJ01-04	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGAGGCTTCGGGTGCCGCTGAAGCTTTCTTTGGACAA	CASSQEASGAAEAFF	In	VDJ	3	221	7.272057202462628E-4	9.128006872852234E-4	45	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	0	8	4	6	5	5	23	40	49	45	54						01,02								CASSQEASGAAEAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCACCAGCAGCCCACGAGGGGTCGTTTTCGTCCCATCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	3	228	7.502393855934295E-4		56	TCRBV01	TCRBV01-01	01				TCRBJ02	TCRBJ02-07	01	4	5	2	0	4	15	23	36	45	40	60				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV01-01+TCRBJ02-07	TCRBV01-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCACCAGCAGCCGAGAATGCCGGGACTAGCGGGAGAACCAAGAGACCCAGTACTTCGGGCCA	CTSSRECRD*RENQETQYF	Stop	VDJ	4	274	9.016034721605249E-4		57	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	0	0	2	0	5	1	23	40	59	45	60														CTSSRECRD*RENQETQYF+TCRBV01-01+TCRBJ02-05	TCRBV01-01*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCCTTATCAGGGGCAAGCTGAAGCTTTCTTTGGACAA	CASSPYQGQAEAFF	In	VDJ	6	424	0.001395182015314097	0.0017512556172349987	42	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	4	2	6	5	4	23	36	47	41	51														CASSPYQGQAEAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAATCCCCCCCCACTACGGGGTATTACAATGAGCAGTTCTTCGGGCCA	CASSQSPPTTGYYNEQFF	In	VDJ	8	542	0.0017834638025949069	0.0022386333597673802	54	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	8	3	4	13	3	23	38	56	51	59														CASSQSPPTTGYYNEQFF+TCRBV01-01+TCRBJ02-01	TCRBV01-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCCCGGAGCGGTCCTCCACAGATACGCAGTATTTTGGCCCA	CASSPERSSTDTQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	45	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	4	6	5	2	4	5	19	31	40	35	45						01,02							Vb 5.1	CASSPERSSTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTCGGCGGGGGGTATAATGAGCAGTTCTTCGGGCCA	CASSFGGGYNEQFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	7	1	7	2	3	19	33	43	35	46													Vb 5.1	CASSFGGGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGACAGGGCGGACAATGAGCAGTTCTTCGGGCCA	CASSLDRADNEQFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	3	3	5	0	3	19	-1	41	35	44													Vb 5.1	CASSLDRADNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGTATGGTCACAGATACGCAGTATTTTGGCCCA	CASSLGMVTDTQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	42	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-03	01	0	0	10	2	4	1	19	35	41	39	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSLGMVTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCGGCAGGACAGGGCGTTGGGTAGAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	21	6.910099604150008E-5		55	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	1	3	1	4	10	19	31	43	35	53													Vb 5.1	X+TCRBV05-01+TCRBJ01-05	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTAGATGGGACAGGGCTTCGGGTATAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	21	6.910099604150008E-5		58	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	0	3	0	4	10	19	33	46	37	56													Vb 5.1	X+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGCCTAGCGGCTACAATGAGCAGTTCTTCGGGCCA	CASSLPSGYNEQFF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	4	5	3	1	0	19	34	-1	35	42						01,02							Vb 5.1	CASSLPSGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGTTCGGCGGGGGGGTACAATGAGCAGTTCTTCGGGCCA	CASSSAGGYNEQFF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	7	0	4	4	0	19	30	-1	34	43													Vb 5.1	CASSSAGGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGTAGGACTAGCGGGACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	23	7.568204328354771E-5		46	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	1	1	3	2	2	0	19	34	-1	36	48													Vb 5.1	X+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCACCGCTAGCGGGGGGTACAATGAGCAGTTCTTCGGGCCA	CASTASGGYNEQFF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	4	1	4	3	0	19	29	-1	32	43													Vb 5.1	CASTASGGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGGGATCGGGGTTACGAGCAGTACTTCGGGCCG	CASSLGDRGYEQYF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	8	3	4	5	1	19	35	45	40	46													Vb 5.1	CASSLGDRGYEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGTCGGCAGGGGTGAACGAGCAGTACTTCGGGCCG	CASSLSAGVNEQYF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	4	2	5	4	3	19	34	44	38	47													Vb 5.1	CASSLSAGVNEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGACCCGGCGCAGGTCCTAACCGAGCAGTACTTCGGGCCG	CASSLDPAQVLTEQYF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	48	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	4	4	6	8	7	19	35	47	43	54													Vb 5.1	CASSLDPAQVLTEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCGCCCCCAGCGGGGGGGCTCCGGGGGGGAGCAGTTCTTCGGGCCA		Out	VDJ	1	27	8.884413776764296E-5		50	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	6	0	10	6	10	19	31	47	37	57													Vb 5.1	X+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCAGGGGGCTATTCACCCCTCCACTTTGGGAAC	CASSLAGGYSPLHF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	0	4	0	8	0	1	19	-1	43	35	44													Vb 5.1	CASSLAGGYSPLHF+TCRBV05-01+TCRBJ01-06	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCTGGGGGTTACACTGAAGCTTTCTTTGGACAA	CASSLAGGYTEAFF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	42	TCRBV05	TCRBV05-01	01				TCRBJ01	TCRBJ01-01	01	0	6	1	3	2	2	19	35	42	37	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSLAGGYTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGTGGGGGCGGCACTGAAGCTTTCTTTGGACAA	CASSLGGGGTEAFF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	6	0	4	2	2	19	35	43	37	45													Vb 5.1	CASSLGGGGTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGGCAGGGGGCGCCGACAGATACGCAGTATTTTGGCCCA	CASSLGQGAPTDTQYF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	48	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	4	0	3	2	4	19	35	45	37	49													Vb 5.1	CASSLGQGAPTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGTGGGACAGGGTTTGCGTGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	29	9.54251850096906E-5		47	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	1	0	3	7	1	6	19	34	44	35	50													Vb 5.1	X+TCRBV05-01+TCRBJ01-04	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCCCCGGTAGGGGGAAAGGTTCGGACACTGAAGCTTTCTTTGGACAA	CASSPGRGKGSDTEAFF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	51	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	5	1	3	6	10	19	31	43	37	53													Vb 5.1	CASSPGRGKGSDTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTACAGGGTACGATAGGTAACACTGAAGCTTTCTTTGGACAA	CASSLQGTIGNTEAFF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	48	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	3	3	2	0	10	19	-1	39	33	49													Vb 5.1	CASSLQGTIGNTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGCGGGGGATACAATGAGCAGTTCTTCGGGCCA	CASSLGGGYNEQFF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	7	2	4	0	1	19	-1	42	35	43													Vb 5.1	CASSLGGGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGTAAGGCCGCCGACACACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	32	1.0529675587276204E-4		49	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	2	6	2	10	0	19	35	-1	45	49													Vb 5.1	X+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCATGTCTGGGTCTGGGTGGAACACTGAAGCTTTCTTTGGACAA	CASMSGSGWNTEAFF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	45	TCRBV05	TCRBV05-01	01				TCRBJ01	TCRBJ01-01	01	6	0	9	1	5	8	19	29	37	34	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASMSGSGWNTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGCGAGACAGGGACGGACATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	33	1.0858727949378584E-4		50	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	2	3	5	4	6	19	35	46	39	52													Vb 5.1	X+TCRBV05-01+TCRBJ01-05	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCCCCCAGGGCCTAGCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	34	1.1187780311480965E-4		44	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	4	3	0	3	5	19	31	39	34	44													Vb 5.1	X+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTAACAGGGGGGTACAATGAGCAGTTCTTCGGGCCA	CASSLTGGYNEQFF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	3	1	4	1	1	19	33	42	34	43													Vb 5.1	CASSLTGGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGGGTACCCCGGCTCGAGCAGTACTTCGGGCCG	CASSLGVPRLEQYF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	42	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-07	01	0	0	9	6	0	10	19	-1	38	35	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSLGVPRLEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGTTGGGGGGGCTCACAGATACGCAGTATTTTGGCCCA	CASSLLGGLTDTQYF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	45	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	9	0	2	2	2	19	34	43	36	45													Vb 5.1	CASSLLGGLTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGGGGTGGGACAGGGTTTACACCCCCTAACGAGCAGTACTTCGGGCCG	CASRGGTGFTPPNEQYF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	51	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	3	5	4	13	19	30	43	34	56													Vb 5.1	CASRGGTGFTPPNEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCACCACGACTAGCGGGGGCTACAATGAGCAGTTCTTCGGGCCA	CATTTSGGYNEQFF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	9	2	2	3	4	0	19	26	-1	30	42													Vb 5.1	CATTTSGGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCACGGGACAGGGTAGTTCCTATAATTCACCCCTCCACTTTGGGAAC	CASSTGQGSSYNSPLHF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	51	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	0	3	1	2	4	19	31	42	33	46													Vb 5.1	CASSTGQGSSYNSPLHF+TCRBV05-01+TCRBJ01-06	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCAGGGGGGTACTCTGAAGCTTTCTTTGGACAA	CASSLAGGYSEAFF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	4	1	6	0	5	19	-1	42	35	47													Vb 5.1	CASSLAGGYSEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCCATTATAACCACGACAGTTTAGCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	37	1.217493739778811E-4		58	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	2	5	0	13	5	19	35	53	48	58													Vb 5.1	X+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCACGACCGGTGGGGGGTACAATGAGCAGTTCTTCGGGCCA	CASTTGGGYNEQFF	In	VDJ	1	38	1.2503989759890492E-4	1.569521543748348E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	9	1	4	8	0	19	29	-1	37	43													Vb 5.1	CASTTGGGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTCCGCGGGGGGTTACAATGAGCAGTTCTTCGGGCCA	CASSSAGGYNEQFF	In	VDJ	1	39	1.2833042121992871E-4	1.6108247422680412E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	7	1	4	2	1	19	32	42	34	43													Vb 5.1	CASSSAGGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTCTAGCGGGGGCTACAATGAGCAGTTCTTCGGGCCA	CASSSSGGYNEQFF	In	VDJ	1	39	1.2833042121992871E-4	1.6108247422680412E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	4	2	3	0	0	19	-1	-1	32	42													Vb 5.1	CASSSSGGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGCGGGGGCAAAAACATTCAGTACTTCGGCGCC	CASSLGGGKNIQYF	In	VDJ	1	39	1.2833042121992871E-4	1.6108247422680412E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-04	01	0	7	2	3	0	0	19	-1	-1	35	42													Vb 5.1	CASSLGGGKNIQYF+TCRBV05-01+TCRBJ02-04	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTCTGCAGGGGGATTCACTGAAGCTTTCTTTGGACAA	CASSSAGGFTEAFF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	1	4	3	3	19	32	42	35	45													Vb 5.1	CASSSAGGFTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCCACAGGGATGGTTCAACTAATGAAAAACTGTTTTTTGGCAGT	CASHRDGSTNEKLFF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	45	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	7	3	3	0	1	6	19	28	35	29	41													Vb 5.1	CASHRDGSTNEKLFF+TCRBV05-01+TCRBJ01-04	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGAACAGCTTCCGTAGAAAAACTGTTTTTTGGCAGT	CASSLGTASVEKLFF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	45	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	3	5	8	2	8	19	35	41	37	49													Vb 5.1	CASSLGTASVEKLFF+TCRBV05-01+TCRBJ01-04	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTACCCCGGGACAGGGGACACCGGGGAGCTGTTTTTTGGAGAA	CASSYPGTGDTGELFF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	48	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	0	2	3	5	0	19	32	-1	37	47													Vb 5.1	CASSYPGTGDTGELFF+TCRBV05-01+TCRBJ02-02	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCGATGGCCGGGGGGGAGATACGCAGTATTTTGGCCCA	CASSDGRGGDTQYF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	8	0	5	6	0	19	31	-1	37	45													Vb 5.1	CASSDGRGGDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCGCCGCGGGAGGTTACACTGAGCAGTTCTTCGGGCCA	CASSAAGGYTEQFF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	7	1	9	3	6	19	31	42	34	48													Vb 5.1	CASSAAGGYTEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTCGTCCGGGGGATATGAAAAACTGTTTTTTGGCAGT	CASSSSGGYEKLFF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	3	8	2	6	4	2	19	32	42	36	44													Vb 5.1	CASSSSGGYEKLFF+TCRBV05-01+TCRBJ01-04	TCRBV05-01*01	TCRBD02-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTTAGCGGGGCCTACAATGAGCAGTTCTTCGGGCCA	CASSFSGAYNEQFF	In	VDJ	1	59	1.94140893640405E-4	2.4368887126619086E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	5	3	2	0	0	19	-1	-1	33	41													Vb 5.1	CASSFSGAYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCCTCCTGGGGGTAGGTGGTGAAAAACTGTTTTTTGGCAGT	CASSLLGVGGEKLFF	In	VDJ	1	62	2.0401246450347642E-4	2.560798308220989E-4	45	TCRBV05	TCRBV05-01	01				TCRBJ01	TCRBJ01-04	01	4	6	1	7	5	7	19	31	41	36	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSLLGVGGEKLFF+TCRBV05-01+TCRBJ01-04	TCRBV05-01*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCAGCCGGGACTTCAACAATGAGCAGTTCTTCGGGCCA	CASSSRDFNNEQFF	In	VDJ	1	63	2.0730298812450025E-4	2.602101506740682E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	0	10	5	4	3	19	31	41	35	44						01,02							Vb 5.1	CASSSRDFNNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCACCACCGGGACGAACACTGAAGCTTTCTTTGGACAA	CASSTTGTNTEAFF	In	VDJ	1	71	2.3362717709269075E-4	2.932527094898229E-4	42	TCRBV05	TCRBV05-01	01				TCRBJ01	TCRBJ01-01	01	4	0	7	1	6	0	19	31	-1	37	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSTTGTNTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCTGCCTAGCGGGAGGGTACAATGAGCAGTTCTTCGGGCCA	CASCLAGGYNEQFF	In	VDJ	1	74	2.434987479557622E-4	3.056436690457309E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	4	0	4	3	0	19	28	-1	31	43													Vb 5.1	CASCLAGGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCCCCGCGGGAGGCTATTCACCCCTCCACTTTGGGAAC	CASSPAGGYSPLHF	In	VDJ	1	91	2.9943764951316705E-4	3.7585910652920964E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	4	7	1	8	3	2	19	31	42	34	44													Vb 5.1	CASSPAGGYSPLHF+TCRBV05-01+TCRBJ01-06	TCRBV05-01*01	TCRBD02-01*02	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGACAACCTGATCCATGGCTACACCTTCGGTTCG	CASSLDNLIHGYTF	In	VDJ	1	101	3.3234288572340517E-4	4.1716230504890297E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	3	6	6	0	9	19	-1	38	35	47													Vb 5.1	CASSLDNLIHGYTF+TCRBV05-01+TCRBJ01-02	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCCGGGGGGTACACTGAAGCTTTCTTTGGACAA	CASSLAGGYTEAFF	In	VDJ	2	112	3.6853864555466714E-4	4.6259582342056567E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	0	8	1	3	1	1	19	35	43	36	44													Vb 5.1	CASSLAGGYTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCTCGCTACCAGGGGAGTTGCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	2	151	4.968690667745959E-4		47	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	7	4	2	2	7	5	19	28	41	35	46													Vb 5.1	X+TCRBV05-01+TCRBJ01-03	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGTACTAGCGGCCGGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	2	153	5.034501140166435E-4		47	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	3	5	1	1	3	19	34	43	35	46						01,02							Vb 5.1	X+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCAGGGGCATATGAAAAACTGTTTTTTGGCAGT	CASSLAGAYEKLFF	In	VDJ	2	172	5.659700628160959E-4	7.104150145387258E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	4	2	6	0	3	19	-1	41	35	44													Vb 5.1	CASSLAGAYEKLFF+TCRBV05-01+TCRBJ01-04	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCGGGATTGGAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	3	185	6.087468698894055E-4		41	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-03	01	4	0	8	0	0	4	19	-1	35	31	39				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	X+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTTCCCCCAACGAGCAGTACTTCGGGCCG	CASSFSPNEQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	4	6	5	6	0	25	39	-1	45	47													Vb 3	CASSFSPNEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCACCCTTTCCGGGCCAACAGAAAAACTGTTTTTTGGCAGT	CATLSGPTEKLFF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	39	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-04	01	10	8	0	8	8	5	25	32	44	40	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CATLSGPTEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCTCACCCCCACTCCGGTCAGGGGGTGGCTGAAGCTTTCTTTGGACAA	CASSSHPHSGQGVAEAFF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	54	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	4	1	6	17	3	25	38	62	55	65													Vb 3	CASSSHPHSGQGVAEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAAACTCGGACACTGAAGCTTTCTTTGGACAA	CASSLNSDTEAFF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	39	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	2	3	10	3	1	3	25	40	44	41	47						01,02							Vb 3	CASSLNSDTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCAGGGGGTCGCTATTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	23	7.568204328354771E-5		43	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	4	1	4	0	7	25	-1	46	39	53													Vb 3	X+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCCGTTTAAGTAGGGAGGAGACCCAGTACTTCGGGCCA	CASSFRLSREETQYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	3	9	2	5	11	0	25	39	-1	50	55													Vb 3	CASSFRLSREETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCCGTTTCGGACAGAAATCTTATAGCAATCAGCCCCAGCATTTTGGTGAT	CASRFGQKSYSNQPQHF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	51	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	1	5	0	1	8	25	39	46	40	54													Vb 3	CASRFGQKSYSNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACGTTTGGTGGCACCAACCAGACATCTATGTACTCTGTGCCAGCAGATTCGGGACAGGAATAATCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	23	7.568204328354771E-5		44	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	20	0	4	6	17	6	37	34	59	51	65													Vb 3	X+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTGTTAGCGGGACAGATACGCAGTATTTTGGCCCA	CASSFVSGTDTQYF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	5	4	3	3	0	25	39	-1	42	49						01,02							Vb 3	CASSFVSGTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACGTTTGGTGGCACCACCAGACATCTATGTACCTCTGTGCCAGCAGATTCGGGACAGGAATAATCAATGAGCAGTTCTTCGGGCCA	CASRFGTGIINEQFF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	0	4	6	4	6	36	47	59	51	65													Vb 3	CASRFGTGIINEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTAACCAATTTAGTGGGACGGTTGCAATCAGCCCCAGCATTTTGGTGAT	CASS*PI*WDGCNQPQHF	Stop	VDJ	1	26	8.555361414661915E-5		54	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-05	01	4	0	7	2	12	4	25	38	55	50	59				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASS*PI*WDGCNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCATAGAGGCAGGGCAGAACACTGAAGCTTTCTTTGGACAA	CASIEAGQNTEAFF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	4	3	1	6	2	25	35	46	41	48													Vb 3	CASIEAGQNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCCTGGCAGGGGGTACTGAAAAACTGTTTTTTGGCAGT	CASLAGGTEKLFF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	8	4	1	7	4	3	25	34	45	38	48													Vb 3	CASLAGGTEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATGCGGAGCGGGACTAGCGGGAGGAAGTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	27	8.884413776764296E-5		56	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	0	1	4	6	3	25	42	63	48	66													Vb 3	X+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCCTCGAGGGTAACACCGGGGAGCTGTTTTTTGGAGAA	CASLEGNTGELFF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	39	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	8	11	0	2	3	1	25	34	42	37	43													Vb 3	CASLEGNTGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTAATGCCGGACAGGGTTATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSNAGQGYSNQPQHF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	51	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	1	3	0	6	3	25	37	51	43	54													Vb 3	CASSNAGQGYSNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGTGCCAGCAGTCCGACCCTCGGGACTCGATCCTCCCGGGTATAACCTTTAAACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	28	9.213466138866678E-5		70	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	0	10	2	9	26	0	12	27	21	53						01,02							Vb 3	X+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTAGGGGTATGGGGAGCACAGATACGCAGTATTTTGGCCCA	CASSRGMGSTDTQYF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	5	2	0	0	7	25	-1	42	37	49													Vb 3	CASSRGMGSTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGCCCGGTGGGGCTTCGAAGCTTTCTTTGGACAA	CASSARWGFEAFF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	7	0	8	7	3	25	37	49	44	52													Vb 3	CASSARWGFEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCACCAGCGGGAGGGCCTACGAGCAGTACTTCGGGCCG	CASSSTSGRAYEQYF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	6	0	2	5	0	25	38	-1	43	53													Vb 3	CASSSTSGRAYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTGGACGTCAACGGGCTATGGCTACACCTTCGGTTCG	CASSWTSTGYGYTF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-02	01	4	1	7	4	0	9	25	-1	42	38	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSWTSTGYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCGCGGGGGGACCAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSRGGTSSYNEQFF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	7	1	0	2	5	25	36	46	38	51													Vb 3	CASSRGGTSSYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATATATAGGGATTCAAGCTTTCTTTGGACAA	CASSLYIGIQAFF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	39	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-01	01	1	0	8	9	5	3	25	41	50	46	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSLYIGIQAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATCCGGGGAGTTTGGTCGGGACACTGAAGCTTTCTTTGGACAA	CASSLSGEFGRDTEAFF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	51	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	1	8	3	3	1	12	25	41	47	42	59						01,02							Vb 3	CASSLSGEFGRDTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACCCCGCAGGGGTATGAGCAGTTCTTCGGGCCA	CASTPQGYEQFF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	4	2	8	5	1	25	35	46	40	47													Vb 3	CASTPQGYEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCTCCGGACAGGCAAGCTCCTACGAGCAGTACTTCGGGCCG	CASSSGQASSYEQYF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	1	4	0	4	4	25	36	47	40	51													Vb 3	CASSSGQASSYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTAGAAATGTCAGGGAGCAGTTCTTCGGGCCA	CASSRNVREQFF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	4	4	10	8	0	25	37	-1	45	49													Vb 3	CASSRNVREQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAACCGGGACAGTTACACAGATACGCAGTATTTTGGCCCA	CASNRDSYTDTQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	7	0	5	2	3	3	25	35	45	38	48													Vb 3	CASNRDSYTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCGACGGGAACACTGAAGCTTTCTTTGGACAA	CASSFDGNTEAFF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	39	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-01	01	3	2	7	1	1	2	25	39	43	40	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSFDGNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCCAATTTACCTCCGGCACAGATACGCAGTATTTTGGCCCA	CASQFTSGTDTQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-03	01	8	3	7	1	6	5	25	34	42	40	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASQFTSGTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCGCGACAGGGCTTAATGAAAAACTGTTTTTTGGCAGT	CAATGLNEKLFF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	11	2	3	4	2	2	25	31	40	33	42													Vb 3	CAATGLNEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGAGACGGACAGGGGAGATCCGCAACGGCTACACCTTCGGTTCG	CASRRRTGEIRNGYTF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	1	2	8	5	11	25	36	50	41	61													Vb 3	CASRRRTGEIRNGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATATCCAGGGCGTACCGGGGAGCTGTTTTTTGGAGAA	CASSLYPGRTGELFF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	1	4	3	5	3	3	25	41	49	44	52													Vb 3	CASSLYPGRTGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGCACAGGTCACCCCCTACGAGCAGTACTTCGGGCCG	CASSAQVTPYEQYF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	3	4	2	2	6	25	37	44	39	50													Vb 3	CASSAQVTPYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAAATGGTGGGGACAGGGATGGGGCTTTCTTTGGACAA	CASSLNGGDRDGAFF	In	VDJ	1	39	1.2833042121992871E-4	1.6108247422680412E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	0	3	11	7	5	25	40	56	47	61													Vb 3	CASSLNGGDRDGAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATACCCAAATAATGAAAAACTGTTTTTTGGCAGT	CASSLYPNNEKLFF	In	VDJ	1	39	1.2833042121992871E-4	1.6108247422680412E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-04	01	1	3	7	4	0	5	25	-1	43	41	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSLYPNNEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAATCTTCAACAGGGAGACGGCTACACCTTCGGTTCG	CASNLQQGDGYTF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	3	3	8	7	4	25	35	48	42	52													Vb 3	CASNLQQGDGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAAGGCAGGGAGAACAGCCCCAGCATTTTGGTGAT	CASSLRQGEQPQHF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-05	01	2	4	3	7	3	4	25	40	48	43	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSLRQGEQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCCGACAGGGTACGAGCAGTACTTCGGGCCG	CASSPTGYEQYF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	3	4	3	0	25	36	-1	39	46													Vb 3	CASSPTGYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATGTAGGGACAGGGGAAGACTAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	42	1.3820199208300016E-4		56	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	0	2	0	2	6	25	42	54	44	60													Vb 3	X+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCATTCCGACAGGGCACGCAACTAATGAAAAACTGTTTTTTGGCAGT	CASIPTGHATNEKLFF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	7	2	3	0	4	4	25	35	46	39	50													Vb 3	CASIPTGHATNEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCCGACGGGCGGGCGTCTACAATGAGCAGTTCTTCGGGCCA	CASRRAGVYNEQFF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	8	7	4	3	6	3	25	34	45	40	48						01,02							Vb 3	CASRRAGVYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAATTTAATGGCCAGGGACAGTTTCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	43	1.4149251570402398E-4		49	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	0	5	4	7	3	25	40	54	47	57													Vb 3	X+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCGCCTTTTACCCGACAGGGGCGAGCACTGAAGCTTTCTTTGGACAA	CAAFYPTGASTEAFF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	11	2	2	4	11	4	25	31	50	42	54													Vb 3	CAAFYPTGASTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTACCACAAATAAGACTAGCGCAGTTCTACGAGCAGTACTTCGGGCCG	CASSLPQIRLAQFYEQYF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	54	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	2	6	3	10	5	25	40	58	50	63						01,02							Vb 3	CASSLPQIRLAQFYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCACCTCCGAGGCAGTTGATACGCAGTATTTTGGCCCA	CATSEAVDTQYF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	36	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	10	11	1	6	5	5	25	32	41	37	46													Vb 3	CATSEAVDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCGAAGACTAGCGGGTTCCGGGGAGCTGTTTTTTGGAGAA	CASSRRLAGSGELFF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	5	2	4	6	4	2	25	37	51	41	53						01,02							Vb 3	CASSRRLAGSGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTGGGACAGGGGGCGCACAGATACGCAGTATTTTGGCCCA	CASSWDRGRTDTQYF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	0	0	1	0	0	25	-1	-1	38	50													Vb 3	CASSWDRGRTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTACTGGGGGTATCCTACAATGAGCAGTTCTTCGGGCCA	CASSLLGVSYNEQFF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	45	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-01	01	2	6	1	1	2	2	25	40	47	42	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSLLGVSYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATCGTACGAAAACATTCAGTACTTCGGCGCC	CASSLSYENIQYF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	39	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-04	01	1	3	7	5	3	1	25	41	46	44	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSLSYENIQYF+TCRBV28-01+TCRBJ02-04	TCRBV28-01*01		TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCCTTATTGCTGGCGGCTACACCTTCGGTTCG	CASSSLIAGGYTF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	9	0	8	11	0	25	38	-1	49	52													Vb 3	CASSSLIAGGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTACAGGACGAAACGGCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	48	1.5794513380914304E-4		44	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-07	01	2	1	7	3	2	7	25	40	46	42	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	X+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCTCCCTCCGACTTTGGAAACACCATATATTTTGGAGAG	CASSPPSDFGNTIYF	In	VDJ	1	49	1.6123565743016686E-4	2.023856727464975E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	5	2	10	3	9	1	25	37	50	46	51						01,02							Vb 3	CASSPPSDFGNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01	TCRBD02-01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCTCCGACAGGGGGGGCAATCAGCCCCAGCATTTTGGTGAT	CASSSDRGGNQPQHF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	2	1	2	4	1	25	36	49	40	50													Vb 3	CASSSDRGGNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCATCAACCAAGCCAACACCGGGGAGACCCAGTACTTCGGGCCA	CASINQANTGETQYF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	7	8	4	5	16	0	25	35	-1	51	55						01,02							Vb 3	CASINQANTGETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCGACCTGACGGACCTCCCTTGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	52	1.711072282932383E-4		50	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-01	01	6	1	7	0	9	6	25	36	49	45	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	X+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGTACACAGGGAACGGTCAGCCCCAGCATTTTGGTGAT	CASRYTGNGQPQHF	In	VDJ	1	52	1.711072282932383E-4	2.147766323024055E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	3	3	6	4	5	25	36	46	40	51													Vb 3	CASRYTGNGQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACCAATGGGGGGAGGGTCTACAATGAGCAGTTCTTCGGGCCA	CASTNGGRVYNEQFF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	9	0	3	8	1	25	35	50	43	51													Vb 3	CASTNGGRVYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCATGACAGCGAGTATGGACACTGAAGCTTTCTTTGGACAA	CASMTASMDTEAFF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	2	5	3	1	9	25	35	41	36	50													Vb 3	CASMTASMDTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCAAACAGGACGGGACTAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	54	1.7768827553528592E-4		49	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-05	01	5	0	7	0	10	0	25	37	-1	47	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	X+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCGGGGGAGATAATGAAAAACTGTTTTTTGGCAGT	CASSFGGDNEKLFF	In	VDJ	1	54	1.7768827553528592E-4	2.2303727200634416E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	3	8	2	4	0	3	25	-1	45	39	48													Vb 3	CASSFGGDNEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01	TCRBD02-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGAAGAGGGACATTTTACGAGCAGTACTTCGGGCCG	CASRRGTFYEQYF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	6	4	4	3	25	36	46	40	49													Vb 3	CASRRGTFYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGTTACGAGGGGGCGGGACACTGAAGCTTTCTTTGGACAA	CASSVTRGRDTEAFF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	5	0	3	6	3	25	37	50	43	53													Vb 3	CASSVTRGRDTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCGCGACTAGCGGCACGCACAGATACGCAGTATTTTGGCCCA	CASSSRLAARTDTQYF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	4	2	5	1	3	3	25	38	50	41	53						01,02							Vb 3	CASSSRLAARTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTGGGGGACAGACAGCCCCAGCATTTTGGTGAT	CASSLGDRQPQHF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	0	5	7	2	1	25	39	48	41	49													Vb 3	CASSLGDRQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCAGGGAACCTACGAGCAGTACTTCGGGCCG	CASSQGTYEQYF	In	VDJ	1	56	1.8426932277733357E-4	2.3129791171028284E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	4	3	2	1	2	25	36	42	37	44													Vb 3	CASSQGTYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAGGGCAGGGGTATGGCTACACCTTCGGTTCG	CASSLGQGYGYTF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	4	2	5	3	0	25	40	-1	43	49													Vb 3	CASSLGQGYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGGAATTCGGACAGAGTACGAGCAGTACTTCGGGCCG	CASSGIRTEYEQYF	In	VDJ	1	58	1.908503700193812E-4	2.395585514142215E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	5	4	7	2	25	37	50	44	52													Vb 3	CASSGIRTEYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCCTACACCCCAAACAGGGTTCGGTCAAGCGGGGAGCTGTTTTTTGGAGAA	CASSPYTPNRVRSSGELFF	In	VDJ	1	59	1.94140893640405E-4	2.4368887126619086E-4	57	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	3	3	7	13	10	24	36	55	49	65													Vb 3	CASSPYTPNRVRSSGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGTACCCTTCCGGGGACCTACGAGCAGTACTTCGGGCCG	CASTLPGTYEQYF	In	VDJ	1	59	1.94140893640405E-4	2.4368887126619086E-4	39	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	9	8	3	2	8	1	25	33	46	41	47													Vb 3	CASTLPGTYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGACAGTGAGCTACGAGCAGTACTTCGGGCCG	CASRTVSYEQYF	In	VDJ	1	60	1.974314172614288E-4	2.478191911181602E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	5	3	0	4	25	-1	41	36	45													Vb 3	CASRTVSYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCGGCAGGGACGGACCCTACGAGCAGTACTTCGGGCCG	CASGRDGPYEQYF	In	VDJ	1	60	1.974314172614288E-4	2.478191911181602E-4	39	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-07	01	8	0	7	2	4	4	25	34	43	38	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASGRDGPYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACCCTCCTCCCGGGGGATACGCAGTATTTTGGCCCA	CASTLLPGDTQYF	In	VDJ	1	61	2.0072194088245263E-4	2.5194951097012955E-4	39	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	7	8	3	6	9	0	25	35	-1	44	49													Vb 3	CASTLLPGDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACCGAGCCCGGACTAAATGAGCAGTTCTTCGGGCCA	CASTEPGLNEQFF	In	VDJ	1	61	2.0072194088245263E-4	2.5194951097012955E-4	39	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	7	1	9	7	8	0	25	35	-1	43	49						01,02							Vb 3	CASTEPGLNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCTACCCGGGACAGACTACAATCAGCCCCAGCATTTTGGTGAT	CASSLPGTDYNQPQHF	In	VDJ	1	63	2.0730298812450025E-4	2.602101506740682E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	0	5	3	7	4	25	36	50	43	54													Vb 3	CASSLPGTDYNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCACACCGGGACGTTTCTGAAGCTTTCTTTGGACAA	CASSPHRDVSEAFF	In	VDJ	1	63	2.0730298812450025E-4	2.602101506740682E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-01	01	5	0	7	6	7	4	25	37	49	44	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSPHRDVSEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCTGGATTTGGCATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	63	2.0730298812450025E-4		41	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-04	01	4	1	8	6	2	6	25	38	43	40	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	X+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTGACTAGCGACTACGAGCAGTACTTCGGGCCG	CASSLTSDYEQYF	In	VDJ	1	68	2.237556062296193E-4	2.8086174993391486E-4	39	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	3	2	6	3	0	1	25	-1	47	39	48						01,02							Vb 3	CASSLTSDYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTACGGGGGCGCTGACAGATACGCAGTATTTTGGCCCA	CASSFTGALTDTQYF	In	VDJ	1	68	2.237556062296193E-4	2.8086174993391486E-4	45	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-03	01	3	6	0	3	3	4	25	39	48	42	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSFTGALTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCATAGACAGGAGATACGAGCAGTACTTCGGGCCG	CASSIDRRYEQYF	In	VDJ	1	70	2.3033665347166695E-4	2.8912238963785356E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	4	4	4	3	25	36	46	40	49													Vb 3	CASSIDRRYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTACATTCTCGCGGCCCGGGACAGGTTTCTACGAGCAGTACTTCGGGCCG	CASSTFSRPGTGFYEQYF	In	VDJ	1	70	2.3033665347166695E-4	2.8912238963785356E-4	54	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	4	3	15	3	25	37	60	52	63													Vb 3	CASSTFSRPGTGFYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGACAGGGGGCGCAGATACGCAGTATTTTGGCCCA	CASRTGGADTQYF	In	VDJ	1	73	2.402082243347384E-4	3.015133491937616E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	2	0	4	0	1	25	-1	46	36	47													Vb 3	CASRTGGADTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCGGGGGACAGGGCGGTCCACGAGCAGTACTTCGGGCCG	CASSPGDRAVHEQYF	In	VDJ	1	74	2.434987479557622E-4	3.056436690457309E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	3	5	4	6	25	37	50	41	56													Vb 3	CASSPGDRAVHEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCGCGACAGAAACCCATCTACAATGAGCAGTTCTTCGGGCCA	CASSSRQKPIYNEQFF	In	VDJ	1	80	2.632418896819051E-4	3.3042558815754694E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	2	5	3	3	8	25	38	46	41	54													Vb 3	CASSSRQKPIYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTGACCTCCCAACCACTGAAGCTTTCTTTGGACAA	CASSFDLPTTEAFF	In	VDJ	1	80	2.632418896819051E-4	3.3042558815754694E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-01	01	3	2	7	4	1	8	25	39	43	40	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSFDLPTTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACACCCATAGGGGACAATTCTGGAAACACCATATATTTTGGAGAG	CASTPIGDNSGNTIYF	In	VDJ	1	81	2.6653241330292887E-4	3.3455590800951626E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	7	0	6	1	9	2	25	35	50	44	52													Vb 3	CASTPIGDNSGNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACCCGGCCGGGGGGCAGGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	81	2.6653241330292887E-4		46	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	7	8	1	1	6	3	25	35	48	41	51													Vb 3	X+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGACGGACTAGCGGGAGGACCCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	83	2.731134605449765E-4		49	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	1	1	4	3	3	25	37	54	40	57													Vb 3	X+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGGGGACAGCTCCTACGAGCAGTACTTCGGGCCG	CASSGDSSYEQYF	In	VDJ	1	85	2.7969450778702416E-4	3.510771874173936E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	5	0	1	0	25	37	-1	38	45													Vb 3	CASSGDSSYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCCATTATGGAGCGGGGGCTGACTCTGGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	86	2.8298503140804796E-4		59	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-06	01	5	6	2	0	10	4	22	34	52	44	56													Vb 3	X+TCRBV28-01+TCRBJ02-06	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTACGCCCCTCTCTGGAAACACCATATATTTTGGAGAG	CASSTPLSGNTIYF	In	VDJ	1	88	2.895660786500956E-4	3.634681469733016E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-03	01	5	3	7	0	0	6	25	-1	39	37	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSTPLSGNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACCATGGGGGTCTGGAGAGCAGTTCTTCGGGCCA		Out	VDJ	1	90	2.961471258921432E-4		37	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-01	01	7	6	1	10	4	6	25	35	44	39	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	X+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCCCACAGGGGGCCGCCCGCCCCAGCATTTTGGTGAT	CASSPTGGRPPQHF	In	VDJ	1	91	2.9943764951316705E-4	3.7585910652920964E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	3	0	9	4	5	25	36	49	40	54													Vb 3	CASSPTGGRPPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGACCCTTGAACACTGAAGCTTTCTTTGGACAA	CASRPLNTEAFF	In	VDJ	1	92	3.0272817313419084E-4	3.7998942638117896E-4	36	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-01	01	6	3	7	0	0	3	25	-1	38	36	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASRPLNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCATACCCTCGAAGACAATCATTAATGAAAAACTGTTTTTTGGCAGT	CASIPSKTIINEKLFF	In	VDJ	1	93	3.0601869675521464E-4	3.841197462331483E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	7	2	6	4	10	5	25	35	49	45	54													Vb 3	CASIPSKTIINEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTGGCGACTAGCGGGACACACCGGGGAGCTGTTTTTTGGAGAA	CASSWRLAGHTGELFF	In	VDJ	1	94	3.093092203762385E-4	3.882500660851176E-4	48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	4	2	3	3	3	1	25	38	52	41	53													Vb 3	CASSWRLAGHTGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGGGTAGGATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	95	3.125997439972623E-4		35	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-04	01	6	0	9	6	0	4	25	-1	39	36	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	X+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGACCAGGACAGGGGAATCAGCCCCAGCATTTTGGTGAT	CASRPGQGNQPQHF	In	VDJ	1	98	3.224713148603337E-4	4.04771345492995E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	1	2	4	4	0	25	36	-1	40	49													Vb 3	CASRPGQGNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCGGGCCAGGGGCCCTCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASGPGALSGANVLTF	In	VDJ	1	98	3.224713148603337E-4	4.04771345492995E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	8	4	2	0	4	4	25	34	44	38	48													Vb 3	CASGPGALSGANVLTF+TCRBV28-01+TCRBJ02-06	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGCCGTGGAGAGCTGGGCCAACGTCCTGACTTTCGGGGCC	CASSAVESWANVLTF	In	VDJ	1	100	3.2905236210238137E-4	4.1303198519693365E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	5	10	2	5	5	4	25	37	46	42	50													Vb 3	CASSAVESWANVLTF+TCRBV28-01+TCRBJ02-06	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTACTTACAGGGGCTGGAAACACCATATATTTTGGAGAG	CASSLLTGAGNTIYF	In	VDJ	1	101	3.3234288572340517E-4	4.1716230504890297E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	2	3	2	2	3	0	25	40	-1	43	50													Vb 3	CASSLLTGAGNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCGGACAGGGGAAGAGAAACACCATATATTTTGGAGAG	CASSSGQGKRNTIYF	In	VDJ	1	102	3.3563340934442896E-4	4.2129262490087234E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	4	1	2	5	2	4	25	38	49	40	53													Vb 3	CASSSGQGKRNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCGGGACGGAAGTTTCAATCAGCCCCAGCATTTTGGTGAT	CASSRDGSFNQPQHF	In	VDJ	1	104	3.422144565864766E-4	4.29553264604811E-4	45	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-05	01	6	0	7	3	2	8	25	36	43	38	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSRDGSFNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGCCTCAAGTCCGGCGAGCAACTAATGAAAAACTGTTTTTTGGCAGT	CASRPQVRRATNEKLFF	In	VDJ	2	108	3.5537655107057185E-4	4.4607454401268833E-4	51	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-04	01	6	9	0	0	11	3	25	36	50	47	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASRPQVRRATNEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTACCCACAGTTGGGGGAGCAGTACTTCGGGCCG	CASSYPQLGEQYF	In	VDJ	2	109	3.586670746915957E-4	4.502048638646577E-4	39	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-07	01	4	3	5	7	4	6	25	38	46	42	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSYPQLGEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTGGGGCCCCGACAGGGAACTATGGCTACACCTTCGGTTCG	CASSFGAPTGNYGYTF	In	VDJ	2	110	3.619575983126195E-4	4.5433518371662703E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	2	3	2	9	0	25	39	-1	48	55													Vb 3	CASSFGAPTGNYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCTCGGTGACCTACGAGCAGTACTTCGGGCCG	CASSSVTYEQYF	In	VDJ	2	119	3.915723109018338E-4	4.91508062384351E-4	36	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	8	5	2	2	3	25	36	41	38	44						01,02							Vb 3	CASSSVTYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGAGGTCCTCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	121	3.9815335814388146E-4		41	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	11	1	0	0	4	25	-1	40	36	44													Vb 3	X+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCAGGGGGGGAAGAGGTTCCTACGAGCAGTACTTCGGGCCG	CASSFRGGRGSYEQYF	In	VDJ	2	121	3.9815335814388146E-4	4.997687020882897E-4	48	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-07	01	3	4	1	1	0	9	25	-1	46	39	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSFRGGRGSYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAATAGCGGCGGGTCGGACGAGCAGTACTTCGGGCCG	CASNSGGSDEQYF	In	VDJ	2	122	4.0144388176490526E-4	5.038990219402591E-4	39	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	7	5	5	5	1	8	25	35	42	36	50						01,02							Vb 3	CASNSGGSDEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCGCGGGGGCGGTACGAGCAGTACTTCGGGCCG		Out	VDJ	2	122	4.0144388176490526E-4		40	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	3	7	2	4	1	3	25	39	47	40	50													Vb 3	X+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAATCCGGCGTGGGGAGGTAGCACAGATACGCAGTATTTTGGCCCA	CASNPAWGGSTDTQYF	In	VDJ	2	124	4.0802492900695285E-4	5.121596616441978E-4	48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	7	9	1	0	10	1	25	35	51	45	52													Vb 3	CASNPAWGGSTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTACCAACAGTTTAAATCCTGGAGGGGACTATGGCTACACCTTCGGTTCG	CTNSLNPGGDYGYTF	In	VDJ	2	126	4.146059762490005E-4	5.204203013481364E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	2	10	0	3	6	1	25	40	52	46	53													Vb 3	CTNSLNPGGDYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCGGCCGGGCTAGCGGGAGGTTGGAACGAGCAGTACTTCGGGCCG	CASSSAGLAGGWNEQYF	In	VDJ	2	126	4.146059762490005E-4	5.204203013481364E-4	51	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	4	1	5	8	5	25	38	57	46	62													Vb 3	CASSSAGLAGGWNEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCCACTTTCCGCCCTAGACAGATACGCAGTATTTTGGCCCA	CASSFHFPP*TDTQYF	Stop	VDJ	2	130	4.2776807073309573E-4		48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	4	8	3	12	0	25	39	-1	51	55						01,02							Vb 3	CASSFHFPP*TDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTACTCCAGCGGGGGGCTCCTACGAGCAGTACTTCGGGCCG	CASSTPAGGSYEQYF	In	VDJ	2	133	4.376396415961672E-4	5.493325403119218E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	6	1	0	5	0	25	37	-1	42	51													Vb 3	CASSTPAGGSYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCCAACAGGGCCTGAAAACATTCAGTACTTCGGCGCC	CASSPTGPENIQYF	In	VDJ	2	135	4.442206888382148E-4	5.575931800158604E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	6	3	3	5	4	4	25	36	46	40	50													Vb 3	CASSPTGPENIQYF+TCRBV28-01+TCRBJ02-04	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCGCAAGGGGACAGTCTTCTGAAGCTTTCTTTGGACAA	CASSARGQSSEAFF	In	VDJ	2	136	4.475112124592386E-4	5.617234998678297E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	0	5	6	6	4	25	36	49	42	53													Vb 3	CASSARGQSSEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCTCGGACAGGGAATTTTACAATGAGCAGTTCTTCGGGCCA	CASSSDREFYNEQFF	In	VDJ	2	136	4.475112124592386E-4	5.617234998678297E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	1	3	4	3	5	25	36	47	39	52													Vb 3	CASSSDREFYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCGAAACTCCGGGGCCCACCTATGAAGCTTTCTTTGGACAA	CASETPGPTYEAFF	In	VDJ	2	138	4.5409225970128626E-4	5.699841395717685E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-01	01	8	7	0	7	8	7	25	34	47	42	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASETPGPTYEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCCGTAATGGGGGGGCCCGTAGTGAAGCTTTCTTTGGACAA	CASRNGGARSEAFF	In	VDJ	2	140	4.606733069433339E-4	5.782447792757071E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	8	9	0	7	6	7	25	34	47	40	54													Vb 3	CASRNGGARSEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGCAATCGGGGGTTATGGGCTATGGCTACACCTTCGGTTCG	CASRQSGVMGYGYTF	In	VDJ	2	143	4.7054487780640535E-4	5.906357388316151E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	6	8	2	4	5	7	25	36	47	41	54													Vb 3	CASRQSGVMGYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCCACCTAGCGGACTCACAGATACGCAGTATTTTGGCCCA	CASSPPSGLTDTQYF	In	VDJ	2	145	4.7712592504845294E-4	5.988963785355538E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	4	5	2	5	3	25	36	48	41	51						01,02							Vb 3	CASSPPSGLTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCTGAGGACCTCGGGCCAAAAACATTCAGTACTTCGGCGCC	CASS*GPRAKNIQYF	Stop	VDJ	2	149	4.902880195325482E-4		45	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-04	01	6	1	7	1	4	5	25	36	44	40	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASS*GPRAKNIQYF+TCRBV28-01+TCRBJ02-04	TCRBV28-01*01		TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTGGGGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSWGSYNEQFF	In	VDJ	2	150	4.93578543153572E-4	6.195479777954004E-4	39	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-01	01	4	6	2	0	0	0	25	-1	-1	38	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSWGSYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGGTCGACGTCTCTGGAAACACCATATATTTTGGAGAG	CASRVDVSGNTIYF	In	VDJ	2	151	4.968690667745959E-4	6.236782976473698E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-03	01	6	2	7	0	4	2	25	36	43	40	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASRVDVSGNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGACCCCAGGGTGCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASRPQGAGANVLTF	In	VDJ	2	152	5.001595903956197E-4	6.278086174993392E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	6	4	3	2	4	2	25	36	45	40	47													Vb 3	CASRPQGAGANVLTF+TCRBV28-01+TCRBJ02-06	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACCGAAGTGGGACACGTCGGGCGAAATGAAAAACTGTTTTTTGGCAGT	CASTEVGHVGRNEKLFF	In	VDJ	2	153	5.034501140166435E-4	6.319389373513085E-4	51	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	7	0	6	5	7	10	25	35	48	42	58													Vb 3	CASTEVGHVGRNEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTACAACCAGGGGCAATCAGCCCCAGCATTTTGGTGAT	CASSTTRGNQPQHF	In	VDJ	2	154	5.067406376376673E-4	6.360692572032778E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	4	3	2	5	0	25	37	-1	42	47													Vb 3	CASSTTRGNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCATGGGACAGATTTAAAGGAGACCCAGTACTTCGGGCCA	CASSHGTDLKETQYF	In	VDJ	2	156	5.133216848797149E-4	6.443298969072165E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	0	5	5	4	8	25	36	47	40	55													Vb 3	CASSHGTDLKETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCAACACGGTTGGAAAAACTGTTTTTTGGCAGT	CASSSTRLEKLFF	In	VDJ	2	158	5.199027321217626E-4	6.525905366111551E-4	39	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-04	01	4	3	6	8	2	6	25	38	43	40	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSSTRLEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCGCGACAATGGCAGGTCACAATGAGCAGTTCTTCGGGCCA	CASSATMAGHNEQFF	In	VDJ	2	164	5.396458738479054E-4	6.773724557229712E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	2	6	5	3	10	25	36	43	39	53													Vb 3	CASSATMAGHNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCCGGGACAGACCGGACTAGCCAAAAACATTCAGTACTTCGGCGCC	CASSPGQTGLAKNIQYF	In	VDJ	2	177	5.82422680921215E-4	7.310666137985726E-4	51	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	6	0	5	0	3	8	25	36	46	39	54													Vb 3	CASSPGQTGLAKNIQYF+TCRBV28-01+TCRBJ02-04	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTGTTGTACTCTGGCTACACCTTCGGTTCG	CASSLLYSGYTF	In	VDJ	3	183	6.021658226473579E-4	7.558485329103886E-4	36	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	3	3	10	7	5	1	25	39	47	44	48						01,02							Vb 3	CASSLLYSGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCAGAACCAGGGTTTTTTCCGTACTTCGGGCCG	CASSPEPGFFPYF	In	VDJ	3	186	6.120373935104293E-4	7.682394924662966E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	3	12	7	8	25	37	49	44	57													Vb 3	CASSPEPGFFPYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCTCGACAGGGGATGGAGTCTATGGCTACACCTTCGGTTCG	CASSTGDGVYGYTF	In	VDJ	3	187	6.153279171314532E-4	7.723698123182659E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	8	2	2	4	2	7	25	34	44	36	51													Vb 3	CASSTGDGVYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCTCCTCAGGGGCCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSSSGASYNEQFF	In	VDJ	3	189	6.219089643735008E-4	7.806304520222046E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	4	2	0	5	1	25	36	47	41	48													Vb 3	CASSSSGASYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACCCAACCTAGCGGGGGTTTCAATGAGCAGTTCTTCGGGCCA	CASTQPSGGFNEQFF	In	VDJ	3	195	6.416521060996437E-4	8.054123711340206E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	7	4	2	6	6	3	25	35	51	41	54													Vb 3	CASTQPSGGFNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGGTACTCGACTCCTTTGAGCAGTTCTTCGGGCCA	CASRVLDSFEQFF	In	VDJ	3	206	6.778478659309056E-4	8.508458895056833E-4	39	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	2	10	9	7	4	25	36	47	43	51						01,02							Vb 3	CASRVLDSFEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCTGGGGGGGGGCGCAGAATCAGCCCCAGCATTTTGGTGAT	CASWGGAQNQPQHF	In	VDJ	3	209	6.87719436793977E-4	8.632368490615913E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	8	9	0	4	1	7	25	34	42	35	49													Vb 3	CASWGGAQNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD02-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTGACGACAGGGGAGTATGGCTACACCTTCGGTTCG	CASSLTTGEYGYTF	In	VDJ	3	231	7.60110956456501E-4	9.541038858049167E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	2	2	5	3	2	25	39	50	42	52													Vb 3	CASSLTTGEYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCGGACGTCGGGGGGGAGCCAAAAACATTCAGTACTTCGGCGCC	CASGRRGGAKNIQYF	In	VDJ	3	235	7.732730509405961E-4	9.706251652127941E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-04	01	8	8	0	0	6	0	25	34	-1	40	48													Vb 3	CASGRRGGAKNIQYF+TCRBV28-01+TCRBJ02-04	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCCGGGACAGGGCCCAATGAAAAACTGTTTTTTGGCAGT	CASSPGTGPNEKLFF	In	VDJ	3	246	8.094688107718581E-4	0.0010160586835844569	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	0	3	5	3	3	25	37	49	40	52													Vb 3	CASSPGTGPNEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACCTCATCGGGACTAGCATCCTACGAGCAGTACTTCGGGCCG	CASTSSGLASYEQYF	In	VDJ	3	251	8.259214288769772E-4	0.0010367102828443035	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	7	0	7	1	7	1	25	35	51	42	52						01,02							Vb 3	CASTSSGLASYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCGGACTGAGCCACGATACGCAGTATTTTGGCCCA	CASGLSHDTQYF	In	VDJ	4	252	8.29211952498001E-4	0.0010408406026962728	36	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	8	1	10	6	0	7	25	-1	39	34	46						01,02							Vb 3	CASGLSHDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCCGGACAGACAATTCACCCCTCCACTTTGGGAAC	CASSSRTDNSPLHF	In	VDJ	4	259	8.522456178451677E-4	0.0010697528416600583	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	1	5	7	3	2	25	38	47	41	49													Vb 3	CASSSRTDNSPLHF+TCRBV28-01+TCRBJ01-06	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGAACATCCGACTAGCGGGATACGAGCAGTACTTCGGGCCG	CASRNIRLAGYEQYF	In	VDJ	4	263	8.65407712329263E-4	0.0010862741210679355	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	2	3	4	8	0	25	36	-1	44	55													Vb 3	CASRNIRLAGYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGAACGCCCATGCTAGCGGGGGAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	4	284	9.34508708370763E-4		52	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	6	4	2	0	10	0	25	36	-1	46	56													Vb 3	X+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGAGGTCGGGACAGGGGGCAGCCCTGGAAACACCATATATTTTGGAGAG	CASSEVGTGGSPGNTIYF	In	VDJ	4	294	9.674139445810012E-4	0.001214314036478985	54	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	0	0	2	6	4	25	37	55	43	59													Vb 3	CASSEVGTGGSPGNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCACCGTAGTGTTTCGTCAGACGATACGCAGTATTTTGGCCCA		Out	VDJ	4	301	9.904476099281679E-4		49	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-03	01	5	2	7	6	19	0	25	37	-1	56	59				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	X+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATCTGGCATTTACTCCTACGAGCAGTACTTCGGGCCG	CASSLSGIYSYEQYF	In	VDJ	4	303	9.970286571702154E-4	0.001251486915146709	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	9	0	0	2	5	25	41	46	43	51													Vb 3	CASSLSGIYSYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCCCCGGGACAGGGTCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	4	315	0.0010365149406225012		46	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	3	0	5	1	25	37	51	42	52													Vb 3	X+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCGGGACTAGCGGACCGTGGGATGAGCAGTTCTTCGGGCCA	CASGTSGPWDEQFF	In	VDJ	5	330	0.0010858727949378585	0.001363005551149881	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	8	0	5	8	0	8	25	-1	45	34	53						01,02							Vb 3	CASGTSGPWDEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCCTTGGGGATTTGGGAGAGACCCAGTACTTCGGGCCA	CASSFLGDLGETQYF	In	VDJ	5	332	0.001092453842179906	0.0013712661908538196	45	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-05	01	3	0	8	4	5	6	25	39	48	44	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSFLGDLGETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTTCTGTTCCGAGACAGGGGAGTTGTGGCTACACCTTCGGTTCG	CASSFSVPRQGSCGYTF	In	VDJ	5	344	0.0011319401256321918	0.0014208300290774517	51	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	2	2	7	11	5	25	39	58	50	63													Vb 3	CASSFSVPRQGSCGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCCTAGGGGGACAGGGGAACACTGAAGCTTTCTTTGGACAA	CASSSLGGQGNTEAFF	In	VDJ	5	365	0.0012010411216736919	0.0015075667459688079	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	0	3	1	7	0	25	38	-1	45	54													Vb 3	CASSSLGGQGNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACTTCGGACACCTACGAGCAGTACTTCGGGCCG	CASTSDTYEQYF	In	VDJ	5	376	0.001237236881504954	0.0015530002643404704	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	1	6	2	4	0	25	35	-1	39	44													Vb 3	CASTSDTYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTGGGAGGACGGGTCTACAATGAGCAGTTCTTCGGGCCA	CASSLGGRVYNEQFF	In	VDJ	6	418	0.001375438873587954	0.0017264736981231826	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	9	1	3	0	6	25	-1	45	39	51													Vb 3	CASSLGGRVYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCGATCGGGACTCTTTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	7	472	0.00155312714912324		47	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	0	10	1	5	3	25	37	48	42	51						01,02							Vb 3	X+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAGGGTTACAGGTGGGAGGCTACACCTTCGGTTCG	CASSLGLQVGGYTF	In	VDJ	7	482	0.001586032385333478	0.00199081416864922	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	3	4	8	5	5	25	40	50	45	55													Vb 3	CASSLGLQVGGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATCCCCGGGACACTCTGCTGGAAACACCATATATTTTGGAGAG	CASSLSPGHSAGNTIYF	In	VDJ	7	522	0.0017176533301744307	0.002156026962727994	51	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	1	0	6	2	4	5	25	41	51	45	56													Vb 3	CASSLSPGHSAGNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCTTCCATCCGGAGGGGCCCAGAGATACGCAGTATTTTGGCCCA	CASSFHPEGPRDTQYF	In	VDJ	10	716	0.0023560149126530504	0.002957309014010045	48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	6	10	0	5	9	6	25	36	51	45	57													Vb 3	CASSFHPEGPRDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCGGGCAGGGTTTAACAGATACGCAGTATTTTGGCCCA	CASSFGQGLTDTQYF	In	VDJ	15	1087	0.0035767991760528852	0.0044896576790906684	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	4	3	3	4	4	25	39	48	43	52													Vb 3	CASSFGQGLTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAGGCGGGAGGGTATACAATGAGCAGTTCTTCGGGCCA	CASSLGGRVYNEQFF	In	VDJ	20	1465	0.004820617104799887	0.006050918583135078	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	7	0	4	1	2	25	40	50	41	52													Vb 3	CASSLGGRVYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGATTCGGGACAGGAATAATCAATGAGCAGTTCTTCGGGCCA	CASRFGTGIINEQFF	In	VDJ	115	8273	0.027222501916730008	0.03417013613534232	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	0	4	6	4	6	25	36	48	40	54													Vb 3	CASRFGTGIINEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCAAGTCGCTCACGGGGGGGGGTCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	22	7.23915196625239E-5		41	TCRBV12	TCRBV12-02	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	4	8	0	6	2	2	18	31	41	33	43														X+TCRBV12-02+TCRBJ01-05	TCRBV12-02*01	TCRBD02-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCGAGGAGGGCGGGGGGCCGCATTTCTACAATGAGCAGTTCTTCGGGCCA	CAEEGGGPHFYNEQFF	In	VDJ	1	54	1.7768827553528592E-4	2.2303727200634416E-4	48	TCRBV12	TCRBV12-02	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	12	7	1	3	8	8	18	23	39	31	47														CAEEGGGPHFYNEQFF+TCRBV12-02+TCRBJ02-01	TCRBV12-02*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCAAGTCGCTTAGATAGGCGGGGTAACGGACTGAACACTGAAGCTTTCTTTGGACAA	CASRLDRRGNGLNTEAFF	In	VDJ	1	62	2.0401246450347642E-4	2.560798308220989E-4	54	TCRBV12	TCRBV12-02	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	1	7	3	0	4	8	18	34	44	38	52														CASRLDRRGNGLNTEAFF+TCRBV12-02+TCRBJ01-01	TCRBV12-02*01	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGTTCGGCAGATGTTATGAACACTGAAGCTTTCTTTGGACAA	CASSADVMNTEAFF	In	VDJ	1	79	2.599513660608813E-4	3.2629526830557756E-4	42	TCRBV12	TCRBV12-02	01				TCRBJ01	TCRBJ01-01	01	8	4	5	0	4	6	18	27	34	31	40				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSADVMNTEAFF+TCRBV12-02+TCRBJ01-01	TCRBV12-02*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAAAGGGGCTTCACCCAACGAGCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	83	2.731134605449765E-4		49	TCRBV12	TCRBV12-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	12	5	2	0	3	14	18	23	31	26	45														X+TCRBV12-02+TCRBJ02-01	TCRBV12-02*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCAAGTCGCCTAGGGACTCAAGCTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	2	119	3.915723109018338E-4		47	TCRBV12	TCRBV12-02	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	1	1	10	0	0	4	18	-1	39	34	43						01,02								X+TCRBV12-02+TCRBJ01-03	TCRBV12-02*01	TCRBD02-01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGTTTATGGGGGGGCCAGAGCGGCTACACCTTCGGTTCG	CASSLWGGQSGYTF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	42	TCRBV27	TCRBV27-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	1	9	0	8	0	7	23	-1	46	39	53													Vb 14	CASSLWGGQSGYTF+TCRBV27-01+TCRBJ01-02	TCRBV27-01*01	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGTTTCGCCGGGGGTAGTAATGAAAAACTGTTTTTTGGCAGT	CASSFAGGSNEKLFF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	45	TCRBV27	TCRBV27-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	3	8	2	4	3	3	23	37	46	40	49													Vb 14	CASSFAGGSNEKLFF+TCRBV27-01+TCRBJ01-04	TCRBV27-01*01	TCRBD02-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGGGGGCCAGGGATCGGTAGCGACACTGAAGCTTTCTTTGGACAA	CASRGPGIGSDTEAFF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	48	TCRBV27	TCRBV27-01	01				TCRBJ01	TCRBJ01-01	01	6	4	3	3	5	10	23	34	44	39	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 14	CASRGPGIGSDTEAFF+TCRBV27-01+TCRBJ01-01	TCRBV27-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGTCCGGGACAGGGCAATCAGCCCCAGCATTTTGGTGAT	CASSPGQGNQPQHF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	42	TCRBV27	TCRBV27-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	0	4	2	2	0	23	35	-1	37	45													Vb 14	CASSPGQGNQPQHF+TCRBV27-01+TCRBJ01-05	TCRBV27-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCGGTAAATTAGGGGATCCTGGCTACACCTTCGGTTCG	CASGKLGDPGYTF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	39	TCRBV27	TCRBV27-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	8	5	2	7	8	4	23	32	45	40	49													Vb 14	CASGKLGDPGYTF+TCRBV27-01+TCRBJ01-02	TCRBV27-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGTTTCCGGGTGGGATATGGCTACACCTTCGGTTCG	CASSFRVGYGYTF	In	VDJ	1	52	1.711072282932383E-4	2.147766323024055E-4	39	TCRBV27	TCRBV27-01	01				TCRBJ01	TCRBJ01-02	01	3	0	8	5	6	0	23	37	-1	43	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 14	CASSFRVGYGYTF+TCRBV27-01+TCRBJ01-02	TCRBV27-01*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GTTTGGTGGCCCTGAAGACAGCAGCAATATCTCTGCAGCGCATCGGACCAAGTGGGGTCTGGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	20	6.581047242047627E-5		47	TCRBV29	TCRBV29-01	01				TCRBJ02	TCRBJ02-06	01	22	1	7	1	18	9	34	26	48	44	57				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	X+TCRBV29-01+TCRBJ02-06	TCRBV29-01*01		TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTCAAAAGAAGGTGGGGGGGGTATTTCAATGGCTACACCTTCGGTTCG	CSVKRRWGGYFNGYTF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	48	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	6	9	0	6	11	8	25	33	51	44	59													Vb 4	CSVKRRWGGYFNGYTF+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGACGGCGGGGATACGCAGTATTTTGGCCCA	CSVEDGGDTQYF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	36	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	7	4	6	2	0	25	39	-1	41	46						01,02							Vb 4	CSVEDGGDTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGGCCGCCTAGCGGTTAGCACAGATACGCAGTATTTTGGCCCA	CSVEGRLAVSTDTQYF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	48	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	4	5	0	5	2	25	38	50	43	52						01,02							Vb 4	CSVEGRLAVSTDTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTAAAACATCACAGGGGTGGGACGAGCAGTACTTCGGGCCG	CSVKTSQGWDEQYF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	42	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	3	2	5	8	4	25	34	49	42	53													Vb 4	CSVKTSQGWDEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAAAGGAAGAAGGACTCCCCACCGAACACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	34	1.1187780311480965E-4		55	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	2	1	10	2	9	10	25	37	51	46	61						01,02							Vb 4	X+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGACAGTCCAGGCGCTGAAGCTTTCTTTGGACAA	CSVDSPGAEAFF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	36	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	4	6	5	2	25	36	45	41	47													Vb 4	CSVDSPGAEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCGGCAGAACAGGGAGTGGGAGGCTACACCTTCGGTTCG	CSAAEQGVGGYTF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	3	3	8	7	7	25	32	45	39	52													Vb 4	CSAAEQGVGGYTF+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGTTTTGGGGAACTATGGCTACACCTTCGGTTCG	CSVVLGNYGYTF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	36	TCRBV29	TCRBV29-01	01				TCRBJ01	TCRBJ01-02	01	4	6	2	2	4	0	25	35	-1	39	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVVLGNYGYTF+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCAGCATATATCTCTGCAGCGTTGGACGGGGATGACATGGTAGAAGGACAGGGAGCGTGGGGGACCCAGTACTTCGGGCCA		Out	VDJ	1	36	1.1845885035685729E-4		61	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	1	3	7	21	9	14	24	53	45	62													Vb 4	X+TCRBV29-01+TCRBJ02-05	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTAGTGGACAGGGAACTGAGCAGTACTTCGGGCCG	CSVSGQGTEQYF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	36	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	3	7	3	4	25	34	45	37	49													Vb 4	CSVSGQGTEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAGAGAGGGGAAGGAGGGTATGGCTACACCTTCGGTTCG	CSVERGEGGYGYTF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	42	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	3	10	0	5	10	0	25	36	-1	46	52													Vb 4	CSVERGEGGYGYTF+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCCCCCCGACAGACCCCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	46	1.5136408656709542E-4		41	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	7	2	5	3	6	4	25	32	43	38	47													Vb 4	X+TCRBV29-01+TCRBJ01-05	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGACTTAGGGGGGACAGGGGCAACTGAAGCTTTCTTTGGACAA	CSVDLGGTGATEAFF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	45	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	0	2	5	7	2	25	36	53	43	55													Vb 4	CSVDLGGTGATEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCATCAGACAGGGGGAAGACTGAAGCTTTCTTTGGACAA	CSASDRGKTEAFF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	2	1	5	5	3	25	32	46	37	49													Vb 4	CSASDRGKTEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAGCGGCAGCGCGAGACCCAGTACTTCGGGCCA	CSVERQRETQYF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	36	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	3	6	6	5	5	1	25	36	45	41	46						01,02							Vb 4	CSVERQRETQYF+TCRBV29-01+TCRBJ02-05	TCRBV29-01*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGCTTCAGCGGGGGTAGGCTACGAGCAGTACTTCGGGCCG	CSVASAGVGYEQYF	In	VDJ	1	58	1.908503700193812E-4	2.395585514142215E-4	42	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	4	6	2	3	4	4	25	35	47	39	51													Vb 4	CSVASAGVGYEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGGAACGGGACAGTCCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	63	2.0730298812450025E-4		37	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	0	5	2	4	2	25	32	43	36	45													Vb 4	X+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGACGAGGAGGGGGCTTCCCCAGATACGCAGTATTTTGGCCCA	CSDEEGASPDTQYF	In	VDJ	1	66	2.171745589875717E-4	2.726011102299762E-4	42	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	7	5	0	4	6	5	25	32	45	38	50													Vb 4	CSDEEGASPDTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAGAGGGGCGGGAGGAGAAAGACCCAGTACTTCGGGCCA	CSVERGGRRKTQYF	In	VDJ	1	66	2.171745589875717E-4	2.726011102299762E-4	42	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	3	7	1	6	5	4	25	36	49	41	53													Vb 4	CSVERGGRRKTQYF+TCRBV29-01+TCRBJ02-05	TCRBV29-01*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGCCAGGGGGATGAAAAACTGTTTTTTGGCAGT	CSVGQGDEKLFF	In	VDJ	1	69	2.2704612985064313E-4	2.8499206978588424E-4	36	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	4	1	6	2	0	25	35	-1	37	44													Vb 4	CSVGQGDEKLFF+TCRBV29-01+TCRBJ01-04	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGAGATTCCACCGGGGAGCTGTTTTTTGGAGAA	CSVGDSTGELFF	In	VJ	1	77	2.5337031881883363E-4	3.180346286016389E-4	36	TCRBV29	TCRBV29-01	01				TCRBJ02	TCRBJ02-02	01	0	0	0	4	0	3	25	-1	39	-1	42													Vb 4	CSVGDSTGELFF+TCRBV29-01+TCRBJ02-02	TCRBV29-01*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGTGGGGGAACCTACGAGCAGTACTTCGGGCCG	CSVGGGTYEQYF	In	VDJ	1	85	2.7969450778702416E-4	3.510771874173936E-4	36	TCRBV29	TCRBV29-01	01				TCRBJ02	TCRBJ02-07	01	4	6	1	2	2	2	25	35	42	37	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVGGGTYEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGCTCCTAGCACAGATACGCAGTATTTTGGCCCA	CSVAPSTDTQYF	In	VDJ	1	99	3.257618384813575E-4	4.089016653449643E-4	36	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	4	4	10	0	0	3	25	-1	37	35	40						01,02							Vb 4	CSVAPSTDTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGTGCTCAGGGGATAGGATTTACTGAAGCTTTCTTTGGACAA	CSAQGIGFTEAFF	In	VDJ	1	106	3.4879550382852425E-4	4.378139043087497E-4	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	9	4	2	5	4	9	25	30	40	34	49													Vb 4	CSAQGIGFTEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTGATAGACAGGGGTCGAGCAGATACGCAGTATTTTGGCCCA	CSVIDRGRADTQYF	In	VDJ	2	111	3.652481219336433E-4	4.5846550356859635E-4	42	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	2	2	4	4	5	25	33	45	37	50													Vb 4	CSVIDRGRADTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGACCAGGACGGAACCTACGAGCAGTACTTCGGGCCG	CSVEDQDGTYEQYF	In	VDJ	2	131	4.310585943541196E-4	5.410719006079831E-4	42	TCRBV29	TCRBV29-01	01				TCRBJ02	TCRBJ02-07	01	0	1	7	2	3	4	25	39	46	42	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVEDQDGTYEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTCGCTAGCGGGGGTTTATCCGAGCAGTACTTCGGGCCG	CSVASGGLSEQYF	In	VDJ	2	151	4.968690667745959E-4	6.236782976473698E-4	39	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	4	2	6	2	6	25	33	45	35	51													Vb 4	CSVASGGLSEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTCGGGTAGCGGGAGGCCTTATTCAAGAGACCCAGTACTTCGGGCCA	CSVRVAGGLIQETQYF	In	VDJ	2	173	5.692605864371197E-4	7.145453343906952E-4	48	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	5	1	2	4	7	25	34	48	38	55													Vb 4	CSVRVAGGLIQETQYF+TCRBV29-01+TCRBJ02-05	TCRBV29-01*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAATCAGGGGGGAGCAACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	3	222	7.304962438672866E-4		46	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	2	4	1	0	1	3	25	37	45	38	48													Vb 4	X+TCRBV29-01+TCRBJ01-04	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGTGGGACAGGGGGGCCTTTGGGCTGAAGCTTTCTTTGGACAA	CSVVGQGGLWAEAFF	In	VDJ	3	224	7.370772911093343E-4	9.251916468411313E-4	45	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	0	1	6	1	9	25	35	47	36	56													Vb 4	CSVVGQGGLWAEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGAGCGGACGAGATGAACACTGAAGCTTTCTTTGGACAA	CRADEMNTEAFF	In	VDJ	3	251	8.259214288769772E-4	0.0010367102828443035	36	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	9	6	5	0	0	6	25	-1	35	30	41						01,02							Vb 4	CRADEMNTEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTCGGAGGGCAGGGGGGAGATACGCAGTATTTTGGCCCA	CSVGGQGGDTQYF	In	VDJ	4	255	8.390835233610725E-4	0.0010532315622521808	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	4	1	5	7	1	25	33	47	40	48													Vb 4	CSVGGQGGDTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAAAGGGAGTCCTTGATGAGCAGTTCTTCGGGCCA	CSVEKGVLDEQFF	In	VDJ	4	308	0.0010134812752753345	0.0012721385144065557	39	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	9	2	8	2	6	25	37	44	39	50													Vb 4	CSVEKGVLDEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGCTAGCGGGGGCTACGAGCAGTACTTCGGGCCG	CSVASGGYEQYF	In	VDJ	4	318	0.0010463865114855727	0.0013134417129262491	36	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	4	4	2	3	0	0	25	-1	-1	35	45													Vb 4	CSVASGGYEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGATGGACAGGACTACGACTCCGCGGAGACCCAGTACTTCGGGCCA	CSVDGQDYDSAETQYF	In	VDJ	5	358	0.0011780074563265252	0.0014786545070050224	48	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	1	4	5	1	14	25	36	44	37	58													Vb 4	CSVDGQDYDSAETQYF+TCRBV29-01+TCRBJ02-05	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCATCGGACCAAGTGGGGTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CSASDQVGSGANVLTF	In	VDJ	34	2414	0.007943324021151487	0.009970592122653978	48	TCRBV29	TCRBV29-01	01				TCRBJ02	TCRBJ02-06	01	7	1	7	1	4	9	25	32	40	36	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSASDQVGSGANVLTF+TCRBV29-01+TCRBJ02-06	TCRBV29-01*01		TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCACTCCGGGACGATAGGAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	20	6.581047242047627E-5		41	TCRBV02	TCRBV02-01	01				TCRBJ02	TCRBJ02-03	01	7	0	7	5	4	6	23	33	42	37	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 22	X+TCRBV02-01+TCRBJ02-03	TCRBV02-01*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGGACAGGGGTCACCTACGAGCAGTACTTCGGGCCG	CASRTGVTYEQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	39	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	2	2	0	3	23	-1	42	34	45													Vb 22	CASRTGVTYEQYF+TCRBV02-01+TCRBJ02-07	TCRBV02-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGGTTAGGGGGCCGGGAGCTGTTTTTTGGAGAA	CASRLGGRELFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	36	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	5	0	9	3	1	23	34	44	37	45													Vb 22	CASRLGGRELFF+TCRBV02-01+TCRBJ02-02	TCRBV02-01*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTAGATCGCCGGGACTAGGGGGAGCAGATACGCAGTATTTTGGCCCA	CASSRSPGLGGADTQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	51	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	0	8	4	8	6	23	35	51	43	57						01,02							Vb 22	CASSRSPGLGGADTQYF+TCRBV02-01+TCRBJ02-03	TCRBV02-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCATGTCCGGGGTGGGAGAGACCCAGTACTTCGGGCCA	CASMSGVGETQYF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	39	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	7	8	3	4	4	4	23	33	42	37	46													Vb 22	CASMSGVGETQYF+TCRBV02-01+TCRBJ02-05	TCRBV02-01*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTGGGTGGCAGGGTCGGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSGWQGRNTGELFF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	48	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	4	3	1	5	3	23	36	46	41	49													Vb 22	CASSGWQGRNTGELFF+TCRBV02-01+TCRBJ02-02	TCRBV02-01*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTGAAGTGAGAGGACTGACAGATACGCAGTATTTTGGCCCA	CASSEVRGLTDTQYF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	45	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	1	10	3	5	1	23	39	49	44	50						01,02							Vb 22	CASSEVRGLTDTQYF+TCRBV02-01+TCRBJ02-03	TCRBV02-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTGTCGGTGTCAGTGGAATCGATGGCTACACCTTCGGTTCG	CASSVGVSGIDGYTF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	45	TCRBV02	TCRBV02-01	01				TCRBJ01	TCRBJ01-02	01	4	1	8	6	11	4	23	36	50	47	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 22	CASSVGVSGIDGYTF+TCRBV02-01+TCRBJ01-02	TCRBV02-01*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCCGAAATACTAAAAACACCATATATTTTGGAGAG	CASRNTKNTIYF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	36	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	8	3	9	6	6	1	23	32	42	38	43						01,02							Vb 22	CASRNTKNTIYF+TCRBV02-01+TCRBJ01-03	TCRBV02-01*01	TCRBD02-01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGAACCCTAGGACAGAATAATTCACCCCTCCACTTTGGGAAC	CARTLGQNNSPLHF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	42	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	9	1	5	5	7	1	23	31	44	38	45													Vb 22	CARTLGQNNSPLHF+TCRBV02-01+TCRBJ01-06	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCATGGGGAGGGGGCTGAACACTGAAGCTTTCTTTGGACAA	CASMGRGLNTEAFF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	42	TCRBV02	TCRBV02-01	01				TCRBJ01	TCRBJ01-01	01	7	5	0	0	5	0	23	33	-1	38	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 22	CASMGRGLNTEAFF+TCRBV02-01+TCRBJ01-01	TCRBV02-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCATGGCGGGCTCCTACGAGCAGTACTTCGGGCCG	CASMAGSYEQYF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	36	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	7	7	4	0	2	0	23	33	-1	35	40						01,02							Vb 22	CASMAGSYEQYF+TCRBV02-01+TCRBJ02-07	TCRBV02-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTCGGACAGGGGTTAATAGCGAGCAGTACTTCGGGCCG	CASSRTGVNSEQYF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	42	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	2	6	1	7	23	35	45	36	52													Vb 22	CASSRTGVNSEQYF+TCRBV02-01+TCRBJ02-07	TCRBV02-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCACGGCTAGCGGGCCTGAGCAGTTCTTCGGGCCA	CASTASGPEQFF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	36	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	7	4	4	9	3	2	23	33	44	36	46						01,02							Vb 22	CASTASGPEQFF+TCRBV02-01+TCRBJ02-01	TCRBV02-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGAGGACAGGGGGGCACTGAAGCTTTCTTTGGACAA	CASRGQGGTEAFF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	39	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	1	1	4	1	1	23	34	45	35	46													Vb 22	CASRGQGGTEAFF+TCRBV02-01+TCRBJ01-01	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCGTGCTCGGCAGGGGAAGCACAGATACGCAGTATTTTGGCCCA	CASVLGRGSTDTQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	45	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	8	4	2	0	8	1	23	32	46	40	47													Vb 22	CASVLGRGSTDTQYF+TCRBV02-01+TCRBJ02-03	TCRBV02-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAAGAAGATACCGGGACAGGGGCCTAGCACAGATACGCAGTATTTTGGCCCA	CASKKIPGQGPSTDTQYF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	54	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	7	0	2	0	10	3	23	33	53	43	56													Vb 22	CASKKIPGQGPSTDTQYF+TCRBV02-01+TCRBJ02-03	TCRBV02-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTGGAATGGGACAGAGTACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	35	1.1516832673583348E-4		44	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	0	5	3	4	3	23	36	47	40	50													Vb 22	X+TCRBV02-01+TCRBJ01-01	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCACAGGAAGCCAGTTTCGGGGCTACACCTTCGGTTCG	CASTGSQFRGYTF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	39	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	4	4	8	0	13	23	-1	37	33	50													Vb 22	CASTGSQFRGYTF+TCRBV02-01+TCRBJ01-02	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGGACGGGACTAGCGGGGATGGGGGCCCAGTACTTCGGGCCA	CASRTGLAGMGAQYF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	45	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	6	0	3	9	3	7	23	34	50	37	57													Vb 22	CASRTGLAGMGAQYF+TCRBV02-01+TCRBJ02-05	TCRBV02-01*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCGGAGCGACAGACACACCACTGAACACTGAAGCTTTCTTTGGACAA	CAGATDTPLNTEAFF	In	VDJ	1	39	1.2833042121992871E-4	1.6108247422680412E-4	45	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	11	2	5	0	5	9	23	29	39	34	48													Vb 22	CAGATDTPLNTEAFF+TCRBV02-01+TCRBJ01-01	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAACCCCGACAGGGTTTATACCGGGGAGCTGTTTTTTGGAGAA	CASNPDRVYTGELFF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	45	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	7	2	3	5	5	5	23	33	45	38	50													Vb 22	CASNPDRVYTGELFF+TCRBV02-01+TCRBJ02-02	TCRBV02-01*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGCCCGGGGCGGGGGGCCACAGATACGCAGTATTTTGGCCCA	CASSPGRGATDTQYF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	45	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	6	7	1	2	6	1	23	34	48	40	49													Vb 22	CASSPGRGATDTQYF+TCRBV02-01+TCRBJ02-03	TCRBV02-01*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTGAGAATTCGGGGGGAAAGGGTATGGCTACACCTTCGGTTCG		Out	VDJ	1	51	1.6781670467221448E-4		47	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	3	8	1	5	5	6	23	37	49	42	55													Vb 22	X+TCRBV02-01+TCRBJ01-02	TCRBV02-01*01	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTTGGAGCACAGGGGGTGAAGCTTTCTTTGGACAA	CASSWSTGGEAFF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	39	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	1	7	6	0	23	35	-1	41	49													Vb 22	CASSWSTGGEAFF+TCRBV02-01+TCRBJ01-01	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTGAAGGGATTATGACTGAAGCTTTCTTTGGACAA	CASSEGIMTEAFF	In	VDJ	1	59	1.94140893640405E-4	2.4368887126619086E-4	39	TCRBV02	TCRBV02-01	01				TCRBJ01	TCRBJ01-01	01	1	1	8	5	0	5	23	-1	42	39	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 22	CASSEGIMTEAFF+TCRBV02-01+TCRBJ01-01	TCRBV02-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGAGAGAGGAGGGGGAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	72	2.3691770071371457E-4		40	TCRBV02	TCRBV02-01	01				TCRBJ02	TCRBJ02-03	01	6	5	1	5	7	0	23	34	-1	41	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 22	X+TCRBV02-01+TCRBJ02-03	TCRBV02-01*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGGGCCCAAGGACAGGTTGGTCAGCCCCAGCATTTTGGTGAT	CASRAQGQVGQPQHF	In	VDJ	1	72	2.3691770071371457E-4	2.973830293417922E-4	45	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	1	4	6	7	4	23	34	48	41	52													Vb 22	CASRAQGQVGQPQHF+TCRBV02-01+TCRBJ01-05	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCTCGGCCGGGGAGGGGACTGAAGCTTTCTTTGGACAA	CASSAGEGTEAFF	In	VDJ	1	78	2.5666084243985743E-4	3.2216494845360824E-4	39	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	8	9	0	5	7	1	23	32	46	39	47													Vb 22	CASSAGEGTEAFF+TCRBV02-01+TCRBJ01-01	TCRBV02-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAAAACTAGCGGGGGCGCAGATACGCAGTATTTTGGCCCA	CASKTSGGADTQYF	In	VDJ	1	80	2.632418896819051E-4	3.3042558815754694E-4	42	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	7	3	2	4	2	2	23	33	46	35	48													Vb 22	CASKTSGGADTQYF+TCRBV02-01+TCRBJ02-03	TCRBV02-01*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCACCGCCGGGACTAGCGGGAGAGTGGATACGCAGTATTTTGGCCCA	CASTAGTSGRVDTQYF	In	VDJ	1	83	2.731134605449765E-4	3.428165477134549E-4	48	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	7	0	2	6	5	4	23	33	52	38	56													Vb 22	CASTAGTSGRVDTQYF+TCRBV02-01+TCRBJ02-03	TCRBV02-01*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCAGCCATGTACTTCTGTGCCAGCAGTGCGTCACCCGCGCAGCGGGGGATCAAAGCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	107	3.5208602744954805E-4		62	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	6	2	0	12	7	19	32	52	44	59													Vb 22	X+TCRBV02-01+TCRBJ02-01	TCRBV02-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTGAACTAGAATTGGAGACCCAGTACTTCGGGCCA	CASSELELETQYF	In	VDJ	2	115	3.784102164177386E-4	4.749867829764737E-4	39	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	2	4	8	5	0	5	23	-1	42	38	47						01,02							Vb 22	CASSELELETQYF+TCRBV02-01+TCRBJ02-05	TCRBV02-01*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCAGTTTCGACAGAGATAGCCAAAAACATTCAGTACTTCGGCGCC	CAVSTEIAKNIQYF	In	VDJ	2	120	3.948628345228576E-4	4.956383822363204E-4	42	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	12	2	5	0	6	4	23	28	39	34	43													Vb 22	CAVSTEIAKNIQYF+TCRBV02-01+TCRBJ02-04	TCRBV02-01*01	TCRBD01-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGCGGTGGAGGGCCCGGGGCTGAAGCTTTCTTTGGACAA	CASSGGGPGAEAFF	In	VDJ	2	137	4.5080173608026247E-4	5.658538197197992E-4	42	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	6	10	0	6	4	7	23	34	44	38	51													Vb 22	CASSGGGPGAEAFF+TCRBV02-01+TCRBJ01-01	TCRBV02-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTCCCCTGGGTAGCGGGAGGGGGACAGATACGCAGTATTTTGGCCCA	CASSPLGSGRGTDTQYF	In	VDJ	2	147	4.837069722905006E-4	6.071570182394925E-4	51	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	5	0	3	8	2	23	35	54	43	56													Vb 22	CASSPLGSGRGTDTQYF+TCRBV02-01+TCRBJ02-03	TCRBV02-01*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGGCAGCTAGAAACAGATACGCAGTATTTTGGCCCA	CASRQLETDTQYF	In	VDJ	2	178	5.857132045422388E-4	7.351969336505419E-4	39	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	4	8	3	4	2	23	34	42	38	44						01,02							Vb 22	CASRQLETDTQYF+TCRBV02-01+TCRBJ02-03	TCRBV02-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAAGGCGGGGGAAATAGATACGCAGTATTTTGGCCCA	CASKAGEIDTQYF	In	VDJ	3	188	6.18618440752477E-4	7.765001321702352E-4	39	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	7	7	2	5	2	4	23	33	42	35	46													Vb 22	CASKAGEIDTQYF+TCRBV02-01+TCRBJ02-03	TCRBV02-01*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGCCAAAACTGGAGGGTCCCCTCCTACGAGCAGTACTTCGGGCCG	CASSQNWRVPSYEQYF	In	VDJ	11	807	0.0026554525621662176	0.0033331681205392544	48	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	10	0	0	8	4	23	34	48	42	52													Vb 22	CASSQNWRVPSYEQYF+TCRBV02-01+TCRBJ02-07	TCRBV02-01*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGTACCCTCTCAGACATCTGTGTACTTCTGTGCCAGCAGTGAAGGGGGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSEGGSGANVLTF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	45	TCRBV06	TCRBV06-04		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	3	5	1	0	0	0	28	-1	-1	42	48			01,02											CASSEGGSGANVLTF+TCRBV06-04+TCRBJ02-06	TCRBV06-04	TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTGTTTAAGAGACCCAGTACTTCGGGCCA	CASSV*ETQYF	Stop	VJ	1	21	6.910099604150008E-5		33	TCRBV06	TCRBV06-07	01				TCRBJ02	TCRBJ02-05	01	5	0	0	3	0	4	26	-1	38	-1	42														CASSV*ETQYF+TCRBV06-07+TCRBJ02-05	TCRBV06-07*01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTTACCAGGGGGGCGGTTTAACGATGGCTACACCTTCGGTTCG		Out	VDJ	1	21	6.910099604150008E-5		47	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	4	1	6	0	11	26	-1	48	41	59														X+TCRBV06-07+TCRBJ01-02	TCRBV06-07*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCGCCCCCGATGACAGAGACAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	24	7.897256690457152E-5		41	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	8	2	5	7	9	3	26	35	49	44	52														X+TCRBV06-07+TCRBJ01-05	TCRBV06-07*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTAGGCCCAAAAACATTCAGTACTTCGGCGCC	CASSRPKNIQYF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	36	TCRBV06	TCRBV06-07	01				TCRBJ02	TCRBJ02-04	01	5	5	4	2	0	1	26	-1	41	38	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRPKNIQYF+TCRBV06-07+TCRBJ02-04	TCRBV06-07*01		TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTTACGGGGGTCTCACCAGAAACACCGGGGAGCTGTTTTTTGGAGAA	CASSYGGLTRNTGELFF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	51	TCRBV06	TCRBV06-07	01				TCRBJ02	TCRBJ02-02	01	2	6	1	2	0	10	26	-1	46	41	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYGGLTRNTGELFF+TCRBV06-07+TCRBJ02-02	TCRBV06-07*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTGACAGGGGGCGCGACGAAAAACTGTTTTTTGGCAGT	CASSDRGRDEKLFF	In	VDJ	1	61	2.0072194088245263E-4	2.5194951097012955E-4	42	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	2	0	8	0	5	26	-1	48	38	53														CASSDRGRDEKLFF+TCRBV06-07+TCRBJ01-04	TCRBV06-07*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAAGCTTGCGGGACCCACCGGGGAGCTGTTTTTTGGAGAA	CASKLAGPTGELFF	In	VDJ	1	63	2.0730298812450025E-4	2.602101506740682E-4	42	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	7	7	3	4	5	2	26	36	47	41	49														CASKLAGPTGELFF+TCRBV06-07+TCRBJ02-02	TCRBV06-07*01	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTTACACTAGCGGGAGCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	73	2.402082243347384E-4		43	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	3	2	4	0	0	26	-1	-1	41	52														X+TCRBV06-07+TCRBJ02-03	TCRBV06-07*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAAGCTTGAGGATTCAGCAGTGTATTTTTGTGCCAGCAGCCAATCGTATATGCAGGGAAACCATGGCTACACCTTCGGTTCG	CASSQSYMQGNHGYTF	In	VDJ	1	69	2.2704612985064313E-4	2.8499206978588424E-4	48	TCRBV16	TCRBV16-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	3	6	7	5	29	46	58	53	63			01,02											CASSQSYMQGNHGYTF+TCRBV16-01+TCRBJ01-02	TCRBV16-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAGCCAAACAGCTTTGTACTTCTGTGCCAGCAGTTATGGACAGGGGAGCTATGGCTACACCTTCGGTTCG	CASSYGQGSYGYTF	In	VDJ	2	117	3.8499126365978617E-4	4.832474226804124E-4	42	TCRBV22	TCRBV22-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	13	1	2	4	12	2	25	28	49	40	51														CASSYGQGSYGYTF+TCRBV22-01+TCRBJ01-02	TCRBV22-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTSTATCTCTGTGCCAGCAGCCGTGGACAGGGGGAAGAGACCCAGTACTTCGGGCCA	CASSRGQGEETQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	42	TCRBV05	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	1	1	3	3	0	19	31	-1	34	44		TCRBV05-05,TCRBV05-06,TCRBV05-07												CASSRGQGEETQYF+TCRBV05-X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTYGGCYGTGTATCTCTGTGCCAGCAGCTTAAAGGGCGACACTGAAGCTTTCTTTGGACAA	CASSLKGDTEAFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	39	TCRBV07	unresolved					TCRBJ01	TCRBJ01-01	01	4	5	3	3	3	2	22	35	42	38	44		TCRBV07-01,TCRBV07-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLKGDTEAFF+TCRBV07-X+TCRBJ01-01	unresolved		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGTACCCTCYCAGACATCTGTGTACTTSTGTGCCAGCAGTTACTCGGGGCTCCTAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	21	6.910099604150008E-5		44	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	7	0	0	0	2	28	-1	50	45	52		TCRBV06-04,TCRBV06-08												X+TCRBV06-X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTYGGCYRTGTATCKCTGTGCCAGCAGCTATGCGGGGGAGGGACAGCCCCAGCATTTTGGTGAT	CASSYAGEGQPQHF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	42	TCRBV07	unresolved		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	4	7	2	7	2	5	18	31	40	33	45		TCRBV07-01,TCRBV07-06				01,02								CASSYAGEGQPQHF+TCRBV07-X+TCRBJ01-05	unresolved	TCRBD02-01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTTACGGAGACGGGAGCAATCAGCCCCAGCATTTTGGTGAT	CASSYGDGSNQPQHF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	45	TCRBV06	unresolved		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	2	8	4	1	5	0	23	38	-1	43	47		TCRBV06-05,TCRBV06-06,TCRBV06-08				01,02								CASSYGDGSNQPQHF+TCRBV06-X+TCRBJ01-05	unresolved	TCRBD02-01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCCCAGACATCTGTRTACTTSTGTGCCAGCACCCAGGGGGCGCGGGGTCAGCCCCAGCATTTTGGTGAT	CASTQGARGQPQHF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	42	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	7	4	0	6	2	6	26	36	46	38	52		TCRBV06-08,TCRBV06-09												CASTQGARGQPQHF+TCRBV06-X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTYRGCTGTGTATCTCTGTGCCAGCAGCTCGGACAGGGTGCGGGGCTACACCTTCGGTTCG	CASSSDRVRGYTF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	39	TCRBV07	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	1	3	8	0	5	22	-1	44	36	49		TCRBV07-01,TCRBV07-04												CASSSDRVRGYTF+TCRBV07-X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTYGGCYGTGTATCTCTGTGCCAGCAGCCCGAGTGGGGCAGATACGCAGTATTTTGGCCCA	CASSPSGADTQYF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	39	TCRBV07	unresolved					TCRBJ02	TCRBJ02-03	01	5	6	2	4	6	0	18	30	-1	36	40		TCRBV07-01,TCRBV07-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPSGADTQYF+TCRBV07-X+TCRBJ02-03	unresolved		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCRTGTATSTCTGTGCCAGCAGCTTAGGGTCGGGTGCCTTCTATGGCTACACCTTCGGTTCG	CASSLGSGAFYGYTF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	45	TCRBV11	unresolved		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	1	8	4	4	3	6	18	34	41	37	47		TCRBV11-01,TCRBV11-03				01,02								CASSLGSGAFYGYTF+TCRBV11-X+TCRBJ01-02	unresolved	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCRGCCATGTATCGCTGTGCCAGCAGCTTAACGGACAGCGCGTCACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	26	8.555361414661915E-5		47	TCRBV07	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	1	5	2	2	7	19	34	42	36	49		TCRBV07-06,TCRBV07-07												X+TCRBV07-X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTTTAGCAGGGGAACATCAGCCCCAGCATTTTGGTGAT	CASSLAGEHQPQHF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	42	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	4	2	5	3	3	26	39	48	42	51		TCRBV06-07,TCRBV06-08												CASSLAGEHQPQHF+TCRBV06-X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCAGTAGATGGGGGAGGGGCGATACGCAGTATTTTGGCCCA	CASSRWGRGDTQYF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	42	TCRBV10	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	9	0	6	6	2	26	38	51	44	53		TCRBV10-01,TCRBV10-02												CASSRWGRGDTQYF+TCRBV10-X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTYGGCYGTGTATCTCTGTGCCAGCAGCCCCGGGATTCGTCAGCCCCAGCATTTTGGTGAT	CASSPGIRQPQHF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	39	TCRBV07	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	5	8	3	6	2	4	18	30	37	32	41		TCRBV07-01,TCRBV07-02												CASSPGIRQPQHF+TCRBV07-X+TCRBJ01-05	unresolved	TCRBD02-01*02	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTTACGCTGGGGACCCTTAAAAAGCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	28	9.213466138866678E-5		56	TCRBV06	unresolved					TCRBJ02	TCRBJ02-01	01	2	0	7	0	4	10	25	40	49	44	59		TCRBV06-07,TCRBV06-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-X+TCRBJ02-01	unresolved		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGYWCCCTCYCAGACATCTGTRTACTTCTGTGCCAGCAGTTACTTATGGGCCCCGGTACTTCGGGCCG		Out	VDJ	1	28	9.213466138866678E-5		34	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	8	0	12	3	4	28	44	51	47	55		TCRBV06-04,TCRBV06-09												X+TCRBV06-X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGTCAGAAGCTTCGGGGGGGGCGGAGGAATTTTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	31	1.0200623225173821E-4		49	TCRBV07	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	3	8	0	9	0	11	18	-1	40	32	51		TCRBV07-05,TCRBV07-06												X+TCRBV07-X+TCRBJ01-06	unresolved	TCRBD02-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCACCCGACAGGGGGCTAGCACCGGGGAGCTGTTTTTTGGAGAA	CATRQGASTGELFF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	42	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	10	2	0	4	3	3	23	30	43	33	46		TCRBV06-07,TCRBV06-08												CATRQGASTGELFF+TCRBV06-X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTTACAGCCAGGGTTTTTATGGCTACACCTTCGGTTCG	CASSYSQGFYGYTF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	42	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	4	3	5	3	4	26	41	49	44	53		TCRBV06-07,TCRBV06-08												CASSYSQGFYGYTF+TCRBV06-X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTTCTCCGGGTGCCGTGGCTTTCTTTGGACAA	CASSSPGAVAFF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	36	TCRBV06	unresolved		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	4	8	4	11	3	7	26	39	46	42	53		TCRBV06-07,TCRBV06-08				01,02								CASSSPGAVAFF+TCRBV06-X+TCRBJ01-01	unresolved	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGGACTCSGCCGTGTATCTCTGTGCCAGCAGCTTACTTTCCGGGGAGGGCTACACCTTCGGTTCG	CASSLLSGEGYTF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	39	TCRBV07	unresolved		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	2	8	3	8	5	2	18	33	43	38	45		TCRBV07-02,TCRBV07-08				01,02								CASSLLSGEGYTF+TCRBV07-X+TCRBJ01-02	unresolved	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCGGGTCGGGGGTAAACTATGGCTACACCTTCGGTTCG	CASGSGVNYGYTF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	39	TCRBV12	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	8	8	2	2	4	2	22	31	41	35	43		TCRBV12-03,TCRBV12-04,TCRBV12-05				unresolved								CASGSGVNYGYTF+TCRBV12-X+TCRBJ01-02	unresolved	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCGTACGGCTCCCCGGTCTAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	38	1.2503989759890492E-4		41	TCRBV06	unresolved					TCRBJ01	TCRBJ01-02	01	11	9	0	0	4	8	23	29	36	33	44		TCRBV06-07,TCRBV06-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-X+TCRBJ01-02	unresolved		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGTACCCTCYCAGACATCTGTGTACTTSTGTGCCAGCAGTGACAAAAACACCGGGGAGCTGTTTTTTGGAGAA	CASSDKNTGELFF	In	VDJ	1	39	1.2833042121992871E-4	1.6108247422680412E-4	39	TCRBV06	unresolved		unresolved			TCRBJ02	TCRBJ02-02	01	5	2	6	2	0	2	23	-1	39	35	41		TCRBV06-04,TCRBV06-08		TCRBD01										CASSDKNTGELFF+TCRBV06-X+TCRBJ02-02	unresolved	unresolved	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCAGTGACCGACAAACTGGGGCAGATTACAATGAGCAGTTCTTCGGGCCA	CASSDRQTGADYNEQFF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	51	TCRBV10	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	7	0	4	10	4	26	40	55	50	59		TCRBV10-01,TCRBV10-02												CASSDRQTGADYNEQFF+TCRBV10-X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGTACCCTCYCAGACATCTGTGTACTTSTGTGCCAGCAGTAAAAACCGGGACTAGCGGCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	46	1.5136408656709542E-4		46	TCRBV06	unresolved		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	0	5	3	7	0	23	35	-1	42	53		TCRBV06-04,TCRBV06-08				01,02								X+TCRBV06-X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCCAGCGGGAATTGGACAATGAGCAGTTCTTCGGGCCA	CASQRELDNEQFF	In	VDJ	1	49	1.6123565743016686E-4	2.023856727464975E-4	39	TCRBV12	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	8	6	3	5	1	5	22	31	39	32	44		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASQRELDNEQFF+TCRBV12-X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCATCACTCAGGCGGGCCTGAACACTGAAGCTTTCTTTGGACAA	CASITQAGLNTEAFF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	45	TCRBV12	unresolved		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	12	7	4	0	13	2	26	31	49	44	51		TCRBV12-03,TCRBV12-04,TCRBV12-05				01,02								CASITQAGLNTEAFF+TCRBV12-X+TCRBJ01-01	unresolved	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCATCCCATCCCCCCAGACACCGCACACTGAAGCTTTCTTTGGACAA	CASIPSPQTPHTEAFF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	48	TCRBV12	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	12	2	6	3	18	4	26	31	53	49	57		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASIPSPQTPHTEAFF+TCRBV12-X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCAGTGAGGGACTAGCGGGAGCCAATGAGCAGTTCTTCGGGCCA	CASSEGLAGANEQFF	In	VDJ	1	62	2.0401246450347642E-4	2.560798308220989E-4	45	TCRBV10	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	1	2	6	0	1	26	-1	54	41	55		TCRBV10-01,TCRBV10-02												CASSEGLAGANEQFF+TCRBV10-X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGTACCCTCYCAGACATCTGTGTACTTSTGTGCCAGCAGTCCGGGACAGGACTACAATGAGCAGTTCTTCGGGCCA	CASSPGQDYNEQFF	In	VDJ	1	69	2.2704612985064313E-4	2.8499206978588424E-4	42	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	0	4	3	2	1	28	40	50	42	51		TCRBV06-04,TCRBV06-08												CASSPGQDYNEQFF+TCRBV06-X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGTACACGTGGCGAACCAAATGAAACCGGGACACAAGAGACCCAGTACTTCGGGCCA	CASTRGEPNETGTQETQYF	In	VDJ	1	81	2.6653241330292887E-4	3.3455590800951626E-4	57	TCRBV12	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	8	0	6	2	24	0	24	33	-1	57	63		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASTRGEPNETGTQETQYF+TCRBV12-X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTGAACAGGACAGGGTTGGAAACACCATATATTTTGGAGAG	CASSEQDRVGNTIYF	In	VDJ	1	88	2.895660786500956E-4	3.634681469733016E-4	45	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	2	1	3	3	2	1	23	38	48	40	49		TCRBV06-01,TCRBV06-07,TCRBV06-08												CASSEQDRVGNTIYF+TCRBV06-X+TCRBJ01-03	unresolved	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCYRTGTATCKCTGTGCCAGCAGCTTAGTGACAGGGGACTCCTACAATGAGCAGTTCTTCGGGCCA	CASSLVTGDSYNEQFF	In	VDJ	1	89	2.928566022711194E-4	3.6759846682527094E-4	48	TCRBV07	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	2	2	0	1	1	19	35	44	36	45		TCRBV07-05,TCRBV07-06												CASSLVTGDSYNEQFF+TCRBV07-X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGTACCCTCYCAGACATCTGTGTACTTSTGTGCCAGCAGCCCTACTAGCAACTACAATGAGCAGTTCTTCGGGCCA	CASSPTSNYNEQFF	In	VDJ	1	99	3.257618384813575E-4	4.089016653449643E-4	42	TCRBV06	unresolved		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	3	7	3	4	2	28	39	49	43	51		TCRBV06-04,TCRBV06-08				01,02								CASSPTSNYNEQFF+TCRBV06-X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGGACTCSGCCGTGTATCTCTGTGCCAGAAGCAAGAGGTGGAGGCGGGAGCTGTTTTTTGGAGAA	CARSKRWRRELFF	In	VDJ	1	104	3.422144565864766E-4	4.29553264604811E-4	39	TCRBV07	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	5	10	1	9	7	1	20	32	44	39	45		TCRBV07-02,TCRBV07-08												CARSKRWRRELFF+TCRBV07-X+TCRBJ02-02	unresolved	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCAGTGAGTATTGGCTCCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	104	3.422144565864766E-4		41	TCRBV10	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	9	0	2	3	2	26	42	48	45	50		TCRBV10-01,TCRBV10-02												X+TCRBV10-X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCRTGTATSTCTGTGCCAGCAGCTCATTCTGGTCGGGAGAGACAGATACGCAGTATTTTGGCCCA	CASSSFWSGETDTQYF	In	VDJ	2	124	4.0802492900695285E-4	5.121596616441978E-4	48	TCRBV11	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	4	8	2	3	9	2	19	32	47	41	49		TCRBV11-01,TCRBV11-03												CASSSFWSGETDTQYF+TCRBV11-X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTCGTCAGGGTATTGGTGCCAAAAACATTCAGTACTTCGGCGCC	CASSRQGIGAKNIQYF	In	VDJ	2	125	4.113154526279767E-4	5.162899814961671E-4	48	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	5	4	3	1	3	7	23	35	43	38	50		TCRBV06-07,TCRBV06-08												CASSRQGIGAKNIQYF+TCRBV06-X+TCRBJ02-04	unresolved	TCRBD01-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGTCAACTGGGCGGGAGCGAGACCCAGTACTTCGGGCCA	CASQLGGSETQYF	In	VDJ	2	132	4.343491179751434E-4	5.452022204599524E-4	39	TCRBV06	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	9	7	2	5	8	1	23	31	46	39	47		TCRBV06-07,TCRBV06-08												CASQLGGSETQYF+TCRBV06-X+TCRBJ02-05	unresolved	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GTACCCTCYCAGACATCTGTGTACTTSTGTGCCAGCGATACCTCCATAGGACTAGCGGGGGCGAAAGAGACCCAGTACTTCGGGCCA	CASDTSIGLAGAKETQYF	In	VDJ	2	135	4.442206888382148E-4	5.575931800158604E-4	54	TCRBV06	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	8	1	2	3	12	3	23	32	57	44	60		TCRBV06-04,TCRBV06-08												CASDTSIGLAGAKETQYF+TCRBV06-X+TCRBJ02-05	unresolved	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCAGTGAGGGACCTCTTACGGAGCAGTACTTCGGGCCG	CASSEGPLTEQYF	In	VDJ	2	135	4.442206888382148E-4	5.575931800158604E-4	39	TCRBV10	unresolved					TCRBJ02	TCRBJ02-07	01	2	1	7	7	0	8	26	-1	45	41	53		TCRBV10-01,TCRBV10-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEGPLTEQYF+TCRBV10-X+TCRBJ02-07	unresolved		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCRTGTATSTCTGTGCCAGCAGCTTGATGGAAACGCTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	2	161	5.297743029848339E-4		46	TCRBV11	unresolved					TCRBJ01	TCRBJ01-03	01	3	1	8	0	3	4	19	33	39	36	43		TCRBV11-01,TCRBV11-03		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-X+TCRBJ01-03	unresolved		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCGGGGAGATTCTGAATTCACCCCTCCACTTTGGGAAC	CASGEILNSPLHF	In	VDJ	2	173	5.692605864371197E-4	7.145453343906952E-4	39	TCRBV06	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	8	9	2	7	1	6	23	32	38	33	44		TCRBV06-07,TCRBV06-08												CASGEILNSPLHF+TCRBV06-X+TCRBJ01-06	unresolved	TCRBD02-01*02	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGTACCCTCYCAGACATCTGTGTACTTSTGTGCCAGCAGTACAGGCGCAAGGGAGACCCAGTACTTCGGGCCA	CASSTGARETQYF	In	VDJ	2	177	5.82422680921215E-4	7.310666137985726E-4	39	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	3	4	5	0	7	23	-1	40	35	47		TCRBV06-04,TCRBV06-08												CASSTGARETQYF+TCRBV06-X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCAGTGAGGGCGGATCAACCTACGAGCAGTACTTCGGGCCG	CASSEGGSTYEQYF	In	VDJ	3	182	5.988752990263341E-4	7.517182130584193E-4	42	TCRBV10	unresolved		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	7	5	2	1	5	23	38	43	39	48		TCRBV10-01,TCRBV10-02				01,02								CASSEGGSTYEQYF+TCRBV10-X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGTACCCTCYCAGACATCTGTGTACTTSTGTGCCAGCAGAATCGACGGGTAGGAGCAGTTCTTCGGGCCA	CASRIDG*EQFF	Stop	VDJ	3	217	7.140436257621675E-4		36	TCRBV06	unresolved		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	8	4	10	6	3	28	39	49	45	52		TCRBV06-04,TCRBV06-08				01,02								CASRIDG*EQFF+TCRBV06-X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTYGGCYGTGTATCTCTGTGCCAGCAGCCCTTCCGGGATTGAAACGCAGTATTTTGGCCCA	CASSPSGIETQYF	In	VDJ	3	230	7.568204328354772E-4	9.499735659529474E-4	39	TCRBV07	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	8	3	9	5	5	18	30	40	35	45		TCRBV07-01,TCRBV07-02												CASSPSGIETQYF+TCRBV07-X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCAGTCAGGGGCCGAACACTGAAGCTTTCTTTGGACAA	CASSQGPNTEAFF	In	VDJ	4	258	8.489550942241439E-4	0.0010656225218080887	39	TCRBV10	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	2	1	0	2	26	-1	44	38	46		TCRBV10-01,TCRBV10-02												CASSQGPNTEAFF+TCRBV10-X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGTACCCTCYCAGACATCTGTGTACTTSTGTGCCAGCAGTGACTCGACAGGGGGCCCAGATACGCAGTATTTTGGCCCA	CASSDSTGGPDTQYF	In	VDJ	4	297	9.772855154440727E-4	0.001226704996034893	45	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	2	0	4	0	1	23	-1	50	40	51		TCRBV06-04,TCRBV06-08												CASSDSTGGPDTQYF+TCRBV06-X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGGGGGGGACTAGCGGGAACCGACGAGCAGTACTTCGGGCCG	CASRGGLAGTDEQYF	In	VDJ	5	375	0.00123394635788393	0.001548869944488501	45	TCRBV06	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	0	3	5	3	4	23	34	50	37	54		TCRBV06-07,TCRBV06-08												CASRGGLAGTDEQYF+TCRBV06-X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCAGTGACTCGCCGGGGCTTCGGGATACGCAGTATTTTGGCCCA	CASSDSPGLRDTQYF	In	VDJ	5	387	0.0012734326413362158	0.0015984337827121332	45	TCRBV10	unresolved					TCRBJ02	TCRBJ02-03	01	3	7	0	6	6	5	26	40	51	46	56		TCRBV10-01,TCRBV10-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDSPGLRDTQYF+TCRBV10-X+TCRBJ02-03	unresolved		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCACCCCGCCCGGGACAGGAAGCCCCCAACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	6	403	0.0013260810192725968		56	TCRBV10	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	7	0	4	0	8	7	23	33	49	41	56		TCRBV10-01,TCRBV10-02												X+TCRBV10-X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTCATAGCAGGGGTCAGGGAATAAGCCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	10	728	0.0023955011961053364		53	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	2	2	5	13	23	35	46	40	59		TCRBV06-07,TCRBV06-08												X+TCRBV06-X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCACCAACCAGACATCTGTGTATCTCTATGCCAGCAACGATAACACTGAAGCTTTCTTTGGACAA	YASNDNTEAFF	In	VDJ	2	119	3.915723109018338E-4	4.91508062384351E-4	33	TCRBV26	TCRBV26-01	01				TCRBJ01	TCRBJ01-01	01	7	2	8	2	2	1	27	37	41	39	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									YASNDNTEAFF+TCRBV26-01+TCRBJ01-01	TCRBV26-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGATTGGTCACAGGCGATGTTCTATGGCTACACCTTCGGTTCG	CASSQDWSQAMFYGYTF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	51	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	3	4	4	6	7	23	40	51	46	58													Vb 7.1	CASSQDWSQAMFYGYTF+TCRBV04-01+TCRBJ01-02	TCRBV04-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGCGGTCGGGAAAGAGACCCAGTACTTCGGGCCA	CASSQAVGKETQYF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	42	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	1	8	3	3	4	0	23	39	-1	43	48													Vb 7.1	CASSQAVGKETQYF+TCRBV04-01+TCRBJ02-05	TCRBV04-01*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCGCCGGGGCTCTGACAATGAAAAACTGTTTTTTGGCAGT	CASSRRGSDNEKLFF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	45	TCRBV04	TCRBV04-01	01				TCRBJ01	TCRBJ01-04	01	4	7	0	5	3	6	23	36	44	39	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 7.1	CASSRRGSDNEKLFF+TCRBV04-01+TCRBJ01-04	TCRBV04-01*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGGGTAAGCTCCAGGGGGGGATCCGGGGTATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	30	9.87157086307144E-5		55	TCRBV04	TCRBV04-01	01				TCRBJ01	TCRBJ01-04	01	6	4	1	6	9	11	23	34	50	43	61				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 7.1	X+TCRBV04-01+TCRBJ01-04	TCRBV04-01*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGATATAGTGTCGGGAGAACCCTACAATGAGCAGTTCTTCGGGCCA	CASSQDIVSGEPYNEQFF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	54	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	8	2	2	8	3	23	40	54	48	57													Vb 7.1	CASSQDIVSGEPYNEQFF+TCRBV04-01+TCRBJ02-01	TCRBV04-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGAACCTTCTACGGGGCTAGCCTACGAGCAGTACTTCGGGCCG	CASSQEPSTGLAYEQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	51	TCRBV04	TCRBV04-01	01				TCRBJ02	TCRBJ02-07	01	0	7	0	2	9	3	23	40	54	49	57				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 7.1	CASSQEPSTGLAYEQYF+TCRBV04-01+TCRBJ02-07	TCRBV04-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGAAGGAGGCCTTGCTGAAGCTTTCTTTGGACAA	CASSQEGGLAEAFF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	42	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	0	10	1	6	1	5	23	40	46	41	51													Vb 7.1	CASSQEGGLAEAFF+TCRBV04-01+TCRBJ01-01	TCRBV04-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCTCCCGGGACAGGTACACAGATACGCAGTATTTTGGCCCA	CASSRDRYTDTQYF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	42	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	8	0	4	2	4	2	23	32	44	36	46													Vb 7.1	CASSRDRYTDTQYF+TCRBV04-01+TCRBJ02-03	TCRBV04-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGATTCGGCGGGACAGAAACGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	38	1.2503989759890492E-4		56	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	0	0	5	0	6	3	23	40	53	46	56													Vb 7.1	X+TCRBV04-01+TCRBJ02-02	TCRBV04-01*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGGGACTCAGCCGTGTATCTCTACGCCAGCAGCCAAGATAGAACGGGACAGGGGCTGGACGAGCAGTACTTCGGGCCG	YASSQDRTGQGLDEQYF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	51	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	0	2	5	6	4	22	39	55	45	59													Vb 7.1	YASSQDRTGQGLDEQYF+TCRBV04-01+TCRBJ02-07	TCRBV04-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGGGACTCAGCCGTGTATCTCTACGCCAGCAGCCAAGCCTTACCTGGGGATGGAAACACCATATATTTTGGAGAG	YASSQALPGDGNTIYF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	48	TCRBV04	TCRBV04-01	01				TCRBJ01	TCRBJ01-03	01	1	0	8	3	9	0	22	38	-1	47	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 7.1	YASSQALPGDGNTIYF+TCRBV04-01+TCRBJ01-03	TCRBV04-01*01		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGTGGAGCGGGGGGGCTGGGAGACCCAGTACTTCGGGCCA	CASSQVERGGWETQYF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	48	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	1	6	0	5	3	4	23	39	52	42	56													Vb 7.1	CASSQVERGGWETQYF+TCRBV04-01+TCRBJ02-05	TCRBV04-01*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CRRRRGACTCAGCCSTGTATCTCTRCGCCAGCAGCCAAGATTCGCAGGCCCAGGGTTCACCCCTCCACTTTGGGAAC	XASSQDSQAQGSPLHF	In	VDJ	1	102	3.3563340934442896E-4	4.2129262490087234E-4	48	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	0	4	3	9	10	0	23	40	-1	50	55													Vb 7.1	XASSQDSQAQGSPLHF+TCRBV04-01+TCRBJ01-06	TCRBV04-01*01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGAGACAGGGAATGAAAAACTGTTTTTTGGCAGT	CASSQETGNEKLFF	In	VDJ	4	258	8.489550942241439E-4	0.0010656225218080887	42	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	2	3	5	0	0	23	-1	-1	40	47													Vb 7.1	CASSQETGNEKLFF+TCRBV04-01+TCRBJ01-04	TCRBV04-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGTGACACGACAGATACGCAGTATTTTGGCCCA	CASSDTTDTQYF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	36	TCRBV10	TCRBV10-01					TCRBJ02	TCRBJ02-03	01	3	3	7	3	1	1	26	40	43	41	44			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CASSDTTDTQYF+TCRBV10-01+TCRBJ02-03	TCRBV10-01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGTATATTTCTGCGCCAGCAGCAGAAAGGGCCGGGACAGGGGGCCTAATATAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	25	8.226309052559534E-5		62	TCRBV10	TCRBV10-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	0	0	0	11	6	10	21	44	32	50			01,02										Vb 12	X+TCRBV10-01+TCRBJ01-05	TCRBV10-01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGTGTCGCATACGAGCAGTACTTCGGGCCG	CASSVAYEQYF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	33	TCRBV10	TCRBV10-01					TCRBJ02	TCRBJ02-07	01	4	4	6	4	3	0	26	39	-1	42	44			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CASSVAYEQYF+TCRBV10-01+TCRBJ02-07	TCRBV10-01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCATTCCGGGGCAGGAGACCCAGTACTTCGGGCCA	CASIPGQETQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	36	TCRBV10	TCRBV10-01					TCRBJ02	TCRBJ02-05	01	7	7	0	5	4	2	26	36	45	40	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CASIPGQETQYF+TCRBV10-01+TCRBJ02-05	TCRBV10-01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGTAAGGGACCTCTTACGGAACAGTACTTCGGGCCG	CASSKGPLTEQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	39	TCRBV10	TCRBV10-01					TCRBJ02	TCRBJ02-07	01	5	0	7	10	2	11	26	38	45	40	56			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CASSKGPLTEQYF+TCRBV10-01+TCRBJ02-07	TCRBV10-01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGTGAACTAGCGGATTACAATGAGCAGTTCTTCGGGCCA	CASSELADYNEQFF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	42	TCRBV10	TCRBV10-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	3	5	4	0	2	26	-1	48	40	50			01,02			01,02							Vb 12	CASSELADYNEQFF+TCRBV10-01+TCRBJ02-01	TCRBV10-01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCTACGAGAGAAGACAGGGGGAACAAGGCTACACCTTTGGTTCG		Out	VDJ	1	50	1.6452618105119069E-4		41	TCRBV10	TCRBV10-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	12	2	1	20	10	17	26	31	50	41	67			01,02										Vb 12	X+TCRBV10-01+TCRBJ01-02	TCRBV10-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCTCCCAGACATCTGTATATTTCTGCACCAGCAGTGTGACACCAGCCAAGGAGACCCAGTACTTCGGGCCA	CTSSVTPAKETQYF	In	VDJ	1	64	2.1059351174552407E-4	2.643404705260375E-4	42	TCRBV10	TCRBV10-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	2	6	5	1	9	26	39	44	40	53			01,02										Vb 12	CTSSVTPAKETQYF+TCRBV10-01+TCRBJ02-05	TCRBV10-01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGTGAGTTGGTAGCCTCCACTGGGGAGCTGTTTTTTGGAGAA	CASSELVASTGELFF	In	VDJ	1	72	2.3691770071371457E-4	2.973830293417922E-4	45	TCRBV10	TCRBV10-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	1	5	7	8	3	7	26	42	49	45	56			01,02			01,02							Vb 12	CASSELVASTGELFF+TCRBV10-01+TCRBJ02-02	TCRBV10-01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAAAGGGACTAGCGGGGGGTCACAGAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	94	3.093092203762385E-4		46	TCRBV10	TCRBV10-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	10	0	1	5	2	6	26	33	50	35	56			01,02										Vb 12	X+TCRBV10-01+TCRBJ02-03	TCRBV10-01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGTTCGGACGAACCCTGAAGCTTTCTTTGGACAA		Out	VDJ	1	106	3.4879550382852425E-4		37	TCRBV10	TCRBV10-01					TCRBJ01	TCRBJ01-01	01	5	1	7	6	2	5	26	38	44	40	49			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	X+TCRBV10-01+TCRBJ01-01	TCRBV10-01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGAGACAGGTGATCACGTCCGAGCAGTACTTCGGGCCG		Out	VDJ	2	163	5.363553502268816E-4		41	TCRBV10	TCRBV10-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	4	6	1	10	26	37	44	38	54			01,02										Vb 12	X+TCRBV10-01+TCRBJ02-07	TCRBV10-01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCACCCTCGTGACAGGGATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	2	176	5.791321573001912E-4		41	TCRBV10	TCRBV10-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	7	2	3	6	7	0	26	36	-1	43	50			01,02										Vb 12	X+TCRBV10-01+TCRBJ01-04	TCRBV10-01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTTGGGCCTATATTTCTGTGCCAGCAGCGCGGGGCCTTGGGTCAGCCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	20	6.581047242047627E-5		50	TCRBV12	TCRBV12-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-04	01	5	7	3	2	0	12	22	-1	40	34	52														X+TCRBV12-01+TCRBJ02-04	TCRBV12-01*01	TCRBD02-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTTGGGCCTATATTTCTGTGCCAGCAGCGGCCGACAGGGTGACACCGGGGAGCTGTTTTTTGGAGAA	CASSGRQGDTGELFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	45	TCRBV12	TCRBV12-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	2	3	3	4	2	22	34	45	38	47														CASSGRQGDTGELFF+TCRBV12-01+TCRBJ02-02	TCRBV12-01*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTTGGGCCTATATTTCTGTGCCAGCAGCTTTCGATATAGCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	40	1.3162094484095254E-4		43	TCRBV12	TCRBV12-01	01				TCRBJ02	TCRBJ02-04	01	2	2	8	0	1	3	22	37	40	38	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV12-01+TCRBJ02-04	TCRBV12-01*01		TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACTAGCAGAGGTGTTGGCTCCAATGAGCAGTTCTTCGGGCCA	CATSRGVGSNEQFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	42	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	9	0	6	5	2	18	34	42	39	44														CATSRGVGSNEQFF+TCRBV15-01+TCRBJ02-01	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGATCTTAATAGCGGGAGTATAGCCTACGAGCAGTACTTCGGGCCG	CATSRDLNSGSIAYEQYF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	54	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	5	2	2	6	5	18	35	50	41	55														CATSRDLNSGSIAYEQYF+TCRBV15-01+TCRBJ02-07	TCRBV15-01*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCGCGAGGGACAGGAATTCCGGTGCTTTCTTTGGACAA	CATSARDRNSGAFF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	42	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	4	11	4	9	18	30	42	34	51														CATSARDRNSGAFF+TCRBV15-01+TCRBJ01-01	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGCTCGAGACAGGGGGTGGGACATTCAGTACTTCGGCGCC	CATSRARDRGWDIQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	48	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	1	2	1	8	5	4	18	34	48	39	52														CATSRARDRGWDIQYF+TCRBV15-01+TCRBJ02-04	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAACAGAGATCTCGGGACAGCGAACACTGAAGCTTTCTTTGGACAA	CATNRDLGTANTEAFF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	48	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	0	5	1	4	1	18	35	46	39	47														CATNRDLGTANTEAFF+TCRBV15-01+TCRBJ01-01	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGAACGACGGGGCTAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	35	1.1516832673583348E-4		44	TCRBV15	TCRBV15-01	01				TCRBJ02	TCRBJ02-05	01	0	7	0	4	5	1	18	35	45	40	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV15-01+TCRBJ02-05	TCRBV15-01*01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCTCAGGTGAGGGAGGGCAAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	37	1.217493739778811E-4		44	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	9	0	7	8	2	18	30	45	38	47														X+TCRBV15-01+TCRBJ02-01	TCRBV15-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGTAAATCGGGCCGACAGGGAGTAACTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	44	1.447830393250478E-4		55	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	2	3	3	11	5	18	34	52	45	57														X+TCRBV15-01+TCRBJ02-07	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGATTACGGCTCTGGAAACACCATATATTTTGGAGAG	CATSRDYGSGNTIYF	In	VDJ	1	52	1.711072282932383E-4	2.147766323024055E-4	45	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	0	8	5	0	3	0	18	35	-1	38	41						01,02								CATSRDYGSGNTIYF+TCRBV15-01+TCRBJ01-03	TCRBV15-01*01	TCRBD02-01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGGACAGGGGTTTTCACCCCTCCACTTTGGGAAC	CATSRGQGFSPLHF	In	VDJ	1	60	1.974314172614288E-4	2.478191911181602E-4	42	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	1	2	2	9	0	2	18	-1	42	34	44														CATSRGQGFSPLHF+TCRBV15-01+TCRBJ01-06	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGATCTTGGCACCTTGAACACTGAAGCTTTCTTTGGACAA	CATSRDLGTLNTEAFF	In	VDJ	1	80	2.632418896819051E-4	3.3042558815754694E-4	48	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	9	0	0	4	4	18	35	42	39	46														CATSRDLGTLNTEAFF+TCRBV15-01+TCRBJ01-01	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGAGGGGCTGCTCCAAGAGACCCAGTACTTCGGGCCA	CATSREGLLQETQYF	In	VDJ	1	87	2.8627555502907175E-4	3.593378271213323E-4	45	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	7	0	1	0	4	18	-1	40	35	44														CATSREGLLQETQYF+TCRBV15-01+TCRBJ02-05	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGATTTACCAGTCCCGGGACAGGGTTTAGGTTGAACACTGAAGCTTTCTTTGGACAA	CATSRFTSPGTGFRLNTEAFF	In	VDJ	1	87	2.8627555502907175E-4	3.593378271213323E-4	63	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	0	3	0	12	7	18	33	54	45	61														CATSRFTSPGTGFRLNTEAFF+TCRBV15-01+TCRBJ01-01	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGATTCACAGGGGTGGAGAGGCAAGAGACCCAGTACTTCGGGCCA	CATSRFTGVERQETQYF	In	VDJ	1	97	3.1918079123930993E-4	4.0064102564102563E-4	51	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	3	2	2	3	8	18	33	43	36	51														CATSRFTGVERQETQYF+TCRBV15-01+TCRBJ02-05	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGACCAAAGCCAGCGGGGGGGCTAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	105	3.455049802075004E-4		56	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	2	6	0	0	8	2	18	33	51	41	53														X+TCRBV15-01+TCRBJ02-03	TCRBV15-01*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAAAAAAGGGAGCGACACTGAAGCTTTCTTTGGACAA	CATSKKGSDTEAFF	In	VDJ	2	116	3.817007400387624E-4	4.79117102828443E-4	42	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	4	9	2	3	5	2	18	31	41	36	43														CATSKKGSDTEAFF+TCRBV15-01+TCRBJ01-01	TCRBV15-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCACGGGACAGGGGTCCTACAATGAGCAGTTCTTCGGGCCA	CATSTGQGSYNEQFF	In	VDJ	2	134	4.40930165217191E-4	5.534628601638911E-4	45	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	0	2	1	1	0	18	31	-1	32	42														CATSTGQGSYNEQFF+TCRBV15-01+TCRBJ02-01	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGGGAGACAGGGGGCGCATACGAGCAGTACTTCGGGCCG	CATSRETGGAYEQYF	In	VDJ	2	148	4.869974959115244E-4	6.112873380914618E-4	45	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	2	0	4	3	3	18	32	45	35	48														CATSRETGGAYEQYF+TCRBV15-01+TCRBJ02-07	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGATATCGGACCGGGATACGAAGCTTTCTTTGGACAA	CATSRDIGPGYEAFF	In	VDJ	2	150	4.93578543153572E-4	6.195479777954004E-4	45	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	0	8	3	8	8	3	18	35	48	43	51														CATSRDIGPGYEAFF+TCRBV15-01+TCRBJ01-01	TCRBV15-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCACCTTCAGCGGTCCAACCCTCAATGAGCAGTTCTTCGGGCCA	CATSTFSGPTLNEQFF	In	VDJ	2	154	5.067406376376673E-4	6.360692572032778E-4	48	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	6	5	6	5	9	18	31	41	36	50						01,02								CATSTFSGPTLNEQFF+TCRBV15-01+TCRBJ02-01	TCRBV15-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGGGGGGGCCGGAGCGATTGATACCTCCGGCTACACCTTCGGTTCG	CATSRGGAGAIDTSGYTF	In	VDJ	2	154	5.067406376376673E-4	6.360692572032778E-4	54	TCRBV15	TCRBV15-01	01				TCRBJ01	TCRBJ01-02	01	1	6	0	8	1	19	18	34	41	35	60				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSRGGAGAIDTSGYTF+TCRBV15-01+TCRBJ01-02	TCRBV15-01*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGACCAGGGACAGGCCACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	159	5.231932557427864E-4		46	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	2	0	4	4	3	1	18	33	44	36	45														X+TCRBV15-01+TCRBJ02-02	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGGAAGACAGGAGCTAACTATGGCTACACCTTCGGTTCG	CATRKTGANYGYTF	In	VDJ	3	202	6.646857714468103E-4	8.343246100978059E-4	42	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	2	4	0	3	2	18	29	38	32	40														CATRKTGANYGYTF+TCRBV15-01+TCRBJ01-02	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGTAGAGACGTCGGTGACTATGGCTACACCTTCGGTTCG	CATSRDVGDYGYTF	In	VDJ	3	241	7.93016192666739E-4	9.9540708432461E-4	42	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	0	8	5	3	3	2	18	35	41	38	43						01,02								CATSRDVGDYGYTF+TCRBV15-01+TCRBJ01-02	TCRBV15-01*01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGATCGAGGGACAGGGGGCGAGCAGTACTTCGGGCCG	CATSRDRGTGGEQYF	In	VDJ	4	269	8.851508540554058E-4	0.0011110560401797515	45	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	0	1	6	4	0	18	35	-1	39	50														CATSRDRGTGGEQYF+TCRBV15-01+TCRBJ02-07	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCTCCAGGGGGCGGGAGTTAACTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	4	314	0.0010332244170014775		44	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	7	2	0	3	4	18	29	39	32	43														X+TCRBV15-01+TCRBJ02-07	TCRBV15-01*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGAAAGGGGAGGGGCCGCTGAAGCTTTCTTTGGACAA	CATSRERGGAAEAFF	In	VDJ	6	406	0.0013359525901356683	0.0016769098598995505	45	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	0	9	0	6	3	4	18	35	45	38	49														CATSRERGGAAEAFF+TCRBV15-01+TCRBJ01-01	TCRBV15-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGTGGGTGCGGGCAGCAACACTGAAGCTTTCTTTGGACAA	CATSRVGAGSNTEAFF	In	VDJ	6	433	0.0014247967279033113	0.0017884284959027226	48	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	1	7	4	2	5	4	18	34	44	39	48						01,02								CATSRVGAGSNTEAFF+TCRBV15-01+TCRBJ01-01	TCRBV15-01*01	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGATCGAGGACCCTACGAGCAGTACTTCGGGCCG	CATSRDRGPYEQYF	In	VDJ	6	440	0.001447830393250478	0.0018173407348665081	42	TCRBV15	TCRBV15-01	01				TCRBJ02	TCRBJ02-07	01	0	1	7	2	4	0	18	35	-1	39	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSRDRGPYEQYF+TCRBV15-01+TCRBJ02-07	TCRBV15-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCGGACTAGCGGGGGGGCTGCAAGAGACCCAGTACTTCGGGCCA	CATSGLAGGLQETQYF	In	VDJ	6	448	0.0014741545822186685	0.0018503832936822627	48	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	1	0	2	0	3	18	-1	45	30	48														CATSGLAGGLQETQYF+TCRBV15-01+TCRBJ02-05	TCRBV15-01*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACGCAGCCATGTACCTGTGTGCCACCCGTTCGGAGGGGGGGCTGGAGACCCAGTACTTCGGGCCA	CATRSEGGLETQYF	In	VDJ	14	1025	0.003372786711549409	0.00423357784826857	42	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	8	9	0	5	8	3	18	27	42	35	45														CATRSEGGLETQYF+TCRBV15-01+TCRBJ02-05	TCRBV15-01*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTTGGCTGTGTATCTCTGTGCCAGCAGCTGGAACAGGGTCAACACTGAAGCTTTCTTTGGACAA	CASSWNRVNTEAFF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	42	TCRBV07	TCRBV07-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	3	3	2	3	2	22	35	44	38	46														CASSWNRVNTEAFF+TCRBV07-01+TCRBJ01-01	TCRBV07-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTTGGCTGTGTATCTCTGTGCCACGGTGTGGACAGGGGCAGATACGCAGTATTTTGGCCCA	CATVWTGADTQYF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	39	TCRBV07	TCRBV07-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	10	1	2	4	6	0	22	29	-1	35	44														CATVWTGADTQYF+TCRBV07-01+TCRBJ02-03	TCRBV07-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTTGGCTGTGTATCTCTGTGCCAGCAGCTTATGGGAGAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	36	1.1845885035685729E-4		38	TCRBV07	TCRBV07-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	4	9	2	3	3	0	22	35	-1	38	43														X+TCRBV07-01+TCRBJ02-05	TCRBV07-01*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTTGGCTGTGTATCTCTGTGCCAGCAGCTTAGGTCGCAGCCCTTGAAGCTTTCTTTGGACAA		Out	VDJ	1	43	1.4149251570402398E-4		40	TCRBV07	TCRBV07-01	01				TCRBJ01	TCRBJ01-01	01	4	4	5	7	7	4	22	35	45	42	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV07-01+TCRBJ01-01	TCRBV07-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTTGGCTGTGTATCTCTGTGCCAGCAGCCCCCGGCGAACCTACGAGCAGTACTTCGGGCCG	CASSPRRTYEQYF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	39	TCRBV07	TCRBV07-01	01				TCRBJ02	TCRBJ02-07	01	5	9	0	2	4	3	22	34	41	38	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPRRTYEQYF+TCRBV07-01+TCRBJ02-07	TCRBV07-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTTGGCTGTGTATCTCTGTGCCAGCAGCTCGACCGCCACCGGGGAGCTGTTTTTTGGAGAA	CASSSTATGELFF	In	VDJ	1	61	2.0072194088245263E-4	2.5194951097012955E-4	39	TCRBV07	TCRBV07-01	01				TCRBJ02	TCRBJ02-02	01	3	2	7	4	0	3	22	-1	39	36	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSTATGELFF+TCRBV07-01+TCRBJ02-02	TCRBV07-01*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGGACTCCGCCGTGTATCTCTGTGCCAGCAGAAAGGCAGGGCTCACTGAAGCTTTCTTTGGACAA	CASRKAGLTEAFF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	39	TCRBV07	TCRBV07-08		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	4	3	4	5	2	20	31	41	36	43			01,02											CASRKAGLTEAFF+TCRBV07-08+TCRBJ01-01	TCRBV07-08	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTGAGATGCTGGGGGGTAGACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	23	7.568204328354771E-5		44	TCRBV10	TCRBV10-02	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	2	9	1	5	5	3	23	38	49	43	52													Vb 12	X+TCRBV10-02+TCRBJ01-01	TCRBV10-02*01	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCACCAAGGGACAGGGTGGGGCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	26	8.555361414661915E-5		46	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	7	0	3	2	4	5	23	33	46	37	51													Vb 12	X+TCRBV10-02+TCRBJ02-05	TCRBV10-02*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGACGGACTATGTACAATGAGCAGTTCTTCGGGCCA	CASRRTMYNEQFF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	39	TCRBV10	TCRBV10-02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	1	9	4	2	2	23	34	42	36	44						01,02							Vb 12	CASRRTMYNEQFF+TCRBV10-02+TCRBJ02-01	TCRBV10-02*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAAGATCCAGGGGAGGGGGGAAAGCGAGCAGTACTTCGGGCCG	CAKIQGRGESEQYF	In	VDJ	1	39	1.2833042121992871E-4	1.6108247422680412E-4	42	TCRBV10	TCRBV10-02	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	10	9	0	6	8	7	23	30	45	38	52													Vb 12	CAKIQGRGESEQYF+TCRBV10-02+TCRBJ02-07	TCRBV10-02*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTGAACAGGGGAGGGTTCACTACGAGCAGTACTTCGGGCCG	CASSEQGRVHYEQYF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	45	TCRBV10	TCRBV10-02	01				TCRBJ02	TCRBJ02-07	01	3	3	2	3	0	8	23	-1	44	37	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CASSEQGRVHYEQYF+TCRBV10-02+TCRBJ02-07	TCRBV10-02*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCTAGCAGTGAGTCGATGTCAGCGGGGAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	46	1.5136408656709542E-4		47	TCRBV10	TCRBV10-02	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	0	6	3	3	6	0	23	40	-1	46	53													Vb 12	X+TCRBV10-02+TCRBJ02-05	TCRBV10-02*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTGATCCAGGGGGCGTCCCTGAAGCTTTCTTTGGACAA	CASSDPGGVPEAFF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	42	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	0	6	2	4	23	37	47	39	51													Vb 12	CASSDPGGVPEAFF+TCRBV10-02+TCRBJ01-01	TCRBV10-02*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGCATAATCCCCGGGACAGGGGGCGCGGTCCCATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	59	1.94140893640405E-4		58	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	0	0	6	10	8	23	34	56	44	64													Vb 12	X+TCRBV10-02+TCRBJ01-04	TCRBV10-02*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTGACAACTTGAACACTGAAGCTTTCTTTGGACAA	CASSDNLNTEAFF	In	VDJ	1	64	2.1059351174552407E-4	2.643404705260375E-4	39	TCRBV10	TCRBV10-02	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	3	3	10	0	2	0	23	37	-1	39	42						01,02							Vb 12	CASSDNLNTEAFF+TCRBV10-02+TCRBJ01-01	TCRBV10-02*01	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCCACTAAGGAATTGGAAACACCATATATTTTGGAGAG	CASH*GIGNTIYF	Stop	VDJ	1	66	2.171745589875717E-4		39	TCRBV10	TCRBV10-02	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	8	3	9	3	1	6	23	32	37	33	43						01,02							Vb 12	CASH*GIGNTIYF+TCRBV10-02+TCRBJ01-03	TCRBV10-02*01	TCRBD02-01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGCCCCTATGACTAGCCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	88	2.895660786500956E-4		43	TCRBV10	TCRBV10-02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	2	8	1	7	0	23	34	-1	41	47						01,02							Vb 12	X+TCRBV10-02+TCRBJ02-05	TCRBV10-02*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTGAGTCGCCGGGGAATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSESPGNSNQPQHF	In	VDJ	1	104	3.422144565864766E-4	4.29553264604811E-4	48	TCRBV10	TCRBV10-02	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	0	8	3	0	2	2	23	40	47	42	49													Vb 12	CASSESPGNSNQPQHF+TCRBV10-02+TCRBJ01-05	TCRBV10-02*01	TCRBD02-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTGAGTCGAGACAGGGATCGGGGTATGGCTACACCTTCGGTTCG	CASSESRQGSGYGYTF	In	VDJ	2	136	4.475112124592386E-4	5.617234998678297E-4	48	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	2	3	5	2	7	23	40	49	42	56													Vb 12	CASSESRQGSGYGYTF+TCRBV10-02+TCRBJ01-02	TCRBV10-02*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGAGTAGGCCCCGAGGGAAACACCATATATTTTGGAGAG	CASRVGPEGNTIYF	In	VDJ	2	152	5.001595903956197E-4	6.278086174993392E-4	42	TCRBV10	TCRBV10-02	01				TCRBJ01	TCRBJ01-03	01	6	5	4	4	3	7	23	34	40	37	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CASRVGPEGNTIYF+TCRBV10-02+TCRBJ01-03	TCRBV10-02*01		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAACGAAGGTCAGGGGGCGGGTGAAAAACTGTTTTTTGGCAGT	CASNEGQGAGEKLFF	In	VDJ	3	221	7.272057202462628E-4	9.128006872852234E-4	45	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	7	4	0	7	8	3	23	33	49	41	52													Vb 12	CASNEGQGAGEKLFF+TCRBV10-02+TCRBJ01-04	TCRBV10-02*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCATTGGGGACGGATATACAGATACGCAGTATTTTGGCCCA	CAIGDGYTDTQYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	39	TCRBV10	TCRBV10-03	01				TCRBJ02	TCRBJ02-03	01	9	0	7	3	2	6	24	32	39	34	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CAIGDGYTDTQYF+TCRBV10-03+TCRBJ02-03	TCRBV10-03*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGTTAGGTCAGAACAATGGCTACACCTTCGGTTCG	CAISELGQNNGYTF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	42	TCRBV10	TCRBV10-03	01				TCRBJ01	TCRBJ01-02	01	1	3	6	6	9	0	23	39	-1	48	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CAISELGQNNGYTF+TCRBV10-03+TCRBJ01-02	TCRBV10-03*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGCCTCCCGGACGGTCGTAAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	24	7.897256690457152E-5		50	TCRBV10	TCRBV10-03	01				TCRBJ01	TCRBJ01-04	01	2	1	7	5	6	7	23	38	48	44	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	X+TCRBV10-03+TCRBJ01-04	TCRBV10-03*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGTCGCAAGAAGGGGGCTACACCTTCGGTTCG	CAISESQEGGYTF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	39	TCRBV10	TCRBV10-03	01				TCRBJ01	TCRBJ01-02	01	0	5	3	8	6	0	23	40	-1	46	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CAISESQEGGYTF+TCRBV10-03+TCRBJ01-02	TCRBV10-03*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGTAAGAAGGGGTCCAGAACACTGAAGCTTTCTTTGGACAA	CAISE*EGVQNTEAFF	Stop	VDJ	1	33	1.0858727949378584E-4		48	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	5	2	1	4	4	23	39	48	43	52													Vb 12	CAISE*EGVQNTEAFF+TCRBV10-03+TCRBJ01-01	TCRBV10-03*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGTCGATCTCTAGCGGGGGGATCCATGAGCAGTTCTTCGGGCCA	CAISESISSGGIHEQFF	In	VDJ	1	39	1.2833042121992871E-4	1.6108247422680412E-4	51	TCRBV10	TCRBV10-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	4	1	8	5	4	23	40	56	45	60													Vb 12	CAISESISSGGIHEQFF+TCRBV10-03+TCRBJ02-01	TCRBV10-03*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGTCGAAGGGGGGTAGTGAAAAACTGTTTTTTGGCAGT	CAISESKGGSEKLFF	In	VDJ	1	54	1.7768827553528592E-4	2.2303727200634416E-4	45	TCRBV10	TCRBV10-03	01				TCRBJ01	TCRBJ01-04	01	0	5	1	7	2	4	23	40	48	42	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CAISESKGGSEKLFF+TCRBV10-03+TCRBJ01-04	TCRBV10-03*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCATCAGGGTGGACAGATCGGGATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	62	2.0401246450347642E-4		43	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	1	5	6	3	6	24	35	44	38	50													Vb 12	X+TCRBV10-03+TCRBJ01-04	TCRBV10-03*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGTCCGAGGGGGAATCACCCCTCCACTTTGGGAAC	CAISESEGESPLHF	In	VDJ	1	72	2.3691770071371457E-4	2.973830293417922E-4	42	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	0	5	1	10	2	2	23	40	48	42	50													Vb 12	CAISESEGESPLHF+TCRBV10-03+TCRBJ01-06	TCRBV10-03*01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGTCGGACCAAAAACAGGGGTTCCCCGGGGAGCTGTTTTTTGGAGAA	CAISESDQKQGFPGELFF	In	VDJ	1	75	2.46789271576786E-4	3.097739888977002E-4	54	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	0	3	2	6	9	4	23	40	56	49	60													Vb 12	CAISESDQKQGFPGELFF+TCRBV10-03+TCRBJ02-02	TCRBV10-03*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGGGCGGGACAGGGTACTACTCAGAGACCCAGTACTTCGGGCCA	CAISEGGTGYYSETQYF	In	VDJ	2	127	4.178964998700243E-4	5.245506212001057E-4	51	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	0	3	4	3	8	23	38	50	41	58													Vb 12	CAISEGGTGYYSETQYF+TCRBV10-03+TCRBJ02-05	TCRBV10-03*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCAGCCTCGGGACAGGGGGATCACGAGCAGTACTTCGGGCCG		Out	VDJ	2	156	5.133216848797149E-4		40	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	10	0	1	5	5	3	24	31	47	36	50													Vb 12	X+TCRBV10-03+TCRBJ02-07	TCRBV10-03*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGTCGGCAGGGAAAAGACCCAGTACTTCGGGCCA		Out	VDJ	3	183	6.021658226473579E-4		41	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	4	3	6	2	3	23	40	47	42	50													Vb 12	X+TCRBV10-03+TCRBJ02-05	TCRBV10-03*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGCGCACGGCCCCTACGAGCAGTACTTCGGGCCG	CASSIAHGPYEQYF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	42	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-07	01	1	9	0	2	5	1	27	43	51	48	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIAHGPYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGTTTGGTGCCAAAAGAACCCGACAGCTTTTATCTCTGTGCCAGTAGTATCGGGACAGGGACGGACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	23	7.568204328354771E-5		44	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	24	0	3	3	21	4	37	30	60	51	64			01,02										Vb 17	X+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGTTTGGTGCCAAAAGACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGGGACAGGGACGGACTATGGCTACACCTTCGGTTCG	CASSIGTGTDYGYTF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	0	3	3	1	4	36	50	60	51	64			01,02										Vb 17	CASSIGTGTDYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCTCTGTGCCAGTAGTTCAGAGGTTGGGGGCTAGCGGGGGGCCGAGCTAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	23	7.568204328354771E-5		65	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	4	1	0	14	7	4	16	41	30	48			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACTTCAACTACGCGCGTGAAGCTTTCTTTGGACAA		Out	VDJ	1	24	7.897256690457152E-5		38	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	7	3	9	7	5	6	27	37	46	42	52			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGGGACAGGGGCGAAGTGGCAGCCCCAGCATTTTGGTGAT	CASGTGAKWQPQHF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	8	0	2	7	0	8	27	-1	46	36	54			01,02										Vb 17	CASGTGAKWQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCACGGACGCGGGACAAACTAATGAAAAACTGTTTTTTGGCAGT	CATDAGQTNEKLFF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-04	01	10	0	6	1	7	0	27	34	-1	41	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CATDAGQTNEKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCGGACAGGGCGAAAACTATGGCTACACCTTCGGTTCG	CASSGQGENYGYTF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	1	3	2	1	4	27	38	47	39	51			01,02										Vb 17	CASSGQGENYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTTTGGGACATTGGGTCAGCCCCAGCATTTTGGTGAT	CASSFGTLGQPQHF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	0	6	6	3	5	27	39	48	42	53			01,02										Vb 17	CASSFGTLGQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAATAGTATAGGGGGCTCTTACAATGAGCAGTTCTTCGGGCCA	CANSIGGSYNEQFF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	7	0	4	0	3	27	-1	48	43	51			01,02										Vb 17	CANSIGGSYNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGCAAGGCCGGGCTACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	26	8.555361414661915E-5		37	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-01	01	9	8	0	3	7	1	27	35	46	42	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ01-01	TCRBV19-01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCGAGGGACGGAAAATCAGCCCCAGCATTTTGGTGAT	CASSRGTENQPQHF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	42	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	5	0	7	4	3	4	27	39	47	42	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSRGTENQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCTCGGGACAGTGAAAAACTGTTTTTTGGCAGT	CASSPRDSEKLFF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	0	5	7	4	0	27	39	-1	43	50			01,02										Vb 17	CASSPRDSEKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCTGGCCCGGGCGGGAGGAAACACCATATATTTTGGAGAG	CASSLARAGGNTIYF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	5	7	3	4	9	0	27	39	-1	48	54			01,02										Vb 17	CASSLARAGGNTIYF+TCRBV19-01+TCRBJ01-03	TCRBV19-01	TCRBD02-01*02	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCGCAGGAGAGGGGTCGACTACCACAGATACGCAGTATTTTGGCCCA	CAAGEGSTTTDTQYF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	45	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-03	01	11	5	2	2	7	8	27	33	45	40	53			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CAAGEGSTTTDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGATCTCGAACACTGAAGCTTTCTTTGGACAA	CASSMISNTEAFF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	39	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-01	01	3	2	8	1	0	4	27	-1	43	41	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSMISNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCCCGGGCCCACTATGGCTACACCTTCGGTTCG	CASSSRAHYGYTF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	39	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-02	01	5	8	0	3	4	2	27	39	47	43	49			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSSRAHYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACGACAGGGTCTGGCTACACCTTCGGTTCG	CASSTTGSGYTF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	36	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	2	3	7	1	2	27	40	48	41	50			01,02										Vb 17	CASSTTGSGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGCCTCAGGGTTTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSIASGFGANVLTF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	1	4	3	3	3	2	27	43	51	46	53			01,02										Vb 17	CASSIASGFGANVLTF+TCRBV19-01+TCRBJ02-06	TCRBV19-01	TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGGGAGTGAAGTTAGGTCACCCCTCCACTTTGGGAAC	CASSIGSEVRSPLHF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	3	8	2	10	0	10	27	-1	47	41	57			01,02										Vb 17	CASSIGSEVRSPLHF+TCRBV19-01+TCRBJ01-06	TCRBV19-01	TCRBD02-01*02	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGCCTCGGCAGGGCCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSIASAGPNTGELFF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	51	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	1	4	3	0	6	1	27	43	54	49	55			01,02										Vb 17	CASSIASAGPNTGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCCCCGACAGGGTCAATCAGCCCCAGCATTTTGGTGAT	CASSPDRVNQPQHF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	2	3	3	4	1	27	38	49	42	50			01,02										Vb 17	CASSPDRVNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGTTTGGTGCCAAAAGAACCCGACAGTTTCTATCTCTGTGCCAGTAGTATCGGGACAGGGACGGACTATGGCTACACCTTCGGTTCG	CASSIGTGTDYGYTF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	0	3	3	1	4	36	50	60	51	64			01,02										Vb 17	CASSIGTGTDYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGCCGGGGGGGGAAACAAGAGACCCAGTACTTCGGGCCA	CASRGGKQETQYF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	9	8	0	2	1	4	27	35	44	36	48			01,02										Vb 17	CASRGGKQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGGGAAGACAGGGCGAGGGTGGCTACACCTTCGGTTCG		Out	VDJ	1	36	1.1845885035685729E-4		38	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	9	2	3	7	4	6	27	35	46	39	52			01,02										Vb 17	X+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTTAACAGGGGTCACTGGAAACACCATATATTTTGGAGAG	CASSLTGVTGNTIYF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	3	2	2	3	3	27	39	49	42	52			01,02										Vb 17	CASSLTGVTGNTIYF+TCRBV19-01+TCRBJ01-03	TCRBV19-01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCAGACAGGGATCGGAGTTACGTGAAAAACTGTTTTTTGGCAGT	CASSIRQGSELREKLFF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	51	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	2	3	7	2	12	27	41	50	43	62			01,02										Vb 17	CASSIRQGSELREKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACAGTCCAAGAGACCCAGTACTTCGGGCCA	CASSTVQETQYF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	36	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	4	5	1	0	1	27	-1	43	40	44			01,02										Vb 17	CASSTVQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGTCGGCTCACGGAAGTTGAAGCGCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	40	1.3162094484095254E-4		52	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	6	6	2	19	0	27	39	-1	58	62			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGGATTTAGACACTGAAGCTTTCTTTGGACAA	CASRDLDTEAFF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	36	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-01	01	6	1	8	3	0	5	27	-1	41	38	46			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASRDLDTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTTGAGGACAGGGGGCAGACAGACCCAGTACTTCGGGCCA	CASSLRTGGRQTQYF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	1	0	6	4	4	27	39	54	43	58			01,02										Vb 17	CASSLRTGGRQTQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGGACGGGAGGAACACTGAAGCTTTCTTTGGACAA	CASRDGRNTEAFF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	6	8	2	1	3	0	27	38	-1	41	47			01,02										Vb 17	CASRDGRNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGCCAGTAGTCAACAGGCCATCCGGACCCATGGGCACTAAACTAGCACTAAGTCAGCCACCCCTCCACTTTGGGAAC		Out	VDJ	1	42	1.3820199208300016E-4		73	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	5	3	7	11	30	11	-1	10	46	40	57			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ01-06	TCRBV19-01	TCRBD02-01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAATCAAGACCGGGACAGGGTAATACGAGCAGTACTTCGGGCCG		Out	VDJ	1	43	1.4149251570402398E-4		46	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	0	3	4	9	3	27	37	55	46	58			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTACGAGACAGGGGGCGGGTGAGCAGTTCTTCGGGCCA	CASSITRQGAGEQFF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	2	0	9	5	3	27	41	56	46	59			01,02										Vb 17	CASSITRQGAGEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCTTACAGGGGGCCAAGAAAAACTGTTTTTTGGCAGT	CASSLTGGQEKLFF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	3	0	8	3	3	27	39	51	42	54			01,02										Vb 17	CASSLTGGQEKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCTCTGTGCCAGTAGTATCAGGGGGACCGTCCCCCTTCCCCCGCCCGGGCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	43	1.4149251570402398E-4		65	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	4	1	2	0	24	4	-1	25	18	49			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTAATCCGGGAGGTTACGAGCAGTACTTCGGGCCG	CASSINPGGYEQYF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	8	1	4	5	1	27	41	53	46	54			01,02										Vb 17	CASSINPGGYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGACGGACCTGGGCAGGGGGAGACTATGGCTACACCTTCGGTTCG	CASRRTWAGGDYGYTF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	4	1	3	11	2	27	38	56	49	58			01,02										Vb 17	CASRRTWAGGDYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCCTGGGACAGGGGTGGCGGCCCCAGCATTTTGGTGAT	CASSLGQGWRPQHF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	0	2	9	3	5	27	38	51	41	56			01,02										Vb 17	CASSLGQGWRPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGATCTAGGCCAGCCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	46	1.5136408656709542E-4		44	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	0	4	8	4	1	6	27	44	49	45	55			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCGGGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSGNTGELFF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	36	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	6	8	5	1	0	0	27	-1	-1	38	41			01,02			01,02							Vb 17	CASSGNTGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGTGGGGGACGAACACCGGGGAGCTGTTTTTTGGAGAA	CASRWGTNTGELFF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	42	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-02	01	6	6	1	0	2	1	27	38	45	40	46			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASRWGTNTGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGAAAGTGGACAGGGGAAATACGCAGTATTTTGGCCCA	CASSMKVDRGNTQYF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	1	2	7	6	2	27	41	56	47	58			01,02										Vb 17	CASSMKVDRGNTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCGGGGACAGGGGGCGCGGGATACGCAGTATTTTGGCCCA	CASSRGQGARDTQYF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	0	0	6	2	4	27	39	53	41	57			01,02										Vb 17	CASSRGQGARDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGATTACGGGGGCAATCAGCCCCAGCATTTTGGTGAT	CASSIDYGGNQPQHF	In	VDJ	1	49	1.6123565743016686E-4	2.023856727464975E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	0	8	3	2	3	0	27	44	-1	47	52			01,02										Vb 17	CASSIDYGGNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD02-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCTAGCCGGTGCGGGGGGGCTCGAGAGACCCAGTACTTCGGGCCA	CASRCGGARETQYF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	12	7	0	4	8	4	27	32	49	40	53			01,02										Vb 17	CASRCGGARETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTTCAGGGTTTCCGGGGAGCTGTTTTTTGGAGAA	CASSFRVSGELFF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	4	3	6	2	3	27	39	46	41	49			01,02										Vb 17	CASSFRVSGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGTAGGTTGGGGCTTCCTTCACGAGCAGTACTTCGGGCCG	CASSVGWGFLHEQYF	In	VDJ	1	52	1.711072282932383E-4	2.147766323024055E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	7	0	5	3	7	27	43	51	46	58			01,02										Vb 17	CASSVGWGFLHEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCTATCAGAACAATCAGCCCCAGCATTTTGGTGAT	CASSIYQNNQPQHF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	42	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	3	4	5	3	4	2	27	41	48	45	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIYQNNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGGAGGGGACACTGAAGCTTTCTTTGGACAA	CASSIGGDTEAFF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	3	10	0	3	1	1	27	41	48	42	49			01,02										Vb 17	CASSIGGDTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGGGTAGCGGATACAATGAGCAGTTCTTCGGGCCA	CASRGSGYNEQFF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	5	5	4	3	1	27	38	47	41	48			01,02			01,02							Vb 17	CASRGSGYNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACAGGGAGAGCCACGAGCAGTACTTCGGGCCG		Out	VDJ	1	58	1.908503700193812E-4		38	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-07	01	4	4	3	5	0	6	27	-1	45	40	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCCTAAAATGGGGTCTAGCGGAGCCCACAGATACGCAGTATTTTGGCCCA	CASSLKWGLAEPTDTQYF	In	VDJ	1	59	1.94140893640405E-4	2.4368887126619086E-4	54	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	4	5	2	13	4	27	38	58	51	62			01,02			01,02							Vb 17	CASSLKWGLAEPTDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCTCCGGGTTCCCAGAGATGGCTACACCTTCGGTTCG	CASSLRVPRDGYTF	In	VDJ	1	61	2.0072194088245263E-4	2.5194951097012955E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	5	8	4	6	3	9	27	39	46	42	55			01,02			01,02							Vb 17	CASSLRVPRDGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCCCAGGCGGCCCCCTACAATGAGCAGTTCTTCGGGCCA	CASSSQAAPYNEQFF	In	VDJ	1	61	2.0072194088245263E-4	2.5194951097012955E-4	45	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-01	01	5	4	4	2	3	6	27	39	46	42	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSSQAAPYNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGGTAAGGGGGAGGCTACACCTTCGGTTCG		Out	VDJ	1	62	2.0401246450347642E-4		38	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	5	1	8	3	1	27	43	52	46	53			01,02										Vb 17	X+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGGGATTTCGTCGGGAAACACCTTCGGTTCG	CASSIGISSGNTF	In	VDJ	1	62	2.0401246450347642E-4	2.560798308220989E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	3	8	3	12	0	12	27	-1	46	41	58			01,02										Vb 17	CASSIGISSGNTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCGTCGCGGGAGCTCCTACGAGCAGTACTTCGGGCCG	CASSRRGSSYEQYF	In	VDJ	1	62	2.0401246450347642E-4	2.560798308220989E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	7	2	0	4	0	27	39	-1	43	50			01,02										Vb 17	CASSRRGSSYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACCGCGGGAGGCGCGACCCAGTACTTCGGGCCA	CASSTAGGATQYF	In	VDJ	1	64	2.1059351174552407E-4	2.643404705260375E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	4	7	1	7	2	3	27	40	50	42	53			01,02										Vb 17	CASSTAGGATQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGTTAGGGGGAGCTCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	64	2.1059351174552407E-4		44	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	5	5	1	3	3	4	27	39	48	42	52			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-04	TCRBV19-01	TCRBD01-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTATTCTAGCGTACAGGGTCCCGACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	65	2.1388403536654787E-4		47	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-01	01	7	3	3	3	9	5	27	37	52	46	57			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ01-01	TCRBV19-01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGGCAGGGACCAATTCACCCCTCCACTTTGGGAAC	CASRAGTNSPLHF	In	VDJ	1	66	2.171745589875717E-4	2.726011102299762E-4	39	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-06	01	6	0	7	7	4	1	27	38	47	42	48			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASRAGTNSPLHF+TCRBV19-01+TCRBJ01-06	TCRBV19-01		TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGGGGGCCTAGTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	66	2.171745589875717E-4		40	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-07	01	3	6	0	4	1	4	27	41	48	42	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCCCACCACAGGGGCGGTGGCTACACCTTCGGTTCG	CASSPHHRGGGYTF	In	VDJ	1	69	2.2704612985064313E-4	2.8499206978588424E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	3	2	7	7	3	27	39	53	46	56			01,02										Vb 17	CASSPHHRGGGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTATGGGGATGAGAGCCTTGGCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	69	2.2704612985064313E-4		47	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-01	01	7	0	8	3	2	12	27	37	43	39	55			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ02-01	TCRBV19-01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTGTCGCTAGAGACTATGGCTACACCTTCGGTTCG	CASSIVARDYGYTF	In	VDJ	1	70	2.3033665347166695E-4	2.8912238963785356E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	3	4	8	3	5	2	27	41	50	46	52			01,02			01,02							Vb 17	CASSIVARDYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCAGCGGGAGAACCCTCTCCTACGAGCAGTACTTCGGGCCG	CASTSGRTLSYEQYF	In	VDJ	1	74	2.434987479557622E-4	3.056436690457309E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	7	6	2	0	2	6	27	37	47	39	53			01,02										Vb 17	CASTSGRTLSYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACGCAGGGTAGGGATGAGCAGTTCTTCGGGCCA	CASSTQGRDEQFF	In	VDJ	1	75	2.46789271576786E-4	3.097739888977002E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	4	3	8	2	5	27	40	47	42	52			01,02										Vb 17	CASSTQGRDEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTTAGTCGGACAGCCTAAACTGTTTTTTGGCAGT	CASSLVGQPKLFF	In	VDJ	1	75	2.46789271576786E-4	3.097739888977002E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	1	1	5	11	2	3	27	43	51	45	54			01,02										Vb 17	CASSLVGQPKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGCAAATAGGGGGGCCTACGAGCAGTACTTCGGGCCG	CASANRGAYEQYF	In	VDJ	1	75	2.46789271576786E-4	3.097739888977002E-4	39	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-07	01	8	5	1	2	6	1	27	36	48	42	49			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASANRGAYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGGATTCCAGGGTTACTGAAGCTTTCTTTGGACAA	CASRDSRVTEAFF	In	VDJ	1	76	2.5007979519780984E-4	3.139043087496696E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	4	3	5	6	2	27	38	49	44	51			01,02										Vb 17	CASRDSRVTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACAGGGGATCGGGGTGCTGAAGCTTTCTTTGGACAA	CASSTGDRGAEAFF	In	VDJ	1	76	2.5007979519780984E-4	3.139043087496696E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	4	2	6	0	9	27	-1	46	40	55			01,02										Vb 17	CASSTGDRGAEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCGAAGGCATTAATGAAAAACTGTTTTTTGGCAGT	CASSEGINEKLFF	In	VDJ	1	77	2.5337031881883363E-4	3.180346286016389E-4	39	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-04	01	6	5	4	4	3	3	27	38	44	41	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSEGINEKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGCGAGCGGGAGCTTGCGAGTAACCACCGGGGAGCTGTTTTTTGGAGAA	CASASGSLRVTTGELFF	In	VDJ	1	79	2.599513660608813E-4	3.2629526830557756E-4	51	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	8	6	2	4	3	12	27	36	47	39	59			01,02										Vb 17	CASASGSLRVTTGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCAGGACAGGGTAAATCAGCCCCAGCATTTTGGTGAT	CASSQDRVNQPQHF	In	VDJ	1	82	2.698229369239527E-4	3.386862278614856E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	1	3	4	2	2	27	39	49	41	51			01,02										Vb 17	CASSQDRVNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTTCCGGGACAGGAACACTGAAGCTTTCTTTGGACAA	CASSFRDRNTEAFF	In	VDJ	1	82	2.698229369239527E-4	3.386862278614856E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	5	1	4	0	27	39	-1	43	50			01,02										Vb 17	CASSFRDRNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCGACAGGAGGGTAATTCACCCCTCCACTTTGGGAAC	CASSRQEGNSPLHF	In	VDJ	1	86	2.8298503140804796E-4	3.552075072693629E-4	42	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-06	01	5	2	4	6	1	4	27	39	46	40	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSRQEGNSPLHF+TCRBV19-01+TCRBJ01-06	TCRBV19-01		TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGGCGTACTACAGGGAAACACTGAAGCTTTCTTTGGACAA	CASSGVLQGNTEAFF	In	VDJ	1	88	2.895660786500956E-4	3.634681469733016E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	3	2	8	1	27	39	53	47	54			01,02										Vb 17	CASSGVLQGNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACATGGACTAGCGGGGGGATCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	92	3.0272817313419084E-4		52	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	1	1	1	3	1	27	40	57	43	58			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGGGGGGGACAGCTGGGTACAATGAGCAGTTCTTCGGGCCA	CASRGGTAGYNEQFF	In	VDJ	1	97	3.1918079123930993E-4	4.0064102564102563E-4	45	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-01	01	6	0	5	4	4	5	27	38	49	42	54			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASRGGTAGYNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTATAAGGCGGCTGATAGATACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	100	3.2905236210238137E-4		47	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	7	7	5	3	4	9	27	37	45	41	54			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGACGCAGGCCCTCGCGAGACCCAGTACTTCGGGCCA	CASSIDAGPRETQYF	In	VDJ	1	102	3.3563340934442896E-4	4.2129262490087234E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	4	4	5	5	7	27	41	50	46	57			01,02										Vb 17	CASSIDAGPRETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGGAGGGCCCCCTCTACGAGCAGTACTTCGGGCCG	CASSMEGPLYEQYF	In	VDJ	1	103	3.389239329654528E-4	4.2542294475284167E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	10	0	3	0	6	27	-1	47	41	53			01,02										Vb 17	CASSMEGPLYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTCGGGGCCAGATCCTAACCTACGAGCAGTACTTCGGGCCG	CASSIRGQILTYEQYF	In	VDJ	1	103	3.389239329654528E-4	4.2542294475284167E-4	48	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-07	01	3	7	0	2	2	10	27	41	48	43	58			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIRGQILTYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGGCTTCGGGGAGCTGTTTTTTGGAGAA	CASSIGFGELFF	In	VDJ	1	104	3.422144565864766E-4	4.29553264604811E-4	36	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-02	01	1	10	0	7	0	2	27	-1	45	43	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIGFGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGGGGGGGCACCAGAACACTGAAGCTTTCTTTGGACAA	CASSMGGHQNTEAFF	In	VDJ	1	105	3.455049802075004E-4	4.336835844567803E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	3	9	0	1	0	5	27	-1	48	41	53			01,02										Vb 17	CASSMGGHQNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGTTGGGTCACTACAAGAGACCCAGTACTTCGGGCCA	CASSIVGSLQETQYF	In	VDJ	1	107	3.5208602744954805E-4	4.41944224160719E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	3	3	9	2	9	0	27	41	-1	50	54			01,02			01,02							Vb 17	CASSIVGSLQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGCCACAGGGGCCACTGAAGCTTTCTTTGGACAA	CASSATGATEAFF	In	VDJ	1	107	3.5208602744954805E-4	4.41944224160719E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	2	4	3	1	27	39	49	42	50			01,02										Vb 17	CASSATGATEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTACGGGACAGCAGGGGGTCAGCCCCAGCATTTTGGTGAT	CASSYGTAGGQPQHF	In	VDJ	1	107	3.5208602744954805E-4	4.41944224160719E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	0	5	6	3	7	27	39	49	42	56			01,02										Vb 17	CASSYGTAGGQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCTGGGCAGGGGCTAACTATGGCTACACCTTCGGTTCG	CASSWAGANYGYTF	In	VDJ	2	111	3.652481219336433E-4	4.5846550356859635E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	4	2	0	5	0	27	38	-1	43	49			01,02										Vb 17	CASSWAGANYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGATCCCAGGGGGCAGCGAGCAATCAGCCCCAGCATTTTGGTGAT	CASRSQGAASNQPQHF	In	VDJ	2	113	3.7182916917569093E-4	4.6672614327253505E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	4	0	1	4	4	27	38	50	42	54			01,02										Vb 17	CASRSQGAASNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCTCTCTTACCGGGACAAACAACTATGGCTACACCTTCGGTTCG	CASSSLTGTNNYGYTF	In	VDJ	2	114	3.7511969279671473E-4	4.7085646312450437E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	6	2	10	3	27	38	54	48	57			01,02										Vb 17	CASSSLTGTNNYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAATTCAGGGACCCGCAAAAACATTCAGTACTTCGGCGCC	CASSNSGTRKNIQYF	In	VDJ	2	119	3.915723109018338E-4	4.91508062384351E-4	45	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-04	01	4	0	7	3	5	3	27	40	50	45	53			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSNSGTRKNIQYF+TCRBV19-01+TCRBJ02-04	TCRBV19-01		TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACAGACAGGGCGCGGGGCACTGAAGCTTTCTTTGGACAA	CASSTDRARGTEAFF	In	VDJ	2	124	4.0802492900695285E-4	5.121596616441978E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	0	7	3	4	6	0	27	44	-1	50	56			01,02										Vb 17	CASSTDRARGTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTATACCCCGGGACAGGAGTAACTATGGCTACACCTTCGGTTCG	CASIPRDRSNYGYTF	In	VDJ	2	124	4.0802492900695285E-4	5.121596616441978E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	0	4	1	6	2	27	37	51	43	53			01,02										Vb 17	CASIPRDRSNYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAATCGACCCGGATTGGATTCACCCCTCCACTTTGGGAAC	CASNRPGLDSPLHF	In	VDJ	2	125	4.113154526279767E-4	5.162899814961671E-4	42	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-06	01	7	1	8	8	8	4	27	37	48	45	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASNRPGLDSPLHF+TCRBV19-01+TCRBJ01-06	TCRBV19-01		TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCCCAGGACCGTTCTCCTACAATGAGCAGTTCTTCGGGCCA	CASTPGPFSYNEQFF	In	VDJ	2	125	4.113154526279767E-4	5.162899814961671E-4	45	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-01	01	7	1	7	0	5	4	27	37	46	42	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASTPGPFSYNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGCCCCAAAGGCGGAGGGAAATGAGCAGTTCTTCGGGCCA	CASAPKAEGNEQFF	In	VDJ	2	132	4.343491179751434E-4	5.452022204599524E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	8	10	0	7	11	1	27	36	53	47	54			01,02										Vb 17	CASAPKAEGNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCGGGGACTAGCGCCTTCTACGAGCAGTACTTCGGGCCG	CASSSGTSAFYEQYF	In	VDJ	2	133	4.376396415961672E-4	5.493325403119218E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	0	6	3	3	4	27	39	52	42	56			01,02			01,02							Vb 17	CASSSGTSAFYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTATGGGAGTTGTGGAAAAACTGTTTTTTGGCAGT	CASMGVVEKLFF	In	VDJ	2	135	4.442206888382148E-4	5.575931800158604E-4	36	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	7	9	2	8	1	5	27	37	43	38	48			01,02										Vb 17	CASMGVVEKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01	TCRBD02-01*02	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCCCACCGGGGTCCTGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	2	136	4.475112124592386E-4		38	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	11	8	3	0	4	3	27	33	42	37	45			01,02										Vb 17	X+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAAGGGACTAGCGGAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	2	137	4.5080173608026247E-4		46	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	4	0	5	0	1	0	27	40	-1	41	52			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAGGGACAATAATTCACCCCTCCACTTTGGGAAC	CASSRDNNSPLHF	In	VDJ	2	139	4.5738278332231006E-4	5.741144594237378E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	0	6	5	0	0	27	-1	-1	40	46			01,02										Vb 17	CASSRDNNSPLHF+TCRBV19-01+TCRBJ01-06	TCRBV19-01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCCCTACTAGCGGGTATTCCTACAATGAGCAGTTCTTCGGGCCA	CASSPTSGYSYNEQFF	In	VDJ	2	141	4.639638305643577E-4	5.823750991276764E-4	48	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	3	4	1	4	3	27	38	51	42	54			01,02			01,02							Vb 17	CASSPTSGYSYNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGCAGACCGGGACAGGGGAAGTCAGATACGCAGTATTTTGGCCCA	CASRPGQGKSDTQYF	In	VDJ	2	142	4.672543541853815E-4	5.865054189796458E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	9	0	2	4	6	4	27	35	51	41	55			01,02										Vb 17	CASRPGQGKSDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGCGGCAGGGGGCTATGGCTACACCTTCGGTTCG	CASSIAAGGYGYTF	In	VDJ	2	147	4.837069722905006E-4	6.071570182394925E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	4	1	4	3	0	27	43	-1	46	53			01,02										Vb 17	CASSIAAGGYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATATCAGGGTCCATGAACACTGAAGCTTTCTTTGGACAA	CASSISGSMNTEAFF	In	VDJ	2	148	4.869974959115244E-4	6.112873380914618E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	4	3	0	1	4	27	42	48	43	52			01,02										Vb 17	CASSISGSMNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTTGAGTACCGGGACAGACTATGGCTACACCTTCGGTTCG	CASSLSTGTDYGYTF	In	VDJ	2	154	5.067406376376673E-4	6.360692572032778E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	5	3	9	0	27	39	-1	48	55			01,02										Vb 17	CASSLSTGTDYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAATTGACCGCCGGTTGCGTCCTCTCCTATGGCTACACCTTCGGTTCG		Out	VDJ	2	159	5.231932557427864E-4		55	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-02	01	2	2	7	4	3	18	26	41	47	44	65			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ01-02	TCRBV19-01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGCGGACAGGGGCCTACGAGCAGTACTTCGGGCCG	CASRRTGAYEQYF	In	VDJ	2	159	5.231932557427864E-4	6.567208564631246E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	1	2	2	2	0	27	38	-1	40	49			01,02										Vb 17	CASRRTGAYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCTGAGGAATAACTATGGCTACACCTTCGGTTCG	CASSLRNNYGYTF	In	VDJ	2	161	5.297743029848339E-4	6.649814961670632E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	5	11	1	1	2	2	27	39	45	41	47			01,02										Vb 17	CASSLRNNYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGATGGGCAGGGGGCTAGAGATACGCAGTATTTTGGCCCA	CASSIDGQGARDTQYF	In	VDJ	2	162	5.330648266058577E-4	6.691118160190325E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	4	0	5	4	3	27	44	56	48	59			01,02										Vb 17	CASSIDGQGARDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGTGGGACAGGGGGCTTGGAACGAGCAGTACTTCGGGCCG	CASSIVGQGAWNEQYF	In	VDJ	2	162	5.330648266058577E-4	6.691118160190325E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	0	0	5	1	5	27	43	56	44	61			01,02										Vb 17	CASSIVGQGAWNEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAMCCGGGACGGAGCCTACGAGCAGTACTTCGGGCCG	CASSXRDGAYEQYF	In	VDJ	2	164	5.396458738479054E-4	6.773724557229712E-4	42	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-07	01	4	0	7	2	3	4	27	40	48	43	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSXRDGAYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCACAGGGAGATACGCAGTATTTTGGCCCA	CASSPQGDTQYF	In	VDJ	2	164	5.396458738479054E-4	6.773724557229712E-4	36	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	3	3	5	2	0	27	39	-1	41	47			01,02										Vb 17	CASSPQGDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAGAGATATGGGCCCAGGGGGCTATGGCTACACCTTCGGTTCG	CASSRDMGPGGYGYTF	In	VDJ	2	166	5.46226921089953E-4	6.856330954269098E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	1	4	8	0	27	44	-1	52	59			01,02										Vb 17	CASSRDMGPGGYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCAGGGCAGTTGAGCAGTTCTTCGGGCCA	CASSRAVEQFF	In	VDJ	2	172	5.659700628160959E-4	7.104150145387258E-4	33	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	4	3	9	0	4	27	-1	43	38	47			01,02										Vb 17	CASSRAVEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCTCCGGTTTGAACACTGAAGCTTTCTTTGGACAA	CASSSGLNTEAFF	In	VDJ	2	173	5.692605864371197E-4	7.145453343906952E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	6	8	5	0	3	2	27	38	44	41	46			01,02			01,02							Vb 17	CASSSGLNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCAACAGGGGAGGGCTACACCTTCGGTTCG	CASSSTGEGYTF	In	VDJ	2	176	5.791321573001912E-4	7.269362939466032E-4	36	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	3	2	8	3	2	27	39	49	42	51			01,02										Vb 17	CASSSTGEGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCTGAAGATTAAAGTAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	2	179	5.890037281632626E-4		49	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	3	2	8	0	2	9	27	41	45	43	54			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGGTCCAGGGGGAGGATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	3	180	5.922942517842864E-4		40	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	8	4	1	5	4	3	27	36	47	40	50			01,02										Vb 17	X+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGCGTGCAGGGACCAATGAGCAGTTCTTCGGGCCA	CASRRAGTNEQFF	In	VDJ	3	184	6.054563462683817E-4	7.599788527623579E-4	39	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-01	01	6	0	7	6	7	0	27	38	-1	45	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASRRAGTNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGTTTGAGGGGGGAGGCCAAGAGACCCAGTACTTCGGGCCA	CASRFEGGGQETQYF	In	VDJ	3	189	6.219089643735008E-4	7.806304520222046E-4	45	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-05	01	6	5	1	1	5	4	27	38	49	43	53			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASRFEGGGQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGCTTTCTATCTCTGTGCCAGTAGTAGGGGGTACACAGGGGGCGAACCCCTAGCCAAAAACATTCAGTACTTCGGCGCC	CASSRGYTGGEPLAKNIQYF	In	VDJ	3	195	6.416521060996437E-4	8.054123711340206E-4	60	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	4	3	0	0	8	8	14	27	44	35	52			01,02										Vb 17	CASSRGYTGGEPLAKNIQYF+TCRBV19-01+TCRBJ02-04	TCRBV19-01	TCRBD01-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACCCAGGACAGGGACAATTCACCCCTCCACTTTGGGAAC	CASSTQDRDNSPLHF	In	VDJ	3	196	6.449426297206674E-4	8.0954269098599E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	1	3	7	4	2	27	40	52	44	54			01,02										Vb 17	CASSTQDRDNSPLHF+TCRBV19-01+TCRBJ01-06	TCRBV19-01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCAGGACAGAAACTGTTTTTTGGCAGT	CASSPGQKLFF	In	VDJ	3	199	6.548142005837388E-4	8.21933650541898E-4	33	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	1	5	11	3	0	27	39	-1	42	48			01,02										Vb 17	CASSPGQKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGACGAGAGGGTGGCACCGGGGAGCTGTTTTTTGGAGAA	CASRREGGTGELFF	In	VDJ	3	202	6.646857714468103E-4	8.343246100978059E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	6	11	0	4	4	3	27	38	47	42	50			01,02										Vb 17	CASRREGGTGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCGGGGCTACGAGCAGTACTTCGGGCCG	CASSRGYEQYF	In	VDJ	3	204	6.712668186888579E-4	8.425852498017447E-4	33	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	8	3	3	0	0	27	-1	-1	39	44			01,02										Vb 17	CASSRGYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGGGTGGGGGGACAGATACAATGAGCAGTTCTTCGGGCCA	CASSIGWGDRYNEQFF	In	VDJ	3	207	6.811383895519294E-4	8.549762093576527E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	0	5	4	6	1	27	43	56	49	57			01,02										Vb 17	CASSIGWGDRYNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCTCGGACTACCAGGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	3	209	6.87719436793977E-4		46	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	5	1	9	4	4	3	27	39	49	43	52			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ02-06	TCRBV19-01	TCRBD02-01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGGGGGGGACAGTTTACGAGCAGTACTTCGGGCCG		Out	VDJ	3	215	7.074625785201199E-4		35	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	9	0	5	4	3	2	27	35	45	38	47			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTTCTCCGGGGCAGGGCGCAGATACGCAGTATTTTGGCCCA	CASSPGQGADTQYF	In	VDJ	3	215	7.074625785201199E-4	8.880187681734073E-4	42	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-03	01	8	4	3	4	9	2	27	36	50	45	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSPGQGADTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCCTCTCCTTAGCGGGAGGGAATGAGCAGTTCTTCGGGCCA		Out	VDJ	3	216	7.107531021411437E-4		47	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	5	0	7	9	0	27	39	-1	48	59			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCCCCCAGCGGGAGGTCCACCGGGGAGCTGTTTTTTGGAGAA	CASSPPSGRSTGELFF	In	VDJ	3	217	7.140436257621675E-4	8.96279407877346E-4	48	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	5	6	1	4	6	2	27	39	54	45	56			01,02										Vb 17	CASSPPSGRSTGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCCGGGGCAGGGGGAGTGGGAAACATTCAGTACTTCGGCGCC	CASSPGAGGVGNIQYF	In	VDJ	3	217	7.140436257621675E-4	8.96279407877346E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	5	4	1	6	7	6	27	39	53	46	59			01,02										Vb 17	CASSPGAGGVGNIQYF+TCRBV19-01+TCRBJ02-04	TCRBV19-01	TCRBD01-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTCTTGGGAGACTAGCAATAAGGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	3	217	7.140436257621675E-4		44	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	8	2	7	8	7	6	27	36	50	43	56			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGGCCGCGCTTCTTAATGGCTACACCTTCGGTTCG	CASSMAALLNGYTF	In	VDJ	3	218	7.173341493831914E-4	9.004097277293154E-4	42	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-02	01	3	9	0	6	0	11	27	-1	44	41	55			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSMAALLNGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGAAGGGGCCGGAGACAGATACGCAGTATTTTGGCCCA	CASRKGPETDTQYF	In	VDJ	3	222	7.304962438672866E-4	9.169310071371927E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	5	2	3	2	6	27	38	45	40	51			01,02										Vb 17	CASRKGPETDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATATCCCAAGGTCTCAGCCAAGAGACCCAGTACTTCGGGCCA	CASSISQGLSQETQYF	In	VDJ	3	225	7.403678147303581E-4	9.293219666931007E-4	48	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-05	01	2	4	5	1	11	0	27	42	-1	53	56			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSISQGLSQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAATGCGGGGCCCAGCACCGGGGAGCTGTTTTTTGGAGAA	CASSNAGPSTGELFF	In	VDJ	3	229	7.535299092144533E-4	9.458432461009781E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	4	7	3	4	2	5	27	40	48	42	53			01,02										Vb 17	CASSNAGPSTGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD02-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAAGGGACAGATCTACGAGCAGTACTTCGGGCCG	CASSKGQIYEQYF	In	VDJ	3	233	7.666920036985485E-4	9.623645255088555E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	5	3	1	2	27	40	48	41	50			01,02										Vb 17	CASSKGQIYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCCGGGACAGGGGTGCAGAGACCCAGTACTTCGGGCCA	CASSRDRGAETQYF	In	VDJ	3	235	7.732730509405961E-4	9.706251652127941E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	0	2	4	2	3	27	38	50	40	53			01,02										Vb 17	CASSRDRGAETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCCTAGGGTATCGGGATGGCTATGGCTACACCTTCGGTTCG	CASTLGYRDGYGYTF	In	VDJ	3	243	7.995972399087867E-4	0.0010036677240285487	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	7	8	3	4	11	3	27	37	53	48	56			01,02										Vb 17	CASTLGYRDGYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGAACCTCGGGCCTCACGTCCACTGAAGCTTTCTTTGGACAA		Out	VDJ	3	243	7.995972399087867E-4		50	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-01	01	0	8	0	4	5	8	27	44	53	49	61			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ01-01	TCRBV19-01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCCCAATCTGCGGGAAAGGGAAGAGGCTACACCTTCGGTTCG	CASSSQSAGKGRGYTF	In	VDJ	4	253	8.325024761190248E-4	0.0010449709225482421	48	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	5	7	3	8	9	9	27	39	54	48	63			01,02										Vb 17	CASSSQSAGKGRGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCTCTTACAGCAATCAGCCCCAGCATTTTGGTGAT	CASSSYSNQPQHF	In	VDJ	4	258	8.489550942241439E-4	0.0010656225218080887	39	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	6	3	7	1	5	0	27	38	-1	43	45			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSSYSNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTTGGGGTGGGCGGGTCCGACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	4	270	8.884413776764296E-4		41	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	14	7	4	2	8	4	27	30	43	38	47			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ01-04	TCRBV19-01	TCRBD02-01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTATCCCACCGGGACAGCCAGGGAACACCATATATTTTGGAGAG	CASIPPGQPGNTIYF	In	VDJ	4	282	9.279276611287154E-4	0.0011647501982553529	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	7	0	5	7	7	6	27	37	51	44	57			01,02										Vb 17	CASIPPGQPGNTIYF+TCRBV19-01+TCRBJ01-03	TCRBV19-01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTCACAGGGGGCAACTGAACACTGAAGCTTTCTTTGGACAA	CASHRGQLNTEAFF	In	VDJ	4	290	9.542518500969059E-4	0.0011977927570711077	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	8	3	0	0	1	3	27	36	46	37	49			01,02										Vb 17	CASHRGQLNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGGTGTGGGCAGGGAAATAAGCTTTCTTTGGACAA		Out	VDJ	4	299	9.838665626861203E-4		35	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	9	4	3	9	7	4	27	35	47	42	51			01,02										Vb 17	X+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TATCTCTGTGCCAGTAGTATACATGAGGGGGAACGGAATGATCGGCAAGTCTATCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	4	308	0.0010134812752753345		64	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	5	1	6	4	23	6	21	31	25	54			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCAGGGGGCCACGGGAGCGGCTACACCTTCGGTTCG	CASSPGGHGSGYTF	In	VDJ	4	315	0.0010365149406225012	0.001301050753370341	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	4	0	8	1	9	27	39	48	40	57			01,02										Vb 17	CASSPGGHGSGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCACAACAGGGCTCGGGATAGAGCAGTACTTCGGGCCG	CATTGLGIEQYF	In	VDJ	4	323	0.0010628391295906918	0.0013340933121860957	36	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	10	3	3	7	2	9	27	34	42	36	51			01,02										Vb 17	CATTGLGIEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCTGTACTCCAAAGGGGACAGGGGTAAAGAGGGAGCTGTTTTTTGGAGAA	CACTPKGTGVKRELFF	In	VDJ	5	339	0.0011154875075270727	0.001400178429817605	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	7	0	2	9	8	6	27	37	55	45	61			01,02										Vb 17	CACTPKGTGVKRELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGCTTAGGGACAGCCTAAATGGCTACACCTTCGGTTCG	CASRLRDSLNGYTF	In	VDJ	5	364	0.0011977505980526682	0.0015034364261168386	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	5	6	5	5	27	38	50	43	55			01,02										Vb 17	CASRLRDSLNGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGGGGACGGTGGACAATCAGCCCCAGCATTTTGGTGAT	CASRGTVDNQPQHF	In	VDJ	5	381	0.001253689499610073	0.0015736518636003173	42	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	6	0	7	3	1	6	27	38	44	39	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASRGTVDNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGCCGTTCTTCCGGGATGAACACTGAAGCTTTCTTTGGACAA	CASRSSGMNTEAFF	In	VDJ	5	382	0.0012569800232310967	0.0015777821834522866	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	9	8	3	0	9	0	27	35	-1	44	49			01,02										Vb 17	CASRSSGMNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGGCAACCAGGACTCAAGTCTGATACGAGCAGTACTTCGGGCCG		Out	VDJ	6	448	0.0014741545822186685		46	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	8	1	10	4	8	9	27	36	49	44	58			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCCATGGACAGGGGTGTGTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSSMDRGVSGANVLTF	In	VDJ	8	568	0.001869017416741526	0.002346021675918583	54	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	1	2	1	5	4	27	39	53	44	57			01,02										Vb 17	CASSSMDRGVSGANVLTF+TCRBV19-01+TCRBJ02-06	TCRBV19-01	TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCTTGGGACAGTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSSWDSSNQPQHF	In	VDJ	9	619	0.0020368341214137406	0.0025566679883690193	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	0	5	0	4	0	27	39	-1	43	50			01,02										Vb 17	CASSSWDSSNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGGTGACCCCACGACAGAGAACACTGAAGCTTTCTTTGGACAA	CASSGDPTTENTEAFF	In	VDJ	10	711	0.0023395622945479315	0.0029366574147501982	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	5	1	11	1	27	39	55	50	56			01,02										Vb 17	CASSGDPTTENTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCCGGACAGTCCTACGAGCAGTACTTCGGGCCG	CASSSGQSYEQYF	In	VDJ	11	801	0.0026357094204400747	0.0033083862014274385	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	5	1	3	0	27	39	-1	42	48			01,02										Vb 17	CASSSGQSYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCAGCGGGAGGCCGCGAGCAGTACTTCGGGCCG	CASSPAGGREQYF	In	VDJ	12	835	0.0027475872235548844	0.003448817076394396	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	6	1	6	2	3	27	39	50	41	53			01,02										Vb 17	CASSPAGGREQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACAGCAACCGGGACAGATTATGGCTACACCTTCGGTTCG	CASSTATGTDYGYTF	In	VDJ	13	922	0.003033862778583956	0.003808154903515728	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	0	5	5	8	2	27	40	55	48	57			01,02										Vb 17	CASSTATGTDYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCAGCCTAGCGGGAAGCACAGATACGCAGTATTTTGGCCCA	CASTSLAGSTDTQYF	In	VDJ	14	976	0.003211551054119242	0.004031192175522073	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	7	4	3	0	5	0	27	37	-1	42	51			01,02										Vb 17	CASTSLAGSTDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCACCGGCCATCAAGATGAGCAGTTCTTCGGGCCA	CATGHQDEQFF	In	VDJ	14	1029	0.003385948806033504	0.004250099127676447	33	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-01	01	10	9	0	8	2	7	27	34	39	36	46			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CATGHQDEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGTCGGTCGGTACGGCGAGAAAAACTGTTTTTTGGCAGT		Out	VDJ	18	1326	0.004363234321477577		44	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-04	01	5	9	0	8	12	2	27	39	54	51	56			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ01-04	TCRBV19-01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGTCGGCTAGCGGGATATATGAGCAGTTCTTCGGGCCA	CASSMSASGIYEQFF	In	VDJ	19	1391	0.004577118356844124	0.0057452749140893475	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	4	3	8	5	3	27	41	55	46	58			01,02										Vb 17	CASSMSASGIYEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGGTAACGGGAGGGTGGGGACCCAGTACTTCGGGCCA	CASSGNGRVGTQYF	In	VDJ	22	1616	0.005317486171574483	0.0066745968807824475	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	8	0	7	5	4	27	39	52	44	56			01,02										Vb 17	CASSGNGRVGTQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCAAGGGTGGGAGGTACGAGCAGTACTTCGGGCCG	CASSIKGGRYEQYF	In	VDJ	33	2365	0.007782088363721319	0.00976820644990748	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	9	1	4	7	0	27	41	-1	48	54			01,02										Vb 17	CASSIKGGRYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACCCGGGACAGGTTCCAAGAGACCCAGTACTTCGGGCCA	CASSTRDRFQETQYF	In	VDJ	36	2599	0.00855207089104089	0.010734701295268306	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	0	4	1	3	2	27	40	51	43	53			01,02										Vb 17	CASSTRDRFQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGGGACAGGGACGGACTATGGCTACACCTTCGGTTCG	CASSIGTGTDYGYTF	In	VDJ	71	5090	0.016748765231011212	0.021023328046523924	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	0	3	3	1	4	27	41	51	42	55			01,02										Vb 17	CASSIGTGTDYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCACCGTGGCCCTTGGAGCTGAAGCTTTCTTTGGACAA	CATVALGAEAFF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	36	TCRBV25	TCRBV25-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	10	10	2	6	11	0	23	30	-1	41	45													Vb 11	CATVALGAEAFF+TCRBV25-01+TCRBJ01-01	TCRBV25-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAGGACAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSEDSSYNEQFF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	42	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	1	5	0	0	0	23	-1	-1	37	43													Vb 11	CASSEDSSYNEQFF+TCRBV25-01+TCRBJ02-01	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCACTTCGGACAGGTCTAATGAAAAACTGTTTTTTGGCAGT	CATSDRSNEKLFF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	39	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	10	1	4	3	4	1	23	30	41	34	42													Vb 11	CATSDRSNEKLFF+TCRBV25-01+TCRBJ01-04	TCRBV25-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAACCACGGACAGACTCTGGAAACACCATATATTTTGGAGAG	CASSEPRTDSGNTIYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	48	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	2	1	5	0	4	1	23	38	48	42	49													Vb 11	CASSEPRTDSGNTIYF+TCRBV25-01+TCRBJ01-03	TCRBV25-01*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAGGGGAATCAGCCCCAGCATTTTGGTGAT	CASSEGNQPQHF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	36	TCRBV25	TCRBV25-01	01				TCRBJ01	TCRBJ01-05	01	3	6	2	4	0	0	23	-1	-1	37	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 11	CASSEGNQPQHF+TCRBV25-01+TCRBJ01-05	TCRBV25-01*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTCAGAAAAGAAAACTGGACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	37	1.217493739778811E-4		56	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	1	6	5	14	5	23	35	54	49	59													Vb 11	X+TCRBV25-01+TCRBJ02-06	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAATCCAGAGGCACGGGTTGCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	37	1.217493739778811E-4		52	TCRBV25	TCRBV25-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-04	01	1	8	4	1	9	2	23	39	52	48	54						01,02							Vb 11	X+TCRBV25-01+TCRBJ02-04	TCRBV25-01*01	TCRBD02-01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGGACCTACGGGTATGGGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	41	1.3491146846197636E-4		41	TCRBV25	TCRBV25-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	6	8	4	8	6	5	23	34	44	40	49						01,02							Vb 11	X+TCRBV25-01+TCRBJ01-04	TCRBV25-01*01	TCRBD02-01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCGGCGACAGGGGAGATCAGCCCCAGCATTTTGGTGAT	CASGDRGDQPQHF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	39	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	8	2	2	5	3	2	23	32	43	35	45													Vb 11	CASGDRGDQPQHF+TCRBV25-01+TCRBJ01-05	TCRBV25-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAATATTGAAGGACAGGGGGCACGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	42	1.3820199208300016E-4		50	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	1	0	8	5	2	23	40	56	45	58													Vb 11	X+TCRBV25-01+TCRBJ01-04	TCRBV25-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGCCCAGTCAGACAGGGAGGGAATATAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	43	1.4149251570402398E-4		52	TCRBV25	TCRBV25-01	01				TCRBJ02	TCRBJ02-01	01	4	2	3	7	8	9	23	36	51	44	60				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 11	X+TCRBV25-01+TCRBJ02-01	TCRBV25-01*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTCGGATGACAGGGGCCACAGATACGCAGTATTTTGGCCCA	CASSRMTGATDTQYF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	45	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	2	2	2	5	1	23	35	48	40	49													Vb 11	CASSRMTGATDTQYF+TCRBV25-01+TCRBJ02-03	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGACCCCCGAGAGGTCAATTCACCCCTCCACTTTGGGAAC	CASSDPREVNSPLHF	In	VDJ	1	59	1.94140893640405E-4	2.4368887126619086E-4	45	TCRBV25	TCRBV25-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	3	11	1	7	7	2	23	37	48	44	50													Vb 11	CASSDPREVNSPLHF+TCRBV25-01+TCRBJ01-06	TCRBV25-01*01	TCRBD02-01*02	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAATGGGACAGGAGGGGGCTACACCTTCGGTTCG		Out	VDJ	1	85	2.7969450778702416E-4		40	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	0	4	8	0	4	23	-1	47	39	51													Vb 11	X+TCRBV25-01+TCRBJ01-02	TCRBV25-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTAAGACAGGGCAAGCTCGAGACAATGAGCAGTTCTTCGGGCCA	CASSKTGQARDNEQFF	In	VDJ	1	91	2.9943764951316705E-4	3.7585910652920964E-4	48	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	2	3	5	2	10	23	35	44	37	54													Vb 11	CASSKTGQARDNEQFF+TCRBV25-01+TCRBJ02-01	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGGGAGGAGGGTCCTAAAAACATTCAGTACTTCGGCGCC	CASREEGPKNIQYF	In	VDJ	1	99	3.257618384813575E-4	4.089016653449643E-4	42	TCRBV25	TCRBV25-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	6	10	0	4	3	4	23	34	43	37	47													Vb 11	CASREEGPKNIQYF+TCRBV25-01+TCRBJ02-04	TCRBV25-01*01	TCRBD02-01*02	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAATTCAGAGGGGCCCTCTCCCCTATGGCTACACCTTCGGTTCG		Out	VDJ	2	156	5.133216848797149E-4		50	TCRBV25	TCRBV25-01	01				TCRBJ01	TCRBJ01-02	01	1	5	2	4	4	9	23	39	48	43	57				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 11	X+TCRBV25-01+TCRBJ01-02	TCRBV25-01*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGATCGGCAGGGACAGGGTTCATACGAGCAGTACTTCGGGCCG	CASSDRQGQGSYEQYF	In	VDJ	2	157	5.166122085007388E-4	6.484602167591858E-4	48	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	3	4	6	4	23	37	52	43	56													Vb 11	CASSDRQGQGSYEQYF+TCRBV25-01+TCRBJ02-07	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAAGGACAGGGGTTCTATGGCTACACCTTCGGTTCG	CASSEGQGFYGYTF	In	VDJ	2	165	5.429363974689292E-4	6.815027755749405E-4	42	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	1	2	4	0	2	23	-1	47	38	49													Vb 11	CASSEGQGFYGYTF+TCRBV25-01+TCRBJ01-02	TCRBV25-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAGCGGGGGCACCAAGAGACCCAGTACTTCGGGCCA	CASSERGHQETQYF	In	VDJ	3	190	6.251994879945246E-4	7.84760771874174E-4	42	TCRBV25	TCRBV25-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	3	7	2	0	0	1	23	-1	44	37	45													Vb 11	CASSERGHQETQYF+TCRBV25-01+TCRBJ02-05	TCRBV25-01*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGAAGCTTGGAGCAAAGCTAGCGGGTAGGATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	25	8.226309052559534E-5		55	TCRBV05	TCRBV05-03		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	0	4	4	5	7	4	18	34	49	41	53			01,02			01,02								X+TCRBV05-03+TCRBJ01-06	TCRBV05-03	TCRBD02-01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGAAGCTTGAATCGGGGGAAGCGGGAGAGACTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	60	1.974314172614288E-4		55	TCRBV05	TCRBV05-03		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	1	6	2	3	10	3	18	33	51	43	54			01,02											X+TCRBV05-03+TCRBJ02-01	TCRBV05-03	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ACGACTCGGCCCTGTATCTCTGTGCCAGCAGCCTCGACAGCTCCTACGAGCAGTACTTCGGGCCG	CASSLDSSYEQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	39	TCRBV05	TCRBV05-04	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	2	5	0	3	0	20	32	-1	35	40														CASSLDSSYEQYF+TCRBV05-04+TCRBJ02-07	TCRBV05-04*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTTCGGGACAGGGTAGGAGCAGTTCTTCGGGCCA	CASSFGTG*EQFF	Stop	VDJ	1	20	6.581047242047627E-5		39	TCRBV07	TCRBV07-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	0	3	10	1	3	18	32	42	33	45														CASSFGTG*EQFF+TCRBV07-02+TCRBJ02-01	TCRBV07-02*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTTAGGAGTTAGAGAGACCCAGTACTTCGGGCCA	CASSLGVRETQYF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	39	TCRBV07	TCRBV07-02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	1	5	8	4	4	0	18	34	-1	38	41						01,02								CASSLGVRETQYF+TCRBV07-02+TCRBJ02-05	TCRBV07-02*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTCGGGGGGCCCGTACGAGCAGTACTTCGGGCCG	CASSSGGPYEQYF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	39	TCRBV07	TCRBV07-02	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	4	8	1	4	0	4	18	-1	38	31	42														CASSSGGPYEQYF+TCRBV07-02+TCRBJ02-07	TCRBV07-02*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCCAGATGGGGACAGAGATCGCTTTCTTTGGACAA	CASSQMGTEIAFF	In	VDJ	1	56	1.8426932277733357E-4	2.3129791171028284E-4	39	TCRBV07	TCRBV07-02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	5	11	6	5	18	30	43	36	48														CASSQMGTEIAFF+TCRBV07-02+TCRBJ01-01	TCRBV07-02*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTTCTGGGGCGCCGGCACTGAAGCTTTCTTTGGACAA	CASSFWGAGTEAFF	In	VDJ	1	58	1.908503700193812E-4	2.395585514142215E-4	42	TCRBV07	TCRBV07-02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	7	0	4	2	5	18	32	39	34	44														CASSFWGAGTEAFF+TCRBV07-02+TCRBJ01-01	TCRBV07-02*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTTAGGAAGCACAGATACGCAGTATTTTGGCCCA	CASSLGSTDTQYF	In	VDJ	1	70	2.3033665347166695E-4	2.8912238963785356E-4	39	TCRBV07	TCRBV07-02	01				TCRBJ02	TCRBJ02-03	01	1	2	8	0	0	0	18	-1	-1	34	36				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGSTDTQYF+TCRBV07-02+TCRBJ02-03	TCRBV07-02*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGACCGGGGACTAGCGGGAGGGCCGGGCACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	100	3.2905236210238137E-4		62	TCRBV07	TCRBV07-02	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	0	0	0	4	5	5	18	35	56	40	61														X+TCRBV07-02+TCRBJ02-02	TCRBV07-02*01	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTTATACCAGCAGGAGACCCAGTACTTCGGGCCA	CASSLYQQETQYF	In	VDJ	3	201	6.613952478257865E-4	8.301942902458366E-4	39	TCRBV07	TCRBV07-02	01				TCRBJ02	TCRBJ02-05	01	2	4	5	5	3	3	18	33	39	36	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLYQQETQYF+TCRBV07-02+TCRBJ02-05	TCRBV07-02*01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCCCGGACAGTGGCTATGGCTACACCTTCGGTTCG	CASSPDSGYGYTF	In	VDJ	5	327	0.001076001224074787	0.001350614591593973	39	TCRBV07	TCRBV07-02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	1	5	4	2	3	18	30	38	32	41														CASSPDSGYGYTF+TCRBV07-02+TCRBJ01-02	TCRBV07-02*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCGAGGGGGGGGTCTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSPRGGSSNQPQHF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	5	9	0	0	4	3	18	30	41	34	44														CASSPRGGSSNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGAGACCGGGCCGAACAAATTATAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	20	6.581047242047627E-5		55	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-05	01	5	8	0	0	6	11	18	30	40	36	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTACGACAGGTGGACCGGGGAGCTGTTTTTTGGAGAA	CASSYDRWTGELFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	2	4	5	2	3	18	31	39	33	42														CASSYDRWTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTATGGACAGGGGGCTTCCTACGAGCAGTACTTCGGGCCG	CASSYGQGASYEQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	1	0	1	2	1	18	31	44	33	45														CASSYGQGASYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGCAGGGGGTGGGCGGAAACACCATATATTTTGGAGAG	CASSLQGVGGNTIYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	3	4	1	4	1	5	18	32	40	33	45														CASSLQGVGGNTIYF+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTAAAACAGGGCGGGTATCAGCCCCAGCATTTTGGTGAT	CASSLKQGGYQPQHF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	3	3	5	5	5	18	30	41	35	46														CASSLKQGGYQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCCCCCCCCCTTAACGGACCCTGCGCAGTATTTTGGCCCA		Out	VDJ	1	21	6.910099604150008E-5		41	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-03	01	8	1	7	10	13	4	18	27	44	40	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAAGGGAGGGAGAAAACATTCAGTACTTCGGCGCC	CASSLREGENIQYF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	2	9	0	5	1	2	18	33	41	34	43														CASSLREGENIQYF+TCRBV11-03+TCRBJ02-04	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTCCGGGACACAATCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	22	7.23915196625239E-5		46	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	0	6	1	3	3	18	34	43	37	46														X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGGGCCGGGACTAGCGGCACCTACGAGCAGTACTTCGGGCCG	CASSLGAGTSGTYEQYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	0	5	2	5	2	18	34	50	39	52						01,02								CASSLGAGTSGTYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTTCCAGGGAAAGTATGGCAGATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	23	7.568204328354771E-5		47	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	4	3	8	2	12	18	32	39	34	51														X+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCTGGGCTGAGAATGAAAAACTGTTTTTTGGCAGT	CASSSWAENEKLFF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	8	0	5	3	4	18	31	38	34	42														CASSSWAENEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGCCAGGCTACCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	24	7.897256690457152E-5		43	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	4	4	0	3	2	18	32	39	35	41														X+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGGGACTACCCGTACCAAGAGACCCAGTACTTCGGGCCA	CASRDYPYQETQYF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	1	9	0	0	5	18	-1	35	29	40						01,02								CASRDYPYQETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCACCCCAGTGGTTCAGTCCCGGGAGACCCAGTACTTCGGGCCA	CASTPVVQSRETQYF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-05	01	7	4	5	5	3	14	18	28	34	31	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTPVVQSRETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGATGGGACAGGGAGGCACACCATATATTTTGGAGAG	CASSLDGTGRHTIYF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	3	0	3	8	4	4	18	32	45	36	49														CASSLDGTGRHTIYF+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGCACCCCCCGGGGGGCAGACCCAGTACTTCGGGCCA	CASSAPPGGQTQYF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	8	1	6	8	1	18	30	45	38	46														CASSAPPGGQTQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCGGGGATCGGAACGGGGGGCGGGACAGATACGCAGTATTTTGGCCCA	CASSSGIGTGGGTDTQYF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	54	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	8	1	3	12	4	18	31	50	43	54														CASSSGIGTGGGTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAACGCCCAGGGGGCCCGTCGAGCAGTACTTCGGGCCG	CASSLTPRGPVEQYF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	4	0	6	5	4	18	33	46	38	50														CASSLTPRGPVEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGATACGCGGTCCCCAACACTGAAGCTTTCTTTGGACAA	CASRYAVPNTEAFF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	6	7	5	2	4	5	18	29	37	33	42						01,02								CASRYAVPNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCGAGGGGAACAACATGAACACTGAAGCTTTTTTTGGACAA	CASSPEGNNMNTEAFF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	48	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-01	01	5	5	2	17	4	24	18	30	39	34	63				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPEGNNMNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTATCGGGGACAGGGGTTTTTCAGCCCCAGCATTTTGGTGAT	CASSLSGTGVFQPQHF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	0	2	6	3	4	18	33	46	36	50														CASSLSGTGVFQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATSTCTGTGCCAGCATGCGGGACGGCTTCGGTAACTATGGCTACACCTTCGGTTCG	CASMRDGFGNYGYTF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	7	7	3	1	1	9	18	28	35	29	44														CASMRDGFGNYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGGGACTAGCGGGGGGCTAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	29	9.54251850096906E-5		53	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	0	1	0	3	2	18	30	48	33	50														X+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCGACTAGCGGGCAATACAATGAGCAGTTCTTCGGGCCA	CASSSTSGQYNEQFF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	2	4	4	1	3	18	31	42	32	45						01,02								CASSSTSGQYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAACAGTACCGGACCTACGAGCAGTACTTCGGGCCG	CASSQQYRTYEQYF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	3	5	2	2	7	18	30	36	32	43														CASSQQYRTYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCGGGGGGACCTGGCCGGCCGGGGAGCTGTTTTTTGGAGAA	CASSPGGTWPAGELFF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	5	8	1	6	2	10	18	30	39	32	49														CASSPGGTWPAGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGGACTAGCGGGAGCACGAGCAGTACTTCGGGCCG		Out	VDJ	1	30	9.87157086307144E-5		41	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	1	2	5	1	1	18	30	44	31	45														X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGAGGTCAGGATACACAGATACGCAGTATTTTGGCCCA	CASSLRSGYTDTQYF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-03	01	3	4	4	2	5	3	18	32	41	37	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLRSGYTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCCCTATCATCTCCGGGGAGCTGTTTTTTGGAGAA	CASSSPIISGELFF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	4	4	9	6	3	6	18	31	37	34	43						01,02								CASSSPIISGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCTTTGTGACTAGCGGGGGGCGGGAGACCCAGTACTTCGGGCCA	CASSSFVTSGGRETQYF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	4	2	1	5	7	3	18	31	51	38	54														CASSSFVTSGGRETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCGAATGGGGGTCTGGACTCCTACGAGCAGTACTTCGGGCCG	CASSPNGGLDSYEQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	48	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-07	01	5	6	1	0	6	6	18	30	41	36	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPNGGLDSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGGACTAGCGGCAGTTACGAGCAGTACTTCGGGCCG	CASSRTSGSYEQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	1	5	4	1	4	18	30	41	31	45						01,02								CASSRTSGSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGGGACTTGGTGGACTATGGCTACACCTTCGGTTCG	CASSRDLVDYGYTF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	5	0	10	3	1	6	18	30	37	31	43						01,02								CASSRDLVDYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAAGTTCGGGAACTAATGAAAAACTGTTTTTTGGCAGT	CASSLSSGTNEKLFF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	2	8	4	1	4	0	18	33	-1	37	41						01,02								CASSLSSGTNEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD02-01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCAACCGCGGGACAGGGGCTTGGGAGCAGTACTTCGGGCCG	CASSNRGTGAWEQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	2	7	6	5	18	30	46	36	51														CASSNRGTGAWEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATSTCTGTGCCAGCAGCCAAGTAGCGGGGGCCACCGGGGAGCTGTTTTTTGGAGAA	CASSQVAGATGELFF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	5	5	2	4	4	1	18	30	43	34	44														CASSQVAGATGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAGGCGGGGGGCACTGCCAACTATGGCTACACCTTCGGTTCG	CASSQAGGTANYGYTF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	5	7	1	2	3	7	18	30	41	33	48														CASSQAGGTANYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGGGGACTAGCGGGAGGGCATGAGACCCAGTACTTCGGGCCA	CASSRGLAGGHETQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	0	0	5	2	3	18	30	48	32	51														CASSRGLAGGHETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTGCGGACGGTTATAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	35	1.1516832673583348E-4		46	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-05	01	4	1	7	0	2	5	18	31	37	33	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAACCTCACAAGGGGCCGAGCTGGCCGAGCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	35	1.1516832673583348E-4		61	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	5	2	0	8	14	18	33	46	41	60														X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTATTAATTCGCGGGGGGGCCGTCCAAGAGACCCAGTACTTCGGGCCA	CASSLLIRGGAVQETQYF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	54	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	2	7	0	1	7	4	18	33	49	40	53														CASSLLIRGGAVQETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCGGACTCTCGAACACTGAAGCTTTCTTTGGACAA	CASSPGLSNTEAFF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	5	1	10	1	3	3	18	30	38	33	41						01,02								CASSPGLSNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCACAATGAGCGAGACGGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	37	1.217493739778811E-4		50	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	5	6	6	4	6	12	18	30	40	36	52						01,02								X+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGCGGACAGGGTCCAGATACGCAGTATTTTGGCCCA	CASSRGQGPDTQYF	In	VDJ	1	38	1.2503989759890492E-4	1.569521543748348E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	1	3	4	3	2	18	30	41	33	43														CASSRGQGPDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCTGACTGGGGGACTAGGGCGACCGGGGAGACCCAGTACTTCGGGCCA	CASSSDWGTRATGETQYF	In	VDJ	1	38	1.2503989759890492E-4	1.569521543748348E-4	54	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	4	0	8	5	8	10	18	31	47	39	57						01,02								CASSSDWGTRATGETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGACCCCTCCGGGAGCTCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	38	1.2503989759890492E-4		46	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	8	2	3	8	2	18	32	46	40	48														X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCAGGACGCTGACGGGGACCGGGGAGCTGTTTTTTGGAGAA	CASSPRTLTGTGELFF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	5	8	3	5	13	0	18	30	-1	43	48														CASSPRTLTGTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGGTCAAGCGGGGGTCACAGATACGCAGTATTTTGGCCCA	CASSGQAGVTDTQYF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	6	2	2	5	1	18	30	43	35	44														CASSGQAGVTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCAGAACTCGACGCCATGAACACTGAAGCTTTCTTTGGACAA	CASSPELDAMNTEAFF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	48	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-01	01	5	2	7	0	9	4	18	30	42	39	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPELDAMNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCGGGACTAGCGGGGGGGCTTGCTACGAGCAGTACTTCGGGCCG	CASSSGTSGGACYEQYF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	4	0	0	3	2	4	18	31	49	33	53														CASSSGTSGGACYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCATCCGCCTTCGCGGCTAACTCATATGGCTACACCTTCGGTTCG		Out	VDJ	1	43	1.4149251570402398E-4		46	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	7	7	5	5	9	8	18	28	41	37	49						01,02								X+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGAAGCTTACAGGGGGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	44	1.447830393250478E-4		41	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	4	2	2	0	0	18	-1	-1	33	39														X+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCAGGGACATTTTAGCTAACTATGGCTACACCTTCGGTTCG	CASSRDILANYGYTF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	6	0	1	6	18	30	37	31	43														CASSRDILANYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGGGTGGGGGCAGGGAGCACTGAAGCTTTCTTTGGACAA	CASRVGAGSTEAFF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	6	0	4	3	6	18	29	38	32	44														CASRVGAGSTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAATAGGCAGCCCCCCCACAGATACGCAGTATTTTGGCCCA	CASSLIGSPPTDTQYF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	48	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-03	01	2	4	5	2	5	6	18	33	41	38	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLIGSPPTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTATACGGGACAGGGGGTTATGGCTACACCTTCGGTTCG	CASSLYGTGGYGYTF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	0	1	5	3	1	18	33	47	36	48														CASSLYGTGGYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAGGGACTAGCGGGGGGCAAAGAGACCCAGTACTTCGGGCCA	CASSQGLAGGKETQYF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	0	1	3	2	2	18	30	47	32	49														CASSQGLAGGKETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAATAGCGGGGGAGGACCCTACGAGCAGTACTTCGGGCCG	CASNSGGGPYEQYF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	7	5	2	2	1	5	18	28	38	29	43														CASNSGGGPYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCTATCCCGCTACCAAAGGTGGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	47	1.5465461018811924E-4		49	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-05	01	3	5	4	5	15	2	18	32	50	47	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCGCAAGAGGCGGGGGGCTTAGCACCGGGGAGCTGTTTTTTGGAGAA	CASARGGGLSTGELFF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	8	7	1	4	7	5	18	27	42	34	47														CASARGGGLSTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCGCCGGGGCTCACAACACTGAAGCTTTCTTTGGACAA	CASSPAGAHNTEAFF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-01	01	5	7	0	2	6	4	18	30	41	36	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPAGAHNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCGGACTAGCGGGAGGGCCTGGTGATACGCAGTATTTTGGCCCA	CASSFGLAGGPGDTQYF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	1	0	6	1	6	18	32	48	33	54														CASSFGLAGGPGDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCATCGGGACTACCACCGGGGAGCTATTTTTTGGAGAA	CASSIGTTTGELFF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	5	0	9	17	3	14	18	30	40	33	54						01,02								CASSIGTTTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAAGGGGGGGCTCTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSLRGGSSNQPQHF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	2	9	0	0	1	3	18	33	41	34	44														CASSLRGGSSNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCGAGCGGGGGGATAAGCGAGCAGTACTTCGGGCCG	CASSSSGGISEQYF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	4	6	1	6	2	5	18	31	42	33	47														CASSSSGGISEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTCGGGGGTCTAGCGGGAGGGAGCAGTACTTCGGGCCG	CASSRGSSGREQYF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	4	1	7	8	0	18	29	-1	37	48														CASSRGSSGREQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCGGGGACAGGGAGGAATGAAAAACTGTTTTTTGGCAGT	CASSSGTGRNEKLFF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	0	3	5	2	3	18	31	42	33	45														CASSSGTGRNEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTGGAGGGACTAGCGGGAGGGGCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	53	1.7439775191426213E-4		53	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	0	0	2	3	1	18	31	50	34	51														X+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTAAAACCGGGACTAGGGCCAATGAGCAGTTCTTCGGGCCA	CASSKTGTRANEQFF	In	VDJ	1	54	1.7768827553528592E-4	2.2303727200634416E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	0	8	6	7	3	18	29	44	36	47						01,02								CASSKTGTRANEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCCTCGAACAGGATCCGTACGGCTACACCTTCGGTTCG	CASSSLEQDPYGYTF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	3	4	8	7	8	18	31	43	38	51														CASSSLEQDPYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGATGCCGAATGGGACCATGGCTACACCTTCGGTTCG	CASSLDAEWDHGYTF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-02	01	0	0	7	6	8	1	18	35	48	43	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLDAEWDHGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTTGGACGCGGCGGGGGGACGATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	55	1.8097879915630975E-4		50	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	3	7	1	5	8	3	18	32	48	40	51														X+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTTTTCGCGGGACAGCGGAACACTGAAGCTTTCTTTGGACAA	CASSFFAGQRNTEAFF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	0	5	1	6	2	18	32	45	38	47														CASSFFAGQRNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCGCCAAGTTTGGAGGCACCCCTCCACTTTGGGAAC	CASSSPSLEAPLHF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	4	10	1	11	10	0	18	31	-1	41	46														CASSSPSLEAPLHF+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGATGGTTGGGCAATGAGCAGTTCTTCGGGCCA	CASSLGWLGNEQFF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-01	01	1	0	9	6	7	0	18	34	-1	41	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGWLGNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCAGGGGTTGGGCATCAGAACACTGAAGCTTTCTTTGGACAA	CASSPGVGHQNTEAFF	In	VDJ	1	59	1.94140893640405E-4	2.4368887126619086E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	2	1	1	10	18	30	37	31	47														CASSPGVGHQNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTTGGGGCCCCAGGGACTGAAGCTTTCTTTGGACAA	CASSFGAPGTEAFF	In	VDJ	1	60	1.974314172614288E-4	2.478191911181602E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	3	5	8	0	18	32	-1	40	45														CASSFGAPGTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGACTACAGGGTGGTGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	62	2.0401246450347642E-4		46	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	3	0	5	3	18	30	41	35	44														X+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGACTCGTCGGGGGTGGATGAGCAGTTCTTCGGGCCA	CASSLDSSGVDEQFF	In	VDJ	1	62	2.0401246450347642E-4	2.560798308220989E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	8	2	8	8	3	18	32	46	40	49														CASSLDSSGVDEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGTCGGGGAACGGCTACAGATACGCAGTATTTTGGCCCA	CASSLGRGTATDTQYF	In	VDJ	1	64	2.1059351174552407E-4	2.643404705260375E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	8	3	3	2	7	18	34	41	36	48														CASSLGRGTATDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAAAAAGGACCCGGGCTCCGAACACTGAAGCTTTCTTTGGACAA	CASSQKRTRAPNTEAFF	In	VDJ	1	65	2.1388403536654787E-4	2.684707903780069E-4	51	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-01	01	5	1	7	1	7	9	18	30	41	37	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQKRTRAPNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGCAATGGGACAGGTAGTCACTGAAGCTTTCTTTGGACAA	CASSAMGQVVTEAFF	In	VDJ	1	65	2.1388403536654787E-4	2.684707903780069E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	4	4	5	4	18	30	43	35	47														CASSAMGQVVTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGAGGGTGGGGAGGTACTGAAGCTTTCTTTGGACAA	CASSLGGWGGTEAFF	In	VDJ	1	66	2.171745589875717E-4	2.726011102299762E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	1	9	1	5	7	1	18	34	47	41	48														CASSLGGWGGTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTGAATCCGCAGGACGGGAAAAACTGTTTTTTGGCAGT	CASSESAGREKLFF	In	VDJ	1	66	2.171745589875717E-4	2.726011102299762E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-04	01	6	1	7	8	10	2	18	29	43	39	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSESAGREKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAACAGCTTTGATAGCGGGGGAACAGATACGCAGTATTTTGGCCCA	CANSFDSGGTDTQYF	In	VDJ	1	67	2.204650826085955E-4	2.7673143008194554E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	3	5	2	3	3	1	18	32	44	35	45														CANSFDSGGTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCACAACCTGTAGCACGGGACTACAATGAGCAGTTCTTCGGGCCA	CASSPQPVARDYNEQFF	In	VDJ	1	68	2.237556062296193E-4	2.8086174993391486E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	8	3	3	15	0	18	30	-1	45	50														CASSPQPVARDYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCGGTCTGGCTAGCGTCCCCTCGGAGACCCAGTACTTCGGGCCA	CASSSGLASVPSETQYF	In	VDJ	1	69	2.2704612985064313E-4	2.8499206978588424E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	4	4	6	5	9	8	18	31	46	40	54						01,02								CASSSGLASVPSETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGGACTAGCAACCACAATGAGCAGTTCTTCGGGCCA	CASSLGTSNHNEQFF	In	VDJ	1	69	2.2704612985064313E-4	2.8499206978588424E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	1	7	5	0	4	18	-1	42	34	46						01,02								CASSLGTSNHNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGTCGCAGGCTGCCACTGAAGCTTTCTTTGGACAA	CASSLSQAATEAFF	In	VDJ	1	69	2.2704612985064313E-4	2.8499206978588424E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	4	4	4	4	18	32	40	36	44														CASSLSQAATEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAAGGGACATGAACACTGAAGCTTTCTTTGGACAA	CASSLRDMNTEAFF	In	VDJ	1	70	2.3033665347166695E-4	2.8912238963785356E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	0	6	0	1	0	18	33	-1	34	40														CASSLRDMNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAGGTGTTCTAGTTCAAGAGACCCAATACTTCGGGCCA		Out	VDJ	1	72	2.3691770071371457E-4		47	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	0	4	8	14	6	14	18	35	45	41	59						01,02								X+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCAGACTTAACGACGGATGGCTACACCTTCGGTTCG	CASSPDLTTDGYTF	In	VDJ	1	74	2.434987479557622E-4	3.056436690457309E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	5	2	10	6	3	9	18	30	37	33	46						01,02								CASSPDLTTDGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAAGGCCGGTCCTACGAGCAGTACTTCGGGCCG	CASSLEGRSYEQYF	In	VDJ	1	77	2.5337031881883363E-4	3.180346286016389E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-07	01	0	5	4	1	0	4	18	-1	38	35	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLEGRSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTTCTACAGGGAAACTTGAAGACTACACCTTCGGTTCG	CASSSTGKLEDYTF	In	VDJ	1	77	2.5337031881883363E-4	3.180346286016389E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	3	3	10	4	11	18	29	39	33	50														CASSSTGKLEDYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTACCAGCAGCTCGATTCTAAGGGGTGAAAAACTGTTTTTTGGCAGT	CTSSSILRGEKLFF	In	VDJ	1	79	2.599513660608813E-4	3.2629526830557756E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	5	2	7	8	0	18	31	-1	39	44														CTSSSILRGEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAATGGACCGCTGCCACAGATACGCAGTATTTTGGCCCA	CASSLEWTAATDTQYF	In	VDJ	1	79	2.599513660608813E-4	3.2629526830557756E-4	48	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-03	01	0	1	7	2	2	6	18	35	41	37	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLEWTAATDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCGGGACTAGCGGGAGTCCAGGAGAGACCCAGTACTTCGGGCCA	CASSSGTSGSPGETQYF	In	VDJ	1	80	2.632418896819051E-4	3.3042558815754694E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	4	0	2	4	2	6	18	31	47	33	53														CASSSGTSGSPGETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGGGAGTTATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSGSYSNQPQHF	In	VDJ	1	83	2.731134605449765E-4	3.428165477134549E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	5	9	2	0	0	3	18	-1	35	30	38														CASSGSYSNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTTGCAGGGGGCTACAATCAGCCCCAGCATTTTGGTGAT	CASSFAGGYNQPQHF	In	VDJ	1	83	2.731134605449765E-4	3.428165477134549E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	4	0	3	2	2	18	32	42	34	44														CASSFAGGYNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCGGGGGGACTAGCGGTAGAGATACGCAGTATTTTGGCCCA	CASSPGGTSGRDTQYF	In	VDJ	1	84	2.764039841660003E-4	3.469468675654243E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	0	5	5	6	3	18	30	47	36	50						01,02								CASSPGGTSGRDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGTGGGACAGGGAAGGTTGGGAGATACGCAGTATTTTGGCCCA	CASSVGQGRLGDTQYF	In	VDJ	1	84	2.764039841660003E-4	3.469468675654243E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	0	3	5	2	9	18	30	41	32	50														CASSVGQGRLGDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGACTTGCCCGGGAACAAACTGAAGCTTTCTTTGGACAA	CASRLAREQTEAFF	In	VDJ	1	86	2.8298503140804796E-4	3.552075072693629E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	6	8	3	5	7	4	18	29	41	36	45														CASRLAREQTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCCGCCGAATCGCGGGGGATGCCACAGATACGCAGTATTTTGGCCCA	CASSPRRIAGDATDTQYF	In	VDJ	1	86	2.8298503140804796E-4	3.552075072693629E-4	54	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	7	2	2	12	4	18	30	49	42	53														CASSPRRIAGDATDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTTGAGGACAGTCCCCAAAGCTCCTACGAGCAGTACTTCGGGCCG	CASSLVEDSPQSSYEQYF	In	VDJ	1	86	2.8298503140804796E-4	3.552075072693629E-4	54	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	1	5	0	4	9	18	34	44	38	53														CASSLVEDSPQSSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTATCCCTTAAGGACACCGTTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	86	2.8298503140804796E-4		47	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	1	6	4	8	4	18	33	46	41	50														X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGCCGCTAGCGGGGGGGCAAGCGATACGCAGTATTTTGGCCCA	CASSLAASGGASDTQYF	In	VDJ	1	87	2.8627555502907175E-4	3.593378271213323E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	3	4	0	6	5	5	18	32	49	37	54														CASSLAASGGASDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTGGGACTAGCGGGAGTCCCCATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	90	2.961471258921432E-4		46	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	0	2	8	0	5	18	-1	45	31	50														X+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCCCTATTCGGGAGGCGCATACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	94	3.093092203762385E-4		50	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	8	1	4	7	4	18	32	46	39	50														X+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTGCGACACTAGCGGGAGGTAACACCAGATACGCAGTATTTTGGCCCA	CASSLRH*REVTPDTQYF	Stop	VDJ	1	96	3.158902676182861E-4		54	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	3	1	4	7	6	18	30	49	37	55														CASSLRH*REVTPDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCGGGACAATCACCAGGGAGCTGTTTTTTGGAGAA	CASSPGTITRELFF	In	VDJ	1	98	3.224713148603337E-4	4.04771345492995E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	0	6	9	3	7	18	30	39	33	46														CASSPGTITRELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCACGAGGACCTAGCGGGAGGGGTTCTAGATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	104	3.422144565864766E-4		53	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	4	0	8	8	7	18	30	50	38	57														X+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGGCCAGGCTCCGGGACAATTACTGAAAAACTGTTTTTTGGCAGT	CASRPGSGTITEKLFF	In	VDJ	1	105	3.455049802075004E-4	4.336835844567803E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	0	6	7	10	5	18	29	45	39	50														CASRPGSGTITEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTAAGGGTCTACACCGGGGAGCTGTTTTTTGGAGAA	CASSLRVYTGELFF	In	VDJ	1	107	3.5208602744954805E-4	4.41944224160719E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-02	01	5	5	3	3	3	3	18	30	37	33	40				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLRVYTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGAGGGGTGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSLGGVNTGELFF	In	VDJ	1	107	3.5208602744954805E-4	4.41944224160719E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-02	01	1	5	2	1	1	1	18	34	40	35	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGGVNTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCCCGGGACAGTACAATGAGCAGTTCTTCGGGCCA	CASSSPGQYNEQFF	In	VDJ	2	108	3.5537655107057185E-4	4.4607454401268833E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	0	5	4	4	0	18	31	-1	35	42														CASSSPGQYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAATAGGGCAGGGAATTGTCTACGAGCAGTACTTCGGGCCG	CASSLIGQGIVYEQYF	In	VDJ	2	108	3.5537655107057185E-4	4.4607454401268833E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	4	3	3	6	6	18	33	44	39	50														CASSLIGQGIVYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCGCCAGGAGTAGCGGGGGCTCCCAAGAGACCCAGTACTTCGGGCCA	CASARSSGGSQETQYF	In	VDJ	2	109	3.586670746915957E-4	4.502048638646577E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	8	5	2	1	8	3	18	27	44	35	47														CASARSSGGSQETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAACCCTATTGACGGGAACTAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	110	3.619575983126195E-4		56	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	0	8	3	2	10	3	18	35	50	45	53														X+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCATCAATCCGGGACGTCGGGGAGCTGTTTTTTGGAGAA	CASSSSIRDVGELFF	In	VDJ	2	113	3.7182916917569093E-4	4.6672614327253505E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-02	01	4	0	7	7	9	2	18	31	45	40	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSSIRDVGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGGCAGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSLGQSSYNEQFF	In	VDJ	2	117	3.8499126365978617E-4	4.832474226804124E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	7	0	0	0	4	18	-1	37	32	41														CASSLGQSSYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCTCCGGGCCAGCGGGTGCCGGGGAGCTGTTTTTTGGAGAA	CASSPSGPAGAGELFF	In	VDJ	2	119	3.915723109018338E-4	4.91508062384351E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	5	6	4	6	11	2	18	30	47	41	49						01,02								CASSPSGPAGAGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAACAGCGGGGGTCCAAGAGACCCAGTACTTCGGGCCA	CASSLTAGVQETQYF	In	VDJ	2	122	4.0144388176490526E-4	5.038990219402591E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	2	6	2	1	2	1	18	33	43	35	44														CASSLTAGVQETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTATAGACAGGTAACTAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	2	124	4.0802492900695285E-4		44	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	2	4	4	4	5	18	29	39	33	44														X+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCGGTGCTCACCTTGGGGATACGCAGTATTTTGGCCCA	CASSFGAHLGDTQYF	In	VDJ	2	127	4.178964998700243E-4	5.245506212001057E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-03	01	3	0	9	6	13	0	18	32	-1	45	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFGAHLGDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAGCTGGGAGCGGGAGGGGAGACCCAGTACTTCGGGCCA	CASSQLGAGGETQYF	In	VDJ	2	128	4.2118702349104814E-4	5.28680941052075E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	6	0	5	8	0	18	30	-1	38	48														CASSQLGAGGETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCATCGACAGAGAGAGGGAACCGCGAAATATTCCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	128	4.2118702349104814E-4		56	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-02	01	7	2	5	6	2	22	18	28	35	30	57				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTGGGACAGGGTACGTCTGAAGCTTTCTTTGGACAA	CASSLGQGTSEAFF	In	VDJ	2	131	4.310585943541196E-4	5.410719006079831E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	3	6	2	5	18	30	41	32	46														CASSLGQGTSEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTAACTAGCGGGTCAACCGGGGAGACCCAGTACTTCGGGCCA	CASSLVTSGSTGETQYF	In	VDJ	2	133	4.376396415961672E-4	5.493325403119218E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	1	3	4	5	2	9	18	34	45	36	54						01,02								CASSLVTSGSTGETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCACTGGACTAGCGGGGCCGAGATACGCAGTATTTTGGCCCA		Out	VDJ	2	141	4.639638305643577E-4		46	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	1	3	5	3	3	18	30	45	33	48														X+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTGGGGACAGGTGAACACTGAAGCTTTCTTTGGACAA	CASSWGQVNTEAFF	In	VDJ	2	144	4.7383540142742915E-4	5.947660586835844E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	0	4	0	1	0	18	31	-1	32	40														CASSWGQVNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCTCCGACTAGCGGGGTGGTTGGACAGTTCTTCGGGCCA	CASSPPTSGVVGQFF	In	VDJ	2	145	4.7712592504845294E-4	5.988963785355538E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	2	3	13	5	8	18	30	46	35	54														CASSPPTSGVVGQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGAGACCGCAGGCCGGGAGCCCCAGCATTTTGGTGAT	CASSETAGREPQHF	In	VDJ	2	151	4.968690667745959E-4	6.236782976473698E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-05	01	5	4	4	8	7	5	18	30	41	37	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSETAGREPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGAGACAAGGGGACTCCGTTCTGGGTGAAGCTTTCTTTGGACAA	CASSLRQGDSVLGEAFF	In	VDJ	2	152	5.001595903956197E-4	6.278086174993392E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	3	0	10	7	8	10	18	32	46	40	56						01,02								CASSLRQGDSVLGEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCAGTCAGGAGAGGATTCATGAAAAACTGTTTTTTGGCAGT	CASSSSQERIHEKLFF	In	VDJ	2	154	5.067406376376673E-4	6.360692572032778E-4	48	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-04	01	4	4	4	6	5	9	18	31	40	36	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSSQERIHEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCGATTCCAGGGATTCTAGTAGCTTTCTTTGGACAA	CASSSIPGILVAFF	In	VDJ	2	156	5.133216848797149E-4	6.443298969072165E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	4	3	10	6	8	18	31	42	37	50														CASSSIPGILVAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTGGGACAGGGGGTTTACAATGAGCAGTTCTTCGGGCCA	CASSLGQGVYNEQFF	In	VDJ	2	157	5.166122085007388E-4	6.484602167591858E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	0	1	4	2	2	18	30	43	32	45														CASSLGQGVYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAAGGCCCAGGGGACTGGCTACACCTTCGGTTCG		Out	VDJ	2	157	5.166122085007388E-4		41	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	4	2	7	5	2	18	33	44	38	46														X+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCGGACCTGGGGCCGACTGATAGCGGCGAGCAGTACTTCGGGCCG		Out	VDJ	2	162	5.330648266058577E-4		46	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	8	5	5	6	18	0	18	27	-1	45	51						01,02								X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGATAGGGGCGGGGGATATACGCAGTATTTTGGCCCA	CASSLDRGGGYTQYF	In	VDJ	2	171	5.626795391950721E-4	7.062846946867565E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	7	2	7	5	2	18	35	47	40	49														CASSLDRGGGYTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCGGGGCAGGTCTCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSPGAGLSGANVLTF	In	VDJ	2	178	5.857132045422388E-4	7.351969336505419E-4	51	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-06	01	5	7	0	0	3	6	18	30	38	33	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPGAGLSGANVLTF+TCRBV11-03+TCRBJ02-06	TCRBV11-03*01		TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGTACAGGGGAGAGGCAATCAGCCCCAGCATTTTGGTGAT	CASSLVQGRGNQPQHF	In	VDJ	3	186	6.120373935104293E-4	7.682394924662966E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	3	2	2	3	4	18	32	42	35	46														CASSLVQGRGNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCTCAGGCCCCCCAGGGGATCTTAATGAAAAACTGTTTTTTGGCAGT	CASSPSGPPGDLNEKLFF	In	VDJ	3	189	6.219089643735008E-4	7.806304520222046E-4	54	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	4	2	4	13	4	18	30	49	43	53														CASSPSGPPGDLNEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGTCAGGGGAGGGTTCACCCCTCCACTTTGGGAAC	CASSLSGEGSPLHF	In	VDJ	3	190	6.251994879945246E-4	7.84760771874174E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	3	9	0	9	5	0	18	32	-1	37	44														CASSLSGEGSPLHF+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAAACAGGAGCCTACGAGCAGTACTTCGGGCCG	CASSLETGAYEQYF	In	VDJ	3	191	6.284900116155484E-4	7.888910917261433E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	3	4	2	1	2	18	35	41	36	43														CASSLETGAYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCTCTTAGATGGACAGGGTGAAGGCGGGGGGTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	3	196	6.449426297206674E-4		61	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-01	01	5	1	3	4	10	13	18	30	48	40	61				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCTCCCCAGGGGGGTTAACCTACGAGCAGTACTTCGGGCCG	CASSPGGLTYEQYF	In	VDJ	3	212	6.975910076570485E-4	8.756278086174994E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	4	1	2	4	5	18	27	38	31	43														CASSPGGLTYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAGGCTCGGGGGGGCTATACGCAGTATTTTGGCCCA	CASSLEARGGYTQYF	In	VDJ	3	217	7.140436257621675E-4	8.96279407877346E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	8	0	7	4	2	18	35	47	39	49														CASSLEARGGYTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGGACCGACGGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASRTDGSGANVLTF	In	VDJ	3	227	7.469488619724057E-4	9.375826063970394E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-06	01	6	2	7	0	0	6	18	-1	32	29	38				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRTDGSGANVLTF+TCRBV11-03+TCRBJ02-06	TCRBV11-03*01		TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGGCGACAGGGGCTTAGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	3	228	7.502393855934295E-4		50	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	2	2	1	5	4	18	32	45	37	49														X+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAGACCGGGACAGTCCAAGAGACCCAGTACTTCGGGCCA	CASSQTGTVQETQYF	In	VDJ	3	230	7.568204328354772E-4	9.499735659529474E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	0	5	1	6	1	18	30	43	36	44														CASSQTGTVQETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCACCACCGGGACTACAACCGGGGAGCTGTTTTTTGGAGAA	CASTTGTTTGELFF	In	VDJ	3	245	8.061782871508343E-4	0.0010119283637324875	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	7	0	9	5	5	2	18	28	40	33	42						01,02								CASTTGTTTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGCGCGGCGGGGGAGAGACCCAGTACTTCGGGCCA	CASSLRGGGETQYF	In	VDJ	4	252	8.29211952498001E-4	0.0010408406026962728	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	3	7	2	4	5	0	18	32	-1	37	44														CASSLRGGGETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAACTAGCGGGAGTTTAAATGAGCAGTTCTTCGGGCCA	CASSLTSGSLNEQFF	In	VDJ	4	253	8.325024761190248E-4	0.0010449709225482421	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	3	2	7	0	4	18	-1	44	33	48														CASSLTSGSLNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGACCGGCCGCCATCAGCCCCAGCATTTTGGTGAT	CASSLTGRHQPQHF	In	VDJ	4	257	8.456645706031201E-4	0.0010614922019561194	42	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-05	01	3	2	7	5	0	8	18	-1	35	32	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLTGRHQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCAGGGGCGGGGGTCTACAATGAGCAGTTCTTCGGGCCA	CASSSGAGVYNEQFF	In	VDJ	4	261	8.588266650872154E-4	0.001078013481363997	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	7	2	3	5	1	18	31	43	36	44														CASSSGAGVYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGATAGTCCTGGCAATGAGCAGTTCTTCGGGCCA	CASSLDSPGNEQFF	In	VDJ	4	266	8.752792831923343E-4	0.0010986650806238435	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	5	8	6	0	6	18	-1	38	35	44						01,02								CASSLDSPGNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTTACCGACTATCCATCCTACGAGCAGTACTTCGGGCCG	CASSFTDYPSYEQYF	In	VDJ	4	270	8.884413776764296E-4	0.0011151863600317208	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	3	2	9	1	4	4	18	32	41	36	45						01,02								CASSFTDYPSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGCGACAGGGAAATGAAAAACTGTTTTTTGGCAGT	CASSLRQGNEKLFF	In	VDJ	4	293	9.641234209599774E-4	0.0012101837166270156	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	2	3	5	2	1	18	32	41	34	42														CASSLRQGNEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGGCGATCGACAGGTCCGGAGTCTACACCTTCGGTTCG		Out	VDJ	4	305	0.001003609704412263		43	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	2	4	10	7	8	18	30	43	37	51														X+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCAGATACCGGGACAGGGCGGGAGCAGTACTTCGGGCCG	CASSSDTGTGREQYF	In	VDJ	4	311	0.001023352846138406	0.0012845294739624636	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	0	3	7	4	3	18	35	48	39	51														CASSSDTGTGREQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGGGGGACTGCGAACACTGAAGCTTTCTTTGGACAA	CASSLGGTANTEAFF	In	VDJ	4	318	0.0010463865114855727	0.0013134417129262491	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	1	0	10	1	2	2	18	34	42	36	44						01,02								CASSLGGTANTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCGGACAGGGGTCCTACAATGAGCAGTTCTTCGGGCCA	CASSPGQGSYNEQFF	In	VDJ	5	369	0.0012142032161577873	0.0015240880253766852	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	1	2	1	3	0	18	30	-1	33	42														CASSPGQGSYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAACCGGGACAGGGTAATTCACCCCTCCACTTTGGGAAC	CASSQPGQGNSPLHF	In	VDJ	5	381	0.001253689499610073	0.0015736518636003173	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	5	0	3	6	5	0	18	30	-1	35	44														CASSQPGQGNSPLHF+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCGGCCTGGGGGCGGGAGGATACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	7	492	0.0016189376215437162		50	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	7	1	4	10	1	18	31	49	41	50														X+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGAACCTGGCGACTAATGAAAAACTGTTTTTTGGCAGT	CASSLNLATNEKLFF	In	VDJ	7	508	0.0016715859994800972	0.002098202484800423	45	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-04	01	3	9	0	2	6	1	18	32	41	38	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLNLATNEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCGGTACCGGGAGGAGGCGGGGAGCTGTTTTTTGGAGAA	CASSPVPGGGGELFF	In	VDJ	8	574	0.001888760558467669	0.002370803595030399	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	5	8	1	7	7	3	18	30	44	37	47														CASSPVPGGGGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGACCGGACTAGCGCCGTACACAATGAGCAGTTCTTCGGGCCA	CASSDRTSAVHNEQFF	In	VDJ	12	829	0.0027278440818287414	0.00342403515728258	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	1	6	5	4	6	18	30	43	34	49						01,02								CASSDRTSAVHNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCCGGGACTCCAAGGGAGGGGCCAACGTCCTGACTTTCGGGGCC	CASSFRDSKGGANVLTF	In	VDJ	24	1754	0.005771578431275769	0.0072445810203542165	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	3	0	10	4	2	8	18	32	40	34	48						01,02								CASSFRDSKGGANVLTF+TCRBV11-03+TCRBJ02-06	TCRBV11-03*01	TCRBD02-01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCACCTGGGGGAATGAGCAGTTCTTCGGGCCA	CASTWGNEQFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	33	TCRBV12	TCRBV12-05	01				TCRBJ02	TCRBJ02-01	01	12	6	1	7	8	0	26	31	-1	39	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTWGNEQFF+TCRBV12-05+TCRBJ02-01	TCRBV12-05*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGCTCCGAGAGGCTATACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	28	9.213466138866678E-5		46	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	11	1	4	6	3	26	41	51	47	54														X+TCRBV12-05+TCRBJ02-01	TCRBV12-05*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGCCCACAGACACGTTGGGACAGGGAAGGGACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	29	9.54251850096906E-5		56	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	0	3	5	14	5	25	36	59	50	64														X+TCRBV12-05+TCRBJ02-01	TCRBV12-05*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCCGAGGTGGCGACAATGAGCAGTTCTTCGGGCCA	CASRGGDNEQFF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	36	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	12	11	1	5	5	5	26	31	40	36	45														CASRGGDNEQFF+TCRBV12-05+TCRBJ02-01	TCRBV12-05*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCCGCCCGGGAGGGGGCCCCTACGAGCAGTACTTCGGGCCG	CASRPGGGPYEQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	42	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	12	8	0	2	8	4	26	31	47	39	51														CASRPGGGPYEQYF+TCRBV12-05+TCRBJ02-07	TCRBV12-05*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGTTAGTTCTTCCAGGGCGAACCACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	42	1.3820199208300016E-4		40	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	8	4	3	4	5	5	26	35	45	40	50														X+TCRBV12-05+TCRBJ01-01	TCRBV12-05*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGGAACCTCTAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	43	1.4149251570402398E-4		37	TCRBV12	TCRBV12-05	01				TCRBJ02	TCRBJ02-03	01	9	2	8	0	0	6	26	-1	36	34	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV12-05+TCRBJ02-03	TCRBV12-05*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGTAAGGGGCTGATTGCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	47	1.5465461018811924E-4		52	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	5	2	0	1	7	26	43	49	44	56														X+TCRBV12-05+TCRBJ02-01	TCRBV12-05*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTCGGATGGGAGCCTCAGAGACCCAGTACTTCGGGCCA	CASRMGASETQYF	In	VDJ	1	58	1.908503700193812E-4	2.395585514142215E-4	39	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	8	9	2	4	5	4	26	35	45	40	49														CASRMGASETQYF+TCRBV12-05+TCRBJ02-05	TCRBV12-05*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTCAACCCGGACCGCTACCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	79	2.599513660608813E-4		44	TCRBV12	TCRBV12-05	01				TCRBJ02	TCRBJ02-04	01	8	1	7	2	6	5	26	35	45	41	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV12-05+TCRBJ02-04	TCRBV12-05*01		TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTGGACTCCAAGTTAGTCCGAACCCTTCTGAGGGCTACACCTTCGGTTCG		Out	VDJ	1	80	2.632418896819051E-4		55	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	4	1	10	8	0	25	26	-1	44	39	69						01,02								X+TCRBV12-05+TCRBJ01-02	TCRBV12-05*01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTTATTTTGGGGAGAACTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	2	108	3.5537655107057185E-4		47	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	9	2	0	7	2	26	40	52	47	54														X+TCRBV12-05+TCRBJ02-07	TCRBV12-05*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTCCCTCCGGGGGGATGGAGACTGAAGCTTTCTTTGGACAA	CASGPSGGMETEAFF	In	VDJ	2	134	4.40930165217191E-4	5.534628601638911E-4	45	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	5	8	1	5	5	6	26	38	50	43	56														CASGPSGGMETEAFF+TCRBV12-05+TCRBJ01-01	TCRBV12-05*01	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGCTCCTCCCCGGGGCCCAACACTGAAGCTTTCTTTGGACAA	CASGSSPGPNTEAFF	In	VDJ	2	140	4.606733069433339E-4	5.782447792757071E-4	45	TCRBV12	TCRBV12-05	01				TCRBJ01	TCRBJ01-01	01	6	7	0	2	9	2	26	37	51	46	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGSSPGPNTEAFF+TCRBV12-05+TCRBJ01-01	TCRBV12-05*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTCAAAGGGGAGACCCAGTACTTCGGGCCA		Out	VDJ	2	145	4.7712592504845294E-4		34	TCRBV12	TCRBV12-05	01				TCRBJ02	TCRBJ02-05	01	5	5	3	5	3	0	26	38	-1	41	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV12-05+TCRBJ02-05	TCRBV12-05*01		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGTAACCGATAGGCGAGAAAAACTGTTTTTTGGCAGT	CASGLVTDRREKLFF	In	VDJ	3	238	7.831446218036676E-4	9.83016124768702E-4	45	TCRBV12	TCRBV12-05	01				TCRBJ01	TCRBJ01-04	01	0	5	4	8	7	3	26	43	53	50	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGLVTDRREKLFF+TCRBV12-05+TCRBJ01-04	TCRBV12-05*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGCCCCGTCCAGGTTACGAGCAGTACTTCGGGCCG		Out	VDJ	4	257	8.456645706031201E-4		35	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	9	4	4	4	7	1	26	34	45	41	46														X+TCRBV12-05+TCRBJ02-07	TCRBV12-05*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTATTGCGGGACTAGCGGGAGGGCCTGGTCTGAGCAGTTCTTCGGGCCA		Out	VDJ	4	299	9.838665626861203E-4		47	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	10	0	0	9	4	7	26	33	53	37	60														X+TCRBV12-05+TCRBJ02-01	TCRBV12-05*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTATGGGACTAGCGGGAGATACGCAGTATTTTGGCCCA	CASGMGLAGDTQYF	In	VDJ	4	307	0.0010101907516543108	0.0012680081945545864	42	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	2	4	5	0	0	26	-1	-1	42	52						01,02								CASGMGLAGDTQYF+TCRBV12-05+TCRBJ02-03	TCRBV12-05*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGGCAGGGTCGACTCTGGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	12	847	0.00278707350700717		46	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	6	4	3	0	1	4	26	37	43	38	47														X+TCRBV12-05+TCRBJ02-06	TCRBV12-05*01	TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCTTGGGGGGCACAGATACGCAGTATTTTGGCCCA	CASSLGGTDTQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	39	TCRBV23	TCRBV23-01	01				TCRBJ02	TCRBJ02-03	01	6	6	1	1	3	0	20	31	-1	34	39				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGGTDTQYF+TCRBV23-01+TCRBJ02-03	TCRBV23-01*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGCTCCGGGACTGCCCTACAATGAGCAGTTCTTCGGGCCA	CASSQAPGLPYNEQFF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	48	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	0	10	2	5	2	20	35	46	40	48						01,02								CASSQAPGLPYNEQFF+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACGGCACTGTATCTCTGCGCCAGCAGCCGGGTATACTCGGACAGACCCGACTAGCGGATTACACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	22	7.23915196625239E-5		65	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	2	5	2	22	4	16	27	58	49	62						01,02								X+TCRBV23-01+TCRBJ02-03	TCRBV23-01*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGAGGTCAGGGGGAACTATGGCTACACCTTCGGTTCG	CASSQEVRGNYGYTF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	45	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	4	1	2	5	0	20	35	-1	40	47														CASSQEVRGNYGYTF+TCRBV23-01+TCRBJ01-02	TCRBV23-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGATTGGGGCGGAGGGGCAGCGCGCACTGAAGCTTTCTTTGGACAA	CASSQDWGGGAARTEAFF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	54	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	2	10	0	4	9	8	20	35	50	44	58														CASSQDWGGGAARTEAFF+TCRBV23-01+TCRBJ01-01	TCRBV23-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCTTTTCAGGGGGTCAGGGATCCTACGAGCAGTACTTCGGGCCG	CFSGGQGSYEQYF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	39	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	14	4	1	1	4	7	20	23	34	27	41														CFSGGQGSYEQYF+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGATCTAGCCGGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSQDLAGSYNEQFF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	48	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	4	7	0	3	3	20	35	43	38	46						01,02								CASSQDLAGSYNEQFF+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCCCCGACAGGGGTCCAATCAGCCCCAGCATTTTGGTGAT	CASSPRQGSNQPQHF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	45	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	2	2	3	5	2	20	31	44	36	46														CASSPRQGSNQPQHF+TCRBV23-01+TCRBJ01-05	TCRBV23-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCTTGGGACAAGCTTCAAACTATGGCTACACCTTCGGTTCG	CASSLGQASNYGYTF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	45	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	6	2	3	7	20	31	40	34	47														CASSLGQASNYGYTF+TCRBV23-01+TCRBJ01-02	TCRBV23-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCGTCAGGTTTGCAGGGTGCGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	39	1.2833042121992871E-4		46	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	4	3	5	10	3	20	33	48	43	51														X+TCRBV23-01+TCRBJ02-05	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCACCCAAAGCGGGGGGCTCGGCGAGCAGTTCTTCGGGCCA	CASTQSGGLGEQFF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	42	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	7	6	1	10	5	6	20	30	44	35	50														CASTQSGGLGEQFF+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGATTACCAGACATAAATTCGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	41	1.3491146846197636E-4		49	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	2	2	6	8	8	7	20	35	47	43	54														X+TCRBV23-01+TCRBJ01-04	TCRBV23-01*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAATCCGAAGCTCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	41	1.3491146846197636E-4		40	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	6	7	3	3	1	20	37	43	40	44						01,02								X+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGGACTAGGAGGCCCTGAGACCCAGTACTTCGGGCCA	CASSQGLGGPETQYF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	45	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	2	1	8	5	0	8	20	-1	42	35	50						01,02								CASSQGLGGPETQYF+TCRBV23-01+TCRBJ02-05	TCRBV23-01*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGGTTGGGGAGAAAAACTGTTTTTTGGCAGT	CASSQGWGEKLFF	In	VDJ	1	49	1.6123565743016686E-4	2.023856727464975E-4	39	TCRBV23	TCRBV23-01	01				TCRBJ01	TCRBJ01-04	01	2	0	8	8	5	0	20	35	-1	40	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQGWGEKLFF+TCRBV23-01+TCRBJ01-04	TCRBV23-01*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGGCGGCAGGGGGCCGGTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	49	1.6123565743016686E-4		41	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	4	0	4	4	3	20	31	43	35	46														X+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCACTTCTAGCGGGCCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	61	2.0072194088245263E-4		41	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	10	4	4	0	3	1	20	27	38	30	39						01,02								X+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTATTACACGGGGAACAACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	64	2.1059351174552407E-4		44	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	8	3	5	6	4	20	32	43	38	47														X+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCCAGCAGTCGAGGGCCCGCTTCCAGGGGGTCGGTTGGGCAATAGCGGGTTCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	75	2.46789271576786E-4		73	TCRBV23	TCRBV23-01	01				TCRBJ02	TCRBJ02-03	01	4	4	1	2	13	21	-1	10	30	23	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV23-01+TCRBJ02-03	TCRBV23-01*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCACCCTCCCGGGACTAGCGGCACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	79	2.599513660608813E-4		50	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	0	5	5	10	1	20	31	52	41	53						01,02								X+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGATTCCGGGGCCTACTCCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSQDSGAYSSGANVLTF	In	VDJ	1	91	2.9943764951316705E-4	3.7585910652920964E-4	57	TCRBV23	TCRBV23-01	01				TCRBJ02	TCRBJ02-06	01	2	7	0	0	6	6	20	35	46	41	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDSGAYSSGANVLTF+TCRBV23-01+TCRBJ02-06	TCRBV23-01*01		TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAATAACCCAGCTCCTACGAGCAGTACTTCGGGCCG	CASSQ*PSSYEQYF	Stop	VDJ	1	95	3.125997439972623E-4		42	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	4	5	0	4	0	20	36	-1	40	43														CASSQ*PSSYEQYF+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGACGTGGCGGGGGCAGGGAATGAGCAGTTCTTCGGGCCA	CASSQDVAGAGNEQFF	In	VDJ	2	113	3.7182916917569093E-4	4.6672614327253505E-4	48	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	7	2	7	6	5	20	35	48	41	53														CASSQDVAGAGNEQFF+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCGAAAAAAGACAGATACGCAGTATTTTGGCCCA	CASSRKKTDTQYF	In	VDJ	2	119	3.915723109018338E-4	4.91508062384351E-4	39	TCRBV23	TCRBV23-01	01				TCRBJ02	TCRBJ02-03	01	6	2	8	3	2	6	20	31	35	33	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRKKTDTQYF+TCRBV23-01+TCRBJ02-03	TCRBV23-01*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGATAGGGGCCCTTACGAGCAGTACTTCGGGCCG	CASSQDRGPYEQYF	In	VDJ	2	122	4.0144388176490526E-4	5.038990219402591E-4	42	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	5	2	4	3	4	20	35	43	38	47														CASSQDRGPYEQYF+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCACCCCAGGCCCCCCCGGCTAGCGAGCGAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	123	4.0473440538592905E-4		55	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	4	6	7	19	4	20	31	56	50	60						01,02								X+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCTGGGGCAGGGTGGTCTATGGCTACACCTTCGGTTCG		Out	VDJ	2	135	4.442206888382148E-4		43	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	4	3	4	5	4	20	33	43	38	47														X+TCRBV23-01+TCRBJ01-02	TCRBV23-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCCTTGGCTGGCGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSPWLASSYNEQFF	In	VDJ	2	147	4.837069722905006E-4	6.071570182394925E-4	48	TCRBV23	TCRBV23-01	01				TCRBJ02	TCRBJ02-01	01	6	9	0	0	5	7	20	31	39	36	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPWLASSYNEQFF+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGAACGAGGGGTGAACACTGAAGCTTTCTTTGGACAA	CASSQERGVNTEAFF	In	VDJ	2	176	5.791321573001912E-4	7.269362939466032E-4	45	TCRBV23	TCRBV23-01	01				TCRBJ01	TCRBJ01-01	01	2	5	2	0	5	0	20	35	-1	40	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQERGVNTEAFF+TCRBV23-01+TCRBJ01-01	TCRBV23-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCTTAAGCGTGGGGCCCGGAGGGGAGTTGAGCAGTTCTTCGGGCCA		Out	VDJ	3	203	6.679762950678341E-4		44	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	11	10	0	9	15	4	20	26	47	41	51														X+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGATGGACTAGGATGGGGTGGAAGTACTTCGGGCCG		Out	VDJ	3	228	7.502393855934295E-4		44	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	1	8	11	3	11	20	35	45	38	56						01,02								X+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAATACTTGTCGGGGTCATATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSQYLSGSYSNQPQHF	In	VDJ	7	499	0.001641971286890883	0.002061029606132699	54	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	1	8	3	0	6	5	20	36	47	42	52														CASSQYLSGSYSNQPQHF+TCRBV23-01+TCRBJ01-05	TCRBV23-01*01	TCRBD02-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAGCGTCAACCGCTACTACGAGCAGTACTTCGGGCCG		Out	VDJ	41	2980	0.009805760390650965		43	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	3	4	9	3	10	0	20	34	-1	44	47						01,02								X+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAACAAATTTGGCGTTCGAACCGGGGAGCTGTTTTTTGGAGAA	CANKFGVRTGELFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	42	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-02	01	10	3	6	5	0	14	23	-1	33	30	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CANKFGVRTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGAGGAGCGGGCGTGAACTACGAGCAGTACTTCGGGCCG	CASRGAGVNYEQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	6	4	3	3	6	23	34	43	37	49						01,02								CASRGAGVNYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCGGGGGGTGGGACCTACGAGCAGTACTTCGGGCCG	CASSSGGGTYEQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	4	8	1	2	0	5	23	-1	43	36	48														CASSSGGGTYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCGTGGACCATTTGGCAGAAATGCGAACACTGAAGCTTTCTTTGGACAA	CASRGPFGRNANTEAFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	51	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	8	1	7	1	3	16	23	32	39	35	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRGPFGRNANTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCACCCTATAGCGGGAGTCCCCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	20	6.581047242047627E-5		47	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	10	5	2	2	8	4	23	30	47	38	51														X+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCGGGTTCGAAGCGGGGGACCTAGGGGGATCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	20	6.581047242047627E-5		53	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	10	6	2	3	10	12	23	30	48	40	60														X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAAAGGAGAGGGATTCTCCACTGAAGCTTTCTTTGGACAA	CASKGEGFSTEAFF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	7	11	0	4	5	6	23	33	43	38	49														CASKGEGFSTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGACGCGGGACTAGCGGGCCGGTTTTCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	21	6.910099604150008E-5		53	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	0	4	2	4	8	23	34	50	38	58						01,02								X+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGACAGGGGGCACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	21	6.910099604150008E-5		41	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	1	1	4	0	0	23	-1	-1	35	45														X+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGTAGGACTAGCGGGGCCGGATACGCAGTATTTTGGCCCA	CASSVGLAGPDTQYF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	1	3	6	3	3	23	35	50	38	53														CASSVGLAGPDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGGGAGTAAGGCAGGACAGGTTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	21	6.910099604150008E-5		55	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	1	4	1	12	1	23	40	59	52	60														X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCAGAACGGGGGGGATCGAGACCCAGTACTTCGGGCCA	CASTRTGGIETQYF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	7	8	0	5	6	3	23	33	47	39	50														CASTRTGGIETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTAGACAGGGCAATCAGCCCCAGCATTTTGGTGAT	CASSRQGNQPQHF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	2	4	2	1	0	23	35	-1	36	42														CASSRQGNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACTCACCGGACCCCGGGGCAGATACGCAGTATTTTGGCCCA	CASSDSPDPGADTQYF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	8	3	4	9	0	23	40	-1	49	54														CASSDSPDPGADTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGTCGCCGTTAAAATAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	22	7.23915196625239E-5		52	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-05	01	0	10	0	0	3	8	23	40	45	43	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCGTTACACAGATACGCAGTATTTTGGCCCA	CASSRYTDTQYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	36	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	5	9	2	4	0	23	34	-1	38	40						01,02								CASSRYTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGAACAGGGGGGTAGATACGCAGTATTTTGGCCCA	CASRNRGVDTQYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	3	1	5	2	2	23	34	44	36	46														CASRNRGVDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACCGTAAAGGAAATGGCTACACCTTCGGTTCG	CASSDRKGNGYTF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	39	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-02	01	5	1	8	6	9	1	23	35	47	44	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDRKGNGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCCGGGCCGACTTACCCTAATTCACCCCTCCACTTTGGGAAC	CASSYSGPTYPNSPLHF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	51	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-06	01	0	8	0	6	1	10	23	40	45	41	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSGPTYPNSPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01		TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGGGAGGGACACTGAAGCTTTCTTTGGACAA	CAISGRDTEAFF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	36	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	5	9	0	3	0	0	23	-1	-1	35	42														CAISGRDTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCCACGCCGTCCGGGAGGGACGAAAAGAGCAGTACTTCGGGCCG	CASTHAVREGRKEQYF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	7	8	0	7	11	7	23	33	52	44	59														CASTHAVREGRKEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTACGACTAGCGGGACCACCTACGAGCAGTACTTCGGGCCG	CASSTTSGTTYEQYF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	2	3	2	2	3	23	35	48	37	51														CASSTTSGTTYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAGGGACTAGCGGGGGGCAATGAGCAGTTCTTCGGGCCA	CASSEGLAGGNEQFF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	0	1	6	2	0	23	35	-1	37	52														CASSEGLAGGNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACGCTCTCTGTCGGCGGGAGGGAGACCCAGTACTTCGGGCCA	CATLSVGGRETQYF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	10	7	1	5	12	0	23	30	-1	42	50														CATLSVGGRETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGACTCCCGGGACAGCCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	25	8.226309052559534E-5		44	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	0	5	3	6	1	23	34	47	40	48														X+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCAGACCCAGGAGAACACTGAAGCTTTCTTTGGACAA	CASSQTQENTEAFF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	4	4	1	7	1	23	34	45	41	46														CASSQTQENTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCCGAACTATGGGGATAAAGGGGGCCGATACGCAGTATTTTGGCCCA		Out	VDJ	1	25	8.226309052559534E-5		52	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	5	0	6	18	1	23	34	59	52	60														X+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGCCCTTTGGGAGCAGTACTTCGGGCCG	CASSYALWEQYF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	36	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	2	0	10	7	7	0	23	38	-1	45	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYALWEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCAATTACGATGACTGAAGCTTTCTTTGGACAA	CASSSITMTEAFF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	4	2	8	5	7	2	23	36	45	43	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSITMTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCACGAGACGGCGTCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	25	8.226309052559534E-5		38	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-02	01	8	2	7	4	5	5	23	32	40	37	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCTGCCAGAGGACTAGTAGAATAGCTTACAGATACGCAGTATTTTGGCCCA	CAARGLVE*LTDTQYF	Stop	VDJ	1	25	8.226309052559534E-5		48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	12	1	8	3	7	11	23	28	42	35	53						01,02								CAARGLVE*LTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACACAGTTGACACTGAAGCTTTCTTTGGACAA	CASSYTVDTEAFF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	3	5	3	0	3	23	-1	42	38	45														CASSYTVDTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCGCGGGCGCCAATCCTAGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CAAGANPSSGANVLTF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	11	7	4	0	0	12	23	-1	34	29	46						01,02								CAAGANPSSGANVLTF+TCRBV06-08+TCRBJ02-06	TCRBV06-08*01	TCRBD02-01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGCCCAGGGGATCCCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSAQGIPTNEKLFF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	4	2	0	3	4	23	35	44	38	48														CASSAQGIPTNEKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAGGGGGATACCGGAACAGGGATTGAGCAGTTCTTCGGGCCA	CASSEGDTGTGIEQFF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	3	3	9	15	2	23	35	56	50	58														CASSEGDTGTGIEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCTAGGGGGGTCGGGGGGATACGCAGTATTTTGGCCCA		Out	VDJ	1	29	9.54251850096906E-5		43	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-03	01	6	5	1	6	3	8	23	34	43	37	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGTACCCGCGGGCGGATCGAGCTCCTACGAGCAGTACTTCGGGCCG	CASSVPAGGSSSYEQYF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	51	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	7	4	0	6	9	23	35	46	41	55						01,02								CASSVPAGGSSSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCCGAGACTAGCGGGGGGGCCCACGAGCAGTACTTCGGGCCG	CASSSETSGGAHEQYF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	4	2	0	5	4	3	23	36	54	40	57														CASSSETSGGAHEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCCTGGACAGGGGGGGGACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	29	9.54251850096906E-5		41	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	10	1	1	3	4	3	23	30	44	34	47														X+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCAGGGACGGATCCCTCGCGATTACTTCGGGCCG	CASSQGRIPRDYF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	5	0	7	13	2	14	23	35	42	37	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQGRIPRDYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCACAGCTATTGAACACTGAAGCTTTCTTTGGACAA	CASSYSQLLNTEAFF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	3	5	0	0	4	23	-1	44	40	48														CASSYSQLLNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTATCAGGGGCCCAATGAGCAGTTCTTCGGGCCA	CASSYQGPNEQFF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	4	2	6	1	2	23	37	44	38	46														CASSYQGPNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACTCTGGACATAATCAATCAGCCCCAGCATTTTGGTGAT	CATLDIINQPQHF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	10	1	6	3	4	4	23	30	39	34	43														CATLDIINQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCGAACAGGGGTTATGGGGGAATCAGCCCCAGCATTTTGGTGAT	CASTEQGLWGNQPQHF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	7	3	2	4	4	9	23	33	44	37	53														CASTEQGLWGNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCGACAGGTCGTACACCGGGGAGCTGTTTTTTGGAGAA	CASSDRSYTGELFF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	2	4	3	1	4	23	34	41	35	45														CASSDRSYTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTATGGGGGGACCGGCTCCTACGAGCAGTACTTCGGGCCG	CASSYGGTGSYEQYF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	3	9	1	0	1	5	23	37	44	38	49														CASSYGGTGSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCGCGTGACGGGAGGGCCAAGAGACCCAGTACTTCGGGCCA	CASA*REGQETQYF	Stop	VDJ	1	31	1.0200623225173821E-4		42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	8	8	0	1	6	0	23	32	-1	38	46														CASA*REGQETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCGCCAGGGACAATCAGCCCCAGCATTTTGGTGAT	CAIARDNQPQHF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	10	4	3	3	4	1	23	30	39	34	40														CAIARDNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACAGGGCTAGCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	32	1.0529675587276204E-4		43	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-04	01	2	5	3	0	0	2	23	-1	42	38	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ02-04	TCRBV06-08*01		TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTGGACCGGACAGGTTCCGGACGAGCAGTACTTCGGGCCG	CASSWTGQVPDEQYF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	1	4	5	5	6	23	36	48	41	54														CASSWTGQVPDEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCCCCTCGGGAGAACTCTGGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	32	1.0529675587276204E-4		47	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	8	8	2	0	5	2	23	32	43	37	45														X+TCRBV06-08+TCRBJ02-06	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCAAACCTCTATCCTACGAGCAGTACTTCGGGCCG	CASTKPLSYEQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	7	4	9	1	8	0	23	33	-1	41	44						01,02								CASTKPLSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCCAGGCAGAGATACGCAGTATTTTGGCCCA	CASSPGRDTQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	4	4	5	2	3	23	34	40	36	43														CASSPGRDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCCGGCGGCGTTATCGGGGCGACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	33	1.0858727949378584E-4		49	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-02	01	6	7	0	3	15	1	23	34	54	49	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGTTCAGGGGAGAGAGCAATCAGCCCCAGCATTTTGGTGAT	CASRFRGESNQPQHF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	4	2	1	3	4	23	34	43	37	47														CASRFRGESNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGCCCCAGGAGAGAACACTGAAGCTTTCTTTGGACAA	CASSAPGENTEAFF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	5	4	4	1	4	3	23	35	43	39	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSAPGENTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACCCGGACAGGGCAAGACACTGAAGCTTTCTTTGGACAA	CATRTGQDTEAFF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	10	1	3	3	3	4	23	30	41	33	45														CATRTGQDTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGAGAGCCTGAGAGGACTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	35	1.1516832673583348E-4		44	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	11	1	3	9	1	23	34	47	43	48														X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCCTACCGGGACTAGCGGCGAGCAGTACTTCGGGCCG	CASSPTGTSGEQYF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	0	5	6	7	0	23	34	-1	41	52						01,02								CASSPTGTSGEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGACGGGACTAGCGGGGACAGATACGCAGTATTTTGGCCCA	CASRTGLAGTDTQYF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	6	0	3	3	3	0	23	34	-1	37	50														CASRTGLAGTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGCAGGGGGGCCAGGGCGCGCGAAGGAATGGCTACACCTTCGGTTCG	CASRQGGQGARRNGYTF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	51	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	4	1	6	1	18	23	34	42	35	60														CASRQGGQGARRNGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCAGTCGGGGGTTTGGAACACTGAAGCTTTCTTTGGACAA	CASSQSGVWNTEAFF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	5	8	2	1	4	4	23	35	45	39	49														CASSQSGVWNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCGCTGGACTAGGCTCCGAGAAGATACGCAGTATTTTGGCCCA	CASRWTRLREDTQYF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	8	1	8	5	4	9	23	32	43	36	52						01,02								CASRWTRLREDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACAAGGGACGAAAACATTCAGTACTTCGGCGCC	CASTRDENIQYF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	36	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-04	01	7	0	7	5	3	1	23	33	41	36	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTRDENIQYF+TCRBV06-08+TCRBJ02-04	TCRBV06-08*01		TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACAGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSDSSGANVLTF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	2	5	0	0	0	23	-1	-1	35	40														CASSDSSGANVLTF+TCRBV06-08+TCRBJ02-06	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGCCCGGACAGGGTCGTCGGCCAAAAACATTCAGTACTTCGGCGCC	CASSARTGSSAKNIQYF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	51	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	5	1	3	1	4	6	23	35	47	39	53														CASSARTGSSAKNIQYF+TCRBV06-08+TCRBJ02-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGCCCCGGTTTGGGCGGGAGAGACCCAGTACTTCGGGCCA	CASSYAPVWAGETQYF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	2	7	4	4	12	0	23	38	-1	50	55						01,02								CASSYAPVWAGETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGCGGACGGGGGCTATGGCTACACCTTCGGTTCG	CASRADGGYGYTF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	6	8	2	4	6	0	23	34	-1	40	46														CASRADGGYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGTCGCGAAGTCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	37	1.217493739778811E-4		37	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	6	7	6	7	3	4	23	34	40	37	44						01,02								X+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACACTTCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSDTSNTGELFF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	2	6	0	0	3	23	-1	39	35	42														CASSDTSNTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTTGACCGCCCAACTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	37	1.217493739778811E-4		46	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-01	01	1	2	7	3	1	7	23	39	43	40	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCGACTAGCGGGATTTCCTACGAGCAGTACTTCGGGCCG	CASSSTSGISYEQYF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	2	3	1	1	2	23	36	48	37	50														CASSSTSGISYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCGATTCTAGCGGGAGGATGGATGAGCAGTTCTTCGGGCCA	CASDSSGRMDEQFF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	8	4	1	8	4	4	23	32	47	36	51														CASDSSGRMDEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCTAACACCGATGGTTCGCAATGAGCAGTTCTTCGGGCCA	CASSLTPMVRNEQFF	In	VDJ	1	38	1.2503989759890492E-4	1.569521543748348E-4	45	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-01	01	6	3	6	6	4	11	23	34	41	38	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLTPMVRNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGACCGAACCGGGACAGGGACAAGAGACCCAGTACTTCGGGCCA	CASRTEPGQGQETQYF	In	VDJ	1	38	1.2503989759890492E-4	1.569521543748348E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	0	3	2	9	1	23	34	52	43	53														CASRTEPGQGQETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGCGACAGGGAAAGGAACTGAAGCTTTCTTTGGACAA	CASSYATGKGTEAFF	In	VDJ	1	38	1.2503989759890492E-4	1.569521543748348E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	2	3	5	2	6	23	38	47	40	53														CASSYATGKGTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGATTTGACAGGGCTCAATCAGCCCCAGCATTTTGGTGAT	CASSDLTGLNQPQHF	In	VDJ	1	39	1.2833042121992871E-4	1.6108247422680412E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	2	3	3	5	2	23	35	47	40	49														CASSDLTGLNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCCCGCTAGCGGGGCCTTTCAATTATAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	40	1.3162094484095254E-4		61	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	2	4	3	0	4	12	20	35	48	39	60														X+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGGGGGATTTAACTAATGAAAAACTGTTTTTTGGCAGT	CASSYSGDLTNEKLFF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	48	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-04	01	0	6	1	1	0	4	23	-1	45	40	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSGDLTNEKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCGGACGGACGGCCGGGGAAGCTTTCTTTGGACAA	CASGRTAGEAFF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	36	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	8	1	7	8	0	11	23	-1	36	32	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGRTAGEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGACCCCGGACTCTAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	43	1.4149251570402398E-4		43	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	6	1	10	0	7	0	23	34	-1	41	46						01,02								X+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGGGGCCCCACCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	43	1.4149251570402398E-4		44	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	6	0	0	0	3	23	-1	44	38	47														X+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTATGGGGTGATGGGACTAGCCGACACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	43	1.4149251570402398E-4		53	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	0	7	5	9	4	23	37	55	46	59						01,02								X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCTCCCGGAAGGGAGCGGGGGAGCAGTACTTCGGGCCG		Out	VDJ	1	44	1.447830393250478E-4		40	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	8	6	3	7	12	0	23	32	-1	44	51														X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCTCCTAGCGGGAGACCGACCCAATGAGCAGTTCTTCGGGCCA	CASSLLAGDRPNEQFF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	4	2	6	3	7	23	35	48	38	55														CASSLLAGDRPNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCAGGGGGCTATGGGGGCCAACGTCCTGACTTTCGGGGCC	CASSYQGAMGANVLTF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	2	4	0	4	0	4	23	-1	46	38	50														CASSYQGAMGANVLTF+TCRBV06-08+TCRBJ02-06	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCACTTCCAGGGGGCGCAGCTCTAGAAACACCATATATTTTGGAGAG		Out	VDJ	1	47	1.5465461018811924E-4		52	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	6	4	0	5	7	9	23	34	49	41	58														X+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTAATTTAGGAGGCAGCACCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	48	1.5794513380914304E-4		49	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	10	1	2	5	5	23	37	47	42	52														X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACACAGGACCTAACTATGGCTACACCTTCGGTTCG	CASSYTGPNYGYTF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	3	4	0	0	2	23	-1	43	38	45														CASSYTGPNYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCTGGCGGGACAGGGGACCTACGAGCAGTACTTCGGGCCG	CASLAGQGTYEQYF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	0	2	2	5	1	23	32	47	37	48														CASLAGQGTYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGAAACTAGCGGGGGACGGCTACGAGCAGTACTTCGGGCCG	CASRKLAGDGYEQYF	In	VDJ	1	49	1.6123565743016686E-4	2.023856727464975E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	3	2	3	3	4	23	34	48	37	52														CASRKLAGDGYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCCGCGGGACAGAGGGAAGCTTTCTTTGGACAA	CASSPAGQREAFF	In	VDJ	1	49	1.6123565743016686E-4	2.023856727464975E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	5	8	5	3	23	35	47	40	50														CASSPAGQREAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGCCTAGCCGCCGGGGAGCTGTTTTTTGGAGAA	CASSYGLAAGELFF	In	VDJ	1	49	1.6123565743016686E-4	2.023856727464975E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	2	4	7	6	3	2	23	38	46	41	48						01,02								CASSYGLAAGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGAAAAGGCGAGGGACACCTAGAGACCCAGTACTTCGGGCCA	CASRKGEGHLETQYF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	0	6	4	9	3	23	34	49	43	52														CASRKGEGHLETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCGAAGGGGGGATCAACGAGCAGTACTTCGGGCCG	CASSEGGINEQYF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	6	5	1	5	3	5	23	34	43	37	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEGGINEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGCCGACGGGGGTTATGGCTACACCTTCGGTTCG	CASRADGGYGYTF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	6	8	2	5	6	1	23	34	46	40	47														CASRADGGYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCGCCCCCCCAGGGGGAACACCTACGAGTAGTACTTCGGGCCG	CASSRPPRGNTYE*YF	Stop	VDJ	1	50	1.6452618105119069E-4		48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	1	11	8	13	23	35	50	43	63														CASSRPPRGNTYE*YF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGGGGTAGGGAACACCGGGGAGCTGTTTTTTGGAGAA	CASRGVGNTGELFF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-02	01	6	6	1	1	0	4	23	-1	39	34	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRGVGNTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACGGAGGGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSDGGNTGELFF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	5	10	1	1	3	0	23	35	-1	38	43														CASSDGGNTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTATCACGGCAAGTACACTGAAGCTTTCTTTGGACAA	CASSYHGKYTEAFF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	3	9	0	3	4	4	23	37	44	41	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYHGKYTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGATGGGAGGGCCCACTGAAGCTTTCTTTGGACAA	CASRMGGPTEAFF	In	VDJ	1	52	1.711072282932383E-4	2.147766323024055E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	6	9	0	4	3	2	23	34	44	37	46														CASRMGGPTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCCCGTTCGGGCTCTGGAAACACCATATATTTTGGAGAG	CASSPRSGSGNTIYF	In	VDJ	1	52	1.711072282932383E-4	2.147766323024055E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	5	8	4	0	7	0	23	35	-1	42	46						01,02								CASSPRSGSGNTIYF+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01	TCRBD02-01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCTACAGGGGGCTCCGGGGAGCTGTTTTTTGGAGAA	CASSPTGGSGELFF	In	VDJ	1	52	1.711072282932383E-4	2.147766323024055E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	3	0	6	3	1	23	35	47	38	48														CASSPTGGSGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGAGACAGATCAATCAGCCCCAGCATTTTGGTGAT	CASSYSRQINQPQHF	In	VDJ	1	52	1.711072282932383E-4	2.147766323024055E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	2	5	3	2	2	23	40	47	42	49														CASSYSRQINQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCAAAAACCGGGACTAGCGGACTACGAGATGAGCAGTTCTTCGGGCCA	CASSPKTGTSGLRDEQFF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	54	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	0	5	8	9	8	23	35	55	44	63						01,02								CASSPKTGTSGLRDEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACCCCATGGATGGCTACACCTTCGGTTCG	CASSDPMDGYTF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	36	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-02	01	5	2	7	6	0	7	23	-1	38	35	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDPMDGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGTACACCGCGGACGGGGCCTACGAGCAGTACTTCGGGCCG	CASRYTADGAYEQYF	In	VDJ	1	54	1.7768827553528592E-4	2.2303727200634416E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	2	8	3	2	8	0	23	38	-1	46	51														CASRYTADGAYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTATAACCGGGACAACAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	54	1.7768827553528592E-4		44	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	0	6	2	5	1	23	37	48	42	49														X+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCTTCGGGACCCCCTAATGAAAAACTGTTTTTTGGCAGT	CASSSSGPPNEKLFF	In	VDJ	1	54	1.7768827553528592E-4	2.2303727200634416E-4	45	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-04	01	4	0	7	3	4	3	23	36	45	40	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSSGPPNEKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGAGCAGGGGGGGGCAACGAGCAGTACTTCGGGCCG	CASRAGGGNEQYF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	6	4	1	5	2	5	23	34	43	36	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRAGGGNEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACCAGGTCGGCACTGAAGCTTTCTTTGGACAA	CASSDQVGTEAFF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	4	4	3	4	23	35	42	38	46														CASSDQVGTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTTCCTTGGGGTCTGAAGCTTTCTTTGGACAA	CAISSLGSEAFF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	36	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	4	6	2	6	4	1	23	36	44	40	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CAISSLGSEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGGGCATCCGAGCAGTACTTCGGGCCG	CASSYGASEQYF	In	VDJ	1	58	1.908503700193812E-4	2.395585514142215E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	7	0	6	0	3	23	-1	43	38	46														CASSYGASEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTAGTGCAGGGGAAGGCTACACCTTCGGTTCG	CASSSAGEGYTF	In	VDJ	1	59	1.94140893640405E-4	2.4368887126619086E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	4	2	8	4	2	23	35	45	39	47														CASSSAGEGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGCCCCGCTGGAGGTAACTATGGCTACACCTTCGGTTCG	CASSYGPAGGNYGYTF	In	VDJ	1	59	1.94140893640405E-4	2.4368887126619086E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	2	10	1	1	9	0	23	38	-1	47	52														CASSYGPAGGNYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGGGACCTGAGGCTAAATTCCTACGAGCAGTACTTCGGGCCG	CASSGDLRLNSYEQYF	In	VDJ	1	61	2.0072194088245263E-4	2.5194951097012955E-4	48	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	5	0	7	1	1	12	23	35	41	36	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSGDLRLNSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGCATCAGGGCGCGGCACTGAAGCTTTCTTTGGACAA	CASSASGRGTEAFF	In	VDJ	1	62	2.0401246450347642E-4	2.560798308220989E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	3	4	4	5	23	35	44	39	49														CASSASGRGTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGCCCCCGGAGCCAGGGGGCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	63	2.0730298812450025E-4		47	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	1	2	11	0	23	35	-1	46	53														X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGAAATCTGGGGGAACCGGGGAGCTGTTTTTTGGAGAA	CASSYSKSGGTGELFF	In	VDJ	1	63	2.0730298812450025E-4	2.602101506740682E-4	48	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-02	01	0	6	1	5	7	1	23	40	52	47	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSKSGGTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGATGGGGGGAAACACCATATATTTTGGAGAG	CASSYSMGGNTIYF	In	VDJ	1	63	2.0730298812450025E-4	2.602101506740682E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-03	01	0	6	2	4	3	0	23	40	-1	43	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSMGGNTIYF+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGGCGGGACAGGCGGGGGTAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	65	2.1388403536654787E-4		53	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	0	4	1	3	6	23	40	51	43	57														X+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACATCGCGGGAGGGGGCTACAATGAGCAGTTCTTCGGGCCA	CASSDIAGGGYNEQFF	In	VDJ	1	66	2.171745589875717E-4	2.726011102299762E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	7	0	3	6	2	23	35	50	41	52														CASSDIAGGGYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGATGGGACGGAGAATTCACCCCTCCACTTTGGGAAC	CASSDGTENSPLHF	In	VDJ	1	67	2.204650826085955E-4	2.7673143008194554E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-06	01	5	0	7	7	3	4	23	35	43	38	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDGTENSPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01		TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACGGGAGGGGGCTTGTACGAGCAGTACTTCGGGCCG	CASTGGGLYEQYF	In	VDJ	1	68	2.237556062296193E-4	2.8086174993391486E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	7	8	0	4	0	6	23	-1	41	33	47														CASTGGGLYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTACCGCGGACAGAAAAGCTTTCTTTGGACAA	CASSTADRKAFF	In	VDJ	1	69	2.2704612985064313E-4	2.8499206978588424E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	1	5	9	5	2	23	35	46	40	48														CASSTADRKAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGACAGGGAGTGGCTACACCTTCGGTTCG	CASSYSTGSGYTF	In	VDJ	1	72	2.3691770071371457E-4	2.973830293417922E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	2	3	7	0	2	23	-1	47	40	49														CASSYSTGSGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTATGGCCCATGAGCGGGTTCCTACAATGAGCAGTTCTTCGGGCCA	CASSYGP*AGSYNEQFF	Stop	VDJ	1	73	2.402082243347384E-4		51	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	6	4	1	9	1	23	37	52	46	53						01,02								CASSYGP*AGSYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGGATGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	73	2.402082243347384E-4		37	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-02	01	6	2	7	4	7	0	23	34	-1	41	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACTCTAGCGGGGGGGCAGATACGCAGTATTTTGGCCCA	CASSDSSGGADTQYF	In	VDJ	1	74	2.434987479557622E-4	3.056436690457309E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	5	0	4	0	0	23	-1	-1	40	51														CASSDSSGGADTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCCCGGGACGGAGGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	74	2.434987479557622E-4		44	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	4	0	7	1	3	4	23	36	44	39	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGTAGAGGCAGGGGCCACTTCCGACTTTGGGACACTGAAGCTTTCTTTGGACAA	CASRGRGHFRLWDTEAFF	In	VDJ	1	74	2.434987479557622E-4	3.056436690457309E-4	54	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	9	4	2	3	6	17	23	31	43	37	60														CASRGRGHFRLWDTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGACTCCAGGGGGAGGCAGTTTCCTCCTATAATTCACCCCTCCACTTTGGGAAC	CASRLQGEAVSSYNSPLHF	In	VDJ	1	75	2.46789271576786E-4	3.097739888977002E-4	57	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	6	4	1	0	4	10	23	34	45	38	55														CASRLQGEAVSSYNSPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCGGGGGCTGAGACCGGGGAGCTGTTTTTTGGAGAA	CASSPGAETGELFF	In	VDJ	1	77	2.5337031881883363E-4	3.180346286016389E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-02	01	5	6	0	5	2	4	23	35	43	37	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPGAETGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGAGAGACTCGCGGAGGACAGGGAGTTTGGTGAAGCTTTCTTTGGACAA	CASSYERLAEDREFGEAFF	In	VDJ	1	77	2.5337031881883363E-4	3.180346286016389E-4	57	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	1	3	7	14	7	23	38	60	52	67														CASSYERLAEDREFGEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACTCAGCGGGGGGGGACACAGGGCACCGGGGAGCTGTTTTTTGGAGAA	CASTQRGGTQGTGELFF	In	VDJ	1	79	2.599513660608813E-4	3.2629526830557756E-4	51	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	7	6	0	4	3	9	23	33	46	36	55														CASTQRGGTQGTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAGGGTCTGGACACCGGGGAGCTGTTTTTTGGAGAA	CASSEGLDTGELFF	In	VDJ	1	79	2.599513660608813E-4	3.2629526830557756E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	5	11	0	3	0	5	23	-1	40	35	45														CASSEGLDTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCCGATGGGACAGGGTACAATGAGCAGTTCTTCGGGCCA	CASSSDGTGYNEQFF	In	VDJ	1	79	2.599513660608813E-4	3.2629526830557756E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	0	3	4	5	0	23	36	-1	41	50														CASSSDGTGYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCGATATTGGACTAGCGGGCGCCCAACCCCCTACAATGAGCAGTTCTTCGGGCCA	CASSRYWTSGRPTPYNEQFF	In	VDJ	1	80	2.632418896819051E-4	3.3042558815754694E-4	60	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	1	4	2	7	10	21	33	51	40	61						01,02								CASSRYWTSGRPTPYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCAGGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSRSSYNEQFF	In	VDJ	1	82	2.698229369239527E-4	3.386862278614856E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-01	01	6	4	4	0	0	2	23	-1	38	34	40				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRSSYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACAGGGACGGCTACACTGAAGCTTTCTTTGGACAA	CASSYRDGYTEAFF	In	VDJ	1	83	2.731134605449765E-4	3.428165477134549E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	2	0	7	3	1	4	23	38	44	39	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYRDGYTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCCGGGCCAATCAAGGTGAACTTCGGGCCG	CASSPGPIKVNF	In	VDJ	1	84	2.764039841660003E-4	3.469468675654243E-4	36	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	5	8	0	14	3	12	23	35	42	38	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPGPIKVNF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCCGGGACCGTCTATGGCTACACCTTCGGTTCG	CASSSGTVYGYTF	In	VDJ	1	85	2.7969450778702416E-4	3.510771874173936E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-02	01	4	0	7	4	2	3	23	36	43	38	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSGTVYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCCACCAGGCAGGGGAGTCGGTCAGCCCCAGCATTTTGGTGAT	CASPPGRGVGQPQHF	In	VDJ	1	85	2.7969450778702416E-4	3.510771874173936E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	8	4	2	6	8	6	23	32	46	40	52														CASPPGRGVGQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACGGATACAAGAGATAGCAATCAGCCCCAGCATTTTGGTGAT	CATDTRDSNQPQHF	In	VDJ	1	86	2.8298503140804796E-4	3.552075072693629E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-05	01	10	1	8	0	1	9	23	30	34	31	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATDTRDSNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCCCCATTTGCCAGGGCAGCGACGAGCAGTACTTCGGGCCG		Out	VDJ	1	86	2.8298503140804796E-4		47	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	4	3	5	10	5	23	36	51	46	56														X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCCGGCTAGCGGGGAGGATGAGCAGTTCTTCGGGCCA	CASSYPASGEDEQFF	In	VDJ	1	87	2.8627555502907175E-4	3.593378271213323E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	4	3	8	4	3	23	38	51	42	54														CASSYPASGEDEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGCACTCCGGGACAGGGAAAGACTGAAGCTTTCTTTGGACAA	CAISTPGQGKTEAFF	In	VDJ	1	87	2.8627555502907175E-4	3.593378271213323E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	0	3	5	6	4	23	34	49	40	53														CAISTPGQGKTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCTGAGGGGGACAGATACGCAGTATTTTGGCCCA	CASSYLRGTDTQYF	In	VDJ	1	88	2.895660786500956E-4	3.634681469733016E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	5	1	3	3	0	23	38	-1	41	47														CASSYLRGTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGCGACCCTACCGGGGAGCTGTTTTTTGGAGAA	CASSGDPTGELFF	In	VDJ	1	91	2.9943764951316705E-4	3.7585910652920964E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-02	01	5	2	7	5	3	3	23	35	41	38	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSGDPTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACCAATCCAGGGTCCGAGGTTTATGGCTACACCTTCGGTTCG	CATNPGSEVYGYTF	In	VDJ	1	93	3.0601869675521464E-4	3.841197462331483E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	10	4	3	5	6	9	23	30	41	36	50														CATNPGSEVYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCTACGGCGGAACGGGCTGGCTTTCTTTGGACAA	CASSLRRNGLAFF	In	VDJ	1	93	3.0601869675521464E-4	3.841197462331483E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	6	8	0	11	13	2	23	34	51	47	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLRRNGLAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCCGGGACGACCGGCGATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	93	3.0601869675521464E-4		47	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-05	01	2	0	7	5	2	8	23	38	45	40	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCTTACCGCCGCAGACAGAAGCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	94	3.093092203762385E-4		50	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	5	0	12	3	23	34	51	46	54														X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGCCGTCGGTGAAAGCACTGAAGCTTTCTTTGGACAA	CASSAVGESTEAFF	In	VDJ	1	94	3.093092203762385E-4	3.882500660851176E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	5	8	5	4	5	6	23	35	43	40	49						01,02								CASSAVGESTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCGAGGAGGGGGGCAGGGACACTGAAGCTTTCTTTGGACAA	CASEEGGRDTEAFF	In	VDJ	1	94	3.093092203762385E-4	3.882500660851176E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	8	5	1	3	4	6	23	32	42	36	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASEEGGRDTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTTTCAGGGGACTATAATTCACCCCTCCACTTTGGGAAC	CASSFSGDYNSPLHF	In	VDJ	1	96	3.158902676182861E-4	3.965107057890563E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	4	2	3	3	1	23	36	45	39	46														CASSFSGDYNSPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGGCCGACAGGACCCACAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	100	3.2905236210238137E-4		47	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	2	4	3	5	5	23	35	46	40	51														X+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGTTCAGGGGGGCAATCAGCCCCAGCATTTTGGTGAT	CASSVQGGNQPQHF	In	VDJ	1	100	3.2905236210238137E-4	4.1303198519693365E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	4	1	2	3	0	23	35	-1	38	45														CASSVQGGNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGTTCTGGACTCCACGAGCAGTACTTCGGGCCG	CASSGSGLHEQYF	In	VDJ	1	102	3.3563340934442896E-4	4.2129262490087234E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	1	10	5	6	2	23	35	46	41	48						01,02								CASSGSGLHEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTATCCACGGGACAGCTTCCCCGAGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	107	3.5208602744954805E-4		53	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	3	0	5	4	5	9	23	37	49	42	58														X+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTCAACAGGGATGGCTACACCTTCGGTTCG	CASSFNRDGYTF	In	VDJ	1	107	3.5208602744954805E-4	4.41944224160719E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	3	3	6	3	0	23	36	-1	39	45														CASSFNRDGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGACCTACAGGTTACGAGCAGTACTTCGGGCCG	CASRPTGYEQYF	In	VDJ	2	115	3.784102164177386E-4	4.749867829764737E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	3	4	4	4	1	23	34	43	38	44														CASRPTGYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCCCACAGGGGGAAACACTGAAGCTTTCTTTGGACAA	CASSPTGGNTEAFF	In	VDJ	2	116	3.817007400387624E-4	4.79117102828443E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	3	1	2	4	1	23	34	46	38	47														CASSPTGGNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTGGAAGGGTACACTGAAGCTTTYTTTGGACAA	CASSLEGYTEAFF	In	VDJ	2	116	3.817007400387624E-4	4.79117102828443E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	4	5	3	17	4	15	23	36	44	40	59				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLEGYTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACTCCCACGCCGCAGGGTAGGATTCACCCCTCCACTTTGGGAAC	CASSDSHAAG*DSPLHF	Stop	VDJ	2	122	4.0144388176490526E-4		51	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	0	4	3	8	8	4	23	40	53	48	57														CASSDSHAAG*DSPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTACAGGGGAAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	126	4.146059762490005E-4		41	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	3	2	2	0	1	23	-1	42	35	43														X+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCACGGGGGGACTACAATGAGCAGTTCTTCGGGCCA	CASSPRGDYNEQFF	In	VDJ	2	127	4.178964998700243E-4	5.245506212001057E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	8	1	3	3	1	23	35	45	38	46														CASSPRGDYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCTCACTATACACCGGGGAGCTGTTTTTTGGAGAA	CASSSLYTGELFF	In	VDJ	2	129	4.2447754711207194E-4	5.328112609040444E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	6	3	9	3	3	1	23	34	41	37	42						01,02								CASSSLYTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACTTCAGCCCTGCGAGGTAGGCACTGAAGCTTTCTTTGGACAA		Out	VDJ	2	133	4.376396415961672E-4		50	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	1	11	1	4	10	4	23	39	53	49	57														X+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCCGACAGGGGGAGCGACAGATACGCAGTATTTTGGCCCA	CASSPTGGATDTQYF	In	VDJ	2	140	4.606733069433339E-4	5.782447792757071E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	2	1	3	3	4	23	34	46	37	50														CASSPTGGATDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCACCCACTAGCGGGGGGGCCGTTCTAAGAGATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	147	4.837069722905006E-4		52	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	10	3	0	8	6	12	23	30	49	36	61														X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGCCGACTGGGTATGGCTACACCTTCGGTTCG	CASRPTGYGYTF	In	VDJ	2	149	4.902880195325482E-4	6.154176579434311E-4	36	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	6	2	10	5	3	3	23	34	41	37	44						01,02								CASRPTGYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCGGCAGGAGAACACTGAAGCTTTCTTTGGACAA	CASSRQENTEAFF	In	VDJ	2	149	4.902880195325482E-4	6.154176579434311E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	4	1	3	1	23	35	42	38	43														CASSRQENTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCCCGACAGGGTCACAGATACGCAGTATTTTGGCCCA	CASSPDRVTDTQYF	In	VDJ	2	150	4.93578543153572E-4	6.195479777954004E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	2	3	2	4	1	23	34	45	38	46														CASSPDRVTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCCCCGACACAGGGGCGCGCGGCTTTCTTTGGACAA	CASSSPTQGRAAFF	In	VDJ	2	150	4.93578543153572E-4	6.195479777954004E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	3	2	11	7	6	23	36	50	43	56														CASSSPTQGRAAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAAGGCAGCGGGAGGGGGGGAGCAGTTCTTCGGGCCA	CASKAAGGGEQFF	In	VDJ	2	154	5.067406376376673E-4	6.360692572032778E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	6	0	10	4	3	23	33	47	37	50														CASKAAGGGEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTCCCCGGGGATGCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSFPGDAGANVLTF	In	VDJ	2	154	5.067406376376673E-4	6.360692572032778E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-06	01	4	8	3	2	4	3	23	36	45	40	48														CASSFPGDAGANVLTF+TCRBV06-08+TCRBJ02-06	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACCCACAAGGAGAAGACAGGTGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	2	158	5.199027321217626E-4		47	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	10	2	4	2	13	1	23	30	49	43	50														X+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAAATCGGGACAGGGGCTAACAGATACGCAGTATTTTGGCCCA	CASKSGQGLTDTQYF	In	VDJ	2	161	5.297743029848339E-4	6.649814961670632E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	7	0	2	3	4	3	23	33	47	37	50														CASKSGQGLTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCCCTACTGGGATGAACACTGAAGCTTTCTTTGGACAA	CASTPTGMNTEAFF	In	VDJ	2	161	5.297743029848339E-4	6.649814961670632E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	7	0	8	0	8	0	23	33	-1	41	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTPTGMNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGTAGGACCAGTCGGCGGGGAGCTGTTTTTTGGAGAA	CASSVGPVGGELFF	In	VDJ	2	163	5.363553502268816E-4	6.732421358710018E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-02	01	5	1	7	7	3	7	23	35	42	38	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSVGPVGGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGACCAGGCGGAAGGAACACTGAAGCTTTCTTTGGACAA	CASRPGGRNTEAFF	In	VDJ	2	167	5.495174447109768E-4	6.897634152788792E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	6	4	4	1	2	6	23	34	40	36	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRPGGRNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCAGCGGGGGGTAGCACAGATACGCAGTATTTTGGCCCA	CASSPAGGSTDTQYF	In	VDJ	2	171	5.626795391950721E-4	7.062846946867565E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	6	1	0	2	1	23	35	46	37	47														CASSPAGGSTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGTCCTTGGGGTACAATGAGCAGTTCTTCGGGCCA	CASRSLGYNEQFF	In	VDJ	2	172	5.659700628160959E-4	7.104150145387258E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-01	01	6	6	2	4	6	0	23	34	-1	40	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRSLGYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCCCTGCAGGGGAAGACATGGAAACACCATATATTTTGGAGAG		Out	VDJ	2	172	5.659700628160959E-4		49	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	4	4	2	3	5	6	23	36	47	41	53														X+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCGTTACCGGGACTAGCGGGAGGGGCGAGCAGTACTTCGGGCCG		Out	VDJ	2	174	5.725511100581435E-4		49	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	0	0	6	8	1	23	34	58	42	59														X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCGAGCGGGGGACACCTACGAGCAGTACTTCGGGCCG	CASSRAGDTYEQYF	In	VDJ	3	187	6.153279171314532E-4	7.723698123182659E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	6	2	2	3	3	23	34	45	37	48														CASSRAGDTYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCGTATGGGGGGGACAGGGAAGGGACGAGCAGTACTTCGGGCCG	CAVWGGQGRDEQYF	In	VDJ	3	197	6.482331533416912E-4	8.136730108379593E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	11	0	3	5	8	5	23	29	46	37	51														CAVWGGQGRDEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAAATTAGGGTTCCATGAGCAGTTCTTCGGGCCA	CASKLGFHEQFF	In	VDJ	3	206	6.778478659309056E-4	8.508458895056833E-4	36	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-01	01	7	5	3	8	4	4	23	33	41	37	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASKLGFHEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTACAGGGGTACCCTACGAGCAGTACTTCGGGCCG	CASSTGVPYEQYF	In	VDJ	3	213	7.008815312780723E-4	8.797581284694687E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	3	2	2	0	3	23	-1	42	35	45														CASSTGVPYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCAAGGGACTAGCGGGCCCGAGCAGTTCTTCGGGCCA	CASSQGTSGPEQFF	In	VDJ	3	213	7.008815312780723E-4	8.797581284694687E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	0	4	10	3	3	23	35	50	38	53						01,02								CASSQGTSGPEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGGGGGGGAATGGCTACACCTTCGGTTCG	CASSYSGGNGYTF	In	VDJ	3	229	7.535299092144533E-4	9.458432461009781E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	0	9	0	6	0	1	23	-1	47	40	48														CASSYSGGNGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACCACAGGGTCCGCTGGAAACACCATATATTTTGGAGAG	CATTGSAGNTIYF	In	VDJ	3	235	7.732730509405961E-4	9.706251652127941E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	10	3	3	2	2	4	23	30	38	32	42														CATTGSAGNTIYF+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCAAGGCCACGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	4	252	8.29211952498001E-4		37	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-02	01	4	5	4	7	2	3	23	36	41	38	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGACCGCGAACACTGAAGCTTTCTTTGGACAA	CASSYSTANTEAFF	In	VDJ	4	254	8.357929997400486E-4	0.0010491012424002114	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	0	2	7	1	0	3	23	-1	43	40	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSTANTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACGTCCAGCACCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	4	265	8.719887595713106E-4		43	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-03	01	5	2	7	2	0	9	23	-1	38	35	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCATGGGACAGGGGTGCAAAAACTGTTTTTTGGCAGT		Out	VDJ	4	278	9.147655666446201E-4		38	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	10	0	2	9	4	3	23	30	44	34	47														X+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAATAAGATTGGATTACAGAGGTTCTTCGGGCCA	CASNKIGLQRFF	In	VDJ	4	291	9.575423737179298E-4	0.001201923076923077	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	3	5	15	13	2	23	33	50	46	52														CASNKIGLQRFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTATGGGACAGGGGGCTACAATGAGCAGTTCTTCGGGCCA	CASSYYGTGGYNEQFF	In	VDJ	4	300	9.87157086307144E-4	0.0012390959555908009	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	0	1	3	2	0	23	39	-1	41	52														CASSYYGTGGYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACAGGGACAGGTCCACAGATACGCAGTATTTTGGCCCA	CASSYRDRSTDTQYF	In	VDJ	5	339	0.0011154875075270727	0.001400178429817605	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	0	4	2	1	2	23	38	47	39	49														CASSYRDRSTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGGCGGACTAGCGGGAACAGATACGCAGTATTTTGGCCCA	CASRGGLAGTDTQYF	In	VDJ	5	350	0.0011516832673583348	0.0014456119481892678	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	6	1	3	3	4	0	23	34	-1	38	50														CASRGGLAGTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTACCCCGACAGGGAGAGGGAACAGCCCCAGCATTTTGGTGAT		Out	VDJ	5	353	0.001161554838221406		47	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	2	3	7	5	8	23	35	47	40	55														X+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGCGCCGGATCTGGGTTTTCAGGGGGGTCCTACGAGCAGTACTTCGGGCCG	CASSGAGSGFSGGSYEQYF	In	VDJ	6	410	0.0013491146846197634	0.001693431139307428	57	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	1	1	19	1	23	35	61	54	62														CASSGAGSGFSGGSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCGACAGGGGGCAACACTGAAGCTTTCTTTGGACAA	CASSPTGGNTEAFF	In	VDJ	8	607	0.001997347837961455	0.0025071041501453875	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	0	2	2	0	23	35	-1	37	47														CASSPTGGNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGCAGGGGGCGGCTACGAGCAGTACTTCGGGCCG	CASSAGGGYEQYF	In	VDJ	9	643	0.002115806688318312	0.0026557956648162835	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	0	3	1	2	23	35	44	36	46														CASSAGGGYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGCGGGACTAGCGGGCACAGATACGCAGTATTTTGGCCCA	CASRAGLAGTDTQYF	In	VDJ	15	1077	0.003543893939842647	0.004448354480570975	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	0	5	1	3	0	23	34	-1	37	48						01,02								CASRAGLAGTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACGATGGCTACACTTACAATGAGCAGTTCTTCGGGCCA	CASSDDGYTYNEQFF	In	VDJ	31	2230	0.007337867674883104	0.00921061326989162	45	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-01	01	5	2	7	4	0	12	23	-1	38	35	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDDGYTYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCTTCTCAGTCCTTAGATGGCTACACCTTCGGTTCG	CASSPPSQSLDGYTF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	45	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-02	01	0	4	5	6	4	7	24	41	48	45	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPPSQSLDGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCTCCATTGACAGACACCCAAGAGACCCAGTACTTCGGGCCA	CASSPLTDTQETQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	2	5	1	2	4	24	39	46	41	50													Vb 18	CASSPLTDTQETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACTGGAGGCTGGAAGTACTGAAGCTTTCTTTGGACAA	CASSLEAGSTEAFF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	42	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	4	10	1	5	1	8	24	37	43	38	51													Vb 18	CASSLEAGSTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTAACACAGGTTTTGGAAACATTCAGTACTTCGGCGCC	CASSPNTGFGNIQYF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	3	3	4	6	4	6	24	38	47	42	53													Vb 18	CASSPNTGFGNIQYF+TCRBV18-01+TCRBJ02-04	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCGAGCCCGGGACACTACGAGCAGTACTTCGGGCCG	CASSSPGHYEQYF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	6	3	6	0	24	35	-1	41	47													Vb 18	CASSSPGHYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACGACTCGGACGGATGAAGGGGGATACGCAGTATTTTGGCCCA	CASSRLGRMKGDTQYF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	5	2	6	15	0	24	37	-1	52	57													Vb 18	CASSRLGRMKGDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCCTACCCGGGACGGGGAACACTGAAGCTTTCTTTGGACAA	CASLPGTGNTEAFF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-01	01	8	0	7	1	6	3	24	33	44	39	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASLPGTGNTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAGACTAGCGGGGGGGCTACGAGCAGTACTTCGGGCCG	CASSPD*RGGYEQYF	Stop	VDJ	1	25	8.226309052559534E-5		45	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	2	2	0	3	0	0	24	-1	-1	39	53													Vb 18	CASSPD*RGGYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCATCGACGGTGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSSTVNTGELFF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	42	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-02	01	5	2	7	1	2	3	24	36	41	38	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSSTVNTGELFF+TCRBV18-01+TCRBJ02-02	TCRBV18-01*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAGTTAAAGGGGGGCTGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSPVKGGLNTGELFF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	51	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-02	01	2	5	1	1	5	3	24	39	50	44	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPVKGGLNTGELFF+TCRBV18-01+TCRBJ02-02	TCRBV18-01*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGGGACAGAATCAGCCCCAGCATTTTGGTGAT	CASSPGQNQPQHF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	0	5	4	0	0	24	-1	-1	38	45													Vb 18	CASSPGQNQPQHF+TCRBV18-01+TCRBJ01-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAATCTAGGACGGACGAGCAGTACTTCGGGCCG		Out	VDJ	1	28	9.213466138866678E-5		40	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-07	01	2	1	7	5	5	2	24	39	48	44	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	X+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAATGGCGGGAGGGCCCACAGATACGCAGTATTTTGGCCCA	CASSPMAGGPTDTQYF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	48	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	7	0	2	3	2	24	39	51	42	53													Vb 18	CASSPMAGGPTDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCATTTCCTGCTAGCGGGGGAATCTCGGAGACCCAGTACTTCGGGCCA	CASSPFPASGGISETQYF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	54	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	2	4	2	5	7	7	24	39	56	46	63													Vb 18	CASSPFPASGGISETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCACAATGAACACTGAAGCTTTCTTTGGACAA	CASSPTMNTEAFF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	3	6	0	1	1	24	38	42	39	43													Vb 18	CASSPTMNTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGAGCAGGGGACGCGCTCAGCCCCAGCATTTTGGTGAT	CASSPSRGRAQPQHF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	4	2	6	3	6	24	38	47	41	53													Vb 18	CASSPSRGRAQPQHF+TCRBV18-01+TCRBJ01-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGCGAACCAAGAGACCCAGTACTTCGGGCCA	CASSANQETQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	36	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	5	7	6	0	0	1	24	-1	39	36	40						01,02							Vb 18	CASSANQETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCATCAGCGGCCCGCGAGCAGTACTTCGGGCCG	CASSSAAREQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	36	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	6	5	6	2	4	24	36	43	38	47						01,02							Vb 18	CASSSAAREQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCCCAGACCGGGACTAGCGAGCAGTACTTCGGGCCG	CASSQTGTSEQYF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	0	8	6	7	0	24	35	-1	42	50						01,02							Vb 18	CASSQTGTSEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCCAACAGGGCCCCGCAGATACGCAGTATTTTGGCCCA	CASSPQQGPADTQYF	In	VDJ	1	38	1.2503989759890492E-4	1.569521543748348E-4	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	3	3	4	3	5	24	38	47	41	52													Vb 18	CASSPQQGPADTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTTACCGGGAGCGGGGAGTGAGCAGTTCTTCGGGCCA	CASLPGAGSEQFF	In	VDJ	1	39	1.2833042121992871E-4	1.6108247422680412E-4	39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	6	3	9	3	2	24	38	48	41	50													Vb 18	CASLPGAGSEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCAGGGATGCGAACACTGAAGCTTTCTTTGGACAA	CASSPRDANTEAFF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	3	1	0	4	24	-1	43	38	47													Vb 18	CASSPRDANTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCGGTAAGAGGGAACACTGAAGCTTTCTTTGGACAA	CASSPPVRGNTEAFF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	45	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	0	11	1	1	5	0	24	41	-1	46	50													Vb 18	CASSPPVRGNTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTTTGTCGGGGGACCCCCTCCACTTTGGGAAC	CASSPLSGDPLHF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	3	8	2	13	5	2	24	38	49	43	51													Vb 18	CASSPLSGDPLHF+TCRBV18-01+TCRBJ01-06	TCRBV18-01*01	TCRBD02-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAGGCGTGGATTATGGCTACACCTTCGGTTCG	CASSPGVDYGYTF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	39	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-02	01	2	1	8	5	5	1	24	39	47	44	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPGVDYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACAGGGGGGGCCAGATACGCAGTATTTTGGCCCA	CASSPQGGPDTQYF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	42	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	9	0	4	1	1	24	40	48	41	49													Vb 18	CASSPQGGPDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGGCGGACAGGGGCCAGGGACTGAAGCTTTCTTTGGACAA	CASSGGQGPGTEAFF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	1	2	5	3	6	24	36	48	39	54													Vb 18	CASSGGQGPGTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCTCCGTTAGGACAGGATTAGATCGAGAGACCCAGTACTTCGGGCCA	CASSPSVRTGLDRETQYF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	54	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	1	4	4	8	9	24	38	53	46	62													Vb 18	CASSPSVRTGLDRETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCGCCGGGAGGGGCCAACGTCCTGACTTTCGGGGCC	CASSPGGANVLTF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	6	8	3	4	2	0	24	35	-1	37	42													Vb 18	CASSPGGANVLTF+TCRBV18-01+TCRBJ02-06	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAACAACGGGAGGGAATCCCTACGAGCAGTACTTCGGGCCG	CASSTTGGNPYEQYF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	45	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	8	0	2	4	4	24	36	48	40	52													Vb 18	CASSTTGGNPYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGGCCGGGACCTCCTACGAGCAGTACTTCGGGCCG	CASSPAGTSYEQYF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	42	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-07	01	3	0	7	0	4	0	24	38	-1	42	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPAGTSYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCGACTAGCGGGGGCTCCAATGAGCAGTTCTTCGGGCCA	CASSTSGGSNEQFF	In	VDJ	1	52	1.711072282932383E-4	2.147766323024055E-4	42	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	2	2	6	0	3	24	-1	47	35	50													Vb 18	CASSTSGGSNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGGGACCCCCGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	53	1.7439775191426213E-4		41	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-03	01	3	0	7	4	0	4	24	-1	43	38	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	X+TCRBV18-01+TCRBJ01-03	TCRBV18-01*01		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACGGGCCCCCCGGACAGGGGTCACAGATACGCAGTATTTTGGCCCA	CASSRAPRTGVTDTQYF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	51	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	1	2	2	9	1	24	37	55	46	56													Vb 18	CASSRAPRTGVTDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACTTAACCGGGACACGACTTTCTTTGGACAA	CASSLNRDTTFF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	36	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	0	6	12	6	3	24	37	49	43	52													Vb 18	CASSLNRDTTFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTCCAGGCGCGGGGGCTTTCTTTGGACAA	CASSPPGAGAFF	In	VDJ	1	64	2.1059351174552407E-4	2.643404705260375E-4	36	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	3	7	3	11	7	0	24	38	-1	45	51													Vb 18	CASSPPGAGAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCCACTAGCGGGGGGGCGCTTTCGGGGCAGTTCTTCGGGCCA	CASSPPTSGGALSGQFF	In	VDJ	1	70	2.3033665347166695E-4	2.8912238963785356E-4	51	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	3	0	12	1	10	24	41	55	42	65													Vb 18	CASSPPTSGGALSGQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACGGCCGAATCCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSPRPNPNTGELFF	In	VDJ	1	71	2.3362717709269075E-4	2.932527094898229E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	1	9	0	0	0	6	24	-1	43	40	49													Vb 18	CASSPRPNPNTGELFF+TCRBV18-01+TCRBJ02-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGACGGCCCTTGAAAAACTGTTTTTTGGCAGT	CASSPTALEKLFF	In	VDJ	1	72	2.3691770071371457E-4	2.973830293417922E-4	39	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-04	01	3	2	7	7	0	6	24	-1	41	38	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPTALEKLFF+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCCCCAGATCGTCACGAAGCTTTCTTTGGACAA	CASSPDRHEAFF	In	VDJ	1	72	2.3691770071371457E-4	2.973830293417922E-4	36	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-01	01	2	2	8	8	0	7	24	-1	41	39	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPDRHEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCGACAGGGGGCCCCACTGAAGCTTTCTTTGGACAA	CASSPPTGGPTEAFF	In	VDJ	1	74	2.434987479557622E-4	3.056436690457309E-4	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	2	0	4	0	2	24	-1	51	41	53													Vb 18	CASSPPTGGPTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCATCCAGGGCCTGGCAAGAGACCTAGTACTTCGGGCCA	CASSSRAWQET*YF	Stop	VDJ	1	75	2.46789271576786E-4		42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	4	3	12	2	15	24	36	43	38	58													Vb 18	CASSSRAWQET*YF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAATGGAGACGGATGGCTACACCTTCGGTTCG	CASSPMETDGYTF	In	VDJ	1	77	2.5337031881883363E-4	3.180346286016389E-4	39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	2	10	2	6	2	4	24	39	45	41	49													Vb 18	CASSPMETDGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGGGACAGGACTATGGCTACACCTTCGGTTCG	CASSPGQDYGYTF	In	VDJ	1	78	2.5666084243985743E-4	3.2216494845360824E-4	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	0	4	3	0	0	24	-1	-1	38	46													Vb 18	CASSPGQDYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACGCTGGACGGTTCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	81	2.6653241330292887E-4		46	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-03	01	1	1	7	2	3	4	24	40	47	43	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	X+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCCGCCGGGACTAGCCAATCCGAGCAGTACTTCGGGCCG	CASSAGTSQSEQYF	In	VDJ	1	86	2.8298503140804796E-4	3.552075072693629E-4	42	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	0	7	6	4	5	24	35	48	39	53						01,02							Vb 18	CASSAGTSQSEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCCCAATTAAAAGACGAARCTTTCTTTGGACAA	CASSPPQLKDEXFF	In	VDJ	1	87	2.8627555502907175E-4	3.593378271213323E-4	42	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-01	01	0	2	7	12	10	4	24	41	54	51	58				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPPQLKDEXFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACTTCAGATTTCTCAAGAGACCCAGTACTTCGGGCCA	CASSLQISQETQYF	In	VDJ	1	92	3.0272817313419084E-4	3.7998942638117896E-4	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	4	5	2	2	6	24	37	42	39	48													Vb 18	CASSLQISQETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAAAGGGGCGGCCGGGAGTGACTGAAGCTTTCTTTGGACAA	CASSPKGRPGVTEAFF	In	VDJ	1	100	3.2905236210238137E-4	4.1303198519693365E-4	48	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	2	8	2	5	10	2	24	39	55	49	57													Vb 18	CASSPKGRPGVTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGTATCTACAGGAGGCACTGAAGCTTTCTTTGGACAA	CASSVSTGGTEAFF	In	VDJ	1	100	3.2905236210238137E-4	4.1303198519693365E-4	42	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-01	01	5	3	4	4	6	3	24	36	47	42	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSVSTGGTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGTTCACCTAAACGCGCTAAGGGACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	102	3.3563340934442896E-4		47	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-07	01	3	0	8	2	12	0	24	38	-1	50	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	X+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTCCCCAGGGGGCGCATGGCTACACCTTCGGTTCG	CASSPPQGAHGYTF	In	VDJ	1	103	3.389239329654528E-4	4.2542294475284167E-4	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	4	0	6	4	2	24	38	50	42	52													Vb 18	CASSPPQGAHGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAGGACAGGGGAGTTTCGTAGAGACCCAGTACTTCGGGCCA	CASSPGQGSFVETQYF	In	VDJ	1	104	3.422144565864766E-4	4.29553264604811E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	1	2	4	0	8	24	-1	48	39	56													Vb 18	CASSPGQGSFVETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGCCCGCAGCTGAAGCTTTCTTTGGACAA	CASSPPAAEAFF	In	VDJ	1	104	3.422144565864766E-4	4.29553264604811E-4	36	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	5	6	5	0	24	38	-1	43	46													Vb 18	CASSPPAAEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTCGGACTAGCGGGAGCCATGAGCAGTTCTTCGGGCCA	CASSPRTSGSHEQFF	In	VDJ	1	107	3.5208602744954805E-4	4.41944224160719E-4	45	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	1	2	8	2	2	24	38	53	40	55													Vb 18	CASSPRTSGSHEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACTTTCCAGGACAGGGGGCTCCTATGGCTACACCTTCGGTTCG	CASSLSRTGGSYGYTF	In	VDJ	2	109	3.586670746915957E-4	4.502048638646577E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	1	0	4	6	2	24	37	54	43	56													Vb 18	CASSLSRTGGSYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCATTGGACGATTCACCCCTCCACTTTGGGAAC	CASSPLDDSPLHF	In	VDJ	2	125	4.113154526279767E-4	5.162899814961671E-4	39	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-06	01	2	1	7	8	2	1	24	39	45	41	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPLDDSPLHF+TCRBV18-01+TCRBJ01-06	TCRBV18-01*01		TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTGATACCGGGGAGCTGTTTTTTGGAGAA	CASSPDTGELFF	In	VDJ	2	130	4.2776807073309573E-4	5.369415807560138E-4	36	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-02	01	3	2	8	5	1	1	24	38	41	39	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPDTGELFF+TCRBV18-01+TCRBJ02-02	TCRBV18-01*01		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCGCGCAGGGAGGGCCCAACAATGAGCAGTTCTTCGGGCCA	CASAQGGPNNEQFF	In	VDJ	2	132	4.343491179751434E-4	5.452022204599524E-4	42	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	8	9	0	5	5	4	24	33	45	38	49													Vb 18	CASAQGGPNNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCGGGTGGCCGGGCTTCTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	2	132	4.343491179751434E-4		53	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-03	01	0	8	0	0	8	2	24	41	53	49	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	X+TCRBV18-01+TCRBJ01-03	TCRBV18-01*01		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCCCGGGAGCTATCGTGGGAGCAGTACTTCGGGCCG	CASSRELSWEQYF	In	VDJ	2	135	4.442206888382148E-4	5.575931800158604E-4	39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	8	2	7	1	9	24	35	42	36	51													Vb 18	CASSRELSWEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCGGGGACCGGGACACCGGCTAACTATGGCTACACCTTCGGTTCG	CASSGTGTPANYGYTF	In	VDJ	2	138	4.5409225970128626E-4	5.699841395717685E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	6	0	7	4	24	35	48	42	52													Vb 18	CASSGTGTPANYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAAGGGACAGTGCTGAGACCCAGTACTTCGGGCCA	CASSPRDSAETQYF	In	VDJ	2	141	4.639638305643577E-4	5.823750991276764E-4	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	0	5	5	1	4	24	39	47	40	51													Vb 18	CASSPRDSAETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCCGGACAGGGGCCGCCTACGAGCAGTACTTCGGGCCG	CASSPRTGAAYEQYF	In	VDJ	2	141	4.639638305643577E-4	5.823750991276764E-4	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	1	2	2	2	3	24	38	49	40	52													Vb 18	CASSPRTGAAYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACGGGAGGCGGGCGAGCAGTACTTCGGGCCG	CASSREAGEQYF	In	VDJ	2	142	4.672543541853815E-4	5.865054189796458E-4	36	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	9	1	6	0	4	24	-1	43	37	47													Vb 18	CASSREAGEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACGGGGCGTTGTCACAGATACGCAGTATTTTGGCCCA	CASSPRGVVTDTQYF	In	VDJ	2	154	5.067406376376673E-4	6.360692572032778E-4	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	1	7	0	2	0	5	24	-1	45	40	50													Vb 18	CASSPRGVVTDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAGGGTCCCTTTATGGCTACACCTTCGGTTCG	CASSPGSLYGYTF	In	VDJ	2	163	5.363553502268816E-4	6.732421358710018E-4	39	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-02	01	2	0	9	5	0	6	24	-1	42	39	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPGSLYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACAGAGGAACTATGGCTACACCTTCGGTTCG	CASSQRNYGYTF	In	VDJ	3	180	5.922942517842864E-4	7.434575733544805E-4	36	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	4	11	1	2	1	0	24	37	-1	38	42													Vb 18	CASSQRNYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCTGACACGGCCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	3	181	5.955847754053103E-4		38	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	2	6	1	1	3	24	35	40	36	43													Vb 18	X+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGGGGACTGATGAAAAACTGTTTTTTGGCAGT	CASSPGTDEKLFF	In	VDJ	3	197	6.482331533416912E-4	8.136730108379593E-4	39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	3	0	10	6	1	1	24	38	45	39	46						01,02							Vb 18	CASSPGTDEKLFF+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01	TCRBD02-01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACAGGCAGACGGAAATCAGCCCCAGCATTTTGGTGAT	CASSPQADGNQPQHF	In	VDJ	3	199	6.548142005837388E-4	8.21933650541898E-4	45	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-05	01	1	1	8	4	8	0	24	40	-1	48	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPQADGNQPQHF+TCRBV18-01+TCRBJ01-05	TCRBV18-01*01		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGAAGGCTCGCTGGGCGTGAACACTGAAGCTTTCTTTGGACAA	CASSEGSLGVNTEAFF	In	VDJ	3	234	7.699825273195723E-4	9.664948453608248E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	8	0	0	11	1	24	36	51	47	52													Vb 18	CASSEGSLGVNTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCCCGGGGACACCCTACGAGCAGTACTTCGGGCCG	CASSPPGTPYEQYF	In	VDJ	3	241	7.93016192666739E-4	9.9540708432461E-4	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	6	2	4	1	24	38	48	42	49													Vb 18	CASSPPGTPYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGCAAGGGGGCCCAGATACGCAGTATTTTGGCCCA	CASSPQGGPDTQYF	In	VDJ	4	290	9.542518500969059E-4	0.0011977927570711077	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	5	0	4	3	1	24	38	48	41	49													Vb 18	CASSPQGGPDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCAATGCCACAGTCCCGGGGAAACAATGAGCAGTTCTTCGGGCCA	CASSPPMPQSRGNNEQFF	In	VDJ	4	317	0.0010430959878645488	0.0013093113930742796	54	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	8	3	5	13	2	24	41	59	54	61													Vb 18	CASSPPMPQSRGNNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCCCCGGGGGGGACTAGAAGTTACGAGCAGTACTTCGGGCCG	CASSPGGTRSYEQYF	In	VDJ	4	322	0.0010595486059696679	0.0013299629923341264	45	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	0	8	4	7	4	24	35	50	42	54						01,02							Vb 18	CASSPGGTRSYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCATCGGGACAGGGGGTTGCGGAGACCCAGTACTTCGGGCCA	CASSSGQGVAETQYF	In	VDJ	5	349	0.001148392743737311	0.0014414816283372985	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	0	1	5	2	5	24	36	49	38	54													Vb 18	CASSSGQGVAETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCTTGGGGGATGGGACAGATACGCAGTATTTTGGCCCA	CASSPLGDGTDTQYF	In	VDJ	5	367	0.0012076221689157395	0.0015158273856727465	45	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-03	01	3	6	1	3	3	5	24	38	46	41	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPLGDGTDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGACGACAGGGGGCGAGCAGTACTTCGGGCCG	CASSPTTGGEQYF	In	VDJ	5	378	0.0012438179287470015	0.0015612609040444093	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	2	1	6	3	0	24	38	-1	41	50													Vb 18	CASSPTTGGEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCGGGCCGGGCCGGAACTGAAGCTTTCTTTGGACAA	CASSPPGRAGTEAFF	In	VDJ	6	428	0.0014083441097981922	0.001767776896642876	45	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-01	01	0	8	0	5	0	9	24	-1	45	41	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPPGRAGTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTTGCTATCCGGGACTAGTGGAAATGAGCAGTTCTTCGGGCCA	CASLLSGTSGNEQFF	In	VDJ	6	440	0.001447830393250478	0.0018173407348665081	45	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	7	0	8	7	8	4	24	34	50	42	54						01,02							Vb 18	CASLLSGTSGNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACGGACAGGGGGCCCAGATACGCAGTATTTTGGCCCA	CASSRTGGPDTQYF	In	VDJ	6	442	0.0014544114404925256	0.0018256013745704468	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	1	0	4	0	1	24	-1	48	37	49													Vb 18	CASSRTGGPDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACTGGGCGGACAGGGGATGCTGCCCCAGCATTTTGGTGAT	CASSPLGGQGMLPQHF	In	VDJ	6	444	0.0014609924877345731	0.0018338620142743854	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	1	1	2	9	5	5	24	40	54	45	59													Vb 18	CASSPLGGQGMLPQHF+TCRBV18-01+TCRBJ01-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCATCCCGGGACTAGCGGGGCAAGTACCTTATACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	28	1998	0.00657446619480558		58	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	0	3	4	4	11	23	35	52	39	63													Vb 18	X+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCCCGCAGGGACATCCATTCTTTGGACAA	CASSPQGHPFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	33	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	0	6	14	6	4	26	37	49	43	53		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSPQGHPFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ACGTTTGGTGCATCCTGAAGACAGCAGTTCTACATCTGCAGTGCTAGGGGGTTGGCGGGAGGGAGCGAGACCCAGTACTTCGGGCCA	CSARGLAGGSETQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	3	7	0	5	7	3	36	47	63	54	66		TCRBV20-01,TCRBV20-or09_02												CSARGLAGGSETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAACAGGGGGCTGGGGATCAGCCCCAGCATTTTGGTGAT	CASSQQGAGDQPQHF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	45	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	4	0	5	0	5	26	-1	49	41	54		TCRBV03-01,TCRBV03-02												CASSQQGAGDQPQHF+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGCAGGGACACTGAAGCTTTCTTTGGACAA	CASSQGRDTEAFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	4	3	3	1	0	26	42	-1	43	48		TCRBV03-01,TCRBV03-02												CASSQGRDTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCCGACTAGCGGGGGAGCTGTACCAAGAGACCCAGTACTTCGGGCCA	CSATRLAGELYQETQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	51	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	4	2	2	0	3	6	26	36	51	39	57		TCRBV20-01,TCRBV20-or09_02												CSATRLAGELYQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCCTGGGAAGGGCGAGACCCAGTACTTCGGGCCA	CSASPGKGETQYF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	39	TCRBV20						TCRBJ02	TCRBJ02-05	01	3	0	8	5	4	5	26	37	45	41	50		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSASPGKGETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTGAAGATAGCGGGGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSEDSGGTGELFF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	45	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	4	5	2	4	3	0	24	38	-1	41	50		TCRBV24-01,TCRBV24-or09_02												CASSEDSGGTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTCGGCCGTGTATSTCTGTGCCAGCAGCCCTCCGGGTGGCAGGGCGGTAACTAGCGGGGGGGCTTCGCGGAGCAGTTCTTCGGGCCA		Out	VDJ	1	20	6.581047242047627E-5		65				TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	3	0	10	21	7	16	28	62	49	69	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-02,TCRBV11-03												X+X+TCRBJ02-01		TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATSTCTGTGCCAGCAGCTATCAGGGGGCCCGGCAGCCCCAGCATTTTGGTGAT	CASSYQGARQPQHF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	4	0	7	2	4	18	31	41	33	45	TCRBV07,TCRBV11													CASSYQGARQPQHF+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTGGCAAGCCACGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCAGCAGTTTACAAAAGGACTATGGCTACACCTTCGGTTCG	CASSLQKDYGYTF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	39							TCRBJ01	TCRBJ01-02	01	2	5	4	3	4	0	42	57	-1	61	64	TCRBV27,TCRBV28	TCRBV27-01,TCRBV28-01		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLQKDYGYTF+X+TCRBJ01-02			TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCMTSTATCTCTGTGCCAGCAGCCAAGATCCTAGCGGCTATGGCTACACCTTCGGTTCG	CASSQDPSGYGYTF	In	VDJ	1	20	6.581047242047627E-5	8.260639703938673E-5	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	4	4	5	4	7	0	19	31	-1	38	45	TCRBV05,TCRBV11					01,02								CASSQDPSGYGYTF+X+TCRBJ01-02	unresolved	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCGTCGGTCCCTCGACTGCGGGCGTTTATGGCTACACCTTCGGTTCG	CASSVGPSTAGVYGYTF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	51	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	6	7	4	5	16	4	26	37	58	53	62		TCRBV12-03,TCRBV12-04,TCRBV12-05				01,02								CASSVGPSTAGVYGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAAAAATAAGGGGCAGGGGTATGGCTACACCTTCGGTTCG		Out	VDJ	1	21	6.910099604150008E-5		47	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	4	2	5	11	0	26	41	-1	52	58		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAAAAGGCGGGAGGGCCGTTTTGTTGTGAGCAGTTCTTCGGGCCA	CASSQEKAGGPFCCEQFF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	54	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	7	0	9	4	11	26	43	56	47	67		TCRBV03-01,TCRBV03-02												CASSQEKAGGPFCCEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATACCCGGGAGTGGCCGGAGACCCAGTACTTCGGGCCA	CSARDTREWPETQYF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	0	8	2	5	4	6	26	40	50	44	56		TCRBV20-01,TCRBV20-or09_02												CSARDTREWPETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCCCAATGGAACACTGAAGCTTTCTTTGGACAA	CSAPQWNTEAFF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	6	1	3	3	26	35	40	38	43		TCRBV20-01,TCRBV20-or09_02												CSAPQWNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGCCCCTATAGTGACAGCTTAGGGAACACTGAAGCTTTCTTTGGACAA	CASSPYSDSLGNTEAFF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	51	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	2	5	1	10	6	22	33	48	43	54		TCRBV12-03,TCRBV12-04												CASSPYSDSLGNTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTGCGGGGGCGGCCGGGGAGCTGTTTTTTGGAGAA	CASSAGAAGELFF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	39	unresolved			unresolved			TCRBJ02	TCRBJ02-02	01	5	7	2	6	0	3	22	-1	41	34	44	TCRBV02,TCRBV12			TCRBD01,TCRBD02										CASSAGAAGELFF+X+TCRBJ02-02	unresolved	unresolved	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTTTATCAGGGTATGATGAGCAGTACTTCGGGCCG	CASSLSGYDEQYF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	4	3	7	1	6	22	37	43	38	49		TCRBV12-03,TCRBV12-04												CASSLSGYDEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCACCAGTGATACAGGACAGGGGCAAAATGAAAAACTGTTTTTTGGCAGT	CATSDTGQGQNEKLFF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	1	2	5	6	3	23	35	50	41	53	TCRBV24,TCRBV27													CATSDTGQGQNEKLFF+X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCCGAGCCTCCGGGACAGTGTATGGCTACACCTTCGGTTCG	CASRASGTVYGYTF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	11	0	5	5	11	2	24	31	49	42	51		TCRBV24-01,TCRBV24-or09_02												CASRASGTVYGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCWMCCAGACMTCTSTGTACTTSTGTGCCAGCAGTTTATAAGGCTATGGCTACACCTTCGGTTCG	CASSL*GYGYTF	Stop	VDJ	1	21	6.910099604150008E-5		36	unresolved						TCRBJ01	TCRBJ01-02	01	4	5	4	4	4	0	23	36	-1	40	43	TCRBV06,TCRBV27			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSL*GYGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCMTSTATCKCTGTGCCAGCAGCTCCGGTGATTCAGTTGAAAAACTGTTTTTTGGCAGT	CASSSGDSVEKLFF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	42	unresolved						TCRBJ01	TCRBJ01-04	01	4	4	5	7	9	1	18	31	43	40	44	TCRBV05,TCRBV07			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSGDSVEKLFF+X+TCRBJ01-04	unresolved		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTTGGCGGGACAGGGGGCGAAAAACTGTTTTTTGGCAGT	CASSFGGTGGEKLFF	In	VDJ	1	21	6.910099604150008E-5	8.673671689135607E-5	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	0	0	8	4	0	18	32	-1	36	48	TCRBV05,TCRBV11													CASSFGGTGGEKLFF+X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGCCACGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCAGCAGTTTAGGCGGGAGGGTATACAATGAGCAGTTCTTCGGGCCA	CASSLGGRVYNEQFF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	45				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	7	0	4	1	2	36	51	61	52	63	TCRBV27,TCRBV28	TCRBV27-01,TCRBV28-01												CASSLGGRVYNEQFF+X+TCRBJ02-01		TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCATGCCGGGTCGTGAAGCTTTCTTTGGACAA	CASSMPGREAFF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	36	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	5	8	4	7	4	3	26	38	46	42	49		TCRBV03-01,TCRBV03-02				01,02								CASSMPGREAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCAACCACCGGGTCCGGGCTACACCTTCGGTTCG	CSAQPPGPGYTF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	36	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	6	8	4	8	8	4	26	34	46	42	50		TCRBV20-01,TCRBV20-or09_02				01,02								CSAQPPGPGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTAACAGGGTATACTGAAGCTTTCTTTGGACAA	CSARVTGYTEAFF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	3	3	5	2	3	26	39	47	41	50		TCRBV20-01,TCRBV20-or09_02												CSARVTGYTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGATCTCTAGCGACCACAGATACGCAGTATTTTGGCCCA	CSAGSLATTDTQYF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	4	6	2	6	2	26	35	47	41	49		TCRBV20-01,TCRBV20-or09_02				01,02								CSAGSLATTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCMRGRGACWCAGCWSKGTAYTTCTGTGCCAGCACCTCCTTTGGGGGAATCACTGAAGCTTTCTTTGGACAA	CASTSFGGITEAFF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	42	unresolved						TCRBJ01	TCRBJ01-01	01	7	6	1	4	8	3	22	32	45	40	48	TCRBV12,TCRBV21			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTSFGGITEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCACTCCTAGCGGGGTATACAATGAGCAGTTCTTCGGGCCA	CASTPSGVYNEQFF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	42	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	7	4	3	4	3	2	22	32	44	35	46		TCRBV12-03,TCRBV12-04												CASTPSGVYNEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTCCCGCGTGGGGGGGAACAGATACGCAGTATTTTGGCCCA	CASSPAWGGTDTQYF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	45	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	9	0	3	7	1	22	34	48	41	49		TCRBV12-03,TCRBV12-04												CASSPAWGGTDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTCTAGCGGGGGGCAAGAGACCCAGTACTTCGGGCCA	CASSSSGGQETQYF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	3	4	1	2	0	0	19	-1	-1	32	43	TCRBV07,TCRBV11													CASSSSGGQETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGTGGGAGGTCCCTACGAGCAGTACTTCGGGCCG	CASSLAVGGPYEQYF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	45				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	9	1	2	3	2	18	35	44	38	46	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAVGGPYEQYF+X+TCRBJ02-07		TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTAGTTTTTGGGATGAACACTGAAGCTTTCTTTGGACAA	CASSLVFGMNTEAFF	In	VDJ	1	22	7.23915196625239E-5	9.08670367433254E-5	45	unresolved						TCRBJ01	TCRBJ01-01	01	1	0	8	0	5	0	18	34	-1	39	43	TCRBV05,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLVFGMNTEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTGAAGGGGGAACAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	22	7.23915196625239E-5		40	unresolved			unresolved			TCRBJ02	TCRBJ02-05	01	5	5	1	2	3	2	23	34	43	37	45	TCRBV02,TCRBV09			TCRBD01,TCRBD02										X+X+TCRBJ02-05	unresolved	unresolved	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
YRGKGACTCWGCTGTGTATTTYTGTGCCAGCAGCCAAGATGCGTAACGCAGCAGGAACAGGTGGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	22	7.23915196625239E-5		59	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	0	3	4	4	17	2	22	39	61	56	63		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-03	TCRBV03	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCGTAGGGACAGTTAACTCCTACGAGCAGTACTTCGGGCCG	CASSVGTVNSYEQYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	45	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	5	0	4	4	26	37	48	41	52		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSVGTVNSYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACYSRRGGACTCAGCYRTGTAYTTYTGTGCCAGCAGTTTGGCCCTAGATGAGCAGTTCTTCGGGCCA	CASSLALDEQFF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	36	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	4	8	8	4	0	26	40	-1	44	48	TCRBV02,TCRBV12					01,02								CASSLALDEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCGACAGAGCATGAACACTGAAGCTTTCTTTGGACAA	CASSRQSMNTEAFF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	2	5	0	0	4	23	-1	41	36	45	TCRBV01,TCRBV04													CASSRQSMNTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAGGCTGGGCAGCCCCAGCATTTTGGTGAT	CASSQEAGQPQHF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	39	TCRBV03						TCRBJ01	TCRBJ01-05	01	0	0	9	7	4	0	26	43	-1	47	50		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQEAGQPQHF+TCRBV03-X+TCRBJ01-05	TCRBV03		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAGGGGTTAGCGGGAGCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	23	7.568204328354771E-5		50	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	5	2	0	5	0	26	43	-1	48	57		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTTTCGGTGGTACGAGCAGTACTTCGGGCCG	CASSFRWYEQYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	36	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	8	5	4	3	3	26	38	44	41	47		TCRBV03-01,TCRBV03-02				01,02								CASSFRWYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCAGACACTAGCGGGAGGACCTACAATGAGCAGTTCTTCGGGCCA	CSADTSGRTYNEQFF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	3	1	2	4	1	26	34	50	38	51		TCRBV20-01,TCRBV20-or09_02												CSADTSGRTYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCCTCCGCGGGGCAGAACTCTGGAAACACCATATATTTTGGAGAG	CSAPSAGQNSGNTIYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	48	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-03	01	6	7	3	0	7	5	26	34	47	41	52		TCRBV20-01,TCRBV20-or09_02												CSAPSAGQNSGNTIYF+TCRBV20-X+TCRBJ01-03	TCRBV20	TCRBD02-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGTCCGGGACATAACGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	23	7.568204328354771E-5		41	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	0	6	1	4	4	26	34	44	38	48		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACAAACCCACTCCCCAGGAACACTGAAGCTTTCTTTGGACAA	CSATNPLPRNTEAFF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	45	TCRBV20						TCRBJ01	TCRBJ01-01	01	4	4	5	1	13	0	26	36	-1	49	52		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSATNPLPRNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCGGGACGTCGGCGGGTCTGGAAACACCATATATTTTGGAGAG	CSARDVGGSGNTIYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	45	TCRBV20						TCRBJ01	TCRBJ01-03	01	5	0	7	1	1	9	26	35	41	36	50		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDVGGSGNTIYF+TCRBV20-X+TCRBJ01-03	TCRBV20		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCTCGGGAGCTCCTATAATTCACCCCTCCACTTTGGGAAC	CSALGSSYNSPLHF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	5	8	2	0	2	0	26	35	-1	37	43		TCRBV20-01,TCRBV20-or09_02												CSALGSSYNSPLHF+TCRBV20-X+TCRBJ01-06	TCRBV20	TCRBD02-01*02	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGGCCCAGGACAGGGAGGGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	23	7.568204328354771E-5		43	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	7	1	3	2	5	3	26	33	46	38	49		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CYMCCWSYCARACWKCTKTKTACTTCTGTGCCAGCAGACGAGGGACGGATGGCTACACCTTCGGTTCG	CASRRGTDGYTF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	36	unresolved						TCRBJ01	TCRBJ01-02	01	13	0	7	6	12	2	25	28	45	40	47	TCRBV06,TCRBV22			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRRGTDGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTGGACCCGAACAGGGGGTTAACTATGGCTACACCTTCGGTTCG	CASSGPEQGVNYGYTF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	48	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	3	1	1	8	1	22	34	50	42	51		TCRBV12-03,TCRBV12-04												CASSGPEQGVNYGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTCCTAGCGGGGGTCGAGACCCAGTACTTCGGGCCA	CASSFLAGVETQYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	42	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	6	4	2	5	3	2	24	36	49	39	51		TCRBV24-01,TCRBV24-or09_02												CASSFLAGVETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGCGTGGACCAAAAGAGACCCAGTACTTCGGGCCA	CASSLARGPKETQYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	45							TCRBJ02	TCRBJ02-05	01	0	1	7	3	4	3	18	35	43	39	46	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLARGPKETQYF+X+TCRBJ02-05			TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCTTATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSLAYSNQPQHF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	42				TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	0	5	9	0	1	0	18	35	-1	36	38	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03				01,02								CASSLAYSNQPQHF+X+TCRBJ01-05		TCRBD02-01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGRAGACWCRGCMCTGTATCTCTGCGCCAGCAGCCAAGTATTGGGCGGGGATGAGCAGTTCTTCGGGCCA	CASSQVLGGDEQFF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	7	3	8	7	0	20	35	-1	42	48	TCRBV04,TCRBV23													CASSQVLGGDEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCGTCGGACTTACACACGAGCAGTACTTCGGGCCG	CASSVGLTHEQYF	In	VDJ	1	23	7.568204328354771E-5	9.499735659529474E-5	39	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	1	10	5	1	5	23	37	43	38	48	TCRBV09,TCRBV12					01,02								CASSVGLTHEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGACGGAGCGGGGTACGGAACAGATACGCAGTATTTTGGCCCA	CASSQDGAGYGTDTQYF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	51	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	6	3	3	3	6	23	40	50	43	56	TCRBV01,TCRBV04													CASSQDGAGYGTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCAGCACGGGACAGGGGTCATACGAGCAGTACTTCGGGCCG	CASTGQGSYEQYF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	39				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	0	2	4	1	3	24	34	45	35	48	TCRBV06,TCRBV10	TCRBV06-01,TCRBV06-05,TCRBV06-06,TCRBV10-03												CASTGQGSYEQYF+X+TCRBJ02-07		TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGAAGAGGGGTAGGGTTGTACTTCGGGCCG	CASSQGRGVGLYF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	39	TCRBV03						TCRBJ02	TCRBJ02-07	01	1	5	2	12	4	7	26	42	51	46	58		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQGRGVGLYF+TCRBV03-X+TCRBJ02-07	TCRBV03		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTAAAGAAATACAGGGAAGGGGTGAGGGAGCAGTACTTCGGGCCG	CASSLKKYREGVREQYF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	51	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	3	3	7	9	11	26	39	54	48	65		TCRBV03-01,TCRBV03-02												CASSLKKYREGVREQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCAGAGGGGACTAAGCGTGGAGGGCACAGATACGCAGTATTTTGGCCCA	CSAQRGLSVEGTDTQYF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	51	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	0	9	1	6	10	26	34	47	40	57		TCRBV20-01,TCRBV20-or09_02				01,02								CSAQRGLSVEGTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCCTAGCGGGAGGACCTCCTACGAGCAGTACTTCGGGCCG	CSARDPSGRTSYEQYF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	48	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	4	1	0	2	2	26	40	53	42	55		TCRBV20-01,TCRBV20-or09_02												CSARDPSGRTSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGCTCCGGGGCGAGGTAATTCACCCCTCCACTTTGGGAAC	CSARAPGRGNSPLHF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	45	TCRBV20						TCRBJ01	TCRBJ01-06	01	1	7	0	6	4	4	26	39	48	43	52		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARAPGRGNSPLHF+TCRBV20-X+TCRBJ01-06	TCRBV20		TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTTTTATGGCTAGCGGGGGCAATGAGCAGTTCTTCGGGCCA	CASSFMASGGNEQFF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	45	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	4	2	6	5	0	22	36	-1	41	51		TCRBV12-03,TCRBV12-04												CASSFMASGGNEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGACACCGACAGGGGGCGCTTGGAAAACTGTTTTTTGGCAGT	CATRHRQGALGKLFF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	7	2	0	10	5	6	24	35	50	40	56		TCRBV24-01,TCRBV24-or09_02												CATRHRQGALGKLFF+TCRBV24-X+TCRBJ01-04	TCRBV24	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGCTGAGACGGTCTCTAATCTCTGGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	24	7.897256690457152E-5		53	TCRBV24						TCRBJ02	TCRBJ02-06	01	7	2	7	0	4	10	24	35	42	39	52		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ02-06	TCRBV24		TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAGGGACTAGCGGGTACCTACAATGAGCAGTTCTTCGGGCCA	CATSEGLAGTYNEQFF	In	VDJ	1	24	7.897256690457152E-5	9.912767644726408E-5	48	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	0	4	2	0	2	24	-1	50	38	52		TCRBV24-01,TCRBV24-or09_02				01,02								CATSEGLAGTYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTGTTCGGGGGTGGCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	24	7.897256690457152E-5		41	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	6	8	2	7	5	3	24	36	47	41	50		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD02-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTCCGCCCTCTCCCCGATAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	24	7.897256690457152E-5		46	unresolved						TCRBJ02	TCRBJ02-05	01	3	2	8	4	13	1	18	32	47	45	48	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ02-05	unresolved		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAACCCGGTACCGGCTATGGCTACACCTTCGGTTCG	CASSQPGTGYGYTF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	2	8	5	4	2	6	26	41	46	43	52		TCRBV03-01,TCRBV03-02				01,02								CASSQPGTGYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGCGGGGGGGCGGGTTGAGCAGTTCTTCGGGCCA	CASSQAGGRVEQFF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	1	8	0	9	0	5	26	-1	50	42	55		TCRBV03-01,TCRBV03-02												CASSQAGGRVEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCATAACCTCGGCGGGATTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSHNLGGISNQPQHF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	51	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	3	7	3	0	8	1	26	40	54	48	55		TCRBV03-01,TCRBV03-02												CASSHNLGGISNQPQHF+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD02-01*02	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCGAAGCTGGAAACACCATATATTTTGGAGAG	CASSEAGNTIYF	In	VJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	36	TCRBV03						TCRBJ01	TCRBJ01-03	01	1	0	0	2	0	0	26	-1	-1	-1	42		TCRBV03-01,TCRBV03-02												CASSEAGNTIYF+TCRBV03-X+TCRBJ01-03	TCRBV03		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCGCAGAGGGAAATCAGCCCCAGCATTTTGGTGAT	CASSAEGNQPQHF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	39	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	5	11	0	4	3	1	26	38	46	41	47		TCRBV03-01,TCRBV03-02												CASSAEGNQPQHF+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD02-01*02	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASGACTCSGCCSTGTATCTCTGTGCCAGCAGCCCCGGACTAGCGGGGGGAACCTACAATGAGCAGTTCTTCGGGCCA	CASSPGLAGGTYNEQFF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	51	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	1	1	2	3	2	20	32	49	35	51	TCRBV05,TCRBV07													CASSPGLAGGTYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAATCCAGCGGGAGGGAGACCCAGTACTTCGGGCCA	CSARESSGRETQYF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	0	6	1	5	4	0	26	40	-1	44	53		TCRBV20-01,TCRBV20-or09_02												CSARESSGRETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGCGCCCGGCCCGGGAGATACGCAGTATTTTGGCCCA	CSASAPGPGDTQYF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	8	4	5	11	0	26	37	-1	48	52		TCRBV20-01,TCRBV20-or09_02				01,02								CSASAPGPGDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGAGAGCCTGGGGGGGAAATATGGCTACACCTTCGGTTCG		Out	VDJ	1	25	8.226309052559534E-5		43	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	7	9	0	5	7	3	24	35	49	42	52		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCGCAGGGAAGGACTGAAGCTTTCTTTGGACAA	CASSSQGRTEAFF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	39	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	4	3	5	3	4	24	36	44	39	48		TCRBV24-01,TCRBV24-or09_02												CASSSQGRTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTTGGACTGGGGGTCCTATAATTCACCCCTCCACTTTGGGAAC	CASSLDWGSYNSPLHF	In	VDJ	1	25	8.226309052559534E-5	1.0325799629923341E-4	48							TCRBJ01	TCRBJ01-06	01	0	6	1	1	3	0	18	34	-1	37	42	TCRBV05,TCRBV07	TCRBV05-08,TCRBV07-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLDWGSYNSPLHF+X+TCRBJ01-06			TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGAAGCCCCGGGGGCTAAGACAGGGTGGTCTCCTATAATTCACCCCTCCACTTTGGGAAC	CARSPGG*DRVVSYNSPLHF	Stop	VDJ	1	25	8.226309052559534E-5		60				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	2	3	0	12	4	18	30	49	42	53	TCRBV05,TCRBV11	TCRBV05-03,TCRBV11-03												CARSPGG*DRVVSYNSPLHF+X+TCRBJ01-06		TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGACAGGCGGGGGGTCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	25	8.226309052559534E-5		44	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	0	7	1	6	3	0	18	35	-1	38	46	TCRBV07,TCRBV11													X+X+TCRBJ01-05	unresolved	TCRBD02-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTTGGTGCATCCTGAAGACAGCAGCTTTACATCTGCAGTGCTAGAGAACCGGGACTCCTTGCTAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	25	8.226309052559534E-5		47	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	21	0	10	0	23	5	34	27	56	50	61		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGGGGGGAAGTTTACGAGCAGTACTTCGGGCCG	CASRGEVYEQYF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	36	TCRBV12						TCRBJ02	TCRBJ02-07	01	6	6	1	4	0	5	26	-1	42	37	47		TCRBV12-03,TCRBV12-04,TCRBV12-05		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRGEVYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCACCGGAACAGGGGGAAATGGAGAGACCTAGTACTTCGGGCCA	CASSTGTGGNGET*YF	Stop	VDJ	1	26	8.555361414661915E-5		48	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	3	1	12	6	14	26	38	52	44	66		TCRBV03-01,TCRBV03-02												CASSTGTGGNGET*YF+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAACAAGCGACAGGGAACAATCAGCCCCAGCATTTTGGTGAT	CASSQQATGNNQPQHF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	48	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	2	3	3	5	2	26	41	53	46	55		TCRBV03-01,TCRBV03-02												CASSQQATGNNQPQHF+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGAGGGGACTAGCGGGAGTAGAGACCCAGTACTTCGGGCCA	CSARGLAGVETQYF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	6	0	2	4	3	1	26	34	51	37	52		TCRBV20-01,TCRBV20-or09_02												CSARGLAGVETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACGATTGTTGGCGGGGGGCGCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	26	8.555361414661915E-5		46	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	7	1	4	9	2	26	36	53	45	55		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAAATCTTAGGACAGGGTCGACCACCAGGGAGCTGTTTTTTGGAGAA	CSARNLRTGSTTRELFF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	51	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	2	1	3	9	7	10	26	38	53	45	63		TCRBV20-01,TCRBV20-or09_02												CSARNLRTGSTTRELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTTTAGATTTGGGGGGGGGCACAGATACGCAGTATTTTGGCCCA	CASSLDLGGGTDTQYF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	48	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	9	0	1	4	1	22	38	49	42	50		TCRBV12-03,TCRBV12-04												CASSLDLGGGTDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCGGGGGGACAGGGGAGGGCGTGACTGAAGCTTTCTTTGGACAA	CAGGTGEGVTEAFF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	42	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	11	0	2	5	3	8	22	28	41	31	49		TCRBV12-03,TCRBV12-04												CAGGTGEGVTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTAGAGGGACTCCACAAGAGACCCAGTACTTCGGGCCA	CASSRGTPQETQYF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	42	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	0	10	2	3	3	24	36	45	39	48		TCRBV24-01,TCRBV24-or09_02				01,02								CASSRGTPQETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCCGCGGGACAGGGGAGACTATGGCTACACCTTCGGTTCG	CASSPRDRGDYGYTF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	2	3	4	2	24	36	50	40	52		TCRBV24-01,TCRBV24-or09_02												CASSPRDRGDYGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGAAGTCGGGGGGTATGGGAACACTGAAGCTTTCTTTGGACAA	CASSQEVGGYGNTEAFF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	51				TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	0	8	1	1	3	5	18	35	45	38	50	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03												CASSQEVGGYGNTEAFF+X+TCRBJ01-01		TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTCRGCYSTSTATCTCTGTGCCAGCAGCGAAGGACAGGGAGGGAATGAAAAACTGTTTTTTGGCAGT	CASSEGQGGNEKLFF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	1	3	5	3	4	22	34	45	37	49	TCRBV05,TCRBV07													CASSEGQGGNEKLFF+X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTYGGCYGTGTATSTCTGTGCCAGCAGCCCCCCGGGGGACAGGAATTCACCCCTCCACTTTGGGAAC	CASSPPGDRNSPLHF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	5	0	4	7	7	0	22	34	-1	41	49	TCRBV07,TCRBV11													CASSPPGDRNSPLHF+X+TCRBJ01-06	unresolved	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTGGGAACAGGGGAGGTTACGATGAGCAGTTCTTCGGGCCA	CASSGNRGGYDEQFF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	3	2	8	3	8	23	36	46	39	54	TCRBV02,TCRBV12													CASSGNRGGYDEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCAGTGAAGGAGGGAGGGCAGATCAGCCTCAGCATTTTGGTGAT	CASSEGGRADQPQHF	In	VDJ	1	26	8.555361414661915E-5	1.0738831615120275E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	5	9	0	13	7	11	23	34	48	41	59	TCRBV09,TCRBV12													CASSEGGRADQPQHF+X+TCRBJ01-05	unresolved	TCRBD02-01*02	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCCTTAGGGGGGGAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	27	8.884413776764296E-5		44	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	4	9	0	5	6	0	26	39	-1	45	52		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-04	TCRBV03	TCRBD02-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTACTGAGCTCCCATTAAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	27	8.884413776764296E-5		46	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-04	01	5	3	10	4	1	12	26	38	42	39	54		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-04	TCRBV03	TCRBD02-01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAGGGAGAGCTAGCGGGAGGGCCCTCTGAGACCCAGTACTTCGGGCCA	CSAREGELAGGPSETQYF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	54	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	0	4	0	5	7	6	26	40	59	47	65		TCRBV20-01,TCRBV20-or09_02												CSAREGELAGGPSETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCCTTAGGGGAGCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	27	8.884413776764296E-5		40	TCRBV20						TCRBJ02	TCRBJ02-05	01	3	5	2	2	4	2	26	37	46	41	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV20-X+TCRBJ02-05	TCRBV20		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCTTGGAGGTCTCCCCATATGGCTACACCTTCGGTTCG	CLEVSPYGYTF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	33	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	11	10	1	5	2	8	26	29	36	31	44		TCRBV20-01,TCRBV20-or09_02												CLEVSPYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGGCATCTAGCGGGAGCGTAGGGGAGCAGTACTTCGGGCCG		Out	VDJ	1	27	8.884413776764296E-5		44	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	7	4	2	7	4	7	24	35	49	39	56		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTCCCAACCCGACGCCCGCAGAAGCCTACGAGCAGTACTTCGGGCCG	CASSPNPTPAEAYEQYF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	51	unresolved						TCRBJ02	TCRBJ02-07	01	5	2	7	2	8	11	23	35	46	43	57	TCRBV06,TCRBV10			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPNPTPAEAYEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTGACTCTCCGGGAGGGAGCACAGATACGCAGTATTTTGGCCCA	CASSDSPGGSTDTQYF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	0	8	0	0	2	0	23	40	-1	42	50	TCRBV06,TCRBV10													CASSDSPGGSTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTGCTGCAGGGGGAGAGACCGGGGAGCTGTTTTTTGGAGAA	CASSAAGGETGELFF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	4	1	5	3	4	23	36	46	39	50	TCRBV02,TCRBV12													CASSAAGGETGELFF+X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTTGGTGCATCCTGAAGACAGCAGTTCTACATCTGCAGTGCTAGAGAACCGGGACTCCTTGCTAACTATGGCTACACCTTCGGTTCG	CSAREPGLLANYGYTF	In	VDJ	1	27	8.884413776764296E-5	1.1151863600317208E-4	48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	0	0	10	0	3	5	33	47	56	50	61		TCRBV20-01,TCRBV20-or09_02				01,02								CSAREPGLLANYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTAGGACCCAGACCGAGCAGTACTTCGGGCCG	CASSRTQTEQYF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	36	TCRBV12						TCRBJ02	TCRBJ02-07	01	5	1	7	6	1	6	26	38	43	39	49		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRTQTEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGACGCAACTAGCGGGGGGGTTCCTACAGTACTTCGGGCCG		Out	VDJ	1	28	9.213466138866678E-5		44	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	3	0	10	5	6	26	37	55	42	61		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGCGGTCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSQAVSGANVLTF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	45	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	1	8	5	0	0	1	26	-1	45	42	46		TCRBV03-01,TCRBV03-02				01,02								CASSQAVSGANVLTF+TCRBV03-X+TCRBJ02-06	TCRBV03	TCRBD02-01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAGGGGCAGGATGAAAAACTGTTTTTTGGCAGT	CSAREGQDEKLFF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	7	0	6	0	3	26	-1	45	40	48		TCRBV20-01,TCRBV20-or09_02												CSAREGQDEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCAGCAAAGGACAGGGGCCACTGAAGCTTTCTTTGGACAA	CSARDQQRTGATEAFF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	48	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	1	2	4	8	1	26	40	57	48	58		TCRBV20-01,TCRBV20-or09_02												CSARDQQRTGATEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCCGGACAGGGGACTATGGCTACACCTTCGGTTCG	CSASRTGDYGYTF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	1	2	3	2	0	26	37	-1	39	48		TCRBV20-01,TCRBV20-or09_02												CSASRTGDYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTTCAACCGGGCGGGGTAATTCACCCCTCCACTTTGGGAAC	CSSTGRGNSPLHF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	39	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	8	7	3	6	8	0	26	32	-1	40	46		TCRBV20-01,TCRBV20-or09_02												CSSTGRGNSPLHF+TCRBV20-X+TCRBJ01-06	TCRBV20	TCRBD02-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGCGCAGGGAGCCCCTACGAGCAGTACTTCGGGCCG	CASSAGSPYEQYF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	39	TCRBV12						TCRBJ02	TCRBJ02-07	01	6	4	3	2	2	4	22	33	40	35	44		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSAGSPYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTGAAATGATAAACACTGAAGCTTTCTTTGGACAA	CASSEMINTEAFF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	39	TCRBV12						TCRBJ01	TCRBJ01-01	01	5	2	8	2	0	7	22	-1	36	34	43		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEMINTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCCTCCAATTTAGCTACTCTGGAAACACCATATATTTTGGAGAG	CASLQFSYSGNTIYF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	45	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	8	5	7	0	8	2	22	31	43	39	45		TCRBV12-03,TCRBV12-04				01,02								CASLQFSYSGNTIYF+TCRBV12-X+TCRBJ01-03	TCRBV12	TCRBD02-01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTCAAACCGGGGCCGGGAGTTATGGCTACACCTTCGGTTCG	CASSQTGAGSYGYTF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	5	8	2	5	11	1	23	35	52	46	53	TCRBV24,TCRBV27													CASSQTGAGSYGYTF+X+TCRBJ01-02	unresolved	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTTATATGGGGCTAGGCGCTTTCTTTGGACAA		Out	VDJ	1	28	9.213466138866678E-5		37	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	7	0	11	2	5	23	39	46	41	51	TCRBV24,TCRBV27													X+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTTTGTCAGATGTTTAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	28	9.213466138866678E-5		41	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	4	5	8	6	6	24	36	45	42	51		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGCAACGCGGGCGTTCGTTCACCCCTCCACTTTGGGAAC	CASSNAGVRSPLHF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	6	7	4	9	4	6	23	34	43	38	49	TCRBV06,TCRBV10					01,02								CASSNAGVRSPLHF+X+TCRBJ01-06	unresolved	TCRBD02-01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCTGTGTATCTCTGTGCCAGCAGCCAAGAGGGACTAGCGGACTCCTACGAGCAGTACTTCGGGCCG	CASSQEGLADSYEQYF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	48				TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	0	5	0	0	1	19	-1	47	36	48	TCRBV03,TCRBV07	TCRBV03-01,TCRBV03-02,TCRBV07-05				01,02								CASSQEGLADSYEQYF+X+TCRBJ02-07		TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCCAAGATCGGACAGGGGTTGGCTACACCTTTGGTTCG	CASSQDRTGVGYTF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	42				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	1	2	20	2	14	19	36	47	38	61	TCRBV03,TCRBV07	TCRBV03-01,TCRBV03-02,TCRBV07-05												CASSQDRTGVGYTF+X+TCRBJ01-02		TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTGGACAAAGTTCTTACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	28	9.213466138866678E-5		47	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	2	1	6	3	0	8	19	-1	38	33	46	TCRBV07,TCRBV11													X+X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTCRGCYGTGTATSTCTGTGCCAGCAGCTCGGGACAGGGGCCAGATACGCAGTATTTTGGCCCA	CASSSGQGPDTQYF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	0	2	4	1	1	18	31	42	32	43	TCRBV07,TCRBV11													CASSSGQGPDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAGGGACTCRGCCSTKTATCTYTRCGCCAGCAGCCCGGAAGCTAGCGGGAGAGCCTACGAGCAGTACTTCGGGCCG	XASSPEASGRAYEQYF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	4	2	2	7	2	22	34	51	41	53	TCRBV05,TCRBV07,TCRBV17													XASSPEASGRAYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCMTSTATCKCTGTGCCAGCAGCCTAACCGGGGCCACTAGCACAGATACGCAGTATTTTGGCCCA	CASSLTGATSTDTQYF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	48	unresolved						TCRBJ02	TCRBJ02-03	01	4	7	0	0	6	4	19	31	42	37	46	TCRBV05,TCRBV07			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLTGATSTDTQYF+X+TCRBJ02-03	unresolved		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGTAMSCTCYCAGACATCTGTGTACTTCTGTGCCAGCAGTGAGAGTCCCACAGATACGCAGTATTTTGGCCCA	CASSESPTDTQYF	In	VDJ	1	28	9.213466138866678E-5	1.1564895585514142E-4	39	unresolved			unresolved			TCRBJ02	TCRBJ02-03	01	3	11	2	2	0	3	28	-1	45	42	48	TCRBV06,TCRBV10			TCRBD01,TCRBD02										CASSESPTDTQYF+X+TCRBJ02-03	unresolved	unresolved	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCGCACAGGGCGTAGGACCTAATGAAAAACTGTTTTTTGGCAGT	CASSAQGVGPNEKLFF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	48	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	3	3	3	3	8	26	37	46	40	54		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSAQGVGPNEKLFF+TCRBV12-X+TCRBJ01-04	TCRBV12	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCGTTCGGGTTCCCATTAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	29	9.54251850096906E-5		43	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-04	01	5	8	4	6	3	8	26	38	45	41	53		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-04	TCRBV03	TCRBD02-01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTACTAGATCCCTTGGACTAGCGGGACAAGAGACCCAGTACTTCGGGCCA	CSTRSLGLAGQETQYF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	48	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	2	1	3	2	6	0	26	38	-1	44	56		TCRBV20-01,TCRBV20-or09_02												CSTRSLGLAGQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCAGCGCGCAGGGTAATTTTTACAATGAGCAGTTCTTCGGGCCA	CASSAQGNFYNEQFF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	4	3	4	4	7	22	33	42	37	49	TCRBV09,TCRBV12													CASSAQGNFYNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTGCGGGACAACTTTACGAGCAGTACTTCGGGCCG	CASSAGQLYEQYF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	39	unresolved			unresolved			TCRBJ02	TCRBJ02-07	01	5	0	6	4	2	4	22	34	42	36	46	TCRBV02,TCRBV12			TCRBD01,TCRBD02										CASSAGQLYEQYF+X+TCRBJ02-07	unresolved	unresolved	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGCTTAACAGGGGTGCCCACGATAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	29	9.54251850096906E-5		50	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	7	3	2	4	4	10	24	35	46	39	56		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCATGGGGGACGGTGGTCTAGATACGCAGTATTTTGGCCCA	CATMGDGGLDTQYF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	42	TCRBV24						TCRBJ02	TCRBJ02-03	01	8	0	7	5	3	8	24	34	42	37	50		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATMGDGGLDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATCGCGGAACAATCAGCCCCAGCATTTTGGTGAT	CASSLSRNNQPQHF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	42				TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	6	7	5	3	5	2	24	36	45	41	47	TCRBV24,TCRBV27	TCRBV24-01,TCRBV24-or09_02,TCRBV27-01				01,02								CASSLSRNNQPQHF+X+TCRBJ01-05		TCRBD02-01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCCAAGATGGGGCGGGGACGGATGAGCAGTTCTTCGGGCCA	CASSQDGAGTDEQFF	In	VDJ	1	29	9.54251850096906E-5	1.1977927570711075E-4	45	TCRBV05			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	7	3	8	9	4	19	31	46	40	50		TCRBV05-06,TCRBV05-07												CASSQDGAGTDEQFF+TCRBV05-X+TCRBJ02-01	TCRBV05	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTTAGAGGGGGCTTAGATACGCAGTATTTTGGCCCA	CASSFRGGLDTQYF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	42	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	5	0	5	3	2	26	40	50	43	52		TCRBV12-03,TCRBV12-04												CASSFRGGLDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGTTTCGGACAGGGCTAACGAGCAGTACTTCGGGCCG	CASSQVSDRANEQYF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	1	3	5	4	3	23	39	51	43	54	TCRBV01,TCRBV04													CASSQVSDRANEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGCAAATGGGGCGGGTTTCGGAAGCTTTCTTTGGACAA		Out	VDJ	1	30	9.87157086307144E-5		44	TCRBV20						TCRBJ01	TCRBJ01-01	01	1	7	0	8	6	8	26	39	50	45	58		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGATCTTGGGACTAGCGGACCACCGGGGAGCTGTTTTTTGGAGAA	CSARSWD*RTTGELFF	Stop	VDJ	1	30	9.87157086307144E-5		48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	2	0	5	4	4	2	26	38	53	42	55		TCRBV20-01,TCRBV20-or09_02				01,02								CSARSWD*RTTGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCAGCGTAAACTGGGGTGACGGTGAGCAGTTCTTCGGGCCA	CASSVNWGDGEQFF	In	VDJ	1	30	9.87157086307144E-5	1.239095955590801E-4	42	unresolved						TCRBJ02	TCRBJ02-01	01	6	6	2	9	8	6	22	33	45	41	51	TCRBV09,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSVNWGDGEQFF+X+TCRBJ02-01	unresolved		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTACCCGGGACAAACCTACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	30	9.87157086307144E-5		44	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	6	3	4	5	24	36	46	40	51		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCGTAGCTTACGACAGGGCGGCTACACCTTCGGTTCG		Out	VDJ	1	30	9.87157086307144E-5		41	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	2	3	8	9	1	24	36	52	45	53	TCRBV09,TCRBV21													X+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TRKMMCCWMYCAGACATCTGTGTAYYTCTRTGCCAGCAGTCCAGACTATGGCTACACCTTCGGTTCG	XASSPDYGYTF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	33	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	4	5	3	1	0	27	39	-1	40	43	TCRBV06,TCRBV26													XASSPDYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCGGACTAGCGGGAGCCTTCGTTAGAGACCCAGTACTTCGGGCCA	CSAPD*REPSLETQYF	Stop	VDJ	1	31	1.0200623225173821E-4		48	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	6	1	2	4	3	8	26	34	50	37	58		TCRBV20-01,TCRBV20-or09_02												CSAPD*REPSLETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCGTTGGACCGAGAACTATGGCTACACCTTCGGTTCG	CSARWTENYGYTF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	39	TCRBV20						TCRBJ01	TCRBJ01-02	01	6	1	7	2	5	4	26	34	43	39	47		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARWTENYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGARGACTCRGCCCTKTATCTYTGCGCCAGCAGCCAAGCATCGGGACAGGGAGGATTATTCGAGACCCAGTACTTCGGGCCA	CASSQASGQGGLFETQYF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	54	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	1	0	3	5	4	10	23	39	52	43	62	TCRBV04,TCRBV05													CASSQASGQGGLFETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCAGCGTAGGGGATAGGGAAACTAATGAAAAACTGTTTTTTGGCAGT	CASSVGDRETNEKLFF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	48	unresolved			unresolved			TCRBJ01	TCRBJ01-04	01	6	5	2	1	3	7	22	33	41	36	48	TCRBV09,TCRBV12			TCRBD01,TCRBD02										CASSVGDRETNEKLFF+X+TCRBJ01-04	unresolved	unresolved	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTAATGGGCGGAGAGACCCAGTACTTCGGGCCA	CASSLMGGETQYF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	39	TCRBV24						TCRBJ02	TCRBJ02-05	01	6	8	0	4	5	2	24	36	45	41	47		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLMGGETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTGGTGGAGGGACCTACGGACAATGAGCAGTTCTTCGGGCCA	CASSLVEGPTDNEQFF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	48	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	10	0	5	5	8	24	36	47	41	55		TCRBV24-01,TCRBV24-or09_02												CASSLVEGPTDNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTGCCCCGAAGGACAGAAACAATGAGCAGTTCTTCGGGCCA	CASSAPKDRNNEQFF	In	VDJ	1	31	1.0200623225173821E-4	1.2803991541104944E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	1	5	5	9	2	23	34	49	43	51	TCRBV02,TCRBV09													CASSAPKDRNNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTCCAGACAGGGATCGCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	32	1.0529675587276204E-4		43	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	2	3	3	3	4	26	39	49	42	53		TCRBV12-03,TCRBV12-04												X+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTGGACAGGGGGCTCCGGGGAGCTGTTTTTTGGAGAA	CASSWTGGSGELFF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	42	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	1	0	6	0	1	26	-1	50	39	51		TCRBV12-03,TCRBV12-04												CASSWTGGSGELFF+TCRBV12-X+TCRBJ02-02	TCRBV12	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATCGAGACGAGCAGTACTTCGGGCCG	CASSQDRDEQYF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	36	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	11	2	5	2	0	26	43	-1	45	48		TCRBV03-01,TCRBV03-02												CASSQDRDEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCAAACCTGAATCAGCCCCAGCATTTTGGTGAT	CASSPNLNQPQHF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	39	TCRBV03						TCRBJ01	TCRBJ01-05	01	4	3	7	4	3	3	26	39	44	42	47		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPNLNQPQHF+TCRBV03-X+TCRBJ01-05	TCRBV03		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTTTGAGGTGAACACTGAAGCTTTCTTTGGACAA	CASSFEVNTEAFF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	39	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	5	11	1	0	3	0	26	38	-1	41	45		TCRBV03-01,TCRBV03-02												CASSFEVNTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGGAAGGGTGGGAAGCACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	32	1.0529675587276204E-4		34	TCRBV20						TCRBJ01	TCRBJ01-01	01	9	0	8	4	7	2	26	31	42	38	44		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGACGTCGGACTAGTTGCTGAGCAGTTCTTCGGGCCA	CATSDVGLVAEQFF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	42	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	1	8	9	4	4	24	38	49	42	53		TCRBV24-01,TCRBV24-or09_02				01,02								CATSDVGLVAEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGGTTTTGGGGGTTACAATGAGCAGTTCTTCGGGCCA	CASSLGFGGYNEQFF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	45	unresolved						TCRBJ02	TCRBJ02-01	01	1	6	1	4	5	1	18	34	44	39	45	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGFGGYNEQFF+X+TCRBJ02-01	unresolved		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCCCCGGGTTAGCGGTTACAGATACGCAGTATTTTGGCCCA	CASSPGLAVTDTQYF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	5	5	3	7	2	19	31	44	38	46	TCRBV07,TCRBV11					01,02								CASSPGLAVTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGAGGACAGGACTATGGCTACACCTTCGGTTCG	CASRGQDYGYTF	In	VDJ	1	32	1.0529675587276204E-4	1.3217023526301876E-4	36	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	1	4	3	1	0	23	34	-1	35	42	TCRBV02,TCRBV09													CASRGQDYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCCCCAGCGGGGGGAAGCAAGAGACCCAGTACTTCGGGCCA	CASSPSGGKQETQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	45	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	6	6	1	2	4	3	26	37	50	41	53		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSPSGGKQETQYF+TCRBV12-X+TCRBJ02-05	TCRBV12	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCGTAGAGGGTAGGGAAGGGACAGATACGCAGTATTTTGGCCCA	CASSVEGREGTDTQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	48	unresolved			unresolved			TCRBJ02	TCRBJ02-03	01	6	11	0	3	4	10	26	37	46	41	56	TCRBV09,TCRBV12			TCRBD01,TCRBD02										CASSVEGREGTDTQYF+X+TCRBJ02-03	unresolved	unresolved	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGGGACAGCTAAACTATGGCTACACCTTCGGTTCG	CASSPGQLNYGYTF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	0	5	2	1	3	26	39	47	40	50		TCRBV03-01,TCRBV03-02												CASSPGQLNYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACGGAAACTAGCGGAACAGCCGCCTACGAGCAGTACTTCGGGCCG	CSATETSGTAAYEQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	3	5	2	5	8	26	36	49	41	57		TCRBV20-01,TCRBV20-or09_02				01,02								CSATETSGTAAYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAGTCCACAGGGAACACTGAAGCTTTCTTTGGACAA	CATSESTGNTEAFF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	3	4	1	4	0	24	38	-1	42	47		TCRBV24-01,TCRBV24-or09_02												CATSESTGNTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTACAGGGACTAGCGGGAGTAGGGAGACCCAGTACTTCGGGCCA	CASSTGTSGSRETQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	6	0	2	5	3	4	24	36	53	39	57	TCRBV24,TCRBV27													CASSTGTSGSRETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCCAGCCCCGACAGGGGTAAAGGTATGGCTACACCTTCGGTTCG		Out	VDJ	1	33	1.0858727949378584E-4		50	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	2	2	5	9	6	24	36	53	45	59		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCCCGTATAGCGGACTTAGCACAGATACGCAGTATTTTGGCCCA	CASSPYSGLSTDTQYF	In	VDJ	1	33	1.0858727949378584E-4	1.363005551149881E-4	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	4	5	5	0	5	4	23	35	46	40	50	TCRBV09,TCRBV12					01,02								CASSPYSGLSTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTCTCAGCTACGAGCAGTACTTCGGGCCG	CASSLSYEQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	33	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	5	3	2	0	26	38	-1	40	43		TCRBV12-03,TCRBV12-04												CASSLSYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCCCTGGAGTTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSPWSSGANVLTF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	4	10	2	1	3	1	23	36	43	39	44	TCRBV01,TCRBV04													CASSPWSSGANVLTF+X+TCRBJ02-06	unresolved	TCRBD02-01*02	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCTACAGGGAGACTGAAGCTTTCTTTGGACAA	CASSPYRETEAFF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	3	3	5	3	2	26	39	48	42	50		TCRBV03-01,TCRBV03-02												CASSPYRETEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAATTGGGACAGGCGGATCACAGCCCCAGCATTTTGGTGAT	CSARIGTGGSQPQHF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	0	4	7	3	7	26	38	49	41	56		TCRBV20-01,TCRBV20-or09_02												CSARIGTGGSQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCTCCTAGCCGCCAGCACAGATACGCAGTATTTTGGCCCA	CSARDLLAASTDTQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	4	7	0	4	4	26	40	49	44	53		TCRBV20-01,TCRBV20-or09_02				01,02								CSARDLLAASTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGAGGGTGGGGGGCAGCTAGAAATTCACCCCTCCACTTTGGGAAC	CSAGGWGAARNSPLHF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	48	TCRBV20						TCRBJ01	TCRBJ01-06	01	1	6	0	7	4	7	26	39	49	43	56		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAGGWGAARNSPLHF+TCRBV20-X+TCRBJ01-06	TCRBV20		TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGGCCCAGCGGGACTAACAGGAATAAGCAGTTCTTCGGGCCA		Out	VDJ	1	34	1.1187780311480965E-4		41	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	7	0	9	11	7	9	26	33	47	40	56		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTCCAACCGGGACCTCCGGGAGAGCAGATACGCAGTATTTTGGCCCA	CASSPTGTSGRADTQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	51	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	8	2	4	14	2	23	35	55	49	57	TCRBV24,TCRBV27													CASSPTGTSGRADTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCCTACTAGCGAAGAGACCCAGTACTTCGGGCCA	CASSPTSEETQYF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	39	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	3	6	3	3	0	24	36	-1	39	46		TCRBV24-01,TCRBV24-or09_02				01,02								CASSPTSEETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCACCCTGGGGGAAAACACTGAAGCTTTCTTTGGACAA	CASTLGENTEAFF	In	VDJ	1	34	1.1187780311480965E-4	1.4043087496695743E-4	39	unresolved						TCRBJ01	TCRBJ01-01	01	7	6	1	2	4	2	23	33	42	37	44	TCRBV02,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTLGENTEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGGAGAGAGACTAGGCAGTACTTCGGGCCG	CASSQGRETRQYF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	39	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	2	8	9	7	0	26	42	-1	49	55		TCRBV03-01,TCRBV03-02				01,02								CASSQGRETRQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCAGGAGCAATAATGAAAAACTGTTTTTTGGCAGT	CASSPRSNNEKLFF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	42	TCRBV03						TCRBJ01	TCRBJ01-04	01	4	4	4	4	1	5	26	39	44	40	49		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPRSNNEKLFF+TCRBV03-X+TCRBJ01-04	TCRBV03		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCTCCCTCGGGGGCGGGGAGACCCAGTACTTCGGGCCA	CASSLGGGETQYF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	39	TCRBV03						TCRBJ02	TCRBJ02-05	01	8	6	0	5	6	3	26	35	47	41	50		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGGGETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGATGAGACTGAGCTAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	35	1.1516832673583348E-4		43	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	3	2	10	0	5	3	26	37	46	42	49		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGCTCGGGACTAGCGGGAAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSSGLAGSSYNEQFF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	51	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	0	3	0	3	2	22	33	49	36	51	TCRBV02,TCRBV12													CASSSGLAGSSYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAACCAAAACTAGGGACAGCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	35	1.1516832673583348E-4		43	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	0	5	3	10	0	24	34	-1	44	51		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGCAATGGGGAGCGTGGTCGGGGAGCTGTTTTTTGGAGAA	CASSLAMGSVVGELFF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	0	9	2	7	4	6	18	35	44	39	50	TCRBV07,TCRBV11													CASSLAMGSVVGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTCCTCCGGGGCAGGGATGGATCGAACTATGGCTACACCTTCGGTTCG	CASSFLRGRDGSNYGYTF	In	VDJ	1	35	1.1516832673583348E-4	1.4456119481892678E-4	54	unresolved						TCRBJ01	TCRBJ01-02	01	3	4	3	2	9	8	18	32	46	41	54	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFLRGRDGSNYGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCRGCCMTSTATCKCTGTGCCAGCAGCCACTGATAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	35	1.1516832673583348E-4		40	unresolved			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	5	3	10	0	1	2	19	31	35	32	37	TCRBV05,TCRBV07					01,02								X+X+TCRBJ01-05	unresolved	TCRBD02-01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGCCACCGGGTAGCGGGCAGCTCCTACGAGCAGTACTTCGGGCCG	CASSHRVAGSSYEQYF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	48	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	5	4	0	8	3	26	37	52	45	55		TCRBV12-03,TCRBV12-04,TCRBV12-05				01,02								CASSHRVAGSSYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCATCAGTGGAAGCTTGTCTGGCACTGAAGCTTTCTTTGGACAA	CAISGSLSGTEAFF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	42	unresolved			unresolved			TCRBJ01	TCRBJ01-01	01	4	6	7	4	2	8	24	37	42	39	50	TCRBV06,TCRBV10			TCRBD01,TCRBD02										CAISGSLSGTEAFF+X+TCRBJ01-01	unresolved	unresolved	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCACCTTGGAAGAAAGCACAGATACGCAGTATTTTGGCCCA	CASTLEESTDTQYF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	42	TCRBV03						TCRBJ02	TCRBJ02-03	01	7	1	8	0	4	4	26	36	43	40	47		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTLEESTDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATAGTTGGGCGGCACCAGGGCCGGTTCG		Out	VDJ	1	36	1.1845885035685729E-4		38	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	3	19	14	1	26	43	62	57	63		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGGGGACAGCTCCCAATTCAATCAGCCCCAGCATTTTGGTGAT	CSARGDSSQFNQPQHF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	48	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	0	5	3	2	9	26	37	46	39	55		TCRBV20-01,TCRBV20-or09_02												CSARGDSSQFNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGACTCGGCTAGCGGGGTCACAGATACGCAGTATTTTGGCCCA	CASSQDSASGVTDTQYF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	51				TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	4	3	2	5	1	18	35	49	40	50	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03												CASSQDSASGVTDTQYF+X+TCRBJ02-03		TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTCRGCYGTGTATSTCTGTGCCAGCAGCTTAGAGGGTAGCGGGAGGGCCAACAATGAGCAGTTCTTCGGGCCA	CASSLEGSGRANNEQFF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	51	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	5	0	5	3	3	18	35	49	38	52	TCRBV07,TCRBV11													CASSLEGSGRANNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCCCAGTCGGGGCCCTACGAGCAGTACTTCGGGCCG	CASSLAQSGPYEQYF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	45							TCRBJ02	TCRBJ02-07	01	0	7	0	2	6	0	18	35	-1	41	46	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAQSGPYEQYF+X+TCRBJ02-07			TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGRAGACWCRGCMCTGTATCTCTGCGCCAGCAGCGGGGCAAACCCTAATGAAAAACTGTTTTTTGGCAGT	CASSGANPNEKLFF	In	VDJ	1	36	1.1845885035685729E-4	1.486915146708961E-4	42	unresolved			unresolved			TCRBJ01	TCRBJ01-04	01	6	7	0	3	1	5	20	31	37	32	42	TCRBV04,TCRBV23			TCRBD01,TCRBD02										CASSGANPNEKLFF+X+TCRBJ01-04	unresolved	unresolved	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGCTAGTCAGCCCCAGCATTTTGGTGAT	CASSQASQPQHF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	36	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	1	4	8	6	0	0	26	-1	-1	42	46		TCRBV03-01,TCRBV03-02				01,02								CASSQASQPQHF+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD02-01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCAACTGGGACCGTTGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	37	1.217493739778811E-4		46	TCRBV03						TCRBJ01	TCRBJ01-01	01	4	0	7	0	5	3	26	39	49	44	52		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ01-01	TCRBV03		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTCCCGGGCCGGCAGTCGGCACTGAAGCTTTCTTTGGACAA	CSPGPAVGTEAFF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	39	TCRBV20						TCRBJ01	TCRBJ01-01	01	8	8	0	4	3	10	26	32	39	35	49		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSPGPAVGTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCGGGGAAGCATGATCAACTATGGCTACACCTTCGGTTCG	CSARGSMINYGYTF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	42	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	6	8	3	2	1	10	26	34	40	35	50		TCRBV20-01,TCRBV20-or09_02												CSARGSMINYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATAAGCGGGGGAGCACAGATACGCAGTATTTTGGCCCA	CSARDKRGSTDTQYF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	6	2	0	2	0	26	40	-1	42	50		TCRBV20-01,TCRBV20-or09_02												CSARDKRGSTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGGGAGGGAGAGGCAGGTATTTCTCTGAAGCTTTCTTTGGACAA		Out	VDJ	1	37	1.217493739778811E-4		47	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	5	9	0	6	1	16	26	35	43	36	59		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CMCCAACCAGACAKCTMTKTACYTCTGTGCCAGCAGTACCAGGGAGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSTRESSYNEQFF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	45	unresolved						TCRBJ02	TCRBJ02-01	01	5	4	3	0	2	4	25	37	44	39	48	TCRBV24,TCRBV28			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSTRESSYNEQFF+X+TCRBJ02-01	unresolved		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGAAGGAAGATGGTAGCGGGAGAGGATTGAGCAGTTCTTCGGGCCA		Out	VDJ	1	37	1.217493739778811E-4		46	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	9	5	2	9	11	5	22	30	50	41	55		TCRBV12-03,TCRBV12-04												X+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCAGTGAAGCTGGGGGAATGCATGAAAAACTGTTTTTTGGCAGT	CASSEAGGMHEKLFF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	45	unresolved						TCRBJ01	TCRBJ01-04	01	5	6	1	6	6	5	22	34	45	40	50	TCRBV09,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEAGGMHEKLFF+X+TCRBJ01-04	unresolved		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCCGCCGGGGGGAGCCCCCTTCCTACGAGCAGTACTTCGGGCCG	CASRRGEPPSYEQYF	In	VDJ	1	37	1.217493739778811E-4	1.5282183452286545E-4	45				TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	8	8	1	1	3	8	18	27	37	30	45	TCRBV11,TCRBV12	TCRBV11-03,TCRBV12-02												CASRRGEPPSYEQYF+X+TCRBJ02-07		TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATCTCTGTGCCAGCAGCCTCTTTTACTAGTAGCTGGAAGTTCTTCGGGCCA		Out	VDJ	1	37	1.217493739778811E-4		40	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	3	8	14	7	8	19	31	43	38	51	TCRBV05,TCRBV07					01,02								X+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGTGCCAGCAGCGACCCCGGACTAGCGGGGGGAAGCGTTGGTTGGAGAGGACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	37	1.217493739778811E-4		68				TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	1	1	3	6	18	0	12	32	18	50	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-02,TCRBV11-03												X+X+TCRBJ02-03		TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTTCTGGACTATGGCTACACCTTCGGTTCG	CASSLLDYGYTF	In	VDJ	1	38	1.2503989759890492E-4	1.569521543748348E-4	36	TCRBV03						TCRBJ01	TCRBJ01-02	01	4	0	10	3	4	0	26	39	-1	43	45		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLLDYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCCGTGGACAGCCCTATGGCTACACCTTCGGTTCG	CSATRGQPYGYTF	In	VDJ	1	38	1.2503989759890492E-4	1.569521543748348E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	1	5	4	5	2	26	36	47	41	49		TCRBV20-01,TCRBV20-or09_02												CSATRGQPYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATGAGGGAGTATGACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	38	1.2503989759890492E-4		43	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	9	2	5	3	4	26	40	48	43	52		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCTCGGTGGGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	38	1.2503989759890492E-4		37	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	5	8	5	1	3	3	26	35	41	38	44		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGTCGGCAACGCTCCCACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	38	1.2503989759890492E-4		38	TCRBV20						TCRBJ02	TCRBJ02-01	01	7	9	0	5	2	9	26	33	38	35	47		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV20-X+TCRBJ02-01	TCRBV20		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATCCTAGGACAGGGGGCGGACCCCGAGCAGTACTTCGGGCCG		Out	VDJ	1	38	1.2503989759890492E-4		49	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	1	0	6	4	6	24	39	54	43	60		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCTAGGGGGGCACGAGCAGTACTTCGGGCCG	CASSLGGHEQYF	In	VDJ	1	38	1.2503989759890492E-4	1.569521543748348E-4	36	TCRBV24						TCRBJ02	TCRBJ02-07	01	6	5	1	5	2	2	24	36	44	38	46		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGGHEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCTTTTTGACGAGGGGGAGCTGTTTTTTGGAGAA	CASSLFDEGELFF	In	VDJ	1	38	1.2503989759890492E-4	1.569521543748348E-4	39	TCRBV24						TCRBJ02	TCRBJ02-02	01	6	2	7	8	6	3	24	36	45	42	48		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLFDEGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCCCCAGGGTTAGCGGGGACACCGGGGAGCTGTTTTTTGGAGAA	CASSPRVSGDTGELFF	In	VDJ	1	38	1.2503989759890492E-4	1.569521543748348E-4	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	5	5	3	3	8	0	18	30	-1	38	46	TCRBV07,TCRBV11													CASSPRVSGDTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGGACTAGCGGGAGAAAATGAGCAGTTCTTCGGGCCA	CASSLAGLAGENEQFF	In	VDJ	1	38	1.2503989759890492E-4	1.569521543748348E-4	48				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	0	2	7	0	2	18	-1	49	35	51	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAGLAGENEQFF+X+TCRBJ02-01		TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGTGGGGGGTAACTATAGCTACACCTTCGGTTCG	CASSLAVGGNYSYTF	In	VDJ	1	38	1.2503989759890492E-4	1.569521543748348E-4	45				TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	0	9	1	9	3	8	18	35	44	38	52	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAVGGNYSYTF+X+TCRBJ01-02		TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCACGACAGGGATTGGTACGAGCAGTACTTCGGGCCG	CSAHDRDWYEQYF	In	VDJ	1	39	1.2833042121992871E-4	1.6108247422680412E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	3	4	4	5	26	34	45	38	50		TCRBV20-01,TCRBV20-or09_02												CSAHDRDWYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGACGCCCGACTAGCGGGAGGACGGAACACCGGGGAGCTGTTTTTTGGAGAA	CATSDARLAGGRNTGELFF	In	VDJ	1	39	1.2833042121992871E-4	1.6108247422680412E-4	57	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	4	2	1	1	5	3	24	38	56	43	59		TCRBV24-01,TCRBV24-or09_02												CATSDARLAGGRNTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGCCCGAGAAGTGGGGCACAAAATGAAAAACTGTTTTTTGGCAGT	CASSPRSGAQNEKLFF	In	VDJ	1	39	1.2833042121992871E-4	1.6108247422680412E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	7	7	0	5	10	4	24	35	50	45	54	TCRBV24,TCRBV27													CASSPRSGAQNEKLFF+X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCGTAGGATCTCGGGGTTTGGACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	39	1.2833042121992871E-4		46	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	5	8	3	5	9	5	24	36	50	45	55	TCRBV09,TCRBV21													X+X+TCRBJ01-01	unresolved	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGCTGTGTATTTCTGTGCCAGCAGCCAAGGGGGCGTCCCGGGACAGGGGTGCGTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	39	1.2833042121992871E-4		61	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	0	2	1	10	4	13	29	49	39	53		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCGAAGGAAATGCAGGGGTGGCCTATGGCTACACCTTCGGTTCG	CASSEGNAGVAYGYTF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	48	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	4	2	4	11	4	26	37	54	48	58		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSEGNAGVAYGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTACAGGGGGACTGAAGCTTTCTTTGGACAA	CASSYRGTEAFF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	36	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	1	5	1	0	26	38	-1	39	47		TCRBV03-01,TCRBV03-02												CASSYRGTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGTGGGAGGGGGGCCCCAGCATTTTGGTGAT	CATSVGGGPQHF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	36	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	5	9	0	9	1	2	24	37	45	38	47		TCRBV24-01,TCRBV24-or09_02												CATSVGGGPQHF+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD02-01*02	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCCCCAGGGCGGGCTACACAGATACGCAGTATTTTGGCCCA	CASSPRAGYTDTQYF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	45	unresolved						TCRBJ02	TCRBJ02-03	01	5	4	3	2	2	7	18	30	37	32	44	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPRAGYTDTQYF+X+TCRBJ02-03	unresolved		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCCGAGGCGGCGGGGGGAATGAAAAACTGTTTTTTGGCAGT	CASSRGGGGNEKLFF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	45	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	5	7	1	5	7	0	18	30	-1	37	45	TCRBV05,TCRBV11													CASSRGGGGNEKLFF+X+TCRBJ01-04	unresolved	TCRBD02-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCMTSTATCTCTGTGCCAGCAGCTGGGACAGGGGCAGGGATACGCAGTATTTTGGCCCA	CASSWDRGRDTQYF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	0	2	6	0	4	19	-1	42	32	46	TCRBV05,TCRBV11													CASSWDRGRDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTCRGCYRTGTATCTCTGTGCCAGCAGCTTAAAATCGAGGGGGAGGGAAAAACTGTTTTTTGGCAGT	CASSLKSRGREKLFF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	45	unresolved						TCRBJ01	TCRBJ01-04	01	2	5	1	8	6	3	22	37	49	43	52	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLKSRGREKLFF+X+TCRBJ01-04	unresolved		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCGACAGGGATAACTATGGCTACACCTTCGGTTCG	CASDRDNYGYTF	In	VDJ	1	40	1.3162094484095254E-4	1.6521279407877347E-4	36	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	2	3	1	0	1	23	-1	39	32	40	TCRBV02,TCRBV09													CASDRDNYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGCCCCAACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	41	1.3491146846197636E-4		37	TCRBV03						TCRBJ02	TCRBJ02-01	01	4	4	6	5	5	0	26	39	-1	44	46		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-01	TCRBV03		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTCGGGACGGTCCGTCGGATTGAACTGTTTTTTGGCAGT	CASSLGTVRRIELFF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	45	TCRBV03						TCRBJ01	TCRBJ01-04	01	4	0	7	12	2	14	26	39	46	41	60		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGTVRRIELFF+TCRBV03-X+TCRBJ01-04	TCRBV03		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTGGGACTTGCCCAATGAGCAGTTCTTCGGGCCA	CASSWDLPNEQFF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	39	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	0	10	6	1	4	26	38	45	39	49		TCRBV03-01,TCRBV03-02				01,02								CASSWDLPNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTTAGAATCACCAAACGAGCAGTACTTCGGGCCG	CASSLESPNEQYF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	39	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	5	8	5	1	9	26	38	42	39	51		TCRBV03-01,TCRBV03-02				01,02								CASSLESPNEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACCCGGGACCTACTATGGCTACACCTTCGGTTCG	CSARPGTYYGYTF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	39	TCRBV20						TCRBJ01	TCRBJ01-02	01	2	0	7	3	3	2	26	38	46	41	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARPGTYYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTAAGGCGGCCACCGGGGAGCTGTTTTTTGGAGAA	CSASKAATGELFF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	39	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	3	7	5	4	4	1	26	37	45	41	46		TCRBV20-01,TCRBV20-or09_02				01,02								CSASKAATGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCGACACAGGGGAATAGTCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	41	1.3491146846197636E-4		44	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	3	2	6	3	5	23	36	46	39	51	TCRBV01,TCRBV04													X+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCMRGRGACWCAGCWSKGTAYTTCTGTGCCAGCAGCCGGACTAGCGGGGGCCCAATCTCGAATGAGCAGTTCTTCGGGCCA	CASSRTSGGPISNEQFF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	51	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	1	2	7	2	10	22	33	48	35	58	TCRBV12,TCRBV21													CASSRTSGGPISNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATGGTTGGGATTCGGACAATGAGCAGTTCTTCGGGCCA	CATSDGWDSDNEQFF	In	VDJ	1	41	1.3491146846197636E-4	1.693431139307428E-4	45	TCRBV24						TCRBJ02	TCRBJ02-01	01	3	0	8	5	4	5	24	39	47	43	52		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSDGWDSDNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCTAGCAGAGGGACAGGCCTACTAGCCAAAAACATTCAGTACTTCGGCGCC	CASRGTGLLAKNIQYF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	48				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	6	0	4	0	1	6	24	35	44	36	50	TCRBV06,TCRBV10	TCRBV06-01,TCRBV06-05,TCRBV06-06,TCRBV10-03												CASRGTGLLAKNIQYF+X+TCRBJ02-04		TCRBD01-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAAAACCGGGACAGGGGAATTCACCCCTCCACTTTGGGAAC	CSARKPGQGNSPLHF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	2	0	2	7	5	0	26	38	-1	43	53		TCRBV20-01,TCRBV20-or09_02												CSARKPGQGNSPLHF+TCRBV20-X+TCRBJ01-06	TCRBV20	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGAGGGGGCCGGATCACTGAAGCTTTCTTTGGACAA	CSARGGGRITEAFF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	5	0	4	1	5	26	39	47	40	52		TCRBV20-01,TCRBV20-or09_02												CSARGGGRITEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAAACAAGCGGGGGGCACCGATACGCAGTATTTTGGCCCA	CASKQAGGTDTQYF	In	VDJ	1	42	1.3820199208300016E-4	1.7347343378271214E-4	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	7	6	1	6	4	4	22	32	45	36	49	TCRBV02,TCRBV12													CASKQAGGTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCGTACAGACGGCATTCACAGATACGCAGTATTTTGGCCCA	CASSVQTAFTDTQYF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	45	unresolved			unresolved			TCRBJ02	TCRBJ02-03	01	6	3	5	2	3	8	26	37	44	40	52	TCRBV09,TCRBV12			TCRBD01,TCRBD02										CASSVQTAFTDTQYF+X+TCRBJ02-03	unresolved	unresolved	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCACCCAGGACAGTACGATACTATGGCTAGTACCTTCGGTTCG	CASSHPGQYDTMASTF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	48	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	1	5	14	4	18	26	40	50	44	68		TCRBV03-01,TCRBV03-02												CASSHPGQYDTMASTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTATGGGGGGCCGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSLWGAGTGELFF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	45	TCRBV03						TCRBJ02	TCRBJ02-02	01	4	6	0	4	4	3	26	39	49	43	52		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLWGAGTGELFF+TCRBV03-X+TCRBJ02-02	TCRBV03		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCAGTAACAGGGACTATGGCTACACCTTCGGTTCG	CSASNRDYGYTF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	3	3	3	5	0	26	34	-1	39	45		TCRBV20-01,TCRBV20-or09_02												CSASNRDYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGATCGTTTCGGGGAGACTATGGCTACACCTTCGGTTCG	CSARSFRGDYGYTF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	2	8	3	3	6	2	26	38	49	44	51		TCRBV20-01,TCRBV20-or09_02				01,02								CSARSFRGDYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGTGGGCATTTGGAGCTGAAGCTTTCTTTGGACAA	CSARWAFGAEAFF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	39	TCRBV20						TCRBJ01	TCRBJ01-01	01	3	8	0	6	2	8	26	37	43	39	51		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARWAFGAEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGACCTGGACTAGCGGGCCCAAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	43	1.4149251570402398E-4		49	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	4	1	4	3	3	4	24	38	52	41	56		TCRBV24-01,TCRBV24-or09_02				01,02								X+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCATGGACAGGGTGAACACTGAAGCTTTCTTTGGACAA	CATMDRVNTEAFF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	39	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	8	1	3	0	1	0	24	34	-1	35	43		TCRBV24-01,TCRBV24-or09_02												CATMDRVNTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATCGCGGACAGGCGGGGTAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	43	1.4149251570402398E-4		50				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	1	4	2	7	6	24	36	50	43	56	TCRBV24,TCRBV27	TCRBV24-01,TCRBV24-or09_02,TCRBV27-01												X+X+TCRBJ01-01		TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCGGGGGGACAGGGGATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSGGTGDSNQPQHF	In	VDJ	1	43	1.4149251570402398E-4	1.7760375363468146E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	0	2	0	2	1	23	36	48	38	49	TCRBV09,TCRBV12													CASSGGTGDSNQPQHF+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCGTAGGCCTAGCGGGAAACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	43	1.4149251570402398E-4		46	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	0	4	3	3	2	1	23	39	50	41	51	TCRBV09,TCRBV21													X+X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGAGATGACCCACCGGATAGGTCACCCCTCCACTTTGGGAAC	CASRDDPPDRSPLHF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	45	TCRBV03						TCRBJ01	TCRBJ01-06	01	6	1	8	10	12	4	26	37	52	49	56		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRDDPPDRSPLHF+TCRBV03-X+TCRBJ01-06	TCRBV03		TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCAGGGGCCTAGGCGGCAATCAGCCCCAGCATTTTGGTGAT	CASSRGLGGNQPQHF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	45	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	5	2	2	0	8	26	-1	43	38	51		TCRBV03-01,TCRBV03-02												CASSRGLGGNQPQHF+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCAAGGGGACAGGGAAGAGTCTACGAGCAGTACTTCGGGCCG	CSARGQGRVYEQYF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	3	3	3	6	26	34	46	37	52		TCRBV20-01,TCRBV20-or09_02												CSARGQGRVYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGAATGACAGGTGACGCAGGGTCACCCCTCCACTTTGGGAAC	CASRMTGDAGSPLHF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	45	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	6	2	4	10	3	10	22	33	42	36	52		TCRBV12-03,TCRBV12-04												CASRMTGDAGSPLHF+TCRBV12-X+TCRBJ01-06	TCRBV12	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGACAGGGTAGATGGGACTGAAGCTTTCTTTGGACAA	CAISDRVDGTEAFF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	42				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	3	5	0	8	23	-1	42	35	50	TCRBV06,TCRBV10	TCRBV06-08,TCRBV10-03												CAISDRVDGTEAFF+X+TCRBJ01-01		TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTTAAGGGACAGGGGAGCGTTGATCGTACCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSLRDRGALIVPGANVLTF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	63				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	2	0	2	2	1	14	18	33	44	34	58	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-02,TCRBV11-03												CASSLRDRGALIVPGANVLTF+X+TCRBJ02-06		TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTGTTTGGACAGACCACAGATACGCAGTATTTTGGCCCA	CASSLFGQTTDTQYF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	1	5	2	4	2	18	32	42	36	44	TCRBV05,TCRBV11													CASSLFGQTTDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCMTSTATCKCTGTGCCAGCAGCCAAGCGAGTAGCGGGGGCCCCTACAATGAGCAGTTCTTCGGGCCA	CASSQASSGGPYNEQFF	In	VDJ	1	44	1.447830393250478E-4	1.817340734866508E-4	51	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	5	2	2	8	2	19	31	48	39	50	TCRBV05,TCRBV07													CASSQASSGGPYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAAGCGGGGGGGCCCGCACAGATACGCAGTATTTTGGCCCA	CASSLSGGARTDTQYF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	48	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	2	6	0	1	0	3	26	-1	51	41	54		TCRBV12-03,TCRBV12-04												CASSLSGGARTDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCACGCCGGGACTAGCGGCTACGAGCAGTACTTCGGGCCG	CASSHAGTSGYEQYF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	45	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	3	0	5	3	4	0	26	40	-1	44	55		TCRBV03-01,TCRBV03-02				01,02								CASSHAGTSGYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGAAAGGGTGACTAGCGTGGGCACAGATACGCAGTATTTTGGCCCA	CASSQERVTSVGTDTQYF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	54	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	2	6	1	6	3	23	40	54	46	57	TCRBV01,TCRBV04					01,02								CASSQERVTSVGTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCCCGGACCTGGGGGACTCGACACCGGGGAGCTGTTTTTTGGAGAA	CASSPGPGGLDTGELFF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	51	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	4	0	10	3	10	2	23	36	52	46	54	TCRBV01,TCRBV04					01,02								CASSPGPGGLDTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTTCCCGAGGGTCTCTGGCGGGCTACACCTTCGGTTCG	CASSSRGSLAGYTF	In	VDJ	1	45	1.480735629460716E-4	1.8586439333862013E-4	42	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	4	11	0	8	3	9	22	35	43	38	52		TCRBV12-03,TCRBV12-04												CASSSRGSLAGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCGTACAACAGGGGATGGGGTATGGCTACACCTTCGGTTCG	CASSVQQGMGYGYTF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	45	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	3	2	5	6	6	26	37	50	43	56		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSVQQGMGYGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGTCCGACAGGGGGCTACGAGCAGTACTTCGGGCCG	CASSPTGGYEQYF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	1	3	3	0	26	37	-1	40	49		TCRBV03-01,TCRBV03-02												CASSPTGGYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGCCCGCAGGTAAACTAAGTAGCAATGAGCAGTTCTTCGGGCCA	CSAPAGKLSSNEQFF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	45	TCRBV20						TCRBJ02	TCRBJ02-01	01	6	4	4	6	5	12	26	34	43	39	55		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAPAGKLSSNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGCCTGAAAGGTTTCAGGAACTATGGCTACACCTTCGGTTCG	CASSLKGFRNYGYTF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	45	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	4	4	2	12	0	22	33	-1	45	49		TCRBV12-03,TCRBV12-04												CASSLKGFRNYGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGACCGCCAGCGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	46	1.5136408656709542E-4		40	TCRBV24						TCRBJ01	TCRBJ01-03	01	4	4	5	4	4	1	24	38	45	42	46		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ01-03	TCRBV24		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTTGACTAGCGGGAGTGGGTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	46	1.5136408656709542E-4		52	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	1	2	2	4	1	4	24	41	54	42	58		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCCAACGACGGAAGCTGAAGCTTTCTTTGGACAA	CASSPTTEAEAFF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	39	TCRBV24						TCRBJ01	TCRBJ01-01	01	6	1	8	6	8	2	24	36	47	44	49		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPTTEAEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGGGACGGACTAGCGGGGACTTACAATGAGCAGTTCTTCGGGCCA	CASRDGLAGTYNEQFF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	1	3	4	4	3	23	34	50	38	53	TCRBV06,TCRBV10													CASRDGLAGTYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAACAAGTTTCGGGGGCCAACGTCCTGACTTTCGGGGCC	CASSEQVSGANVLTF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	45	TCRBV06						TCRBJ02	TCRBJ02-06	01	2	4	6	4	0	7	23	-1	40	38	47		TCRBV06-01,TCRBV06-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEQVSGANVLTF+TCRBV06-X+TCRBJ02-06	TCRBV06		TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGGACTCGGCCSTGTATCTCTGTGCCAGCAGCTCCATGATCCGGGATACGCAGTATTTTGGCCCA	CASSSMIRDTQYF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	39	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	4	8	5	6	8	0	18	31	-1	39	42	TCRBV05,TCRBV07					01,02								CASSSMIRDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTGAAACCTGGTCAGTTGAAGAGACCCAGTACTTCGGGCCA	CASSETWSVEETQYF	In	VDJ	1	46	1.5136408656709542E-4	1.8999471319058948E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	4	5	3	11	3	23	34	48	45	51	TCRBV02,TCRBV09													CASSETWSVEETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATAATAAGCGGGAGGGCCTTAAAGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CATSDNKREGLKANTGELFF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	60	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	3	6	0	0	4	8	21	36	50	40	58		TCRBV24-01,TCRBV24-or09_02												CATSDNKREGLKANTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTAGCGGGGTTCCTCCCTACGAGCAGTACTTCGGGCCG	CASSSGVPPYEQYF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	42	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	6	3	2	0	6	26	-1	45	38	51		TCRBV12-03,TCRBV12-04												CASSSGVPPYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGTGTAGTTGGACAGGGGGGCCCGGAGCAGTTCTTCGGGCCA	CASSVVGQGGPEQFF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	1	1	10	2	5	26	42	54	44	59	TCRBV09,TCRBV12													CASSVVGQGGPEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGCCAAGGAGAAGACGCAGTATTTTGGCCCA	CASSQAKEKTQYF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	39	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	1	10	2	9	4	3	26	42	50	46	53		TCRBV03-01,TCRBV03-02												CASSQAKEKTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAATGGAGGACAACCACCGGGGAGCTGTTTTTTGGAGAA	CASSEWRTTTGELFF	In	VDJ	1	47	1.5465461018811924E-4	1.941250330425588E-4	45	TCRBV06						TCRBJ02	TCRBJ02-02	01	2	1	6	4	4	2	23	38	47	42	49		TCRBV06-01,TCRBV06-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEWRTTTGELFF+TCRBV06-X+TCRBJ02-02	TCRBV06		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGTTATGCGGGACTAGCGGGAAAGGCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	47	1.5465461018811924E-4		59	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	1	0	3	1	6	3	18	34	53	40	56	TCRBV07,TCRBV11													X+X+TCRBJ02-04	unresolved	TCRBD02-01*02	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCACAGGGGGCTATGGCTACACCTTCGGTTCG	CSATGGYGYTF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	33	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	3	1	4	1	0	26	34	-1	35	43		TCRBV20-01,TCRBV20-or09_02												CSATGGYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGGGGCGAGGACTATGGCTACACCTTCGGTTCG	CSARGGEDYGYTF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	7	0	3	0	4	26	-1	44	39	48		TCRBV20-01,TCRBV20-or09_02												CSARGGEDYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAAGGGGCTTTAACTATGGCTACACCTTCGGTTCG	CASSERGFNYGYTF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	42	TCRBV06			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	5	2	1	0	3	23	-1	43	38	46		TCRBV06-01,TCRBV06-08												CASSERGFNYGYTF+TCRBV06-X+TCRBJ01-02	TCRBV06	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGCGACTAGCGGGAGAGGAGTACTTCGGGCCG	CASSLARLAGEEYF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	42				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	2	2	11	2	3	18	35	49	37	52	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLARLAGEEYF+X+TCRBJ02-07		TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGGACAGGGCGCTTACAATGAGCAGTTCTTCGGGCCA	CASSLGQGAYNEQFF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	2	3	4	0	4	18	-1	41	34	45	TCRBV07,TCRBV11													CASSLGQGAYNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTGGTGGCGTCGTCTGGAAACACCATATATTTTGGAGAG	CASSLVASSGNTIYF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	45	unresolved						TCRBJ01	TCRBJ01-03	01	3	9	0	1	3	4	18	32	38	35	42	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLVASSGNTIYF+X+TCRBJ01-03	unresolved		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCCCCACCTCCCGGGTCTAGCGGGAGCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	48	1.5794513380914304E-4		53	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	4	2	2	14	0	19	31	-1	45	55	TCRBV07,TCRBV11													X+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGGAAGTACGCCTTGGACAATCAGCCCCAGCATTTTGGTGAT	CASRKYALDNQPQHF	In	VDJ	1	48	1.5794513380914304E-4	1.9825535289452815E-4	45	unresolved						TCRBJ01	TCRBJ01-05	01	6	1	8	3	12	0	23	34	-1	46	49	TCRBV02,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRKYALDNQPQHF+X+TCRBJ01-05	unresolved		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAGCGGGCTCTAGGTATGGCTACACCTTCGGTTCG	CASSLAGSRYGYTF	In	VDJ	1	49	1.6123565743016686E-4	2.023856727464975E-4	42	TCRBV12						TCRBJ01	TCRBJ01-02	01	0	8	0	5	0	6	26	-1	47	43	53		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAGSRYGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAAGGGACTAGTGTCCACACCGGGGAGCTGTTTTTTGGAGAA	CSAREGTSVHTGELFF	In	VDJ	1	49	1.6123565743016686E-4	2.023856727464975E-4	48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	0	0	8	3	1	5	26	40	49	41	54		TCRBV20-01,TCRBV20-or09_02				01,02								CSAREGTSVHTGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGACCACCTACAGGGGGGAGCTTTCTTTGGACAA	CATSDHLQGGAFF	In	VDJ	1	49	1.6123565743016686E-4	2.023856727464975E-4	39	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	3	1	10	6	1	24	38	52	44	53		TCRBV24-01,TCRBV24-or09_02												CATSDHLQGGAFF+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATAACAGGGGTCAATACGAGCAGTACTTCGGGCCG	CATSDNRGQYEQYF	In	VDJ	1	49	1.6123565743016686E-4	2.023856727464975E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	3	2	4	1	4	24	39	47	40	51		TCRBV24-01,TCRBV24-or09_02												CATSDNRGQYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTAAACAGGGAGCAAATGAAGCTTTCTTTGGACAA	CASSKQGANEAFF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	3	7	2	6	26	38	46	40	52		TCRBV12-03,TCRBV12-04												CASSKQGANEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGAGTCGGGGGATGGTCTACGAGCAGTACTTCGGGCCG	CASSQSRGMVYEQYF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	45	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	3	8	2	3	4	5	26	40	50	44	55		TCRBV03-01,TCRBV03-02												CASSQSRGMVYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGTGACAGGGTGACTGAAGCTTTCTTTGGACAA	CSARGDRVTEAFF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	2	3	5	2	2	26	39	48	41	50		TCRBV20-01,TCRBV20-or09_02												CSARGDRVTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCCCCGCTCGCTTTCAAGAGACCCAGTACTTCGGGCCA	CSASPARFQETQYF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	42	TCRBV20						TCRBJ02	TCRBJ02-05	01	3	10	0	2	4	7	26	37	43	41	50		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSASPARFQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCTCCCGGACGGGGGGGCCCACAGATACGCAGTATTTTGGCCCA	CASSSRTGGPTDTQYF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	8	0	2	7	2	23	35	50	42	52	TCRBV01,TCRBV04													CASSSRTGGPTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCACCGCTAGCGGGAGGCCCAACGGGGAGCTGTTTTTTGGAGAA	CASTASGRPNGELFF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	45	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	11	4	1	7	6	5	24	31	48	37	53		TCRBV24-01,TCRBV24-or09_02												CASTASGRPNGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTCCCTATACAGGATACAATCAGCCCCAGCATTTTGGTGAT	CASSPYTGYNQPQHF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	3	4	3	6	3	23	35	46	41	49	TCRBV06,TCRBV10													CASSPYTGYNQPQHF+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGCTAACCTCAGGGTGTCGGCCCTGAACACTGAAGCTTTCTTTGGACAA	CASSQANLRVSALNTEAFF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	57	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	4	3	0	7	9	24	40	52	47	61		TCRBV03-01,TCRBV03-02												CASSQANLRVSALNTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
SGACTCGGCYSTSTATCTCTGTGCCAGCAGCTTAGGGTCGAGCACAGATACGCAGTATTTTGGCCCA	CASSLGSSTDTQYF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	42	unresolved						TCRBJ02	TCRBJ02-03	01	2	5	3	0	0	3	19	-1	37	33	40	TCRBV05,TCRBV07			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGSSTDTQYF+X+TCRBJ02-03	unresolved		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCAGATCGGACGGCAGCAATCAGCCCCAGCATTTTGGTGAT	CASSRSDGSNQPQHF	In	VDJ	1	50	1.6452618105119069E-4	2.0651599259846682E-4	45	unresolved						TCRBJ01	TCRBJ01-05	01	4	1	7	1	4	3	24	37	45	41	48	TCRBV09,TCRBV21			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRSDGSNQPQHF+X+TCRBJ01-05	unresolved		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CACCAACCAGACMTCTMTGTACYTCTGTGCTAGCAGCCCGCGGTCACCTTACTCTGGAAACACCATATATTTTGGAGAG	CASSPRSPYSGNTIYF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	6	7	5	0	3	8	23	34	41	37	49	TCRBV27,TCRBV28					01,02								CASSPRSPYSGNTIYF+X+TCRBJ01-03	unresolved	TCRBD02-01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GAAGACTCGGCCSTGTATCTCTGTGCCAGCAGACCGGACTAGCGGGGGGCCGAGGGGAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	51	1.6781670467221448E-4		52	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	6	1	1	4	3	8	21	32	49	35	57	TCRBV04,TCRBV07													X+X+TCRBJ02-05	unresolved	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCACGGCAGCGGGAGAGGGAGAGACCCAGTACTTCGGGCCA	CASTAAGEGETQYF	In	VDJ	1	51	1.6781670467221448E-4	2.1064631245043617E-4	42	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	7	6	2	4	4	4	18	28	40	32	44	TCRBV05,TCRBV11													CASTAAGEGETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGCCCAGGATAGTAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	51	1.6781670467221448E-4		43	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	4	4	5	1	5	18	35	40	36	45	TCRBV07,TCRBV11													X+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAAGCGGGAGGGCCGAGGCAGTATTTTGGCCCA	CASSQEAGGPRQYF	In	VDJ	1	52	1.711072282932383E-4	2.147766323024055E-4	42	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	0	6	0	11	0	5	26	-1	53	43	58		TCRBV03-01,TCRBV03-02												CASSQEAGGPRQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGACGAGGACAGCACTCAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	52	1.711072282932383E-4		49	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	0	1	5	7	3	5	23	40	49	43	54	TCRBV01,TCRBV04													X+X+TCRBJ01-06	unresolved	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCCAAGATCAGGGTGGCGACAGGGGACTATCTGGAAACACCATATATTTTGGAGAG	CASSQDQGGDRGLSGNTIYF	In	VDJ	1	52	1.711072282932383E-4	2.147766323024055E-4	60	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	2	2	1	15	4	19	31	54	46	58	TCRBV04,TCRBV07,TCRBV11													CASSQDQGGDRGLSGNTIYF+X+TCRBJ01-03	unresolved	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGCCGGACAGGGGGGGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	53	1.7439775191426213E-4		50	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	1	1	1	4	1	26	39	53	43	54		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCCGGCCTAAGTGGGTTGGGAAACACCATATATTTTGGAGAG	CSAPGLSGLGNTIYF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	45	TCRBV20						TCRBJ01	TCRBJ01-03	01	6	0	9	4	13	3	26	34	50	47	53		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAPGLSGLGNTIYF+TCRBV20-X+TCRBJ01-03	TCRBV20		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTTACAGACAGGGGGCGCCGGCTATGGCTACACCTTCGGTTCG	CASSLQTGGAGYGYTF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	2	0	4	5	5	24	36	51	41	56	TCRBV24,TCRBV27													CASSLQTGGAGYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCGACACGCCAGACACCAACACAGATACGCAGTATTTTGGCCCA	CADTPDTNTDTQYF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	12	2	6	2	1	13	18	23	28	24	41	TCRBV05,TCRBV12													CADTPDTNTDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGRAGACWCRGCWSYGTATCTCTGCGCCAGCAGCCAAGATCAAGCGGGAGAGACCCAGTACTTCGGGCCA	CASSQDQAGETQYF	In	VDJ	1	53	1.7439775191426213E-4	2.1890695215437484E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	2	6	4	4	5	0	20	35	-1	40	46	TCRBV01,TCRBV23					01,02								CASSQDQAGETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCATTAAGGACGGAACCGGGGAGCTGTTTTTTGGAGAA	CASSIKDGTGELFF	In	VDJ	1	54	1.7768827553528592E-4	2.2303727200634416E-4	42	TCRBV12						TCRBJ02	TCRBJ02-02	01	6	1	7	5	6	3	26	37	47	43	50		TCRBV12-03,TCRBV12-04,TCRBV12-05		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSIKDGTGELFF+TCRBV12-X+TCRBJ02-02	TCRBV12		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTGAGGCCGGACACTGAAGCTTTCTTTGGACAA	CASSLRPDTEAFF	In	VDJ	1	54	1.7768827553528592E-4	2.2303727200634416E-4	39	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	3	11	1	3	0	4	26	-1	44	40	48		TCRBV12-03,TCRBV12-04												CASSLRPDTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCTAGAGGAGACACCGGGGAGCTGTTTTTTGGAGAA	CASSPRGDTGELFF	In	VDJ	1	54	1.7768827553528592E-4	2.2303727200634416E-4	42	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	4	4	8	3	0	5	26	-1	43	39	48		TCRBV03-01,TCRBV03-02				01,02								CASSPRGDTGELFF+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTGCGTGGGACAGTGAGAGGGGAAAAACTGTTTTTTGGCAGT	CASSLRGTVRGEKLFF	In	VDJ	1	54	1.7768827553528592E-4	2.2303727200634416E-4	48	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	0	5	8	5	8	26	39	51	44	59		TCRBV03-01,TCRBV03-02												CASSLRGTVRGEKLFF+TCRBV03-X+TCRBJ01-04	TCRBV03	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCATCGTAGGTAGCCTTCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	54	1.7768827553528592E-4		40	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	7	5	7	3	7	3	26	36	47	43	50		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAAGGTCGAACACTGAAGCTTTCTTTGGACAA	CASSERSNTEAFF	In	VDJ	1	54	1.7768827553528592E-4	2.2303727200634416E-4	39	TCRBV06						TCRBJ01	TCRBJ01-01	01	2	5	4	1	0	2	23	-1	41	38	43		TCRBV06-01,TCRBV06-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSERSNTEAFF+TCRBV06-X+TCRBJ01-01	TCRBV06		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTGACAGGGGATCGTAACTATGGCTACACCTTCGGTTCG	CASSLTGDRNYGYTF	In	VDJ	1	54	1.7768827553528592E-4	2.2303727200634416E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	2	2	1	0	4	18	-1	40	32	44	TCRBV05,TCRBV11													CASSLTGDRNYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTGGGATCCTACGAGCAGTACTTCGGGCCG	CASSLGSYEQYF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	36	TCRBV03						TCRBJ02	TCRBJ02-07	01	4	0	8	1	1	0	26	39	-1	40	44		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGSYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTTTCTAGCGGGAGCGGGGCGGAGATACGCAGTATTTTGGCCCA	CASSF*RERGGDTQYF	Stop	VDJ	1	55	1.8097879915630975E-4		48	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	4	2	5	0	8	22	-1	46	36	54		TCRBV12-03,TCRBV12-04												CASSF*RERGGDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTTTTGCTTTGGGCTCCTACGAGCAGTACTTCGGGCCG	CASSFALGSYEQYF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	42	TCRBV12						TCRBJ02	TCRBJ02-07	01	3	0	9	0	6	0	22	36	-1	42	45		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFALGSYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCATGAAAGTGCCCCCAAGCACAGATACGCAGTATTTTGGCCCA	CASSMKVPPSTDTQYF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	48	unresolved						TCRBJ02	TCRBJ02-03	01	5	2	8	0	2	11	18	30	34	32	45	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSMKVPPSTDTQYF+X+TCRBJ02-03	unresolved		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCATTAAGCGGGAGACAGATACGCAGTATTTTGGCCCA	CASSIKRETDTQYF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	42	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	6	2	3	4	0	18	30	-1	34	42	TCRBV07,TCRBV11													CASSIKRETDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTCCATTCGCCCGCCGGACAGGGTTGACGGGACCGAGAGACCCAGTACTTCGGGCCA	CASSLHSPAGQG*RDRETQYF	Stop	VDJ	1	55	1.8097879915630975E-4		63				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	1	3	4	15	12	18	30	53	45	65	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-02,TCRBV11-03												CASSLHSPAGQG*RDRETQYF+X+TCRBJ02-05		TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGGCTCGGGGCTGGGAACACCGGGGAGCTGTTTTTTGGAGAA	CASRLGAGNTGELFF	In	VDJ	1	55	1.8097879915630975E-4	2.2716759185831351E-4	45	unresolved						TCRBJ02	TCRBJ02-02	01	6	7	0	1	4	3	23	34	43	38	46	TCRBV02,TCRBV09			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRLGAGNTGELFF+X+TCRBJ02-02	unresolved		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCGCAGACAGGGTACTCCTACAATGAGCAGTTCTTCGGGCCA	CSAPQTGYSYNEQFF	In	VDJ	1	56	1.8426932277733357E-4	2.3129791171028284E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	2	3	0	6	2	26	34	47	40	49		TCRBV20-01,TCRBV20-or09_02												CSAPQTGYSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATCTTACGGAGACCCAGTACTTCGGGCCA	CASSQDLTETQYF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	39	TCRBV03						TCRBJ02	TCRBJ02-05	01	0	3	7	5	4	1	26	43	49	47	50		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDLTETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTTACCTACAGGGTCCTAACGCTGAAGCTTTCTTTGGACAA	CSYLQGPNAEAFF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	8	3	3	6	5	8	26	32	43	37	51		TCRBV20-01,TCRBV20-or09_02												CSYLQGPNAEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTCAAGGGACAGGCAACTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CATSQGTGNSGANVLTF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	51	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	6	0	4	0	3	3	24	36	47	39	50		TCRBV24-01,TCRBV24-or09_02												CATSQGTGNSGANVLTF+TCRBV24-X+TCRBJ02-06	TCRBV24	TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGTCCCAGGGGGCCCCAAGAGACCCAGTACTTCGGGCCA	CASSPRGPQETQYF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	4	0	1	3	1	18	29	40	32	41	TCRBV07,TCRBV11													CASSPRGPQETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTGATTCACTAGCGGGAGTTTACGATACGCAGTATTTTGGCCCA	CASSDSLAGVYDTQYF	In	VDJ	1	57	1.8755984639835736E-4	2.3542823156225218E-4	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	3	2	6	3	5	23	37	51	40	56	TCRBV02,TCRBV12													CASSDSLAGVYDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATCCGCAGCAGGGTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	58	1.908503700193812E-4		47	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	4	3	4	7	0	26	43	-1	50	55		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCAGCGGGACTAGTCGAGTCTAGCACAGATACGCAGTATTTTGGCCCA	CSAAGLVESSTDTQYF	In	VDJ	1	58	1.908503700193812E-4	2.395585514142215E-4	48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	0	8	0	3	8	26	34	45	37	53		TCRBV20-01,TCRBV20-or09_02				01,02								CSAAGLVESSTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGTCCCCGTTGGATAGCAATCAGCCCCAGCATTTTGGTGAT	CSASPLDSNQPQHF	In	VDJ	1	58	1.908503700193812E-4	2.395585514142215E-4	42	TCRBV20						TCRBJ01	TCRBJ01-05	01	6	1	8	0	9	0	26	34	-1	43	46		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSASPLDSNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTTGACGAGGGACAGGGATAGTCGACGAGCAGTACTTCGGGCCG		Out	VDJ	1	58	1.908503700193812E-4		50	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	0	3	5	7	7	26	39	55	46	62		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCCGATCGCCTGGGGAACCTCCTATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	58	1.908503700193812E-4		50	TCRBV24						TCRBJ01	TCRBJ01-06	01	9	0	8	0	10	2	24	33	47	43	49		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ01-06	TCRBV24		TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCACCGGGACAGACCCAAACTATGGCTACACCTTCGGTTCG	CATGTDPNYGYTF	In	VDJ	1	58	1.908503700193812E-4	2.395585514142215E-4	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	10	0	5	2	2	5	23	30	39	32	44	TCRBV06,TCRBV10													CATGTDPNYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTCTAGCGACAGGGGGAACACTGAAGCTTTCTTTGGACAA	CASSSSDRGNTEAFF	In	VDJ	1	58	1.908503700193812E-4	2.395585514142215E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	2	2	1	5	0	19	32	-1	37	45	TCRBV05,TCRBV11													CASSSSDRGNTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCRGCCMTSTATCKCTGTGCCAGCAGCTTCAAAATCGGACTAGCGGGAGGAAATGAGCAGTTCTTCGGGCCA	CASSFKIGLAGGNEQFF	In	VDJ	1	58	1.908503700193812E-4	2.395585514142215E-4	51	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	1	1	7	7	1	19	33	54	40	55	TCRBV05,TCRBV07													CASSFKIGLAGGNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGTGGGTCGGGGACCCCAAGAAAAACTGTTTTTTGGCAGT	CASSQVGRGPQEKLFF	In	VDJ	1	60	1.974314172614288E-4	2.478191911181602E-4	48	TCRBV03						TCRBJ01	TCRBJ01-04	01	1	0	7	8	7	5	26	42	54	49	59		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQVGRGPQEKLFF+TCRBV03-X+TCRBJ01-04	TCRBV03		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCGGGGATATAGACTATGGCTACACCTTCGGTTCG	CSASGDIDYGYTF	In	VDJ	1	60	1.974314172614288E-4	2.478191911181602E-4	39	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	3	8	3	3	0	6	26	-1	42	37	48		TCRBV20-01,TCRBV20-or09_02												CSASGDIDYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGAGACAGATACGCAGTATTTTGGCCCA	CASSQETDTQYF	In	VJ	1	60	1.974314172614288E-4	2.478191911181602E-4	36	unresolved						TCRBJ02	TCRBJ02-03	01	0	0	0	3	0	1	23	-1	40	-1	41	TCRBV01,TCRBV04													CASSQETDTQYF+X+TCRBJ02-03	unresolved		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCTGTAAAGGACAGGACGAAGGAAACTGTTTTTTGGCAGT		Out	VDJ	1	60	1.974314172614288E-4		41	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	8	1	4	11	6	7	22	31	44	37	51		TCRBV12-03,TCRBV12-04												X+TCRBV12-X+TCRBJ01-04	TCRBV12	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGACCCTGACAGGCCCGAAAAACTGTTTTTTGGCAGT	CATSDPDRPEKLFF	In	VDJ	1	60	1.974314172614288E-4	2.478191911181602E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	2	4	8	4	3	24	38	48	42	51		TCRBV24-01,TCRBV24-or09_02												CATSDPDRPEKLFF+TCRBV24-X+TCRBJ01-04	TCRBV24	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGGGCCAGGGGGAGGCAACAATGAGCAGTTCTTCGGGCCA	CATSGPGGGNNEQFF	In	VDJ	1	60	1.974314172614288E-4	2.478191911181602E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	4	1	5	3	5	24	37	47	40	52		TCRBV24-01,TCRBV24-or09_02												CATSGPGGGNNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCACGGACTTCTTCGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSTDFFANTGELFF	In	VDJ	1	60	1.974314172614288E-4	2.478191911181602E-4	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	5	1	10	0	2	6	18	30	37	32	43	TCRBV05,TCRBV11					01,02								CASSTDFFANTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCCAAGAATGGGGGGCAGGAAATGAGCAGTTCTTCGGGCCA	CASSQEWGAGNEQFF	In	VDJ	1	60	1.974314172614288E-4	2.478191911181602E-4	45	unresolved						TCRBJ02	TCRBJ02-01	01	4	6	0	7	8	4	19	31	45	39	49	TCRBV04,TCRBV05,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQEWGAGNEQFF+X+TCRBJ02-01	unresolved		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCTTAGTGTCGGCGGAAGTGAGCCTTGGAAACACCATATATTTTGGAGAG	CASSLVSAEVSLGNTIYF	In	VDJ	1	60	1.974314172614288E-4	2.478191911181602E-4	54	TCRBV05			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	2	7	5	3	7	10	19	33	44	40	54		TCRBV05-06,TCRBV05-07				01,02								CASSLVSAEVSLGNTIYF+TCRBV05-X+TCRBJ01-03	TCRBV05	TCRBD02-01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCCCCCTTAGACAGGGAGCGGGCTTCTTTGGACAA	CASSPLRQGAGFF	In	VDJ	1	61	2.0072194088245263E-4	2.5194951097012955E-4	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	2	3	14	8	7	26	37	52	45	59		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSPLRQGAGFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTCCCCACAGAAAGGGCCCTAATGAAAAACTGTTTTTTGGCAGT	CSPHRKGPNEKLFF	In	VDJ	1	61	2.0072194088245263E-4	2.5194951097012955E-4	42	TCRBV20						TCRBJ01	TCRBJ01-04	01	8	3	5	3	4	8	26	32	40	36	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSPHRKGPNEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGGTCCCGGTTTTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	61	2.0072194088245263E-4		40	TCRBV20						TCRBJ01	TCRBJ01-04	01	5	0	9	4	0	9	26	-1	38	35	47		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV20-X+TCRBJ01-04	TCRBV20		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCATGACTAGCGGGGGGGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	61	2.0072194088245263E-4		41	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	10	2	1	1	1	0	23	30	-1	31	44	TCRBV06,TCRBV10													X+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAACCCAGGGGCACCTCTCAATTCCTACGAGCAGTACTTCGGGCCG	CASNPGAPLNSYEQYF	In	VDJ	1	61	2.0072194088245263E-4	2.5194951097012955E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	4	2	1	3	11	18	28	37	31	48	TCRBV07,TCRBV11													CASNPGAPLNSYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGATCAGGGGTATTCACCCCTCCACTTTGGGAAC	CASSQDQGYSPLHF	In	VDJ	1	61	2.0072194088245263E-4	2.5194951097012955E-4	42				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	0	4	2	8	1	1	18	35	42	36	43	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03												CASSQDQGYSPLHF+X+TCRBJ01-06		TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGTTTCAGGGTCGTCGGGGAGCTGTTTTTTGGAGAA	CASSQGFRVVGELFF	In	VDJ	1	62	2.0401246450347642E-4	2.560798308220989E-4	45	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	1	4	3	7	4	4	26	42	51	46	55		TCRBV03-01,TCRBV03-02												CASSQGFRVVGELFF+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTTGGGGAGGGGGAGACCCAGTACTTCGGGCCA	CASSFGEGETQYF	In	VDJ	1	62	2.0401246450347642E-4	2.560798308220989E-4	39	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	3	9	0	5	2	1	22	36	45	38	46		TCRBV12-03,TCRBV12-04												CASSFGEGETQYF+TCRBV12-X+TCRBJ02-05	TCRBV12	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTAGACGCGGACAGTATGGCTACACCTTCGGTTCG		Out	VDJ	1	62	2.0401246450347642E-4		41	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	1	5	5	3	0	18	35	-1	38	44	TCRBV05,TCRBV11													X+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGACGTTCAGAAGCGAGGCTACACCTTCGGTTCG		Out	VDJ	1	62	2.0401246450347642E-4		44				TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	0	6	6	8	10	1	18	35	49	45	50	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03				01,02								X+X+TCRBJ01-02		TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTTCGACCGGGACAGGAAGCAATCAGCCCCAGCATTTTGGTGAT	CSASTGTGSNQPQHF	In	VDJ	1	63	2.0730298812450025E-4	2.602101506740682E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	0	4	1	6	1	26	35	49	41	50		TCRBV20-01,TCRBV20-or09_02												CSASTGTGSNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTGTTGCGGGGCTCAATGAACACTGAAGCTTTCTTTGGACAA	CASSLLRGSMNTEAFF	In	VDJ	1	63	2.0730298812450025E-4	2.602101506740682E-4	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	3	7	3	0	3	5	18	32	41	35	46	TCRBV07,TCRBV11													CASSLLRGSMNTEAFF+X+TCRBJ01-01	unresolved	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCTTGTGGAGGCGGCGCCCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	63	2.0730298812450025E-4		47	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	3	10	1	3	2	7	19	33	40	35	47	TCRBV07,TCRBV11													X+X+TCRBJ01-05	unresolved	TCRBD02-01*02	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGTGTCGGGACCGTTGGACAGGAAAAACTGTTTTTTGGCAGT	CASSVGTVGQEKLFF	In	VDJ	1	63	2.0730298812450025E-4	2.602101506740682E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	1	5	8	13	0	23	34	-1	47	53	TCRBV09,TCRBV21													CASSVGTVGQEKLFF+X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGCAATTTAGCGGGGGGGCCGAGTACGCAGTATTTTGGCCCA	CASSNLAGGPSTQYF	In	VDJ	1	64	2.1059351174552407E-4	2.643404705260375E-4	45	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	6	5	0	8	5	5	26	37	53	42	58		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSNLAGGPSTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATCCCAGGCCCTTATGGCTACACCTTCGGTTCG		Out	VDJ	1	64	2.1059351174552407E-4		43	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	4	5	3	4	26	43	50	46	54		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAAATGAGGGCAGGGCGGGCTACACCTTCGGTTCG	CASSQNEGRAGYTF	In	VDJ	1	64	2.1059351174552407E-4	2.643404705260375E-4	42	unresolved						TCRBJ01	TCRBJ01-02	01	2	4	3	8	8	2	23	38	51	46	53	TCRBV01,TCRBV04			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQNEGRAGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTGGGGGGTGGGTCCTACAATGAGCAGTTCTTCGGGCCA	CASSLGGGSYNEQFF	In	VDJ	1	64	2.1059351174552407E-4	2.643404705260375E-4	45	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	9	1	1	2	4	24	36	44	38	48		TCRBV24-01,TCRBV24-or09_02												CASSLGGGSYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCTTAGACAACTTAAGCAATCAGCCCCAGCATTTTGGTGAT	CASSLDNLSNQPQHF	In	VDJ	1	64	2.1059351174552407E-4	2.643404705260375E-4	45	unresolved			unresolved			TCRBJ01	TCRBJ01-05	01	0	3	10	1	2	2	18	35	40	37	42	TCRBV07,TCRBV11			TCRBD01,TCRBD02										CASSLDNLSNQPQHF+X+TCRBJ01-05	unresolved	unresolved	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCCGATCGGACAGGGCAGTCTTCAGCAGTACTTCGGGCCG		Out	VDJ	1	65	2.1388403536654787E-4		41	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	10	1	3	8	7	8	24	31	46	38	54	TCRBV06,TCRBV10													X+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGTTATAGCGGGGGGGCCTACGAGCAGTACTTCGGGCCG	CASSYSGGAYEQYF	In	VDJ	1	65	2.1388403536654787E-4	2.684707903780069E-4	42	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	5	0	2	3	0	26	37	-1	40	51		TCRBV03-01,TCRBV03-02												CASSYSGGAYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGATGGGGCAGGGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	65	2.1388403536654787E-4		41	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	7	0	2	1	3	26	38	44	39	47		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTATCCTAGGGAAAGAGACCCAGTACTTCGGGCCA	CSAILGKETQYF	In	VDJ	1	65	2.1388403536654787E-4	2.684707903780069E-4	36	TCRBV20						TCRBJ02	TCRBJ02-05	01	4	0	8	3	5	0	26	36	-1	41	45		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAILGKETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCGCCCCGGGGGGACGCACAGATACGCAGTATTTTGGCCCA	CASAPGGRTDTQYF	In	VDJ	1	65	2.1388403536654787E-4	2.684707903780069E-4	42	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	11	8	1	1	6	2	24	31	44	37	46		TCRBV24-01,TCRBV24-or09_02												CASAPGGRTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCCACAGGGGGAACTATGGCTACACCTTCGGTTCG	CASHRGNYGYTF	In	VDJ	1	65	2.1388403536654787E-4	2.684707903780069E-4	36	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	3	1	2	1	0	23	32	-1	33	41	TCRBV02,TCRBV09													CASHRGNYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGCCCGACCTCTGGGGGGGGGCAGTTCTTCGGGCCA	CASSPTSGGGQFF	In	VDJ	1	66	2.171745589875717E-4	2.726011102299762E-4	39	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	7	9	0	12	10	1	24	35	52	45	53		TCRBV24-01,TCRBV24-or09_02												CASSPTSGGGQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTGAATTGGGGGGGCTACGAGCAGTACTTCGGGCCG	CASSLNWGGYEQYF	In	VDJ	1	66	2.171745589875717E-4	2.726011102299762E-4	42	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	9	0	3	7	0	24	36	-1	43	50		TCRBV24-01,TCRBV24-or09_02												CASSLNWGGYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTTCTGTGCCAGCAGCCAAGATCTAGCAGGCCATCACCCCGAGCTCCTATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	66	2.171745589875717E-4		64	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	0	4	7	0	1	16	4	21	27	22	43		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ01-06	TCRBV03	TCRBD02-01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTTACTAACACTGAAGCTTTCTTTGGACAA	CASSFTNTEAFF	In	VDJ	1	67	2.204650826085955E-4	2.7673143008194554E-4	36	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	3	3	10	2	1	0	26	40	-1	41	44		TCRBV12-03,TCRBV12-04				01,02								CASSFTNTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATGCCTGGACGGGTGGCTACACCTTCGGTTCG	CASSQDAWTGGYTF	In	VDJ	1	67	2.204650826085955E-4	2.7673143008194554E-4	42	TCRBV03						TCRBJ01	TCRBJ01-02	01	0	1	7	7	5	3	26	43	52	48	55		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDAWTGGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCGGACAGGCGGCAACTCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	67	2.204650826085955E-4		40	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	1	4	6	2	7	26	34	43	36	50		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTTCCCCCAACGACTAGCGGGACAAAAGAGACCCAGTACTTCGGGCCA	CATSDFPPTTSGTKETQYF	In	VDJ	1	67	2.204650826085955E-4	2.7673143008194554E-4	57	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	1	2	3	3	9	3	24	41	61	50	64		TCRBV24-01,TCRBV24-or09_02												CATSDFPPTTSGTKETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATCGGGCACCTTGAACACTGAAGCTTTCTTTGGACAA	CASSLSGTLNTEAFF	In	VDJ	1	67	2.204650826085955E-4	2.7673143008194554E-4	45							TCRBJ01	TCRBJ01-01	01	6	8	0	0	5	4	24	36	45	41	49	TCRBV24,TCRBV27	TCRBV24-01,TCRBV24-or09_02,TCRBV27-01		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLSGTLNTEAFF+X+TCRBJ01-01			TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGAATCAGGTGGGAGCTGTTTTTTGGAGAA	CASSQGIRWELFF	In	VDJ	1	68	2.237556062296193E-4	2.8086174993391486E-4	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	1	4	4	9	4	1	26	42	50	46	51		TCRBV03-01,TCRBV03-02												CASSQGIRWELFF+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCGGATGGGCGGTGAACACTGAAGCTTTCTTTGGACAA	CASSPGWAVNTEAFF	In	VDJ	1	68	2.237556062296193E-4	2.8086174993391486E-4	45	TCRBV03						TCRBJ01	TCRBJ01-01	01	4	8	0	0	6	2	26	39	49	45	51		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPGWAVNTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGGGAAACGTACCCACTTTTGAACACTGAAGCTTTCTTTGGACAA	CSARGETYPLLNTEAFF	In	VDJ	1	68	2.237556062296193E-4	2.8086174993391486E-4	51	TCRBV20						TCRBJ01	TCRBJ01-01	01	1	0	8	0	0	14	26	-1	43	39	57		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARGETYPLLNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTGATTTCAGGATTGGTGGGAATCAGCCCCAGCATTTTGGTGAT	CASSDFRIGGNQPQHF	In	VDJ	1	68	2.237556062296193E-4	2.8086174993391486E-4	48	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	4	4	4	5	9	22	34	43	39	52		TCRBV12-03,TCRBV12-04												CASSDFRIGGNQPQHF+TCRBV12-X+TCRBJ01-05	TCRBV12	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTGGAGCACTAGCATCACTGAGCAGTTCTTCGGGCCA	CATSDWSTSITEQFF	In	VDJ	1	68	2.237556062296193E-4	2.8086174993391486E-4	45	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	3	7	9	5	5	24	40	51	45	56		TCRBV24-01,TCRBV24-or09_02				01,02								CATSDWSTSITEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGCCTGACTGGGCCTCCAGCTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	68	2.237556062296193E-4		50	TCRBV24						TCRBJ01	TCRBJ01-03	01	7	8	0	0	7	6	24	35	46	42	52		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ01-03	TCRBV24		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCCAAGACGTGGGAACCTACAATGAGCAGTTCTTCGGGCCA	CASSQDVGTYNEQFF	In	VDJ	1	68	2.237556062296193E-4	2.8086174993391486E-4	45							TCRBJ02	TCRBJ02-01	01	0	0	8	2	3	1	18	35	42	38	43	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDVGTYNEQFF+X+TCRBJ02-01			TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCCCCCATCGTGTCTGACAGGCCCCGAAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	68	2.237556062296193E-4		55	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	2	4	2	13	6	18	30	49	43	55	TCRBV05,TCRBV11													X+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCCCGAGTCGGGGATTGAGGATGGCTACACCTTCGGTTCG		Out	VDJ	1	68	2.237556062296193E-4		44	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	5	8	3	6	6	7	18	30	41	36	48	TCRBV07,TCRBV11													X+X+TCRBJ01-02	unresolved	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTATTGACGGGCCTACCTTTGTTCGCACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	68	2.237556062296193E-4		53	unresolved						TCRBJ01	TCRBJ01-01	01	2	8	0	4	5	13	18	33	42	38	55	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGGGGACTYGGCYGTGTATSTCTGTGCCAGCAGCCCCGGGCGTGGGGGCGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSPGRGGANTGELFF	In	VDJ	1	68	2.237556062296193E-4	2.8086174993391486E-4	51	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	6	0	0	9	1	22	34	49	43	50	TCRBV07,TCRBV11													CASSPGRGGANTGELFF+X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGAGATAAACCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	69	2.2704612985064313E-4		41	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	1	11	2	2	0	5	26	-1	42	39	47		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-04	TCRBV20	TCRBD02-01*02	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTGAATAGTTGGACAGCCACCGGGGAGCTGTTTTTTGGAGAA	CASSLNSWTATGELFF	In	VDJ	1	69	2.2704612985064313E-4	2.8499206978588424E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	1	5	4	8	1	18	32	46	40	47	TCRBV07,TCRBV11													CASSLNSWTATGELFF+X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACAGCCCACCCCCGGTTATGAGCAGTTCTTCGGGCCA	CSARQPTPGYEQFF	In	VDJ	1	70	2.3033665347166695E-4	2.8912238963785356E-4	42	TCRBV20						TCRBJ02	TCRBJ02-01	01	2	4	5	8	0	13	26	-1	41	38	54		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARQPTPGYEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGGACAGGGGGCAGGCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	70	2.3033665347166695E-4		43	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	1	0	3	0	3	26	-1	50	39	53		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAATCGACCGGGACAGGGTACAATGAGCAGTTCTTCGGGCCA	CASSESTGTGYNEQFF	In	VDJ	1	70	2.3033665347166695E-4	2.8912238963785356E-4	48	TCRBV06			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	0	3	4	6	0	23	38	-1	44	53		TCRBV06-01,TCRBV06-08												CASSESTGTGYNEQFF+TCRBV06-X+TCRBJ02-01	TCRBV06	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGAGGTAGCGGGGAGCACAGATACGCAGTATTTTGGCCCA	CASSQEVAGSTDTQYF	In	VDJ	1	71	2.3362717709269075E-4	2.932527094898229E-4	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	5	3	0	2	0	23	40	-1	42	50	TCRBV01,TCRBV04													CASSQEVAGSTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTGACGGGGACAGGGGGCCCCCTAGCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	71	2.3362717709269075E-4		52	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	0	2	2	7	24	38	52	40	59	TCRBV06,TCRBV10													X+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAAACAGGGGGCAGATACGCAGTATTTTGGCCCA	CSAKQGADTQYF	In	VDJ	1	71	2.3362717709269075E-4	2.932527094898229E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	3	1	4	1	0	26	36	-1	37	45		TCRBV20-01,TCRBV20-or09_02												CSAKQGADTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCTCCTAGCGGGGAGCACAGATACGCAGTATTTTGGCCCA	CSARDLLAGSTDTQYF	In	VDJ	1	72	2.3691770071371457E-4	2.973830293417922E-4	48	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	4	3	0	4	0	26	40	-1	44	53		TCRBV20-01,TCRBV20-or09_02												CSARDLLAGSTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTAGGACAGGGCTCGACAGATACGCAGTATTTTGGCCCA	CATSDLGQGSTDTQYF	In	VDJ	1	72	2.3691770071371457E-4	2.973830293417922E-4	48	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	1	1	3	3	1	4	24	41	50	42	54		TCRBV24-01,TCRBV24-or09_02												CATSDLGQGSTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAAGGGGACGAAAAGCCGGCGCACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	72	2.3691770071371457E-4		50	TCRBV06						TCRBJ01	TCRBJ01-01	01	2	0	7	4	2	12	23	38	45	40	57		TCRBV06-01,TCRBV06-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-X+TCRBJ01-01	TCRBV06		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAGAGGACAATCAGCCCCAGCATTTTGGTGAT	CASSLEDNQPQHF	In	VDJ	1	73	2.402082243347384E-4	3.015133491937616E-4	39	TCRBV12						TCRBJ01	TCRBJ01-05	01	1	1	8	3	1	0	26	42	-1	43	46		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLEDNQPQHF+TCRBV12-X+TCRBJ01-05	TCRBV12		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAAATAGGGGCCGGGATTCACCCCTCCACTTTGGGAAC	CASSQNRGRDSPLHF	In	VDJ	1	73	2.402082243347384E-4	3.015133491937616E-4	45	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	2	5	2	8	3	5	26	41	49	44	54		TCRBV03-01,TCRBV03-02												CASSQNRGRDSPLHF+TCRBV03-X+TCRBJ01-06	TCRBV03	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATTCCGAGCGGGGGATATCCTACGAGCAGTACTTCGGGCCG	CSARDSERGISYEQYF	In	VDJ	1	73	2.402082243347384E-4	3.015133491937616E-4	48	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	6	2	1	5	3	26	40	53	45	56		TCRBV20-01,TCRBV20-or09_02												CSARDSERGISYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAGGAAACAGGGGGCCAAGAGACCCAGTACTTCGGGCCA	CASSQETGGQETQYF	In	VDJ	1	74	2.434987479557622E-4	3.056436690457309E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	3	1	1	4	0	23	37	-1	41	49	TCRBV01,TCRBV04													CASSQETGGQETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGACAGGCCTGGAGAAATTCACCCCTCCACTTTGGGAAC	CASSQGQAWRNSPLHF	In	VDJ	1	74	2.434987479557622E-4	3.056436690457309E-4	48	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	1	2	4	7	0	8	26	-1	48	42	56		TCRBV03-01,TCRBV03-02												CASSQGQAWRNSPLHF+TCRBV03-X+TCRBJ01-06	TCRBV03	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGGACAGGGAGGAGACCCAGTACTTCGGGCCA	CASSPDREETQYF	In	VDJ	1	74	2.434987479557622E-4	3.056436690457309E-4	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	1	3	5	1	2	26	39	48	40	50		TCRBV03-01,TCRBV03-02												CASSPDREETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCGTCCAGGGGTGAGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	74	2.434987479557622E-4		40	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	8	4	2	1	3	3	26	35	44	38	47		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGCGTAGGCACTATCGGTTGGAATGAGCAGTTCTTCGGGCCA	CASSVGTIGWNEQFF	In	VDJ	1	74	2.434987479557622E-4	3.056436690457309E-4	45	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	3	9	7	7	8	22	33	44	40	52		TCRBV12-03,TCRBV12-04				01,02								CASSVGTIGWNEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGGGCCGTCCGGGGAAGCAGTACTTCGGGCCG	CATSDLGRPGKQYF	In	VDJ	1	74	2.434987479557622E-4	3.056436690457309E-4	42	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	8	3	8	7	1	24	42	54	49	55		TCRBV24-01,TCRBV24-or09_02												CATSDLGRPGKQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCGGGACAGGGGGTAACTATGGCTACACCTTCGGTTCG	CSASGTGGNYGYTF	In	VDJ	1	75	2.46789271576786E-4	3.097739888977002E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	0	1	1	1	0	26	37	-1	38	49		TCRBV20-01,TCRBV20-or09_02												CSASGTGGNYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGTCTCCTGGGTGGGGGATAGGTTCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	75	2.46789271576786E-4		52	TCRBV24						TCRBJ02	TCRBJ02-03	01	5	6	1	4	10	7	24	37	52	47	59		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ02-03	TCRBV24		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTAGAAGCCGGGGGGGACGAAAAACTGTTTTTTGGCAGT	CASSLEAGGDEKLFF	In	VDJ	1	75	2.46789271576786E-4	3.097739888977002E-4	45	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	2	8	0	8	6	2	19	33	47	39	49	TCRBV05,TCRBV11													CASSLEAGGDEKLFF+X+TCRBJ01-04	unresolved	TCRBD02-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGTCGGGAAACAGCCCTCTGGGAACACTGAAGCTTTCTTTGGACAA	CASSQVGKQPSGNTEAFF	In	VDJ	1	76	2.5007979519780984E-4	3.139043087496696E-4	54	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	1	8	3	1	1	13	26	42	48	43	61		TCRBV03-01,TCRBV03-02												CASSQVGKQPSGNTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTAGAAGGGTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSLEGSGANVLTF	In	VDJ	1	76	2.5007979519780984E-4	3.139043087496696E-4	45	unresolved						TCRBJ02	TCRBJ02-06	01	0	5	3	1	0	0	18	-1	-1	35	39	TCRBV05,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLEGSGANVLTF+X+TCRBJ02-06	unresolved		TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTGGGCCACGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	76	2.5007979519780984E-4		38	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	9	0	1	0	3	23	-1	39	36	42	TCRBV02,TCRBV09													X+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCAGTCCGGGACCCTCGGGAGAGACCCAGTACTTCGGGCCA	CASSPGPSGETQYF	In	VDJ	1	76	2.5007979519780984E-4	3.139043087496696E-4	42	unresolved						TCRBJ02	TCRBJ02-05	01	5	0	7	4	3	7	23	34	42	37	49	TCRBV09,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPGPSGETQYF+X+TCRBJ02-05	unresolved		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCCGAGGGGTAGATAATTCACCCCTCCACTTTGGGAAC	CASRGVDNSPLHF	In	VDJ	1	77	2.5337031881883363E-4	3.180346286016389E-4	39	TCRBV03						TCRBJ01	TCRBJ01-06	01	8	5	2	5	2	3	26	35	42	37	45		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRGVDNSPLHF+TCRBV03-X+TCRBJ01-06	TCRBV03		TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCAGGGGGGCGGGAGCAATCAGCCCCAGCATTTTGGTGAT	CSAQGGGSNQPQHF	In	VDJ	1	77	2.5337031881883363E-4	3.180346286016389E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	4	1	1	1	5	26	34	42	35	47		TCRBV20-01,TCRBV20-or09_02												CSAQGGGSNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGGGACAGGGGGCTACGAGCAGTACTTCGGGCCG	CSARGTGGYEQYF	In	VDJ	1	77	2.5337031881883363E-4	3.180346286016389E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	1	3	1	0	26	37	-1	38	49		TCRBV20-01,TCRBV20-or09_02												CSARGTGGYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTCCATACACCAGGGGGATGAGCAGTTCTTCGGGCCA	CASSSIHQGDEQFF	In	VDJ	1	77	2.5337031881883363E-4	3.180346286016389E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	4	1	8	9	0	24	36	-1	45	52	TCRBV24,TCRBV27													CASSSIHQGDEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGATTGAGGAAACACCATATATTTTGGAGAG	CASSQD*GNTIYF	Stop	VDJ	1	78	2.5666084243985743E-4		39	unresolved						TCRBJ01	TCRBJ01-03	01	0	2	8	4	2	0	23	40	-1	42	44	TCRBV01,TCRBV04			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQD*GNTIYF+X+TCRBJ01-03	unresolved		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAAGGATTGGCAGGGGGCCGGGTTGGCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	78	2.5666084243985743E-4		56	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	4	0	7	8	8	25	42	58	50	66		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGATAGGACGGACGGAAGATACGAGCAGTACTTCGGGCCG		Out	VDJ	1	79	2.599513660608813E-4		50	TCRBV24						TCRBJ02	TCRBJ02-07	01	0	1	7	4	3	10	24	42	49	45	59		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ02-07	TCRBV24		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCAGAAAGGGACCGGACTCTGGAAACACCATATATTTTGGAGAG	CASRKGPDSGNTIYF	In	VDJ	1	79	2.599513660608813E-4	3.2629526830557756E-4	45	unresolved						TCRBJ01	TCRBJ01-03	01	5	0	7	0	3	4	23	34	42	37	46	TCRBV09,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRKGPDSGNTIYF+X+TCRBJ01-03	unresolved		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTATCAGTGGACCCTACGAGCAGTACTTCGGGCCG	CASSISGPYEQYF	In	VDJ	1	80	2.632418896819051E-4	3.3042558815754694E-4	39	TCRBV12						TCRBJ02	TCRBJ02-07	01	5	1	7	2	6	0	26	38	-1	44	48		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSISGPYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATCCGGCGGGGGTTTGACCGGGGAGCTRTTTTTTGGAGAA		Out	VDJ	1	80	2.632418896819051E-4		50	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	0	7	2	17	4	16	26	43	54	47	70		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD02-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGGGGGGGAGGGAGTCAATTATAGAGCAGTTCTTCGGGCCA	CSAGGRESIIEQFF	In	VDJ	1	80	2.632418896819051E-4	3.3042558815754694E-4	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	9	0	10	0	15	26	-1	41	34	56		TCRBV20-01,TCRBV20-or09_02				01,02								CSAGGRESIIEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATGGGGTTAACTATGGCTACACCTTCGGTTCG	CSARDGVNYGYTF	In	VDJ	1	80	2.632418896819051E-4	3.3042558815754694E-4	39	TCRBV20						TCRBJ01	TCRBJ01-02	01	0	6	2	1	1	1	26	40	45	41	46		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDGVNYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAACTCCCCTAGCGGGAGCGCTAGCACAGATACGCAGTATTTTGGCCCA	CSANSPSGSASTDTQYF	In	VDJ	1	81	2.6653241330292887E-4	3.3455590800951626E-4	51	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	4	4	2	0	6	4	26	36	52	42	56		TCRBV20-01,TCRBV20-or09_02												CSANSPSGSASTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAAGTCCGGGACAGGGTAACAACTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	81	2.6653241330292887E-4		52	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	7	0	3	0	5	6	22	32	46	37	52	TCRBV02,TCRBV12													X+X+TCRBJ01-03	unresolved	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTTGTGCGGGGACCTGGGTATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	81	2.6653241330292887E-4		50	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	6	7	3	4	4	7	24	36	46	40	53	TCRBV24,TCRBV27													X+X+TCRBJ01-06	unresolved	TCRBD02-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCCACCGGGAAGTACAATGAGCAGTTCTTCGGGCCA	CASSLATGKYNEQFF	In	VDJ	1	81	2.6653241330292887E-4	3.3455590800951626E-4	45				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	8	3	4	3	2	18	35	43	38	45	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLATGKYNEQFF+X+TCRBJ02-01		TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCTCCTCCAGGGTGAACACTGAAGCTTTCTTTGGACAA	CASSSSRVNTEAFF	In	VDJ	1	81	2.6653241330292887E-4	3.3455590800951626E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	4	3	0	5	0	23	35	-1	40	45	TCRBV09,TCRBV21													CASSSSRVNTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTTAAGGAGCACCGGGGAGCTGTTTTTTGGAGAA	CASSLRSTGELFF	In	VDJ	1	82	2.698229369239527E-4	3.386862278614856E-4	39	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	2	10	2	4	1	0	23	38	-1	39	43	TCRBV24,TCRBV27													CASSLRSTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01*02	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAACAGAGGATTAATGAAAAACTGTTTTTTGGCAGT	CASSEQRINEKLFF	In	VDJ	1	82	2.698229369239527E-4	3.386862278614856E-4	42	TCRBV06			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	2	11	1	4	2	2	23	38	44	40	46		TCRBV06-01,TCRBV06-08												CASSEQRINEKLFF+TCRBV06-X+TCRBJ01-04	TCRBV06	TCRBD02-01*02	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGAGGAAATGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSQEEMSSYNEQFF	In	VDJ	1	82	2.698229369239527E-4	3.386862278614856E-4	48							TCRBJ02	TCRBJ02-01	01	0	1	8	0	0	6	18	-1	38	35	44	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQEEMSSYNEQFF+X+TCRBJ02-01			TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGTTTCGGACAGTCAATGAGCAGTTCTTCGGGCCA	CASSLAFRTVNEQFF	In	VDJ	1	84	2.764039841660003E-4	3.469468675654243E-4	45				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	1	5	6	5	1	18	35	46	40	47	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAFRTVNEQFF+X+TCRBJ02-01		TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCGTGGACAGTACGAGCAGTACTTCGGGCCG	CASSRGQYEQYF	In	VDJ	1	85	2.7969450778702416E-4	3.510771874173936E-4	36	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	1	5	4	2	0	26	39	-1	41	47		TCRBV03-01,TCRBV03-02												CASSRGQYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGGCCCGACGGGGACAGGGCCAACAATGAGCAGTTCTTCGGGCCA	CRPDGDRANNEQFF	In	VDJ	1	85	2.7969450778702416E-4	3.510771874173936E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	9	0	3	5	8	3	26	31	48	39	51		TCRBV20-01,TCRBV20-or09_02												CRPDGDRANNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGGGGGACGCGGCGCCCCAAGAGACCCAGTACTTCGGGCCA	CSAGDAAPQETQYF	In	VDJ	1	85	2.7969450778702416E-4	3.510771874173936E-4	42	TCRBV20						TCRBJ02	TCRBJ02-05	01	6	0	7	1	2	8	26	34	41	36	49		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAGDAAPQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCACTACAAGGGGGGGGAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	85	2.7969450778702416E-4		40	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	11	9	0	4	9	1	24	31	47	40	48		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ARRRRGACTCAGCYGYGTATCTCTRCGCCAGCAGCCCTGATAGTAACGAGCGACCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	85	2.7969450778702416E-4		49	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	5	6	6	0	13	0	22	34	-1	47	51	TCRBV01,TCRBV07,TCRBV17					01,02								X+X+TCRBJ02-05	unresolved	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGTGTTACCCGGGGAGCTGTTTTTTGGAGAA	CASSQVLPGELFF	In	VDJ	1	86	2.8298503140804796E-4	3.552075072693629E-4	39	TCRBV03						TCRBJ02	TCRBJ02-02	01	1	3	7	6	4	0	26	42	-1	46	48		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQVLPGELFF+TCRBV03-X+TCRBJ02-02	TCRBV03		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCACGCTCGAGGCCTACTCCTACGAGCAGTACTTCGGGCCG	CSATLEAYSYEQYF	In	VDJ	1	86	2.8298503140804796E-4	3.552075072693629E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	11	1	0	7	4	26	34	45	41	49		TCRBV20-01,TCRBV20-or09_02												CSATLEAYSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTCCCGATGGGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	86	2.8298503140804796E-4		40	unresolved						TCRBJ02	TCRBJ02-03	01	6	0	10	1	6	0	24	36	-1	42	44	TCRBV24,TCRBV27			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ02-03	unresolved		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTGGGGGGACAGGGGCGAAAAACTGTTTTTTGGCAGT	CASSWGDRGEKLFF	In	VDJ	1	86	2.8298503140804796E-4	3.552075072693629E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	0	2	8	3	1	19	32	45	35	46	TCRBV07,TCRBV11													CASSWGDRGEKLFF+X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCYGTGTATSTCTGTGCCAGAAGCGCGGGACAGGCCCACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	86	2.8298503140804796E-4		43	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	4	2	2	4	18	30	40	32	44	TCRBV05,TCRBV07,TCRBV11													X+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTAAGGGAGTCATCAAGAAGCGGGCCCGGGGAAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	86	2.8298503140804796E-4		58	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	6	4	7	13	8	23	39	58	52	66		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAGACGGGAGGGCATCCGAGCAGTACTTCGGGCCG	CASSLDGRASEQYF	In	VDJ	1	87	2.8627555502907175E-4	3.593378271213323E-4	42	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	1	8	0	6	1	4	26	42	51	43	55		TCRBV12-03,TCRBV12-04												CASSLDGRASEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACAGGGATATATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	87	2.8627555502907175E-4		41	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	2	4	3	4	0	3	26	-1	43	38	46		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-06	TCRBV20	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGTTCTACCATGATTACGAGCAGTACTTCGGGCCG	CATSDLFYHDYEQYF	In	VDJ	1	87	2.8627555502907175E-4	3.593378271213323E-4	45	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	4	9	4	2	7	24	42	47	44	54		TCRBV24-01,TCRBV24-or09_02				01,02								CATSDLFYHDYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATCCCGATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	87	2.8627555502907175E-4		37				TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	6	5	9	5	1	5	24	36	39	37	44	TCRBV24,TCRBV27	TCRBV24-01,TCRBV24-or09_02,TCRBV27-01				01,02								X+X+TCRBJ01-05		TCRBD02-01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGAAGCTTGGCGAGGGGGATCCGTATTGGGATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	87	2.8627555502907175E-4		50	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	5	1	8	2	12	18	34	42	36	54	TCRBV05,TCRBV07													X+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGAGGGGACAGGGAGAAGCGTCAATGAGCAGTTCTTCGGGCCA	CASSLEGTGRSVNEQFF	In	VDJ	1	87	2.8627555502907175E-4	3.593378271213323E-4	51	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	0	3	6	1	8	18	35	45	36	53	TCRBV07,TCRBV11													CASSLEGTGRSVNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCTATAGCGGGGGGAATGACTACGAGCAGTACTTCGGGCCG	CASSYSGGNDYEQYF	In	VDJ	1	87	2.8627555502907175E-4	3.593378271213323E-4	45	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	4	5	1	3	2	5	23	35	47	37	52	TCRBV09,TCRBV21													CASSYSGGNDYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAGAGGACAGAGGAAAACTGTTTTTTGGCAGT	CASSLEDRGKLFF	In	VDJ	1	88	2.895660786500956E-4	3.634681469733016E-4	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	1	1	5	10	1	3	26	42	49	43	52		TCRBV12-03,TCRBV12-04												CASSLEDRGKLFF+TCRBV12-X+TCRBJ01-04	TCRBV12	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTTCGGGGGGGCTTGGACGAGCAGTACTTCGGGCCG	CASSFRGGLDEQYF	In	VDJ	1	88	2.895660786500956E-4	3.634681469733016E-4	42	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	3	8	0	5	1	5	26	40	49	41	54		TCRBV12-03,TCRBV12-04												CASSFRGGLDEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGAGGAACTAGCGGGGGCTTCCTACGAGCAGTACTTCGGGCCG	CSAEELAGASYEQYF	In	VDJ	1	88	2.895660786500956E-4	3.634681469733016E-4	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	3	2	1	5	2	26	35	51	40	53		TCRBV20-01,TCRBV20-or09_02												CSAEELAGASYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTTCGTCCGGGACGGTGGGGGGAAACACCATATATTTTGGAGAG	CSASSGTVGGNTIYF	In	VDJ	1	88	2.895660786500956E-4	3.634681469733016E-4	45	TCRBV20						TCRBJ01	TCRBJ01-03	01	5	0	7	4	6	7	26	35	46	41	53		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSASSGTVGGNTIYF+TCRBV20-X+TCRBJ01-03	TCRBV20		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGAAGGCCACAGGGCCAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	88	2.895660786500956E-4		43				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	3	3	0	3	2	18	29	38	32	40	TCRBV05,TCRBV11,TCRBV12	TCRBV05-03,TCRBV11-03,TCRBV12-02												X+X+TCRBJ02-03		TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGTAGCCTTCGACACCCCGGAAACACCGGGGAGCTGTTTTTTGGAGAA	CASSLRHPGNTGELFF	In	VDJ	1	88	2.895660786500956E-4	3.634681469733016E-4	48	unresolved						TCRBJ02	TCRBJ02-02	01	9	2	6	2	8	7	23	31	43	39	50	TCRBV02,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLRHPGNTGELFF+X+TCRBJ02-02	unresolved		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAGGAGGCTATGGCTACACCTTCGGTTCG	CASSLGGYGYTF	In	VDJ	1	89	2.928566022711194E-4	3.6759846682527094E-4	36	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	1	11	1	4	0	0	26	-1	-1	42	46		TCRBV12-03,TCRBV12-04												CASSLGGYGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCWMCCAGACAKCTSTKTACTTSTGTGCCAGCAGTCGGAGACAGGGTGGAGATACGCAGTATTTTGGCCCA	CASSRRQGGDTQYF	In	VDJ	1	89	2.928566022711194E-4	3.6759846682527094E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	2	3	5	4	3	24	36	47	40	50	TCRBV06,TCRBV24													CASSRRQGGDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCGAACACGACCCAGGGAGTTGAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	89	2.928566022711194E-4		50	TCRBV24						TCRBJ02	TCRBJ02-03	01	11	4	3	0	12	5	24	31	48	43	53		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ02-03	TCRBV24		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ARRRRGACTCAGCYGYGTATCTCTRCGCCAGCGGAAAGGACTAGCCTCGGGAGCAGTACTTCGGGCCG	XASGKD*PREQYF	Stop	VDJ	1	90	2.961471258921432E-4		39	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	8	1	7	7	5	5	23	32	45	37	50	TCRBV01,TCRBV17					01,02								XASGKD*PREQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGACTTGGCTAGATGGGACGGTGAGCAGTTCTTCGGGCCA	CASSQDLARWDGEQFF	In	VDJ	1	90	2.961471258921432E-4	3.7172878667724027E-4	48	TCRBV03						TCRBJ02	TCRBJ02-01	01	0	0	7	9	11	2	26	43	59	54	61		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDLARWDGEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCGGACAGTTCAATGAGCAGTTCTTCGGGCCA	CSAGQFNEQFF	In	VDJ	1	90	2.961471258921432E-4	3.7172878667724027E-4	33	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	1	5	6	1	2	26	34	41	35	43		TCRBV20-01,TCRBV20-or09_02												CSAGQFNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCGTCGGGGCTTAGATACGCAGTATTTTGGCCCA	CSARDRRGLDTQYF	In	VDJ	1	90	2.961471258921432E-4	3.7172878667724027E-4	42	TCRBV20						TCRBJ02	TCRBJ02-03	01	0	7	0	5	5	2	26	40	50	45	52		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDRRGLDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGCTCTTGGACTAGCGGGAGGGGCAGGTACGCAGTATTTTGGCCCA	CSARALGLAGGAGTQYF	In	VDJ	1	90	2.961471258921432E-4	3.7172878667724027E-4	51	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	1	0	8	7	5	26	37	59	44	64		TCRBV20-01,TCRBV20-or09_02												CSARALGLAGGAGTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTGGGCGAGGGCCAGTACAATGAGCAGTTCTTCGGGCCA	CASSLGEGQYNEQFF	In	VDJ	1	90	2.961471258921432E-4	3.7172878667724027E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	11	0	4	4	4	19	33	42	37	46	TCRBV07,TCRBV11													CASSLGEGQYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATAGGCAGGGAACCTACTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CSARDRQGTYSGANVLTF	In	VDJ	1	91	2.9943764951316705E-4	3.7585910652920964E-4	54	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	0	4	3	0	4	6	26	40	49	44	55		TCRBV20-01,TCRBV20-or09_02												CSARDRQGTYSGANVLTF+TCRBV20-X+TCRBJ02-06	TCRBV20	TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTGGGGGACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	92	3.0272817313419084E-4		35	TCRBV12						TCRBJ02	TCRBJ02-03	01	5	6	1	3	0	0	26	-1	-1	38	43		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV12-X+TCRBJ02-03	TCRBV12		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCCGGGACAGGATAATTCACCCCTCCACTTTGGGAAC	CSASPGQDNSPLHF	In	VDJ	1	92	3.0272817313419084E-4	3.7998942638117896E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	3	0	4	5	3	0	26	37	-1	40	48		TCRBV20-01,TCRBV20-or09_02												CSASPGQDNSPLHF+TCRBV20-X+TCRBJ01-06	TCRBV20	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCGGGAGAGCGGGGGGACCCCGGACGAGCAGTACTTCGGGCCG	CSARESGGTPDEQYF	In	VDJ	1	92	3.0272817313419084E-4	3.7998942638117896E-4	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	6	1	5	6	7	26	35	50	41	57		TCRBV20-01,TCRBV20-or09_02												CSARESGGTPDEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGATTCTGGGGGGTCGCGGGGCTACACCTTCGGTTCG	CSADSGGSRGYTF	In	VDJ	1	94	3.093092203762385E-4	3.882500660851176E-4	39	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	5	9	1	8	6	6	26	35	47	41	53		TCRBV20-01,TCRBV20-or09_02												CSADSGGSRGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGACTTTGTCCGGGACTGATACTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	95	3.125997439972623E-4		53	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	0	10	3	11	4	26	39	56	50	60		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTTTTGACAGGGGGCTCCGAGCAGTACTTCGGGCCG	CSARVLTGGSEQYF	In	VDJ	1	95	3.125997439972623E-4	3.92380385937087E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	2	0	6	4	2	26	39	53	43	55		TCRBV20-01,TCRBV20-or09_02												CSARVLTGGSEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTAGCGATGGGGGGCAGCGGAAAACTGTTTTTTGGCAGT	CASSLAMGGSGKLFF	In	VDJ	1	95	3.125997439972623E-4	3.92380385937087E-4	45	unresolved						TCRBJ01	TCRBJ01-04	01	2	6	0	10	7	5	19	33	46	40	51	TCRBV05,TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAMGGSGKLFF+X+TCRBJ01-04	unresolved		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTGTCCTCCGGGGGGCAAGAGACCCAGTACTTCGGGCCA	CASSLSSGGQETQYF	In	VDJ	1	96	3.158902676182861E-4	3.965107057890563E-4	45	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	4	8	1	2	7	0	26	39	-1	46	53		TCRBV03-01,TCRBV03-02												CASSLSSGGQETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCGTAGCACGGAGCACTAGCACAGATACGCAGTATTTTGGCCCA	CASSVARSTSTDTQYF	In	VDJ	1	97	3.1918079123930993E-4	4.0064102564102563E-4	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	5	7	0	2	10	26	37	43	39	53	TCRBV09,TCRBV12					unresolved								CASSVARSTSTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCTTGGACGGGAGGGGCTGATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	97	3.1918079123930993E-4		46	TCRBV05			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	0	8	0	6	1	4	19	35	44	36	48		TCRBV05-06,TCRBV05-07												X+TCRBV05-X+TCRBJ01-04	TCRBV05	TCRBD02-01*02	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCGGCCGGGACCTTAGCCAGCCCCTAGAGACCCAGTACTTCGGGCCA	CASGRDLSQPLETQYF	In	VDJ	1	97	3.1918079123930993E-4	4.0064102564102563E-4	48	unresolved						TCRBJ02	TCRBJ02-05	01	8	0	7	4	4	14	23	32	41	36	55	TCRBV02,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGRDLSQPLETQYF+X+TCRBJ02-05	unresolved		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCATCAGACAGGGATCGGGATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	98	3.224713148603337E-4		37	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	3	3	8	0	6	24	-1	41	35	47		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAAGGGCTTTAGGGAGCAGTACTTCGGGCCA	CSAKGFREQYF	In	VDJ	1	99	3.257618384813575E-4	4.089016653449643E-4	33	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	4	9	2	11	9	0	26	36	-1	45	50		TCRBV20-01,TCRBV20-or09_02												CSAKGFREQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTCCTCGTGGACGGTAGAAGAGACCCAGTACTTCGGGCCA	CATSDSSWTVEETQYF	In	VDJ	1	99	3.257618384813575E-4	4.089016653449643E-4	48	TCRBV24						TCRBJ02	TCRBJ02-05	01	2	1	7	3	6	5	24	40	50	46	55		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSDSSWTVEETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTAGATCTAGCGGGAGCAATAGATACGCAGTATTTTGGCCCA	CASSLDLAGAIDTQYF	In	VDJ	1	100	3.2905236210238137E-4	4.1303198519693365E-4	48	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	1	4	2	5	2	4	26	42	54	44	58		TCRBV12-03,TCRBV12-04												CASSLDLAGAIDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGTCCAACTAGCGAGCAGTACTTCGGGCCG	CASSQGPTSEQYF	In	VDJ	1	100	3.2905236210238137E-4	4.1303198519693365E-4	39	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	3	8	6	5	0	26	42	-1	47	52		TCRBV03-01,TCRBV03-02				01,02								CASSQGPTSEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAGACAGGGAGCGGCTACACCTTCGGTTCG	CSARETGSGYTF	In	VDJ	1	100	3.2905236210238137E-4	4.1303198519693365E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	2	3	8	0	3	26	-1	47	40	50		TCRBV20-01,TCRBV20-or09_02												CSARETGSGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGCGACAGGGGCGAGCAATCAGCCCCAGCATTTTGGTGAT	CSARATGASNQPQHF	In	VDJ	1	100	3.2905236210238137E-4	4.1303198519693365E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	1	2	2	1	1	2	26	39	48	40	50		TCRBV20-01,TCRBV20-or09_02												CSARATGASNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCGCAGACTAGGTGCCGGGAAGCTGTTTTTTGGAGAA	CASSRRLGAGKLFF	In	VDJ	1	100	3.2905236210238137E-4	4.1303198519693365E-4	42	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	6	2	8	12	4	9	24	36	46	40	55		TCRBV24-01,TCRBV24-or09_02				01,02								CASSRRLGAGKLFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCGACCACCACCGGGCTACCTACGAGCAGTACTTCGGGCCG	CASSDHHRATYEQYF	In	VDJ	1	100	3.2905236210238137E-4	4.1303198519693365E-4	45	unresolved						TCRBJ02	TCRBJ02-07	01	5	8	0	2	10	2	18	30	44	40	46	TCRBV05,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDHHRATYEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTAGATCTGAGGCGGAGCCTGAGTAAATACGAGCAGTACTTCGGGCCG	CASSLDLRRSLSKYEQYF	In	VDJ	1	100	3.2905236210238137E-4	4.1303198519693365E-4	54	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	7	5	4	6	12	18	35	45	41	57	TCRBV07,TCRBV11					01,02								CASSLDLRRSLSKYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTGACTAGCGGGAGTTTGGGGGAGCAGTTCTTCGGGCCA	CASSLTSGSLGEQFF	In	VDJ	1	100	3.2905236210238137E-4	4.1303198519693365E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	2	2	10	0	7	18	-1	44	32	51	TCRBV05,TCRBV11													CASSLTSGSLGEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGCACGGGGACTAGCGGGGGTAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	100	3.2905236210238137E-4		56	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	1	0	2	2	4	1	25	41	59	45	60		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD02-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTATTGTCCCTAGTTGGTGCCGAGCAGTACTTCGGGCCG	CASSLLSLVGAEQYF	In	VDJ	1	101	3.3234288572340517E-4	4.1716230504890297E-4	45	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	4	8	6	6	7	26	41	51	47	58		TCRBV12-03,TCRBV12-04				01,02								CASSLLSLVGAEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACCCATAGCGGGGGGACTCTCCTACGAGCAGTACTTCGGGCCG	CSARPIAGGLSYEQYF	In	VDJ	1	101	3.3234288572340517E-4	4.1716230504890297E-4	48	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	2	5	1	0	4	3	26	38	52	42	55		TCRBV20-01,TCRBV20-or09_02												CSARPIAGGLSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAACGCGGGTCGGGGGGCAGTTTGAAGGTGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	101	3.3234288572340517E-4		56	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	4	8	1	0	8	11	25	35	50	43	61		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGAACTTCGGACTAGCGGTACGCAGTATTTTGGCCCA	CSELRTSGTQYF	In	VDJ	1	104	3.422144565864766E-4	4.29553264604811E-4	36	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	7	1	5	8	6	0	26	33	-1	39	49		TCRBV20-01,TCRBV20-or09_02				01,02								CSELRTSGTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTCCCACGGCATGGGCAACTTCTTCGGGCCA	CASSSHGMGNFF	In	VDJ	1	105	3.455049802075004E-4	4.336835844567803E-4	36	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	8	0	16	10	3	26	39	53	49	56		TCRBV12-03,TCRBV12-04												CASSSHGMGNFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGATCTCTATCACCCCTCCACTTTGGGAAC	CASSQGSLSPLHF	In	VDJ	1	105	3.455049802075004E-4	4.336835844567803E-4	39	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	1	4	9	10	5	0	26	42	-1	47	50		TCRBV03-01,TCRBV03-02				01,02								CASSQGSLSPLHF+TCRBV03-X+TCRBJ01-06	TCRBV03	TCRBD02-01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTGGGTAGCGGGGTCACAGATACGCAGTATTTTGGCCCA	CSARVGSGVTDTQYF	In	VDJ	1	105	3.455049802075004E-4	4.336835844567803E-4	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	5	3	2	4	1	26	39	51	43	52		TCRBV20-01,TCRBV20-or09_02												CSARVGSGVTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGTAGGGAGGGAAGCGATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	105	3.455049802075004E-4		41	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	9	0	8	4	5	26	37	48	41	53		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTTTGGGTTCCCCCTACGAGCAGTACTTCGGGCCG	CASSLGSPYEQYF	In	VDJ	1	105	3.455049802075004E-4	4.336835844567803E-4	39	TCRBV12						TCRBJ02	TCRBJ02-07	01	3	0	9	2	0	5	22	-1	39	36	44		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGSPYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATACCGGAATCTATGGCTACACCTTCGGTTCG	CATSDTGIYGYTF	In	VDJ	1	105	3.455049802075004E-4	4.336835844567803E-4	39	TCRBV24						TCRBJ01	TCRBJ01-02	01	3	1	8	4	3	2	24	39	45	42	47		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSDTGIYGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTAGCCGCTGAGGATGAGCAGTTCTTCGGGCCA	CASSLAAEDEQFF	In	VDJ	1	105	3.455049802075004E-4	4.336835844567803E-4	39	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	5	7	8	1	8	24	36	41	37	49		TCRBV24-01,TCRBV24-or09_02				01,02								CASSLAAEDEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTGGGGGGGCAGCTCGAATGAAAAATTGTTTTTTGGCAGT	CASSWGGSSNEKLFF	In	VDJ	1	106	3.4879550382852425E-4	4.378139043087497E-4	45	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	4	9	0	15	0	17	18	-1	38	31	55	TCRBV05,TCRBV11													CASSWGGSSNEKLFF+X+TCRBJ01-04	unresolved	TCRBD02-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCGTAGCGGGAGGACCACGAGCAGTACTTCGGGCCG		Out	VDJ	1	106	3.4879550382852425E-4		40	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	8	1	5	0	3	23	-1	46	39	49	TCRBV09,TCRBV12													X+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCCACTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSPHSGANVLTF	In	VDJ	1	107	3.5208602744954805E-4	4.41944224160719E-4	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	4	4	6	0	2	0	26	39	-1	41	43		TCRBV03-01,TCRBV03-02												CASSPHSGANVLTF+TCRBV03-X+TCRBJ02-06	TCRBV03	TCRBD01-01*01	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCCCGGGATTAGTGGGTGAGCAGTACTTCGGGCCG	CSATPGLVGEQYF	In	VDJ	1	107	3.5208602744954805E-4	4.41944224160719E-4	39	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	8	3	7	3	9	26	36	44	39	53		TCRBV20-01,TCRBV20-or09_02												CSATPGLVGEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGTCGGGGCGTCTTTACAATGAGCAGTTCTTCGGGCCA	CSARSGRLYNEQFF	In	VDJ	2	108	3.5537655107057185E-4	4.4607454401268833E-4	42	TCRBV20						TCRBJ02	TCRBJ02-01	01	3	7	0	4	3	5	26	37	45	40	50		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARSGRLYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAATCCAGGGGGCGGCGATGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSEIQGAAMNTGELFF	In	VDJ	2	108	3.5537655107057185E-4	4.4607454401268833E-4	54	TCRBV06			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	2	4	0	1	3	6	23	38	49	41	55		TCRBV06-01,TCRBV06-08												CASSEIQGAAMNTGELFF+TCRBV06-X+TCRBJ02-02	TCRBV06	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ARRRRGACTCAGCYGYGTATCTCTRCGCCAGCAGCCAGGGAGGGAACGGCTACGAGCAGTACTTCGGGCCG	XASSQGGNGYEQYF	In	VDJ	2	108	3.5537655107057185E-4	4.4607454401268833E-4	42	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	9	0	3	0	5	22	-1	43	36	48	TCRBV01,TCRBV04,TCRBV07,TCRBV17													XASSQGGNGYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCGGATCTTGAATGGGTTCAACCCTTAATAGCAATCAGCCCCAGCATTTTGGTGAT	CASGS*MGSTLNSNQPQHF	Stop	VDJ	2	109	3.586670746915957E-4		57	TCRBV03						TCRBJ01	TCRBJ01-05	01	8	0	9	0	11	12	24	33	47	44	59		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGS*MGSTLNSNQPQHF+TCRBV03-X+TCRBJ01-05	TCRBV03		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGACACCGAAGGTCAGCCCCAGCATTTTGGTGAT		Out	VDJ	2	110	3.619575983126195E-4		40	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	1	2	6	6	0	7	26	-1	43	39	50		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CRRRRGACTCAGCCSTGTATCTCTRCGCCAGCAGCCTCGAAGCGGTCACAGAGACCCAGTACTTCGGGCCA	XASSLEAVTETQYF	In	VDJ	2	110	3.619575983126195E-4	4.5433518371662703E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	4	6	5	4	4	4	23	36	45	40	49	TCRBV04,TCRBV07,TCRBV17					01,02								XASSLEAVTETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTGAGGGACAGCTTAATTCACCCCTCCACTTTGGGAAC	CASSEGQLNSPLHF	In	VDJ	2	110	3.619575983126195E-4	4.5433518371662703E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	5	0	5	6	2	2	22	34	43	36	45	TCRBV02,TCRBV12													CASSEGQLNSPLHF+X+TCRBJ01-06	unresolved	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCACTTCCGGGACGGCCAACAATGAGCAGTTCTTCGGGCCA	CASTSGTANNEQFF	In	VDJ	2	110	3.619575983126195E-4	4.5433518371662703E-4	42	TCRBV24						TCRBJ02	TCRBJ02-01	01	11	0	7	5	8	5	24	31	44	39	49		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTSGTANNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTGACAGGGAGAATTCACCCCTCCACTTTGGGAAC	CASSDRENSPLHF	In	VDJ	2	111	3.652481219336433E-4	4.5846550356859635E-4	39	unresolved			unresolved			TCRBJ01	TCRBJ01-06	01	5	2	3	7	0	2	23	-1	42	35	44	TCRBV06,TCRBV10			TCRBD01,TCRBD02										CASSDRENSPLHF+X+TCRBJ01-06	unresolved	unresolved	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGAATTCGGGGTCAATTCACCCCTCCACTTTGGGAAC	CASSQEFGVNSPLHF	In	VDJ	2	111	3.652481219336433E-4	4.5846550356859635E-4	45				TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	0	8	3	7	3	2	18	35	43	38	45	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03												CASSQEFGVNSPLHF+X+TCRBJ01-06		TCRBD02-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTTGTGGCTAGCGGGGGGGTAATAAAACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	111	3.652481219336433E-4		55	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	4	0	5	5	7	18	32	49	37	56	TCRBV07,TCRBV11													X+X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAACAGGACACTGAAGCTTTCTTTGGACAA	CASSQQDTEAFF	In	VDJ	2	112	3.6853864555466714E-4	4.6259582342056567E-4	36	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	4	4	3	0	0	26	-1	-1	41	45		TCRBV03-01,TCRBV03-02												CASSQQDTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACCAGGACAGGGTGTAACTGAAGCTTTCTTTGGACAA	CSARPGQGVTEAFF	In	VDJ	2	112	3.6853864555466714E-4	4.6259582342056567E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	1	3	5	3	4	26	38	49	41	53		TCRBV20-01,TCRBV20-or09_02												CSARPGQGVTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTGGACAGGGAGAAATGATCAGCCCCAGCATTTTGGTGAT	CASSWTGRNDQPQHF	In	VDJ	2	112	3.6853864555466714E-4	4.6259582342056567E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	1	3	5	1	7	24	36	45	37	52	TCRBV24,TCRBV27													CASSWTGRNDQPQHF+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCACAGGGGGGCTACGAGCAGTACTTCGGGCCG	CASSLAQGGYEQYF	In	VDJ	2	113	3.7182916917569093E-4	4.6672614327253505E-4	42				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	3	1	3	0	1	18	-1	43	35	44	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAQGGYEQYF+X+TCRBJ02-07		TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGCCGGGACAGGGCCTCTAGAAGTACTTCGGGCCG	CASSPPGQGL*KYF	Stop	VDJ	2	114	3.7511969279671473E-4		42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	3	11	4	8	26	39	52	43	60		TCRBV03-01,TCRBV03-02												CASSPPGQGL*KYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCGGGGGATGGGTGAGCAGTACTTCGGGCCG	CSARGMGEQYF	In	VDJ	2	114	3.7511969279671473E-4	4.7085646312450437E-4	33	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	8	2	7	0	6	26	-1	41	35	47		TCRBV20-01,TCRBV20-or09_02												CSARGMGEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTGGGGTGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	2	114	3.7511969279671473E-4		40	TCRBV24						TCRBJ01	TCRBJ01-01	01	2	6	2	0	0	0	24	-1	-1	40	44		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ01-01	TCRBV24		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAGACATACGGCTCATCGGCTACACCTTCGGTTCG	CASSLDIRLIGYTF	In	VDJ	2	115	3.784102164177386E-4	4.749867829764737E-4	42	TCRBV12						TCRBJ01	TCRBJ01-02	01	1	3	6	8	0	11	26	-1	45	42	56		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLDIRLIGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCGATCCGGGACTAGCGGGGGGTACGCAGTATTTTGGCCCA	CASSPDPGLAGGTQYF	In	VDJ	2	116	3.817007400387624E-4	4.79117102828443E-4	48	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	0	1	8	7	0	26	39	-1	46	61		TCRBV03-01,TCRBV03-02												CASSPDPGLAGGTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAACCATGGGACAGTGGAAACTACGAGCAGTACTTCGGGCCG	CASSQPWDSGNYEQYF	In	VDJ	2	117	3.8499126365978617E-4	4.832474226804124E-4	48	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	0	5	3	4	6	26	41	52	45	58		TCRBV03-01,TCRBV03-02												CASSQPWDSGNYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTAGGGCTAGCGGGAATGACCAAAAACATTCAGTACTTCGGCGCC	CASSLGLAGMTKNIQYF	In	VDJ	2	118	3.8828178728081E-4	4.873777425323817E-4	51	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	1	4	3	2	2	4	26	42	53	44	57		TCRBV12-03,TCRBV12-04												CASSLGLAGMTKNIQYF+TCRBV12-X+TCRBJ02-04	TCRBV12	TCRBD02-01*02	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGTCATGCGGAGTACTCAAGAGACCCAGTACTTCGGGCCA	CASSQVMRSTQETQYF	In	VDJ	2	118	3.8828178728081E-4	4.873777425323817E-4	48	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	1	7	5	2	4	6	26	42	50	46	56		TCRBV03-01,TCRBV03-02				01,02								CASSQVMRSTQETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTTCGGGGGGCAGGGAGAGTAACTATGGCTACACCTTCGGTTCG		Out	VDJ	2	118	3.8828178728081E-4		50	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	1	8	1	1	2	9	26	39	48	41	57		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGCCCCAAGAGACCCAGTACTTCGGGCCA	CSARPQETQYF	In	VDJ	2	118	3.8828178728081E-4	4.873777425323817E-4	33	TCRBV20						TCRBJ02	TCRBJ02-05	01	3	10	0	1	0	1	26	-1	39	37	40		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARPQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20		TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCCGACCCTAGCGGGGGAGCAGTTCTTCGGGCCA	CASSPTLAGEQFF	In	VDJ	2	118	3.8828178728081E-4	4.873777425323817E-4	39	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	4	3	10	6	0	24	36	-1	42	51		TCRBV24-01,TCRBV24-or09_02												CASSPTLAGEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGGGGCAGGGTAAAGTCTACACCTTCGGTTCG	CASSPGQGKVYTF	In	VDJ	2	122	4.0144388176490526E-4	5.038990219402591E-4	39	TCRBV03						TCRBJ01	TCRBJ01-02	01	4	4	3	10	5	6	26	39	49	44	55		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPGQGKVYTF+TCRBV03-X+TCRBJ01-02	TCRBV03		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGACGGACAGGGGCGTTGTTCGCAGATACGCAGTATTTTGGCCCA	CASRRTGALFADTQYF	In	VDJ	2	122	4.0144388176490526E-4	5.038990219402591E-4	48	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	7	1	2	4	2	9	24	35	46	37	55		TCRBV24-01,TCRBV24-or09_02												CASRRTGALFADTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTTGTGGGGCCCCGCCCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	122	4.0144388176490526E-4		50	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	7	0	0	3	6	18	32	40	35	46	TCRBV07,TCRBV11													X+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAATTACAGGGGACCTCCATCTCTGGAAACACCATATATTTTGGAGAG	CASSQLQGTSISGNTIYF	In	VDJ	2	123	4.0473440538592905E-4	5.080293417922284E-4	54	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	2	3	2	0	2	8	26	41	50	43	58		TCRBV03-01,TCRBV03-02												CASSQLQGTSISGNTIYF+TCRBV03-X+TCRBJ01-03	TCRBV03	TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCRGCCRTGTATSKCTGTGCCAGAAGCTTGTTTCAGGGGCACCCTAGCTCCTATAATTCACCCCTCCACTTTGGGAAC	CARSLFQGHPSSYNSPLHF	In	VDJ	2	123	4.0473440538592905E-4	5.080293417922284E-4	57	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	1	4	2	0	3	8	18	33	42	36	50	TCRBV05,TCRBV07													CARSLFQGHPSSYNSPLHF+X+TCRBJ01-06	unresolved	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGGGCCGGGGGAAGACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	2	125	4.113154526279767E-4		41	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	9	8	2	2	3	3	22	30	39	33	42	TCRBV02,TCRBV12													X+X+TCRBJ01-04	unresolved	TCRBD02-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGCGCGGGCAGCGGGACCTGACAGATACGCAGTATTTTGGCCCA		Out	VDJ	2	127	4.178964998700243E-4		52	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	0	6	3	3	6	4	18	35	48	41	52	TCRBV07,TCRBV11													X+X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTATTACGGTGAACACTGAAGCTTTCTTTGGACAA	CSASITVNTEAFF	In	VDJ	2	128	4.2118702349104814E-4	5.28680941052075E-4	39	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	3	8	5	0	5	0	26	37	-1	42	45		TCRBV20-01,TCRBV20-or09_02				01,02								CSASITVNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCCCTATCCGGGACCGGGGAGCTGTTTTTTGGAGAA	CASSLALSGTGELFF	In	VDJ	2	130	4.2776807073309573E-4	5.369415807560138E-4	45				TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	0	8	4	5	6	0	18	35	-1	41	45	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03				01,02								CASSLALSGTGELFF+X+TCRBJ02-02		TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCGGGAGGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	2	131	4.310585943541196E-4		37	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	8	2	1	0	0	26	-1	-1	37	43		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCGGACAGGCTCTTTAAGGTCTAACTATGGCTACACCTTCGGTTCG	CASSRTGSLRSNYGYTF	In	VDJ	2	132	4.343491179751434E-4	5.452022204599524E-4	51	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	1	4	0	0	11	26	-1	46	39	57		TCRBV03-01,TCRBV03-02												CASSRTGSLRSNYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTGAAGGGACTAGCGACTGAGCAGTTCTTCGGGCCA	CASSLKGLATEQFF	In	VDJ	2	132	4.343491179751434E-4	5.452022204599524E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	0	6	9	3	2	18	32	45	35	47	TCRBV07,TCRBV11					01,02								CASSLKGLATEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATAATATGTACGAGCAGTACTTCGGGCCG	CSARDNMYEQYF	In	VDJ	2	133	4.376396415961672E-4	5.493325403119218E-4	36	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	5	9	4	0	5	26	-1	42	40	47		TCRBV20-01,TCRBV20-or09_02				01,02								CSARDNMYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTCGGCAGCCCCGGAGATACGCAGTATTTTGGCCCA	CASSFGSPGDTQYF	In	VDJ	2	133	4.376396415961672E-4	5.493325403119218E-4	42	TCRBV24						TCRBJ02	TCRBJ02-03	01	6	4	5	5	5	6	24	36	44	41	50		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFGSPGDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCGGGTCGACAGGGTCCACTGAAGCTTTCTTTGGACAA	CASSGSTGSTEAFF	In	VDJ	2	133	4.376396415961672E-4	5.493325403119218E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	3	4	5	2	18	30	42	35	44	TCRBV07,TCRBV11													CASSGSTGSTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGACAGCGGGTTAGCCAAAAACATTCAGTACTTCGGCGCC	CASSQDSGLAKNIQYF	In	VDJ	2	135	4.442206888382148E-4	5.575931800158604E-4	48	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-04	01	0	6	4	0	1	2	26	43	50	44	52		TCRBV03-01,TCRBV03-02				01,02								CASSQDSGLAKNIQYF+TCRBV03-X+TCRBJ02-04	TCRBV03	TCRBD02-01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCCCTGGCGGGAGTTGTAGCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	2	135	4.442206888382148E-4		49	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	4	7	2	0	6	4	26	36	49	42	53		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-04	TCRBV20	TCRBD02-01*02	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCACCTGAGGGGGGAACGTCCTGACTTTCGGGGCC	CAST*GGNVLTF	Stop	VDJ	2	136	4.475112124592386E-4		36	TCRBV03						TCRBJ02	TCRBJ02-06	01	7	5	1	10	4	1	26	36	46	40	47		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CAST*GGNVLTF+TCRBV03-X+TCRBJ02-06	TCRBV03		TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGCCGGGACTAGCGGACAGATACGCAGTATTTTGGCCCA	CASSQGRD*RTDTQYF	Stop	VDJ	2	136	4.475112124592386E-4		48	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	0	5	3	3	0	26	42	-1	45	56		TCRBV03-01,TCRBV03-02				01,02								CASSQGRD*RTDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACCTGGACAGGGGCTACAGTACGAGCAGTACTTCGGGCCG	CSARPGQGLQYEQYF	In	VDJ	2	136	4.475112124592386E-4	5.617234998678297E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	1	2	4	3	6	26	38	50	41	56		TCRBV20-01,TCRBV20-or09_02												CSARPGQGLQYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCTGGGGACTAGCGGGGGACGGTGGGAGCAGTACTTCGGGCCG	CSALGTSGGRWEQYF	In	VDJ	2	136	4.475112124592386E-4	5.617234998678297E-4	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	0	2	7	3	7	26	35	52	38	59		TCRBV20-01,TCRBV20-or09_02												CSALGTSGGRWEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACTTCCGGGTCTAGCGGGACCTACGAGCAGTACTTCGGGCCG	CSATSGSSGTYEQYF	In	VDJ	2	137	4.5080173608026247E-4	5.658538197197992E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	4	3	2	9	0	26	36	-1	45	54		TCRBV20-01,TCRBV20-or09_02												CSATSGSSGTYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGRAGACWCRGCWSYGTATCTCTGCGCCAGCAGCCTCCTAACAGGGCTCACAGATACGCAGTATTTTGGCCCA	CASSLLTGLTDTQYF	In	VDJ	2	138	4.5409225970128626E-4	5.699841395717685E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	3	3	2	5	2	23	36	47	41	49	TCRBV01,TCRBV23													CASSLLTGLTDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCAAAATGGCAGGGGGGGACACCGGGGAGCTGTTTTTTGGAGAA	CSAKMAGGDTGELFF	In	VDJ	2	138	4.5409225970128626E-4	5.699841395717685E-4	45	TCRBV20						TCRBJ02	TCRBJ02-02	01	6	4	1	3	8	2	26	34	49	42	51		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAKMAGGDTGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20		TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTATCACAGGGCAGGGCGAGCAGTACTTCGGGCCG	CATSITGQGEQYF	In	VDJ	2	139	4.5738278332231006E-4	5.741144594237378E-4	39	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	3	3	6	3	5	24	36	45	39	50		TCRBV24-01,TCRBV24-or09_02												CATSITGQGEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGAGTCCAGTGCCAGCACTTACGAGCAGTACTTCGGGCCG	CASSQESSASTYEQYF	In	VDJ	2	139	4.5738278332231006E-4	5.741144594237378E-4	48							TCRBJ02	TCRBJ02-07	01	0	4	5	4	3	10	18	35	41	38	51	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQESSASTYEQYF+X+TCRBJ02-07			TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGTCCATACGTGGGCGGTGAAAAACTGTTTTTTGGCAGT	CASSPYVGGEKLFF	In	VDJ	2	139	4.5738278332231006E-4	5.741144594237378E-4	42	unresolved						TCRBJ01	TCRBJ01-04	01	6	8	0	7	9	2	18	29	42	38	44	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPYVGGEKLFF+X+TCRBJ01-04	unresolved		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGACTCTTCCGGGGTGAGCAGTTCTTCGGGCCA	CASRLFRGEQFF	In	VDJ	2	141	4.639638305643577E-4	5.823750991276764E-4	36	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	8	3	9	7	0	26	37	-1	44	49		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASRLFRGEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCATCCCCGTGGGGAACGGCTACGAGCAGTACTTCGGGCCG	CSATIPVGNGYEQYF	In	VDJ	2	141	4.639638305643577E-4	5.823750991276764E-4	45	TCRBV20						TCRBJ02	TCRBJ02-07	01	4	0	8	3	11	4	26	36	51	47	55		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSATIPVGNGYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCCCGGGGATCGGGGACACTGAAGCTTTCTTTGGACAA	CSASPGIGDTEAFF	In	VDJ	2	142	4.672543541853815E-4	5.865054189796458E-4	42	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	3	8	3	3	2	7	26	37	44	39	51		TCRBV20-01,TCRBV20-or09_02												CSASPGIGDTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCAGAGCTAACTATGGCTACACCTTCGGTTCG	CASSRANYGYTF	In	VDJ	2	143	4.7054487780640535E-4	5.906357388316151E-4	36	TCRBV12						TCRBJ01	TCRBJ01-02	01	6	4	5	0	0	2	26	-1	40	37	42		TCRBV12-03,TCRBV12-04,TCRBV12-05		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRANYGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCTAAGCCCTATGAGGACTGAAGCTTTCTTTGGACAA	CSALSPMRTEAFF	In	VDJ	2	143	4.7054487780640535E-4	5.906357388316151E-4	39	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	6	11	1	5	12	0	26	34	-1	46	50		TCRBV20-01,TCRBV20-or09_02												CSALSPMRTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCGGGGACAGTGGTCGCGGCTACACCTTCGGTTCG	CSAGDSGRGYTF	In	VDJ	2	143	4.7054487780640535E-4	5.906357388316151E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	5	8	2	7	26	34	43	36	50		TCRBV20-01,TCRBV20-or09_02												CSAGDSGRGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCGCGGTCCCGGGACAGGGTTCCGGGGAGCTGTTTTTTGGAGAA	CSAAVPGQGSGELFF	In	VDJ	2	144	4.7383540142742915E-4	5.947660586835844E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	0	3	6	9	2	26	34	52	43	54		TCRBV20-01,TCRBV20-or09_02												CSAAVPGQGSGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCGTGGAGTCGGTAACCTATGGCTACACCTTCGGTTCG	CSAVESVTYGYTF	In	VDJ	2	144	4.7383540142742915E-4	5.947660586835844E-4	39	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	6	10	2	4	3	8	26	34	41	37	49		TCRBV20-01,TCRBV20-or09_02												CSAVESVTYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCTCATATCAGGGGGAAAGTGAAAAACTGTTTTTTGGCAGT		Out	VDJ	2	144	4.7383540142742915E-4		46	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	4	1	7	7	4	24	36	50	43	54		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-04	TCRBV24	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGAAGCTTGGCCGGGCAGGTCCATGGCTACACCTTCGGTTCG	CARSLAGQVHGYTF	In	VDJ	2	144	4.7383540142742915E-4	5.947660586835844E-4	42	unresolved						TCRBJ01	TCRBJ01-02	01	0	4	4	6	5	3	18	34	43	39	46	TCRBV05,TCRBV07			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CARSLAGQVHGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTGGGGACTAGCGGGGATATATACGAGCAGTACTTCGGGCCG	CASSLGTSGDIYEQYF	In	VDJ	2	145	4.7712592504845294E-4	5.988963785355538E-4	48	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	3	0	3	4	1	5	26	40	54	41	59		TCRBV12-03,TCRBV12-04												CASSLGTSGDIYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCATACCAGAGCGAGCCCTCCACTTTGGGAAC		Out	VDJ	2	145	4.7712592504845294E-4		37	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	3	6	6	14	6	2	26	40	50	46	52		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ01-06	TCRBV03	TCRBD02-01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGCTAAGGTTGGAGACGGCTACACCTTCGGTTCG	CSARAKVGDGYTF	In	VDJ	2	146	4.804164486694768E-4	6.030266983875232E-4	39	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	1	10	2	8	8	2	26	39	51	47	53		TCRBV20-01,TCRBV20-or09_02												CSARAKVGDGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCACCAACGCCCTACAGGGGAAGACTGAAGCTTTCTTTGGACAA	CASTNALQGKTEAFF	In	VDJ	2	146	4.804164486694768E-4	6.030266983875232E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	11	3	2	5	13	3	24	31	51	44	54		TCRBV24-01,TCRBV24-or09_02												CASTNALQGKTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCACAAGGACTAGCGAGCTACGAGCAGTACTTCGGGCCG	CASSSQGLASYEQYF	In	VDJ	2	146	4.804164486694768E-4	6.030266983875232E-4	45	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	1	6	3	6	2	24	36	51	42	53		TCRBV24-01,TCRBV24-or09_02				01,02								CASSSQGLASYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCACTCGGGAGGTCAACAGCCCCAGCATTTTGGTGAT	CASSHSGGQQPQHF	In	VDJ	2	147	4.837069722905006E-4	6.071570182394925E-4	42	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	3	8	1	7	2	4	26	40	49	42	53		TCRBV03-01,TCRBV03-02												CASSHSGGQQPQHF+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD02-01*02	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCGGACCTGAACAGAGGGGACAGCCTTCCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	2	148	4.869974959115244E-4		52	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	0	5	2	14	5	23	32	53	46	58	TCRBV01,TCRBV04													X+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGACAGGGGGCCCGAAGCTTTCTTTGGACAA	CSADRGPEAFF	In	VDJ	2	149	4.902880195325482E-4	6.154176579434311E-4	33	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	0	8	0	2	26	-1	45	35	47		TCRBV20-01,TCRBV20-or09_02												CSADRGPEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCCCCGGGACAGAGGTACAATGAGCAGTTCTTCGGGCCA	CASSSPGQRYNEQFF	In	VDJ	2	149	4.902880195325482E-4	6.154176579434311E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	0	5	4	5	3	24	36	48	41	51		TCRBV24-01,TCRBV24-or09_02												CASSSPGQRYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGGGGCCCTACGAGCAGTACTTCGGGCCG	CASSQGPYEQYF	In	VDJ	2	150	4.93578543153572E-4	6.195479777954004E-4	36	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	7	0	2	0	0	26	-1	-1	40	45		TCRBV03-01,TCRBV03-02												CASSQGPYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATTTTCCTGAGCAGTTCTTCGGGCCA	CSARDFPEQFF	In	VJ	2	150	4.93578543153572E-4	6.195479777954004E-4	33	TCRBV20						TCRBJ02	TCRBJ02-01	01	0	0	0	9	0	6	26	-1	40	-1	46		TCRBV20-01,TCRBV20-or09_02												CSARDFPEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCACATAGGGTAGGAACCTCCTACGAGCAGTACTTCGGGCCG	CSAHRVGTSYEQYF	In	VDJ	2	151	4.968690667745959E-4	6.236782976473698E-4	42	TCRBV20						TCRBJ02	TCRBJ02-07	01	6	5	3	0	4	7	26	34	42	38	49		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAHRVGTSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGTAGACTAGCGGGGTGAAAACATTCAGTACTTCGGCGCC		Out	VDJ	2	151	4.968690667745959E-4		50				TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-04	01	0	2	3	5	3	2	18	35	49	38	51	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												X+X+TCRBJ02-04		TCRBD02-01*01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGCGCTAACCCCACGTCAGGGGTTTACGAGCAGTACTTCGGGCCG	CATSANPTSGVYEQYF	In	VDJ	2	152	5.001595903956197E-4	6.278086174993392E-4	48	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	4	2	4	14	2	24	35	55	49	57		TCRBV24-01,TCRBV24-or09_02												CATSANPTSGVYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCGGCTGGGGCCTGTATTAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	152	5.001595903956197E-4		43	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	12	7	0	2	4	7	24	30	39	34	46		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGCCCCTTTCAGGGTAACGAGCAGTACTTCGGGCCG	CSPFQGNEQYF	In	VDJ	2	153	5.034501140166435E-4	6.319389373513085E-4	33	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	9	4	3	5	7	2	26	31	43	38	45		TCRBV20-01,TCRBV20-or09_02												CSPFQGNEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCATACCAGGGGGGCCCCCCCTAAGCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	153	5.034501140166435E-4		53	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	4	1	0	4	12	26	34	45	38	57		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGCGACAGGGGTCAGCCCCAGCATTTTGGTGAT	CSAGDRGQPQHF	In	VDJ	2	153	5.034501140166435E-4	6.319389373513085E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	2	2	6	3	0	26	35	-1	38	46		TCRBV20-01,TCRBV20-or09_02												CSAGDRGQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTCCGTAGCGGGGGGGCCCCCCCAAGAGACCCAGTACTTCGGGCCA	CASSSVAGGPPQETQYF	In	VDJ	2	155	5.100311612586911E-4	6.401995770552472E-4	51	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	5	0	1	4	5	26	38	53	42	58		TCRBV03-01,TCRBV03-02												CASSSVAGGPPQETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TTTCTGTGCCAGCAGCCCTCCCGACAGCTTCGGACTAGCGGGATTCCCCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	156	5.133216848797149E-4		64	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	1	3	2	14	5	4	17	43	31	48		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGTCTAACTAGCGGGAAGCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	2	157	5.166122085007388E-4		47	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	6	3	3	0	4	0	26	37	-1	41	51		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-04	TCRBV03	TCRBD02-01*02	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGCGGGTGATCGTGGGTAGCGGGGAGACCCAGTACTTCGGGCCA		Out	VDJ	2	157	5.166122085007388E-4		47	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	7	5	4	5	14	0	24	35	-1	49	56		TCRBV24-01,TCRBV24-or09_02				01,02								X+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAACTAGCGGGAGCAGATACGCAGTATTTTGGCCCA	CASSELAGADTQYF	In	VDJ	2	157	5.166122085007388E-4	6.484602167591858E-4	42	TCRBV06			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	4	2	4	0	0	23	-1	-1	38	48		TCRBV06-01,TCRBV06-08												CASSELAGADTQYF+TCRBV06-X+TCRBJ02-03	TCRBV06	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCTGCCTTATGGCTTCGGCAATCAGCCCCAGCATTTTGGTGAT	CSALPYGFGNQPQHF	In	VDJ	2	158	5.199027321217626E-4	6.525905366111551E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	9	0	2	10	4	26	34	47	44	51		TCRBV20-01,TCRBV20-or09_02												CSALPYGFGNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGTCTGGCAGGGGAGAAGCTATGGCTACACCTTCGGTTCG	CSVWQGRSYGYTF	In	VDJ	2	158	5.199027321217626E-4	6.525905366111551E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	4	2	4	5	5	26	33	44	38	49		TCRBV20-01,TCRBV20-or09_02												CSVWQGRSYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGACCCCCATTCCTACCGTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	158	5.199027321217626E-4		47	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	4	9	4	9	3	24	38	50	47	53		TCRBV24-01,TCRBV24-or09_02				01,02								X+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGAGGTCGCATCAGAGACCCAGTACTTCGGGCCA	CASSQEVASETQYF	In	VDJ	2	158	5.199027321217626E-4	6.525905366111551E-4	42							TCRBJ02	TCRBJ02-05	01	0	0	10	4	0	7	18	-1	37	35	44	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQEVASETQYF+X+TCRBJ02-05			TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCGGGGACTAGCCGTACACGGGGAGACCCAGTACTTCGGGCCA	CSARGLAVHGETQYF	In	VDJ	2	160	5.264837793638101E-4	6.608511763150939E-4	45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	0	7	5	3	10	26	34	46	37	56		TCRBV20-01,TCRBV20-or09_02				01,02								CSARGLAVHGETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAAAAGCGGGAGGGCGCGGGATGAGCAGTTCTTCGGGCCA	CSAKSGRARDEQFF	In	VDJ	2	160	5.264837793638101E-4	6.608511763150939E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	6	0	8	2	6	26	36	48	38	54		TCRBV20-01,TCRBV20-or09_02												CSAKSGRARDEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCTTGGTTAGGTGAGTGTAGCGAGATACGCAGTATTTTGGCCCA	CASSLVR*V*RDTQYF	Stop	VDJ	2	160	5.264837793638101E-4		48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	5	6	5	13	0	18	32	-1	45	50	TCRBV07,TCRBV11					01,02								CASSLVR*V*RDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGCGAACAGGGGTATCCTACAATGAGCAGTTCTTCGGGCCA	CATSDLRTGVSYNEQFF	In	VDJ	2	161	5.297743029848339E-4	6.649814961670632E-4	51	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	3	2	1	3	2	24	42	52	45	54		TCRBV24-01,TCRBV24-or09_02												CATSDLRTGVSYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGCCACGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCAGCAGATTCGGGACAGGAATAATCAATGAGCAGTTCTTCGGGCCA	CASRFGTGIINEQFF	In	VDJ	2	162	5.330648266058577E-4	6.691118160190325E-4	45				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	0	4	6	4	6	36	47	59	51	65	TCRBV25,TCRBV27,TCRBV28	TCRBV25-01,TCRBV25-or09_02,TCRBV27-01,TCRBV28-01												CASRFGTGIINEQFF+X+TCRBJ02-01		TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAATCTCGGGTGCCGGGGACCCAGTACTTCGGGCCA	CASSQSRVPGTQYF	In	VDJ	2	163	5.363553502268816E-4	6.732421358710018E-4	42	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	2	8	4	7	3	7	26	41	48	44	55		TCRBV03-01,TCRBV03-02				01,02								CASSQSRVPGTQYF+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAATCCGGGACAGGCGATCAGCCCCAGCATTTTGGTGAT	CATSESGTGDQPQHF	In	VDJ	2	163	5.363553502268816E-4	6.732421358710018E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	0	4	5	4	2	24	38	50	42	52		TCRBV24-01,TCRBV24-or09_02												CATSESGTGDQPQHF+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGAATTGGAGAAACTTCTGTCTTCCACGAGCAGTACTTCGGGCCG	CASRIGETSVFHEQYF	In	VDJ	2	163	5.363553502268816E-4	6.732421358710018E-4	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	7	10	2	5	4	15	24	35	43	39	58	TCRBV24,TCRBV27													CASRIGETSVFHEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTGTACATCCTAACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	2	164	5.396458738479054E-4		43	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	3	6	1	2	4	26	38	43	40	47		TCRBV12-03,TCRBV12-04												X+TCRBV12-X+TCRBJ01-04	TCRBV12	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCGTAGGCTCGACTAGTTACAATGAGCAGTTCTTCGGGCCA	CASSVGSTSYNEQFF	In	VDJ	2	165	5.429363974689292E-4	6.815027755749405E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	2	8	4	9	1	26	37	52	46	53	TCRBV09,TCRBV12					01,02								CASSVGSTSYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCTTAGGACAGGGTCGACCACCGGGGAGCTGTTTTTTGGAGAA	CSARDLRTGSTTGELFF	In	VDJ	2	165	5.429363974689292E-4	6.815027755749405E-4	51	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	0	1	3	4	5	5	26	40	53	45	58		TCRBV20-01,TCRBV20-or09_02												CSARDLRTGSTTGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTGAAACGGAGGGACAAGAGACCCAGTACTTCGGGCCA	CASSETEGQETQYF	In	VDJ	2	165	5.429363974689292E-4	6.815027755749405E-4	42	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	2	10	0	2	2	1	23	38	46	40	47	TCRBV02,TCRBV09													CASSETEGQETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCCTCCCGCTTGGGAGCAGTACTTCGGGCCG	CSARDPPAWEQYF	In	VDJ	2	167	5.495174447109768E-4	6.897634152788792E-4	39	TCRBV20						TCRBJ02	TCRBJ02-07	01	0	0	10	7	11	0	26	40	-1	51	53		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDPPAWEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGTGGTCCCGTTGGACACTGAAGCTTTCTTTGGACAA	CSVVPLDTEAFF	In	VDJ	2	168	5.528079683320006E-4	6.938937351308486E-4	36	TCRBV20						TCRBJ01	TCRBJ01-01	01	7	0	10	3	1	9	26	33	36	34	45		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSVVPLDTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTAGCGGGGGTTTGAGAAAAACTGTTTTTTGGCAGT		Out	VDJ	2	169	5.560984919530245E-4		40	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	5	6	2	8	0	5	26	-1	46	38	51		TCRBV12-03,TCRBV12-04												X+TCRBV12-X+TCRBJ01-04	TCRBV12	TCRBD02-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGTACGGGATTAGGCACTGAAGCTTTCTTTGGACAA	CSARGTGLGTEAFF	In	VDJ	2	169	5.560984919530245E-4	6.980240549828179E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	1	8	3	4	3	5	26	39	47	42	52		TCRBV20-01,TCRBV20-or09_02												CSARGTGLGTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01*02	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGAGCGGGAGGCACGAGCAGTACTTCGGGCCG		Out	VDJ	2	171	5.626795391950721E-4		41	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	1	6	1	5	1	1	26	42	52	43	53		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*02	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTCCACCCAGTTCGATGAGCAGTTCTTCGGGCCA	CASSSTQFDEQFF	In	VDJ	2	174	5.725511100581435E-4	7.186756542426646E-4	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	4	5	8	6	4	26	38	47	44	51		TCRBV03-01,TCRBV03-02												CASSSTQFDEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTTTCGTCCCTAGCGGGTCGGGATCTTGGGGAGAGACCCAGTACTTCGGGCCA	CSASFVPSGSGSWGETQYF	In	VDJ	2	175	5.758416336791674E-4	7.228059740946339E-4	57	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	3	4	4	4	8	14	24	35	51	43	65		TCRBV20-01,TCRBV20-or09_02				01,02								CSASFVPSGSGSWGETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCGTCGGGACTCTCAACACCGGGGAGCTGTTTTTTGGAGAA	CASSVGTLNTGELFF	In	VDJ	2	176	5.791321573001912E-4	7.269362939466032E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	5	0	10	2	3	3	23	35	44	38	47	TCRBV01,TCRBV04					01,02								CASSVGTLNTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTCCCGCGTTCCTTTGTCATGCAAGATACGCAGTATTTTGGCCCA		Out	VDJ	2	176	5.791321573001912E-4		50	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	7	6	5	4	15	26	38	45	42	60		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGCCTGGCCAGGGGTGACCTACGAGCAGTACTTCGGGCCG	CSASAWPGVTYEQYF	In	VDJ	2	176	5.791321573001912E-4	7.269362939466032E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	4	2	2	8	3	26	37	51	45	54		TCRBV20-01,TCRBV20-or09_02												CSASAWPGVTYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGTCGAGGTACGGGACTGACGAACACTGAAGCTTTCTTTGGACAA	CASSRGTGLTNTEAFF	In	VDJ	2	177	5.82422680921215E-4	7.310666137985726E-4	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	6	0	10	1	9	3	18	29	44	38	47	TCRBV07,TCRBV11					01,02								CASSRGTGLTNTEAFF+X+TCRBJ01-01	unresolved	TCRBD02-01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGACTATCCCTCTCCCCTGGACAGAGGGGAGAGACCCAGTACTTCGGGCCA	CASRLSLSPGQRGETQYF	In	VDJ	3	182	5.988752990263341E-4	7.517182130584193E-4	54	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	1	5	4	16	5	26	37	59	53	64		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASRLSLSPGQRGETQYF+TCRBV12-X+TCRBJ02-05	TCRBV12	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCACACTTCATGTGGGGGGAGGGGCAGATACGCAGTATTTTGGCCCA	CSATLHVGGGADTQYF	In	VDJ	3	184	6.054563462683817E-4	7.599788527623579E-4	48	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	6	9	0	4	15	1	26	34	56	49	57		TCRBV20-01,TCRBV20-or09_02												CSATLHVGGGADTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGATTACAGTCTTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSQDYSLSNQPQHF	In	VDJ	3	185	6.087468698894055E-4	7.641091726143272E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	3	5	0	2	3	23	40	46	42	49	TCRBV01,TCRBV04													CASSQDYSLSNQPQHF+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCTTACGACTAGCGGGAGAATAAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	3	191	6.284900116155484E-4		53	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	2	2	0	1	4	18	33	46	34	50	TCRBV07,TCRBV11													X+X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCAGGACAGGTCCCCACTGAAGCTTTCTTTGGACAA	CSAGQVPTEAFF	In	VDJ	3	192	6.317805352365722E-4	7.930214115781126E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	1	4	4	1	4	26	34	42	35	46		TCRBV20-01,TCRBV20-or09_02												CSAGQVPTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCGACAGACAGGGGCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	3	194	6.383615824786199E-4		43	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	2	2	3	4	0	24	36	-1	40	48	TCRBV09,TCRBV21													X+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGCAGGGGGGGTCCTACGAGCAGTACTTCGGGCCG	CSARQGGSYEQYF	In	VDJ	3	196	6.449426297206674E-4	8.0954269098599E-4	39	TCRBV20						TCRBJ02	TCRBJ02-07	01	3	4	1	1	1	2	26	37	45	38	47		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARQGGSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCGCCTAGCGTCCGGGGAATACGAGCAGTACTTCGGGCCG	CASSRLASGEYEQYF	In	VDJ	3	197	6.482331533416912E-4	8.136730108379593E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	4	6	4	2	9	23	36	44	38	53	TCRBV01,TCRBV04					01,02								CASSRLASGEYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAAATGACCCTCGATGAGCAGTTCTTCGGGCCA	CASSQEMTLDEQFF	In	VDJ	3	197	6.482331533416912E-4	8.136730108379593E-4	42	TCRBV03						TCRBJ02	TCRBJ02-01	01	0	2	7	8	3	5	26	43	49	46	54		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQEMTLDEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGACTCGGACAGGGGGTTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	3	197	6.482331533416912E-4		49	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	1	1	1	3	1	26	43	56	46	57		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCATCTAGCGGGGGCACAAGAGACCCAGTACTTCGGGCCA	CASSHLAGAQETQYF	In	VDJ	3	197	6.482331533416912E-4	8.136730108379593E-4	45	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	3	4	2	2	1	2	26	40	51	41	53		TCRBV03-01,TCRBV03-02												CASSHLAGAQETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD02-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGCCAACTAGCGGGTCCACCAGATACGCAGTATTTTGGCCCA	CSQLAGPPDTQYF	In	VDJ	3	199	6.548142005837388E-4	8.21933650541898E-4	39	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	9	3	4	4	3	5	26	31	43	34	48		TCRBV20-01,TCRBV20-or09_02				01,02								CSQLAGPPDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTTGGGAGACAGGAGACCTACGAGCAGTACTTCGGGCCG	CASSFGRQETYEQYF	In	VDJ	3	202	6.646857714468103E-4	8.343246100978059E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	4	2	7	3	24	36	49	43	52		TCRBV24-01,TCRBV24-or09_02												CASSFGRQETYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTCCGGGGACAGGGTGTACGAGCAGTACTTCGGGCCG	CASSSGDRVYEQYF	In	VDJ	3	203	6.679762950678341E-4	8.384549299497753E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	3	4	4	2	24	36	49	40	51	TCRBV24,TCRBV27													CASSSGDRVYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATCTGAGGGAAGCGGAAACGGCTACACCTTCGGTTCG	CASSLSEGSGNGYTF	In	VDJ	3	204	6.712668186888579E-4	8.425852498017447E-4	45				TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	6	6	5	8	12	4	24	36	53	48	57	TCRBV24,TCRBV27	TCRBV24-01,TCRBV24-or09_02,TCRBV27-01				01,02								CASSLSEGSGNGYTF+X+TCRBJ01-02		TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGCCTAATATTACAGATGGGTCCTCAGCAGTACTTCGGGCCG	CASSQGLILQMGPQQYF	In	VDJ	3	207	6.811383895519294E-4	8.549762093576527E-4	51	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	3	5	8	10	10	26	42	56	52	66		TCRBV03-01,TCRBV03-02												CASSQGLILQMGPQQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCAGGGAAGGGGGAATCTACAATGAGCAGTTCTTCGGGCCA	CSAREGGIYNEQFF	In	VDJ	3	209	6.87719436793977E-4	8.632368490615913E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	5	1	3	6	3	26	34	46	40	49		TCRBV20-01,TCRBV20-or09_02												CSAREGGIYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGGCCTACGAGCAGTACTTCGGGCCG	CASSQAYEQYF	In	VDJ	3	213	7.008815312780723E-4	8.797581284694687E-4	33	TCRBV03						TCRBJ02	TCRBJ02-07	01	3	0	10	2	0	0	26	-1	-1	40	42		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQAYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTCGGCGGGAGTTCCTACAATGAGCAGTTCTTCGGGCCA	CATSDFGGSSYNEQFF	In	VDJ	3	213	7.008815312780723E-4	8.797581284694687E-4	48	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	1	7	2	1	2	1	24	41	50	43	51		TCRBV24-01,TCRBV24-or09_02												CATSDFGGSSYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCTGTCATACCCCGGGACAGGTCCGCTACGAGCAGTACTTCGGGCCG	CACHTPGQVRYEQYF	In	VDJ	3	218	7.173341493831914E-4	9.004097277293154E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	11	0	4	3	11	4	23	29	48	40	52	TCRBV01,TCRBV04													CACHTPGQVRYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTGACAGGGCACGCACAGATACGCAGTATTTTGGCCCA	CASSDRARTDTQYF	In	VDJ	3	218	7.173341493831914E-4	9.004097277293154E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	4	3	1	0	3	23	-1	42	37	45	TCRBV02,TCRBV09													CASSDRARTDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCGCGGGTTGACAGGGGGTATCACTGAAGCTTTCTTTGGACAA	CSARGLTGGITEAFF	In	VDJ	3	219	7.206246730042152E-4	9.045400475812847E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	1	4	8	3	26	35	52	43	55		TCRBV20-01,TCRBV20-or09_02												CSARGLTGGITEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCGCCGGCCAGGGGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	3	227	7.469488619724057E-4		40	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	11	4	3	1	8	0	24	31	-1	39	44		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCGGACAAGGGGGCAGGGGCGCAGATACGCAGTATTTTGGCCCA	CASSGQGGRGADTQYF	In	VDJ	3	228	7.502393855934295E-4	9.417129262490087E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	5	0	4	6	7	26	37	50	43	57	TCRBV09,TCRBV12													CASSGQGGRGADTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGGCGGGGGGCGAGAACGAGCAGTACTTCGGGCCG	CATSDLAGGENEQYF	In	VDJ	3	230	7.568204328354772E-4	9.499735659529474E-4	45	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	7	1	5	0	5	24	-1	50	42	55		TCRBV24-01,TCRBV24-or09_02												CATSDLAGGENEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCAACGTACAGGGAATTCCCCCATTTGGTTGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	3	232	7.634014800775247E-4		59	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	3	0	5	16	22	34	45	39	61		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATGTAAGGCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	3	237	7.798540981826438E-4		46	TCRBV03						TCRBJ02	TCRBJ02-01	01	0	5	4	0	4	0	26	43	-1	47	50		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-01	TCRBV03		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACCCGGAGACTTAGCCAAAAACATTCAGTACTTCGGCGCC	CSARPGDLAKNIQYF	In	VDJ	3	241	7.93016192666739E-4	9.9540708432461E-4	45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-04	01	2	2	10	0	6	1	26	38	48	44	49		TCRBV20-01,TCRBV20-or09_02				01,02								CSARPGDLAKNIQYF+TCRBV20-X+TCRBJ02-04	TCRBV20	TCRBD02-01	TCRBJ02-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCGAGCGGTCACACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	3	242	7.963067162877629E-4		41	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	3	6	5	2	3	5	26	37	45	40	50		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCCTACAGGGGGTCCATCAGCCCCAGCATTTTGGTGAT	CASLQGVHQPQHF	In	VDJ	3	244	8.028877635298105E-4	0.0010077980438805182	39	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	11	3	1	5	4	3	24	31	43	35	46		TCRBV24-01,TCRBV24-or09_02												CASLQGVHQPQHF+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGGCCCCGGTGATAGGGACTAAACAAGAGACCCAGTACTTCGGGCCA	CSAAPVIGTKQETQYF	In	VDJ	3	248	8.160498580139057E-4	0.0010243193232883955	48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	0	9	2	13	2	26	34	54	47	56		TCRBV20-01,TCRBV20-or09_02				01,02								CSAAPVIGTKQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGACCACTCTGGAAACACCATATATTTTGGAGAG	CASSQDHSGNTIYF	In	VDJ	4	254	8.357929997400486E-4	0.0010491012424002114	42				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	0	4	6	0	1	0	18	35	-1	36	38	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03												CASSQDHSGNTIYF+X+TCRBJ01-03		TCRBD01-01*01	TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGACCACAGATACGCAGTATTTTGGCCCA	CASSQTTDTQYF	In	VDJ	4	255	8.390835233610725E-4	0.0010532315622521808	36	TCRBV03						TCRBJ02	TCRBJ02-03	01	3	2	7	2	0	0	26	-1	-1	40	43		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQTTDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTAAGGACAGGGGCCAAATCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	4	255	8.390835233610725E-4		50	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	1	2	2	3	6	26	39	51	42	57		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD01-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGGGGACTGTACCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	4	263	8.65407712329263E-4		44	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	0	10	2	1	3	26	40	47	41	50		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCATGACCTCTCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSHDLSTNEKLFF	In	VDJ	4	263	8.65407712329263E-4	0.0010862741210679355	45	TCRBV03						TCRBJ01	TCRBJ01-04	01	3	2	7	0	1	4	26	40	44	41	48		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSHDLSTNEKLFF+TCRBV03-X+TCRBJ01-04	TCRBV03		TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGGGCTAGCGGGATTGTCCAGATACGCAGTATTTTGGCCCA		Out	VDJ	4	264	8.686982359502868E-4		46	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	4	3	4	4	5	26	37	50	41	55		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGAGGACAGGTTAAAGAGACCCAGTACTTCGGGCCA	CASRGQVKETQYF	In	VDJ	4	267	8.785698068133583E-4	0.0011027954004758128	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	1	4	3	1	3	26	37	45	38	48		TCRBV03-01,TCRBV03-02												CASRGQVKETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGCTTATTGGGGGAGAAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	4	268	8.81860330434382E-4		43	TCRBV24						TCRBJ01	TCRBJ01-05	01	7	6	1	4	6	3	24	35	46	41	49		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ01-05	TCRBV24		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTATTCCCCGGGGGCACAAATGAGCAGTTCTTCGGGCCA	CASSLFPGGTNEQFF	In	VDJ	4	270	8.884413776764296E-4	0.0011151863600317208	45	unresolved						TCRBJ02	TCRBJ02-01	01	2	6	0	7	6	3	18	33	45	39	48	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLFPGGTNEQFF+X+TCRBJ02-01	unresolved		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCGCAATGGTTTACGGTACGAGCAGTACTTCGGGCCG	CSARDRNGLRYEQYF	In	VDJ	4	275	9.048939957815487E-4	0.0011358379592915676	45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	8	5	4	13	0	26	40	-1	53	56		TCRBV20-01,TCRBV20-or09_02				01,02								CSARDRNGLRYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTTACGGCCGGGCCGCACAAACTATGGCTACACCTTCGGTTCG	CASSLRPGRTNYGYTF	In	VDJ	4	280	9.213466138866678E-4	0.0011564895585514142	48	unresolved						TCRBJ01	TCRBJ01-02	01	6	8	0	2	8	6	24	36	48	44	54	TCRBV24,TCRBV27			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLRPGRTNYGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCGCCGCGGCTCTAAGACAGGGTCTCGGGAGCAGTACTTCGGGCCG		Out	VDJ	4	280	9.213466138866678E-4		50	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	2	3	7	13	6	24	36	56	49	62	TCRBV09,TCRBV21													X+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATATGTCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	4	285	9.377992319917869E-4		35	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	5	9	6	0	3	26	-1	42	40	45		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATGATGGGAACAAACAAACACCATATATTTTGGAGAG		Out	VDJ	4	286	9.410897556128107E-4		44	TCRBV20						TCRBJ01	TCRBJ01-03	01	0	0	8	6	4	6	26	40	48	44	54		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV20-X+TCRBJ01-03	TCRBV20		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCACCCGAGGGGGGAACGTCCTGACTTTCGGGGCC	CASTRGGNVLTF	In	VDJ	4	293	9.641234209599774E-4	0.0012101837166270156	36	TCRBV03						TCRBJ02	TCRBJ02-06	01	7	5	1	10	4	1	26	36	46	40	47		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTRGGNVLTF+TCRBV03-X+TCRBJ02-06	TCRBV03		TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCGACTAGCGGGAGATTTGGGGACCCAGTACTTCGGGCCA	CSARLAGDLGTQYF	In	VDJ	4	299	9.838665626861203E-4	0.0012349656357388316	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	2	2	7	1	7	26	35	48	36	55		TCRBV20-01,TCRBV20-or09_02												CSARLAGDLGTQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGACTCGGACAGGCCGGAGACCCAGTACTTCGGGCCA	CATSDSDRPETQYF	In	VDJ	4	299	9.838665626861203E-4	0.0012349656357388316	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	1	4	5	3	3	24	38	48	41	51		TCRBV24-01,TCRBV24-or09_02												CATSDSDRPETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCCCCGTGGCTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	4	316	0.0010398054642435251		41	unresolved						TCRBJ01	TCRBJ01-03	01	5	0	10	0	5	0	18	30	-1	35	37	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ01-03	unresolved		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATCGGGCCTCGGGAACACCATATATTTTGGAGAG	CASSLSGLGNTIYF	In	VDJ	5	324	0.0010661296532117155	0.001338223632038065	42							TCRBJ01	TCRBJ01-03	01	6	8	0	7	5	6	24	36	45	41	51	TCRBV24,TCRBV27	TCRBV24-01,TCRBV24-or09_02,TCRBV27-01		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLSGLGNTIYF+X+TCRBJ01-03			TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTGATCGGGACTATAGCAGTGATGAGCAGTTCTTCGGGCCA	CASSDRDYSSDEQFF	In	VDJ	5	328	0.0010792917476958109	0.0013547449114459423	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	0	9	8	2	8	23	37	46	39	54	TCRBV02,TCRBV12					01,02								CASSDRDYSSDEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGGTCCAGGGGAAATCGAGCAGTACTTCGGGCCG	CASSQGPGEIEQYF	In	VDJ	5	331	0.0010891633185588824	0.0013671358710018503	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	4	2	6	3	4	23	39	48	42	52	TCRBV01,TCRBV04													CASSQGPGEIEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGGGACAGGGGCTACGAGCAGTACTTCGGGCCG		Out	VDJ	5	343	0.0011286496020111681		40	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	2	3	1	0	26	39	-1	40	50		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCCGGGGCTAGCACAGATACGCAGTATTTTGGCCCA	CASSLAGASTDTQYF	In	VDJ	5	346	0.0011385211728742394	0.0014290906687813903	45							TCRBJ02	TCRBJ02-03	01	0	7	0	0	1	1	18	35	41	36	42	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAGASTDTQYF+X+TCRBJ02-03			TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGATAAGTCCTCTGGCGGGAAAAGCGGGAGGCTACACCTTCGGTTCG		Out	VDJ	5	347	0.0011418116964952633		55	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	0	6	3	8	19	0	23	40	-1	59	66	TCRBV01,TCRBV04													X+X+TCRBJ01-02	unresolved	TCRBD02-01*02	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATCGTAGCACGATTACAGATACGCAGTATTTTGGCCCA	CASSQDRSTITDTQYF	In	VDJ	5	348	0.001145102220116287	0.0014373513084853292	48	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	5	7	3	3	6	26	43	50	46	56		TCRBV03-01,TCRBV03-02				01,02								CASSQDRSTITDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGGAAGCGGGGGCCTCCGGGATACGCAGTATTTTGGCCCA		Out	VDJ	5	354	0.00116484536184243		49	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	6	2	6	3	7	26	42	53	45	60		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01*01	TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCGAGAGGGACAGGGGAATTCACCCCTCCACTTTGGGAAC	CASSREGQGNSPLHF	In	VDJ	5	365	0.0012010411216736919	0.0015075667459688079	45	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	0	0	2	7	0	0	26	-1	-1	43	53		TCRBV03-01,TCRBV03-02												CASSREGQGNSPLHF+TCRBV03-X+TCRBJ01-06	TCRBV03	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCTCAGAGGGACAGGGTCGGGAGCAGTACTTCGGGCCG	CASSSEGQGREQYF	In	VDJ	5	369	0.0012142032161577873	0.0015240880253766852	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	3	7	5	4	23	35	49	40	53	TCRBV01,TCRBV04													CASSSEGQGREQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCACGGTCACAGGGGGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	5	369	0.0012142032161577873		41	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	8	3	2	1	5	0	24	34	-1	39	46		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTATTTTTTCCCACGCTAGACTAGCGCTGCAACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	5	371	0.0012207842633998349		56	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	2	6	2	15	6	25	35	58	50	64		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCKGCYGTGTATKTCTGTGCCAGCCGGGGAAGCGGGGCCTACAATGAGCAGTTCTTCGGGCCA	CASRGSGAYNEQFF	In	VDJ	5	378	0.0012438179287470015	0.0015612609040444093	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	8	6	3	2	6	0	26	35	-1	41	48	TCRBV03,TCRBV11													CASRGSGAYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGAAACCTGCGGGGAGGGCCAATTTACAATGAGCAGTTCTTCGGGCCA	CARNLRGGPIYNEQFF	In	VDJ	5	392	0.001289885259441335	0.00161908538197198	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	9	9	0	4	9	6	23	31	47	40	53	TCRBV01,TCRBV04													CARNLRGGPIYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCCTTAGGGGGGGGAATGAAAAACTGTTTTTTGGCAGT	CASSPLRGGNEKLFF	In	VDJ	6	405	0.0013326620665146446	0.0016727795400475812	45	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	4	9	0	5	6	1	26	39	52	45	53		TCRBV03-01,TCRBV03-02												CASSPLRGGNEKLFF+TCRBV03-X+TCRBJ01-04	TCRBV03	TCRBD02-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGAGGTAGCGGGGGGCAGAAACGAGCAGTACTTCGGGCCG	CASSQEVAGGRNEQYF	In	VDJ	6	415	0.0013655673027248825	0.0017140827385672746	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	5	1	5	2	5	23	40	52	42	57	TCRBV01,TCRBV04													CASSQEVAGGRNEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACAAATCAAACAGGGAGCGGTGGCTACACCTTCGGTTCG	CSATNQTGSGGYTF	In	VDJ	6	430	0.0014149251570402398	0.0017760375363468147	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	3	3	7	8	5	26	36	50	44	55		TCRBV20-01,TCRBV20-or09_02												CSATNQTGSGGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CTGTGTATTTCTGTGCCAGCAGCCCATAGACCGGGGCAGGGGGTACCCCACCCGGGATTCACCCCTCCACTTTGGGAAC		Out	VDJ	6	431	0.0014182156806612637		62	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	4	1	8	12	13	11	24	43	36	56		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-06	TCRBV03	TCRBD01-01*01	TCRBJ01-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGGCGGTTGGGGGGTATCCGTCTACGAGCAGTACTTCGGGCCG		Out	VDJ	6	434	0.001428087251524335		46	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	9	1	3	6	7	18	29	41	35	48	TCRBV07,TCRBV11													X+X+TCRBJ02-07	unresolved	TCRBD02-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAAGGACAGGGACTATTAGCAATCAGCCCCAGCATTTTGGTGAT	CSARRTGTISNQPQHF	In	VDJ	6	439	0.001444539869629454	0.0018132104150145388	48	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	1	3	0	1	5	26	38	47	39	52		TCRBV20-01,TCRBV20-or09_02												CSARRTGTISNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTCGGACAGCAAATTCAGATGAAAAACTGTTTTTTGGCAGT	CASSRTANSDEKLFF	In	VDJ	6	447	0.0014708640585976446	0.0018462529738302934	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	1	5	6	1	9	23	35	42	36	51	TCRBV02,TCRBV12													CASSRTANSDEKLFF+X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCACCGGACTAGCGGGAACTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSTGLAGTGANVLTF	In	VDJ	6	451	0.0014840261530817398	0.0018627742532381709	51	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	5	1	3	2	3	1	26	38	53	41	54		TCRBV03-01,TCRBV03-02												CASSTGLAGTGANVLTF+TCRBV03-X+TCRBJ02-06	TCRBV03	TCRBD02-01*02	TCRBJ02-06*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGACCGCCGGGCCGGCGGGGAGACCCAGTACTTCGGGCCA	CSARDRRAGGETQYF	In	VDJ	6	451	0.0014840261530817398	0.0018627742532381709	45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	0	7	4	5	11	0	26	40	-1	51	56		TCRBV20-01,TCRBV20-or09_02				01,02								CSARDRRAGGETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGGCCCCTCAAGGGCGTTCAACTCGGGAAACACCATATATTTTGGAGAG		Out	VDJ	6	458	0.0015070598184289065		56	TCRBV03						TCRBJ01	TCRBJ01-03	01	3	5	3	4	9	11	25	39	52	48	63		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ01-03	TCRBV03		TCRBJ01-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCGGGCCCGGACTAGCGGGCTACGAGCAGTACTTCGGGCCG	CSAGPGLAGYEQYF	In	VDJ	7	469	0.0015432555782601686	0.0019371200105736189	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	1	4	3	7	0	26	34	-1	41	52		TCRBV20-01,TCRBV20-or09_02				01,02								CSAGPGLAGYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
SGACTCGGCYSTSTATCTCTGTGCCAGCAGCTGATGGGAATACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	7	473	0.0015564176727442638		40	unresolved						TCRBJ02	TCRBJ02-07	01	3	0	8	2	3	3	19	32	39	35	42	TCRBV05,TCRBV07			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
TGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCTCCCAACATTACACGCGACAGGGGGCCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	7	479	0.0015761608144704068		59	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	2	1	1	18	0	22	35	-1	53	62		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD01-01*01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGTTCTACAGGGGTACACCGGGGAGCTGTTTTTTGGAGAA	CSVLQGYTGELFF	In	VDJ	7	488	0.001605775527059621	0.0020155960877610364	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	7	3	2	3	4	1	26	33	44	37	45		TCRBV20-01,TCRBV20-or09_02												CSVLQGYTGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD01-01*01	TCRBJ02-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGTGGGGGACAGGTGGCTACGAGCAGTACTTCGGGCCG	CSARWGTGGYEQYF	In	VDJ	7	503	0.0016551333813749783	0.0020775508855405763	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	4	3	4	3	26	37	49	41	52		TCRBV20-01,TCRBV20-or09_02												CSARWGTGGYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGGACATCCGGGCGGTACAATGAGCAGTTCTTCGGGCCA	CASRTSGRYNEQFF	In	VDJ	8	548	0.0018032069443210499	0.0022634152788791966	42	TCRBV24						TCRBJ02	TCRBJ02-01	01	7	2	6	4	0	9	24	-1	39	35	48		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRTSGRYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24		TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGRAGACWCRGCWSYGTATCTCTGCGCCAGCAGCCAGCGGACAGGGAGGGAGCAGTACTTCGGGCCG	CASSQRTGREQYF	In	VDJ	8	563	0.001852564798636407	0.0023253700766587364	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	1	3	7	5	3	20	31	44	36	47	TCRBV01,TCRBV23													CASSQRTGREQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCACGGGGGCAACGAGCAGTACTTCGGGCCG	CASSHGGNEQYF	In	VDJ	9	637	0.002096063546592169	0.0026310137457044675	36	TCRBV03						TCRBJ02	TCRBJ02-07	01	3	6	0	5	1	1	26	40	47	41	48		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSHGGNEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03		TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGAGGCCCGACGAGCTAACTATGGCTACACCTTCGGTTCG	CASSQEARRANYGYTF	In	VDJ	9	657	0.0021618740190126455	0.002713620142743854	48	unresolved						TCRBJ01	TCRBJ01-02	01	0	2	7	0	5	3	23	40	48	45	51	TCRBV01,TCRBV04			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQEARRANYGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGCCTACAGGGGGCAACTATGGCTACACCTTCGGTTCG	CSARPTGGNYGYTF	In	VDJ	9	678	0.0022309750150541455	0.00280035685963521	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	3	0	2	4	0	26	37	-1	41	50		TCRBV20-01,TCRBV20-or09_02												CSARPTGGNYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTAGTTCCGCACCCTATGGCTACACCTTCGGTTCG		Out	VDJ	9	682	0.0022441371095382407		41	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	6	5	8	4	1	9	24	36	40	37	49		TCRBV24-01,TCRBV24-or09_02				01,02								X+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGCGGGGCCTTAGTGAAAAACTGTTTTTTGGCAGT	CASSLARGLSEKLFF	In	VDJ	10	733	0.0024119538142104552	0.0030275244514935237	45				TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	0	7	3	7	0	6	18	-1	41	35	47	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLARGLSEKLFF+X+TCRBJ01-04		TCRBD02-01*01	TCRBJ01-04*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTACAAAAGGACTATGGCTACACCTTCGGTTCG	CASSLQKDYGYTF	In	VDJ	10	751	0.0024711832393888838	0.0031018702088289715	39	TCRBV24						TCRBJ01	TCRBJ01-02	01	6	3	6	3	2	5	24	36	41	38	46		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLQKDYGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24		TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCCCGCGGTCGCCGCAAGAGACCCAGTACTTCGGGCCA	CSASPRSPQETQYF	In	VDJ	12	851	0.002800235601491265	0.0035149021940259055	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	3	7	5	2	3	6	26	37	44	40	50		TCRBV20-01,TCRBV20-or09_02				01,02								CSASPRSPQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAGATCAGTATTGGCTACACCTTCGGTTCG	CASSQEISIGYTF	In	VDJ	15	1072	0.003527441321737528	0.004427702881311129	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	5	7	3	3	26	43	49	46	52		TCRBV03-01,TCRBV03-02												CASSQEISIGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AAGRAGACWCRGCWSYGTATCTCTGCGCCAGCAGCCAAGATGTAGCGGGAGCGGGCAATGAGCAGTTCTTCGGGCCA	CASSQDVAGAGNEQFF	In	VDJ	16	1155	0.0038005547822825047	0.004770519429024584	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	5	2	6	4	4	20	35	48	39	52	TCRBV01,TCRBV23													CASSQDVAGAGNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSHSNQPQHF	In	VJ	19	1355	0.004458659506487267	0.005596583399418451	36	TCRBV03						TCRBJ01	TCRBJ01-05	01	3	0	0	0	0	0	26	-1	-1	-1	40		TCRBV03-01,TCRBV03-02												CASSHSNQPQHF+TCRBV03-X+TCRBJ01-05	TCRBV03		TCRBJ01-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGTTGCCTCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	21	1523	0.005011467474819268		38	TCRBV24						TCRBJ02	TCRBJ02-03	01	5	10	0	2	2	2	24	37	41	39	43		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ02-03	TCRBV24		TCRBJ02-03*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGGGGCTAGCGGACGCTACGAGCAGTACTTCGGGCCG	CASSLGASGRYEQYF	In	VDJ	33	2361	0.0077689262692372234	0.009751685170499604	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	4	5	3	3	3	18	34	44	37	47	TCRBV07,TCRBV11					01,02								CASSLGASGRYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGGGTTGGCGGGAGGGAGCGAGACCCAGTACTTCGGGCCA	CSARGLAGGSETQYF	In	VDJ	35	2498	0.008219728005317487	0.010317538990219402	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	3	7	0	5	7	3	26	37	53	44	56		TCRBV20-01,TCRBV20-or09_02												CSARGLAGGSETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*02	TCRBJ02-05*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGCTATGACAGGGGGCCCAGCTGAAGCTTTCTTTGGACAA	CASSQAMTGGPAEAFF	In	VDJ	44	3160	0.010398054642435251	0.013051810732223104	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	2	0	6	4	4	23	39	53	43	57	TCRBV01,TCRBV04													CASSQAMTGGPAEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAACCGGGACTCCTTGCTAACTATGGCTACACCTTCGGTTCG	CSAREPGLLANYGYTF	In	VDJ	48	3418	0.011247009736659395	0.014117433254031192	48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	0	0	10	0	3	5	26	40	49	43	54		TCRBV20-01,TCRBV20-or09_02				01,02								CSAREPGLLANYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01	TCRBJ01-02*01	4160B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				4738	3774	912	50	0	2203	1715	449	39	0	303903	242112	58529	3262	0	0.143582061	9.2013483	0.127891347	9.68498802				262894	0.0151968114	0.0758533254	0.0604304671	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:51:20	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x1, carbo/docetaxel x 5	0.7965386021811449	MSKCC- Snyder- P01-02		3995.0	
